



MINISTRY OF HEALTH

MALAYSIA NATIONAL CANCER REGISTRY REPORT

2017-2021

NATIONAL CANCER REGISTRY
INSTITUT KANSER NEGARA
MINISTRY OF HEALTH
PUTRAJAYA, MALAYSIA





MINISTRY OF HEALTH
MALAYSIA

MALAYSIA NATIONAL CANCER REGISTRY REPORT (MNCR) 2017-2021

National Cancer Registry Department,
Institut Kanser Negara,
Ministry of Health, No 4, Jln P7, Presint 7,
62250 Putrajaya, MALAYSIA
Tel: (603) 88925555
Fax: (603) 88925625
© National Cancer Registry, December 2025

Email: ncr.putrajaya@nci.gov.my

This book is available in electronic format at
<http://nci.moh.gov.my>

Disclaimer:

Copyright © Ministry of Health Malaysia

All rights reserved. This report may not be produced, in whole or in part, in any form or means, electronic or mechanical, including photocopying, without written permission from publisher



Cataloguing-in-Publication Data

Perpustakaan Negara Malaysia

A catalogue record for this book is available
from the National Library of Malaysia

eISBN 978-967-16142-5-9

ACKNOWLEDGEMENT

The Malaysia National Cancer Registry (MNCR) wishes to extend its deepest appreciation to all hospitals, clinics, healthcare institutions and diagnostic laboratories nationwide for their unwavering cooperation and invaluable contributions in supporting cancer registration. Their dedication and commitment have been fundamental to the completeness and quality of the data presented in this report.

We also gratefully acknowledge the continuous support and collaboration of the Non-Communicable Disease Control teams in every State and Federal Territory Health Department, the Health Informatics Centre (HIC), Ministry of Health Malaysia; the National Registration Department, and the Department of Statistics Malaysia. Their assistance has been instrumental in strengthening the registry and enhancing the reliability of cancer statistics in the country.

Finally, we extend our sincere gratitude to every individual and organization who, through their expertise, effort and collaboration, has contributed to the successful completion of the Malaysia National Cancer Registry Report 2017-2021. We look forward to continuing these fruitful collaborations in the years to come, as we work together to advance cancer control and improve population health in Malaysia.

EDITORIAL TEAM

Director of Institut Kanser Negara

Dr. Nur Aslina Bahakodin

Editor-in-Chief

Dr. Siti Norbayah Yusof, Public Health Medicine Specialist
National Cancer Registry Department

Editors

Dr. Waramlah Ramli, Public Health Medicine Specialist
Wilayah Persekutuan Kuala Lumpur & Putrajaya Health Department

Dr. Mohd Zahiruddin Mohd Khairi, Public Health Medicine Specialist
Johor State Health Department

Dr. Adibah Ibrahim, Public Health Medicine Specialist
Melaka State Health Department

Dr. Noor Rafizah Aminah Aziz, Public Health Medicine Specialist
Selangor State Health Department

Dr. Izwana Hamzah, Public Health Medicine Specialist
Perlis State Health Department

Dr. Tan Hooi Shyuan, Public Health Medicine Specialist
Pulau Pinang State Health Department

Dr. Siti Mariam Ja'afar, Public Health Medicine Specialist
Terengganu State Health Department

Dr. Sukumaran Raman, Medical Officer
National Cancer Registry Department

Dr. Umawathy Sundrarajoo, Medical Officer
National Cancer Registry Department

Dr. Nurulaisyah Hamzah, Medical Officer
National Cancer Registry Department

Dr. Balqis Bahtiar, Medical Officer
National Cancer Registry Department

Dr. Siti Maryam Muhamat, Medical Officer
National Cancer Registry Department

Dr. Rohana Ab Rahman, Medical Officer
Kelantan State Health Department

Dr. Sakinah Zuriati Muhammed Hafiz, Medical Officer
Wilayah Persekutuan Labuan State Health Department

Dr. Kirenjit Kaur, Medical Officer
Negeri Sembilan State Health Department

Dr. Nur Hasanah Sanudin, Medical Officer
Sabah State Health Department

Dr. Norazrul Nasri, Medical Officer
Perak State Health Department

Dr. Mazni Fathinah Nabilah Mazlan, Medical Officer
Wilayah Persekutuan Kuala Lumpur & Putrajaya Health Department

Dr. Nurulhuda Mohd Zaid, Medical Officer
Perak State Health Department

Pn. Nur Adila Daud, Statistician
National Cancer Registry Department

Dr. Muhamad Hairul Nizam Abd Hamid, Medical Officer
Sector for Cancer Prevention and Control, Disease Control Division
Ministry of Health

Technical Officers

Janani S.Saravana
Nur Adila Abd Razak
Rusyaidah Bahirah Baharudin
Siti Sarah Asyikin Mat Rejab
National Cancer Registry Department

Suggested citation: Malaysia National Cancer Registry Report 2017-2021

TABLE OF CONTENTS

	Page
ACKNOWLEDGEMENT	iii
EDITORIAL TEAM	iv
TABLE OF CONTENTS	vi
PREFACE	viii
FOREWORD	ix
MESSAGE	x
LIST OF TABLES	xi
LIST OF FIGURES	xii
LIST OF APPENDICES	xiv
LIST OF ABBREVIATIONS	xv
EXECUTIVE SUMMARY	1
1.0 INTRODUCTION	2
1.1 Geographical Background.....	3
1.2 Population and Health Status	4
1.2.1 Health Status, Socioeconomic and Health Facilities.....	5
1.2.2 Cancer Death Certification.....	7
2.0 METHODOLOGY	8
2.1 Sources of data.....	8
2.2 Registration procedure.....	8
2.3 Quality control.....	10
2.4 Data Analysis.....	11
2.4.1 Description of statistical methods.....	12
3.0 RESULTS	14
3.1 Overall Cancer Incidence	14
3.1.1 Cancer Trends	16
3.2 Age-specific Incidence rates.....	17
3.3 Incidence of Ten Most Common Cancers	19
3.4 Ethnic Variations.....	21
3.5 Staging	26
3.5.1 Validity	26
3.6 Age Groups and Cancers.....	27
3.7 International Comparisons	29
4.0 SUMMARY TABLES	30
4.1 Incidence Summary Table.....	30
4.2 Staging by Cancer Sites	31
4.3 Quality Indicators.....	32
5.0 COMMENTARY ON SELECTED CANCER SITES	33
5.1 Female Breast (ICD-10: C50).....	33
5.2 Colorectal (ICD-10: C18-C21).....	36
5.3 Lung, Trachea and Bronchus (ICD-10: C33-C34)	41
5.4 Lymphoma (ICD-10: C81-C85, C96).....	46

5.5 Leukaemia (ICD-10: C91-C95)	53
5.6 Nasopharynx (ICD-10: C11).....	58
5.7 Liver (ICD-10: C22).....	63
5.8 Stomach and Oesophagus (ICD-10: C15-C16).....	68
5.9 Cervix Uteri (ICD-10: C53)	77
5.10 Ovary (ICD-10: C56).....	80
5.11 Corpus Uteri (ICD-10: C54)	83
5.12 Prostate (ICD-10: C61).....	86
REFERENCES	89
APPENDICES	90

PREFACE

This publication serves as the full report expanding on the e-Summary of the Malaysia National Cancer Registry Report 2017-2021, which was published in July 2024 and is available on the Institut Kanser Negara official website. It provides additional data, analyses, and more detailed coverage, representing the third five-year report produced by the Malaysian National Cancer Registry (MNCR) since the establishment of population-based cancer registries across all states in 2007.

This report includes newly diagnosed cancer cases among Malaysian citizens and residents between 1st January 2017 and 31st December 2021 and is based on data meticulously collected from 13 states and 3 federal territories. As the MNCR database is continuously updated, figures for earlier years may differ slightly from those in previous reports. The data presented reflect the status as of 31st December 2024. This publication also includes Appendix 12, which provides incidence summaries for 12 selected cancers by state and gender for 2017-2021.

This publication provides an essential resource for healthcare professionals, policymakers, researchers and the public, offering more detailed and comprehensive insights for those seeking a deeper understanding of cancer patterns beyond the main trends presented in the e-Summary. Interpretation of these findings should consider multi-year patterns, as annual incidence may fluctuate. In recent years, the MNCR has intensified active case-finding and expanded the use of additional data sources, resulting in improved coverage and completeness compared with previous reporting cycles.

The MNCR is committed to compiling and disseminating high-quality, population-based cancer data to guide the planning and delivery of effective cancer control services, including prevention, diagnosis, treatment and care. Reliable and timely data are essential for shaping evidence-based strategies and optimizing resource allocation. Considerable effort has been invested to ensure the accuracy, completeness and quality of the data in this report.

Acknowledgement is hereby given to all healthcare institutions, pathology laboratories, the Non-Communicable Disease Control teams in every State and Federal Territory Health Department, the Health Informatics Centre (HIC), the National Registration Department (NRD) and the Department of Statistics Malaysia (DOSM) for their invaluable support and collaboration in cancer registration. Their collective contributions have been essential to the preparation of this report and continued fruitful collaboration is anticipated in advancing cancer control in Malaysia.

Editorial Team

FOREWORD



Cancer continues to be a major public health challenge in Malaysia, and reliable data is essential for guiding effective strategies in cancer control. The Malaysia National Cancer Registry Report 2017-2021 represents the third five-year report on cancer incidence in our country, following earlier reports for 2007-2011 and 2012-2016. Together, these reports provide valuable insights into cancer trends over time and strengthen our understanding of the evolving burden of disease.

This report reflects significant progress in the completeness and coverage of cancer data. These improvements were made possible through strengthened collaboration with hospitals, clinics, laboratories and state health departments, as well as the transition to a web-based notification system. Together, these reports provide valuable insights into cancer trends over time and strengthen our understanding of the evolving burden of disease.

Beyond serving as a surveillance tool, the Registry plays a vital role in informing public health planning and policy. The data presented here provides critical evidence for shaping national and state-level cancer control strategies, optimising resource allocation and evaluating cancer care services. By identifying disparities in incidence, stage at diagnosis, and outcomes across different populations, the Registry supports targeted interventions to improve equity in cancer prevention and care.

In developing and implementing national cancer control programmes, it is imperative that all relevant stakeholders work together to foster enabling environments for strategic planning. This requires strong political will, inter-agency collaboration and cost-effective programme development aimed at reducing cancer morbidity and mortality.

As we move forward, the National Cancer Registry is committed to further strengthening the quality and timeliness of cancer data. Priorities include enhancing survival and mortality analyses, improving linkages with health information systems, and expanding collaboration with stakeholders to maximise the use of data for research and planning. These efforts are essential to support Malaysia's continued progress in cancer prevention, early detection, treatment and survivorship.

On behalf of the Ministry of Health, I extend my appreciation to all medical oncologists, surgeons, physicians, public health specialists, pathologists and medical support personnel for their invaluable contributions to the development of this report. Their expertise and dedication have been essential in ensuring the accuracy, quality and comprehensiveness of the data presented.

Thank you.

DATUK DR. MAHATHAR BIN ABD WAHAB
Director General of Health, MALAYSIA

MESSAGE



Cancer remains one of the leading causes of death in Malaysia, placing a heavy burden on individuals, families, and the health system. The Ministry of Health is committed to reducing this impact through prevention, early detection, equitable care, and better patient outcomes.

Globally, the challenge is immense. According to the World Health Organization (WHO), cancer accounted for nearly 10 million deaths in 2022, exerting significant strain on health systems worldwide. However, this reality also underscores a crucial fact: timely diagnosis, evidence-based treatment, and comprehensive survivorship care can dramatically improve survival rates where health systems are robust.

The Malaysia National Cancer Registry Report 2017–2021 reflects this global landscape. The number of recorded cases has risen markedly, largely due to the strengthening of our web-based notification platform and mandatory online reporting directives. While better surveillance is welcome, the report reveals a concerning trend: more than half of breast, colorectal, lung, and prostate cancers are still detected at Stage III or IV. Early detection and screening must, therefore, remain a critical imperative.

Disparities in incidence and outcomes persist across demographics and regions. A unified national response is essential—one that bridges clinical care, public health outreach, and research to ensure health equity, so that no Malaysian is left behind.

Concurrently, Malaysia has recorded encouraging progress. Cervical cancer incidence has declined a testament to sustained screening efforts. The full impact of the nationwide HPV vaccination programme, introduced in 2010, will become increasingly evident as the first cohort of vaccinated girls reaches adulthood. This achievement highlights the importance of long-term foresight in advancing cancer control.

The Ministry of Health supports the World Cancer Day 2025–2027 theme, “United by Unique”. “United” reflects global solidarity, while “Unique” recognizes that every individual’s cancer journey is different. This theme calls for a shift towards personalized, holistic care that involves patients, families, and communities in shaping empathetic cancer services.

I commend the National Cancer Registry, Institut Kanser Negara, and all partners for their dedication in improving the completeness of our cancer data. Let us remain united in purpose, guided by evidence, empathy, and equity, to better serve the unique journeys of every Malaysian affected by cancer.

DATUK SERI DR. DZULKEFLY AHMAD

Minister Of Health, MALAYSIA

LIST OF TABLES

	Page
Table 1. Population by gender, ethnicity and citizenship, Malaysia, 2021	4
Table 2. Malaysia's Human Development Index Trends, 2017-2021	5
Table 3. Health facilities and number of doctors in Malaysia, 2017-2021	6
Table 4. MNCR Data Variables and Operational Definitions	10
Table 5. Incidence summary of new cancer cases by gender, Malaysia, 2017-2021	14
Table 6. Incidence summary by major ethnicity and gender, Malaysia, 2017-2021	14
Table 7. Ten most common cancers, all residents, Malaysia, 2017-2021	19
Table 8. Ten most common cancers by gender, all residents, Malaysia, 2017-2021	20
Table 9. Incidence rates for ten most common cancers: males by ethnicity, 2017-2021	21
Table 10. Incidence rates for ten most common cancers: females by ethnicity, 2017-2021	21
Table 11. Incidence rates for ten most common cancers: Malay by gender, 2017-2021	22
Table 12. Incidence rates for ten most common cancers: Chinese by gender, 2017-2021	23
Table 13. Incidence rates for ten most common cancers: Indian by gender, 2017-2021	24
Table 14. Incidence rates for ten most common cancers: Other Bumiputera by gender,	25
Table 15. Stage Distribution of Screen-Detectable Cancers, Malaysia 2012-2021	26
Table 16. Incidence summary of all cancer sites by year, ethnicity and state, Malaysia	30
Table 17. Staging for all cancer types, Malaysia, 2017-2021	31
Table 18. Quality indicators for all cancer types, Malaysia, 2017-2021	32
Table 19. Female Breast Cancer incidence summary by year, Malaysia	33
Table 20. Female Breast Incidence summary by year and ethnicity, Malaysia	33
Table 21. Colorectal: Cancer incidence summary by year, Malaysia	36
Table 22. Colorectal: Incidence summary by gender, year and ethnicity, Malaysia	36
Table 23. Lung, Trachea and Bronchus: Cancer incidence summary by year, Malaysia	41
Table 24. Lung, Trachea and Bronchus: Incidence summary by gender, year and	41
Table 25. Lymphoma: Cancer incidence summary by year, Malaysia	46
Table 26. Lymphoma: Incidence summary by gender, year and ethnicity, Malaysia	46
Table 27. Lymphoma: Incidence summary by type, gender, year and ethnicity, Malaysia	49
Table 28. Leukaemia: Cancer incidence summary by year, Malaysia	53
Table 29. Leukaemia: Incidence summary by gender, year and ethnicity, Malaysia	53
Table 30. Leukaemia: Incidence summary by type, gender, year and ethnicity, Malaysia	55
Table 31. Nasopharynx: Cancer incidence summary by year, Malaysia	58
Table 32. Nasopharynx: Incidence summary by gender, year and ethnicity, Malaysia	58
Table 33. Liver: Cancer incidence summary by year, Malaysia	63
Table 34. Liver: Incidence summary by gender, year and ethnicity, Malaysia	63
Table 35. Stomach: Cancer incidence summary by year, Malaysia	68
Table 36. Stomach: Incidence summary by gender, year and ethnicity, Malaysia	68
Table 37. Oesophagus: Cancer incidence summary by year, Malaysia	69
Table 38. Oesophagus: Incidence summary by gender, year and ethnicity, Malaysia	69
Table 39. Cervix Uteri: Cancer incidence summary by year, Malaysia	77
Table 40. Cervix Uteri: Incidence summary by year and ethnicity, Malaysia	77
Table 41. Ovary: Cancer incidence summary by year, Malaysia	80
Table 42. Ovary: Incidence summary by year and ethnicity, Malaysia	80
Table 43. Corpus Uteri: Cancer incidence summary by year, Malaysia	83
Table 44. Corpus Uteri: Incidence summary by year and ethnicity, Malaysia	83
Table 45. Prostate: Cancer incidence summary by year, Malaysia	86
Table 46. Prostate: Incidence summary by year and ethnicity, Malaysia	86

LIST OF FIGURES

Figure 1.	Map of Malaysia.....	3
Figure 2.	Population pyramid, all residents, 2021	4
Figure 3.	Perinatal, neonatal, infant mortality rate and maternal mortality ratio in MOH Hospitals, 2017-2021...5	
Figure 4.	Number of medically certified and non-medically certified cancer death, 2017-2021	7
Figure 5.	Certified and uncertified cancer death, 2017-2021	7
Figure 6.	Outline of registration procedure	9
Figure 7.	Comparison of incidence rates by ethnicity and gender, 2007-2021	15
Figure 8.	Number of cases by age group and gender, 2017-2021	15
Figure 9.	Annual number and incidence rates by gender, 2007-2021	16
Figure 10.	Age-specific incidence rates by gender, all sites, 2017-2021	17
Figure 11.	Age-specific incidence rates for five most common cancers, males, 2017-2021.....	18
Figure 12.	Age-specific incidence rates for five most common cancers, females, 2017-2021.....	18
Figure 13.	Comparison of ten most common cancers, all residents, 2012-2021	19
Figure 14.	Incidence rates for ten most common cancers by gender, 2017-2021	20
Figure 15.	Incidence rates for ten most common cancers among Malays by gender, 2017-2021.....	22
Figure 16.	Incidence rates for ten most common cancers among Chinese by gender, 2017-2021.....	23
Figure 17.	Incidence rates for ten most common cancers among Indians by gender, 2017-2021	24
Figure 18.	Incidence rates for ten most common cancers among Other Bumiputera by gender, 2017-2021.....	25
Figure 19.	Most common cancers among 0-14 years age group by gender, 2017-2021	27
Figure 20.	Most common cancers among 15-24 years age group by gender, 2017-2021	27
Figure 21.	Most common cancers among 25-59 years age group by gender, 2017-2021	28
Figure 22.	Most common cancers among 60-74 years age group by gender, 2017-2021	28
Figure 23.	Most common cancers among 75 years and above age group by gender, 2017-2021.....	28
Figure 24.	All Sites: International comparisons - Age-standardised incidence rates	29
Figure 25.	Female Breast: Comparison of age-standardised incidence rates by year and ethnicity	34
Figure 26.	Female Breast: Comparison of age-specific incidence rates by year	34
Figure 27.	Female Breast: Comparison of staging percentage by year.....	35
Figure 28.	Female Breast: International comparisons – Age-standardised incidence rates	35
Figure 29.	Colorectal: Comparison of age-standardised incidence rates by year, ethnicity and gender	37
Figure 30.	Colorectal: Comparison of age-specific incidence rates by year in males	38
Figure 31.	Colorectal: Comparison of age-specific incidence rates by year in females.....	38
Figure 32.	Colorectal: Comparison of staging percentage by year and gender	39
Figure 33.	Colorectal: International comparisons - Age-standardised incidence rates	40
Figure 34.	Lung, Trachea and Bronchus: Comparison of age-standardised incidence rates by year, ethnicity and gender	42
Figure 35.	Lung, Trachea and Bronchus: Age-specific incidence rates by year and gender	43
Figure 36.	Lung, Trachea and Bronchus: Staging percentage by year and gender	44
Figure 37.	Lung, Trachea and Bronchus: International comparisons - Age-standardised incidence rates	45
Figure 38.	Lymphoma: Comparison of age-standardised incidence rates by year, ethnicity and gender	47
Figure 39.	Lymphoma: Staging percentage by year and gender	48
Figure 40.	Hodgkin Disease: Age-specific incidence rates by year and gender	50
Figure 41.	Non-Hodgkin Lymphoma: Age-specific incidence rates by year and gender	50
Figure 42.	Hodgkin lymphoma: International comparisons - Age-standardised incidence rates.....	51
Figure 43.	Non-Hodgkin lymphoma: International comparisons - Age-standardised incidence rates	52
Figure 44.	Leukaemia: Comparison of age-standardised incidence rates by year, ethnicity and gender	54
Figure 45.	Myeloid Leukaemia: Age-specific incidence rates by year and gender	56
Figure 46.	Lymphoid Leukaemia: Age-specific incidence rates by year and gender	56
Figure 47.	Leukaemia: International comparisons - Age-standardised incidence rates	57
Figure 48.	Nasopharynx: Comparison of age-standardised incidence rates by year, ethnicity and gender.....	59
Figure 49.	Nasopharynx: Age-specific incidence rates by year and gender	60
Figure 50.	Nasopharynx: Staging percentage by year and gender	61
Figure 51.	Nasopharynx: International comparisons - Age-standardised incidence rates.....	62
Figure 52.	Liver: Comparison of age-standardised incidence rates by year, ethnicity and gender.....	64

Figure 53. Liver: Age-specific incidence rates by year and gender	65
Figure 54. Liver: Staging percentage by year and gender	66
Figure 55. Liver: International comparisons - Age-standardised incidence rates.....	67
Figure 56. Stomach: Comparison of age-standardised incidence rates by year, ethnicity and gender	70
Figure 57. Oesophagus: Comparison of age-standardised incidence rates by year, ethnicity and gender	71
Figure 58. Stomach and Oesophagus: Age-specific incidence rates by year and gender	72
Figure 59. Stomach: Comparison of staging percentage by year and gender	73
Figure 60. Oesophagus: Comparison of staging percentage by year and gender	74
Figure 61. Stomach: International comparisons - Age-standardised incidence rates	75
Figure 62. Oesophagus: International comparisons - Age-standardised incidence rates	76
Figure 63. Cervix Uteri: Comparison of age-standardised incidence rates by year and ethnicity	78
Figure 64. Cervix Uteri: Age-specific incidence rates by year	78
Figure 65. Cervix Uteri: Comparison of staging percentage by year	79
Figure 66. Cervix Uteri: International comparisons - Age-standardised incidence rates	79
Figure 67. Ovary: Comparison of age-standardised incidence rates by year and ethnicity	80
Figure 68. Ovary: Comparison of age-specific incidence rates by year.....	81
Figure 69. Ovary: Comparison of staging percentage by year	81
Figure 70. Ovary: International comparisons - Age-standardised incidence rates	82
Figure 71. Corpus Uteri: Comparison of age-standardised incidence rates by year and ethnicity	83
Figure 72. Corpus Uteri: Comparison of age-specific incidence rates by year.....	84
Figure 73. Corpus Uteri: Comparison of staging percentage by year	84
Figure 74. Corpus Uteri: International comparisons - Age-standardised incidence rates.....	85
Figure 75. Prostate: Comparison of age-standardised incidence rates by year and ethnicity	86
Figure 76. Prostate: Comparison of age-specific incidence rates by year	87
Figure 77. Prostate: Comparison of staging percentage by year	87
Figure 78. Prostate: International comparisons - Age-standardised incidence rates	88

LIST OF APPENDICES

Appendix 1.	Population at risk (mid-period population), all Malaysian, 2017-2021	90
Appendix 2.	Incidence summary table, all residents, males, 2017-2021	91
Appendix 3.	Incidence summary table, all residents, females, 2017-2021	92
Appendix 4.	Incidence summary table, Malay males, 2017-2021	93
Appendix 5.	Incidence summary table, Malay females, 2017-2021	94
Appendix 6.	Incidence summary table, Chinese males, 2017-2021	95
Appendix 7.	Incidence summary table, Chinese females, 2017-2021	96
Appendix 8.	Incidence summary table, Indian males, 2017-2021	97
Appendix 9.	Incidence summary table, Indian females, 2017-2021	98
Appendix 10.	Incidence summary table, Other Bumiputera males, 2017-2021	99
Appendix 11.	Incidence summary table, Other Bumiputera females, 2017-2021	100
Appendix 12.	Population table by gender and ethnicity (all residents), 2017-2021	101
Appendix 13.	Population table by gender, state and age group (all residents), 2017-2021	102
Appendix 14.	Incidence summary for 13 selected cancers by state and gender, 2017-2021	105
Appendix 15.	Age-standardised incidence rates for 13 selected cancers, 2017-2021	110
Appendix 16.	Number of new cancer cases by site and age group, all residents, males, 2017-2021	115
Appendix 17.	Cancer incidence by site and age group, all residents, males, 2017-2021	116
Appendix 18.	Number of new cancer cases by site and age group, all residents, females, 2017-2021	117
Appendix 19.	Cancer incidence by site and age group, all residents, females, 2017-2021	118
Appendix 20.	Number of new cancer cases by site and age group, Malay males, 2017-2021	119
Appendix 21.	Cancer incidence by site and age group, Malay males, 2017-2021	120
Appendix 22.	Number of new cancer cases by site and age group, Malay females, 2017-2021	121
Appendix 23.	Cancer incidence by site and age group, Malay females, 2017-2021	122
Appendix 24.	Number of new cancer cases by site and age group, Chinese males, 2017-2021	123
Appendix 25.	Cancer incidence by site and age group, Chinese males, 2017-2021	124
Appendix 26.	Number of new cancer cases by site and age group, Chinese females, 2017-2021	125
Appendix 27.	Cancer incidence by site and age group, Chinese females, 2017-2021	126
Appendix 28.	Number of new cancer cases by site and age group, Indian males, 2017-2021	127
Appendix 29.	Cancer incidence by site and age group, Indian males, 2017-2021	128
Appendix 30.	Number of new cancer cases by site and age group, Indian females, 2017-2021	129
Appendix 31.	Cancer incidence by site and age group, Indian females, 2017-2021	130
Appendix 32.	Number of new cancer cases by site and age group, Other Bumiputera males, 2017-2021	131
Appendix 33.	Cancer incidence by site and age group, Other Bumiputera males, 2017-2021	132
Appendix 34.	Number of new cancer cases by site and age group, Other Bumiputera females, 2017-2021	133
Appendix 35.	Cancer incidence by site and age group, Other Bumiputera females, 2017-2021	134
Appendix 36.	List of ICD-10 and ICD-11 codes for each site	135

LIST OF ABBREVIATIONS

95% CL	95% Confidence Limit
ASIR	Age-specific incidence rate
ASR	Age-standardised incidence rate
CI5	Cancer Incidence in Five Continents
CR	Crude incidence rate
CR74	Cumulative Rate
CumR	Cumulative Risk
DCO	Death Certificate Only
DOSM	Department of Statistics Malaysia
ENCR	European Network of Cancer Registries
HIC	Health Informatics Centre
HDI	Human Development Index
IARC	International Agency for Research on Cancer
IACR	International Association of Cancer Registries
ICD-10	International Classification of Diseases, Tenth Revision
ICD-O-3	International Classification of Diseases for Oncology, Third Edition
Lung, T&B	Lung, Trachea and Bronchus
MIMOS	Malaysian Institute of Microelectronic Systems
MNCR	Malaysian National Cancer Registry
MOH	Ministry of Health
MV	Morphological Verified
MyHDW	Malaysian Health Data Warehouse
MySCan	Malaysian Study on Cancer Survival
N. Sembilan	State of Negeri Sembilan
NCR	National Cancer Registry Department
Non-MOH	Non-Ministry of Health
NRD	National Registration Department
NRIC	National Registration Identification Card
Other Bumi	Other Bumiputera or Bumiputera other than the Malays
P. Pinang	State of Pulau Pinang
PRIS	Patient Registry Information System
RN	Registration Number
SMRP	Client Treatment Information System or <i>Sistem Maklumat Rawatan Pelanggan</i>
TNM	Tumour, Node, Metastasis
WHO	World Health Organisation
W.P.KL&P	Federal Territory of Kuala Lumpur & Putrajaya
W.P. Labuan	Federal Territory of Labuan

EXECUTIVE SUMMARY

The Malaysian National Cancer Registry (MNCR) is a nationwide, population-based registry established in 2007. Since the first report (2007-2011) in 2016 and the second (2012-2016) in 2019, this current report presents data for 2017-2021, covering Malaysian citizens and residents diagnosed with cancer. A total of 168,823 new cancer cases were registered, comprising 46.0% males and 54.0% females. The Age-standardised incidence rates (ASR) were 107.3 for males and 120.8 for females per 100,000 population. Compared to the previous five-year period (2012-2016), the incidence rates for all cancer sites combined increased by 21.2 per 100,000 in males and 19.2 per 100,000 in females. The cumulative risk (CumR) of being diagnosed with cancer before age 75 was 11.9% in males and 12.7% in females (lifetime risk: 1 in 8), representing a rise compared to 2012-2016.

The 10 most common cancer sites among males were colorectal, lung, prostate, liver, lymphoma, nasopharynx, leukaemia, non-melanoma skin, stomach and pancreas. Among females, the leading sites were breast, colorectal, lung, corpus uteri, ovary, cervix uteri, lymphoma, thyroid, leukaemia and liver. Among males, the largest increases in incidence rates were seen in colorectal, liver, lung and prostate cancers, while nasopharynx and bladder cancers showed a decline. Among females, the strongest increases occurred in breast, colorectal, corpus uteri and lung cancers, whereas a decrease was observed in cervix uteri cancer.

Cancer patterns vary by age, with leukaemia and central nervous system tumours dominating in children (0-14 years), and lymphoma most common among adolescents and young adults (15-24 years). In adult men, colorectal and lung cancers remain leading sites, while breast cancer continues to predominate among women aged 25-59 years. In older adults, colorectal cancer surpasses breast cancer in women and ranks highest in both genders. Overall, patterns remain broadly consistent over time, with notable shifts such as rising corpus uteri and declining cervical cancer in middle-aged women.

By ethnicity, the overall incidence rates showed an increase across all groups. Among males, The ASR was highest among Chinese, who recorded higher rates for most leading cancers, except for lymphoma, which was predominant in Malays. Among females, cancer incidence patterns varied by ethnicity: Indian women had higher rates of breast cancer, corpus uteri cancer, and leukaemia; Chinese women showed higher rates of colorectal and lung cancers; while Malays recorded higher incidence of lymphoma and thyroid cancer. In contrast, cervical cancer was most common among Other Bumiputera women.

Staging information was reported for only about half of cancer cases, leaving a substantial proportion unrecorded. Among cases with staging, nearly two-thirds (64.8%) were diagnosed at advanced stages (stages III and IV). While stage IV disease showed a slight decline compared to 2012–2016, the proportion of stage III increased, indicating that late presentation remains a significant challenge despite the availability of screening programmes.

The increase in cases reported for 2017-2021 reflects both a true rise in incidence and improved case ascertainment, supported by the introduction of the web-based notification system in 2018 and the mandatory reporting directive in 2020. These advances demonstrate progress in registry coverage and data completeness. Nonetheless, the persistently high proportion of advanced-stage cancers highlights the need for continued efforts in prevention, earlier detection, equitable access to care and ongoing investment in comprehensive, high-quality data to inform and strengthen Malaysia's cancer control strategies.

1.0 INTRODUCTION

Cancer is a major global health challenge, responsible for nearly 10 million deaths in 2020, equivalent to one in six deaths worldwide. Asia bears a substantial share of this burden, accounting for 49.3% of global cancer cases and 58.3% of cancer-related deaths in the same year. The incidence of cancer in the region is projected to rise significantly, from 9.39 million in 2020 to an estimated 14.2 million in 2040. Consequently, cancer mortality in Asia will increase from 5.75 million in 2020 to 9.67 million in 2040.

An estimated one-third of cancer deaths are linked to modifiable lifestyle factors, including tobacco use, high body mass index, alcohol consumption, inadequate intake of fruits and vegetables, and physical inactivity. Environmental exposures such as air pollution also contribute significantly, particularly to lung cancer. Infectious agents including human papillomavirus (HPV) and hepatitis B and C viruses are responsible for approximately 30% of cancer cases in low- and lower-middle-income countries.

Many cancers can be prevented or successfully treated if detected early and managed appropriately. Reducing the overall cancer burden requires a comprehensive strategy that integrates public health initiatives with a strong and responsive healthcare system. It is estimated that between 30% and 50% of cancer-related deaths are preventable by addressing key behavioral, environmental and infectious risk factors. Strengthening cancer screening programmes, ensuring early and accurate diagnosis, delivering timely and effective treatment are essential for improving survival outcomes. In addition, incorporating psychosocial support and palliative care into cancer services is vital to enhancing the quality of life for patients and their families.

In response to the growing cancer burden, the Ministry of Health Malaysia (MOH) established a population-based cancer registry in 1993, beginning with several regional registries. This initiative was expanded into a nationwide system in 2007. The National Cancer Registry Department (NCR) now oversees the MNCR and is responsible for the collection, analysis and reporting of data on cancer incidence, treatment and survival across 13 state registries and 3 federal territories.

This data plays a vital role in monitoring cancer trends, informing national cancer control strategies and improving patient outcomes. The first five-year report, covering 2007-2011, was published in 2016, followed by the second report for 2012-2016, released in 2019. These reports provide a comprehensive epidemiological overview of cancer in Malaysia, serving as a key resource for healthcare professionals, policymakers, researchers and stakeholders involved in planning and evaluating the National Cancer Control Programme.

1.1 Geographical Background

Malaysia is a Southeast Asian nation covering a land area of approximately 328,550 square kilometers as of 2022, according to the World Bank. This figure excludes inland water bodies, continental shelf claims, and exclusive economic zones. When including inland water bodies and certain coastal waterways, Malaysia's total surface area is reported at 330,411 square kilometers, making it the 69th largest country in the world.

Geographically, Malaysia lies between 2° and 7° north of the Equator, placing it within the tropical belt. Its climate is consistently warm and humid, with average temperatures ranging between 23°C and 32°C. The country's location at the southernmost point of continental Eurasia underscores its strategic importance at the intersection of Southeast Asia and the broader Eurasian continent.

Malaysia shares both land and maritime borders with multiple nations. Peninsular Malaysia is bordered by Thailand to the north and shares maritime boundaries with Singapore, Vietnam and Indonesia. East Malaysia, located on the island of Borneo, shares land borders with Brunei and Indonesia, and maritime boundaries with the Philippines and Vietnam.

Malaysia comprises two main regions, Peninsular Malaysia and East Malaysia, and is administratively divided into 13 states and 3 Federal Territories. Peninsular Malaysia consists of 11 states (Perlis, Kedah, Pulau Pinang, Perak, Selangor, Negeri Sembilan, Melaka, Johor, Pahang, Terengganu and Kelantan), along with the Federal Territories of Kuala Lumpur and Putrajaya. East Malaysia, situated on the island of Borneo, includes the states of Sabah and Sarawak, as well as the Federal Territory of Labuan. Kuala Lumpur is the national capital and Malaysia's largest city. It is the seat of the federal legislature. The federal administrative centre is located in Putrajaya, where key ministries and government agencies are based.




Figure 1. Map of Malaysia

1.2 Population and Health Status

While cancer incidence rates for 2017-2021 were calculated using the 2019 Malaysian population as the standard denominator, broader demographic information is presented based on the 2021 population estimates to provide context. In 2021, Malaysia's total population was estimated at 32.6 million, including non-citizens. Among Malaysian citizens, males constituted 50.7% and females 49.3%, with a gender ratio of 103 males per 100 females. By ethnicity, Malays accounted for 57.4%, Other Bumiputera 12.2%, Chinese 23.0%, Indians 6.7%, and Other ethnic groups 0.7%. Other Bumiputera refers to the indigenous populations of Malaysia apart from Malays, including the Orang Asli of Peninsular Malaysia and the native ethnic groups of Sabah and Sarawak, such as the Iban, Bidayuh, Kadazan-Dusun, and Murut.

Table 1. Population by gender, ethnicity and citizenship, Malaysia, 2021

Variables	Characteristics	NO	Percentage (%)
Gender	Male	15,221,550	50.7
	Female	14,795,350	49.3
Ethnic groups	Malays	17,248,400	57.4
	Other Bumiputera	3,654,100	12.2
	Chinese	6,891,700	23.0
	Indians	2,002,600	6.7
	Others	220,100	0.7
	Total	30,016,900	100.0
Citizenship	Malaysian	30,016,900	92.1
	Non-Malaysian	2,559,500	7.9
	Total	32,576,400	100.0

Source: Department of Statistics Malaysia (DOSM), 2021 Current Population Estimates




Figure 2. Population pyramid, all residents, 2021

Source: Department of Statistics Malaysia (DOSM), 2021 Current Population Estimates

1.2.1 Health Status, Socioeconomic and Health Facilities

Health status: The life expectancy of Malaysian residents saw a slight decrease at 74.5 years in 2021 compared to 74.6 years in 2011. According to a report by DOSM, a male child born in 2021 and 2017 can expect to live up to 72.3 years while a female child, up to 77.0 years or decrease 0.3 years compared to 77.6 years in 2017. The important mortality indicators trends in Malaysia for 2017-2021 as shown in figure 3.




Figure 3. Perinatal, neonatal, infant mortality rate and maternal mortality ratio in MOH Hospitals, 2017-2021

Source: Health Indicators, MOH 2018-2022

Socioeconomic: Malaysia's Human Development Index (HDI) value for 2021 was 0.802 which put the country in the high human development category, positioning it at 62 out of 191 countries and territories (United Nation Development Program). Between 1990 and 2021, Malaysia's HDI value increased from 0.643 to 0.802, an increase of 24.9%. The standard of living is measured by Gross National Income (GNI) per capita expressed in constant 2021 international dollars converted using purchasing power parity (PPP) conversion rates. Table 2 reviews Malaysia's progress in each of the HDI indicators.

Table 2. Malaysia's Human Development Index Trends, 2017-2021

	Life expectancy at birth	Expected years of schooling	Mean years of schooling	GNI per capita (2011 PPP\$)	HDI Value
2017	75.5	13.3	10.5	29,081	0.807
2018	75.7	13.1	10.6	29,895	0.809
2019	75.9	13.1	10.6	31,009	0.812
2020	76.1	13.0	10.8	29,117	0.810
2021	73.9	12.9	10.9	29,627	0.802

Source: United Nation Development Program

Health facilities: The following table provides an overview of the health delivery system in Malaysia. An overall number of health facilities and doctors treating all types of diseases are seen in Table 3. Between 2017 to 2021, the doctor-to-population ratio improved from 1:554 to 1:420. Gradual increases in the total number of government hospitals (MOH and non-MOH) were from 154 in 2017 to 158 in 2021 and hospital beds from 46,194 in 2017 to 49,781 in 2021. Other health facilities comprising government and non-government, form a total of 10,794 in 2017 and have increased to 11,566 by the year 2021.

Table 3. Health facilities and number of doctors in Malaysia, 2017-2021

	2017	2018	2019	2020	2021
No. of Medical Officer					
Government(MOH)	40,230	43,052	48,478	NA	56,022
Government(non-MOH)	3,118	3,457	3,651	NA	5,537
Private	14,483	14,649	15,457	NA	16,196
Total	57,832	61,158	67,586	73,996	77,755
Doctor: Population ratio	1:554	1:530	1:482	1:441	1:420
No. of Dentists					
Government(MOH)	5,097	5,768	6,349	6,642	6,917
Government(non-MOH)	639	687	738	801	868
Private	2,862	3,244	3,714	4,154	4,789
Total	8,598	9,699	10,801	11,597	12,574
Dentist: Population ratio	1:3728	1:3339	1:3017	1:2816	1:2597
Hospitals					
Government(MOH)	144	144	144	146	146
Government(non-MOH)	10	10	10	10	12
Private	240	252	250	243	256
Total	394	406	404	399	414
Hospitals Beds					
Government(MOH)	42,302	42,424	42,936	44,117	44,849
Government(non-MOH)	3,892	4,187	4,052	4,188	4,932
Private	15,566	16,839	17,325	18,063	18,639
Total	61,760	63,450	64,313	66,368	68,420
Other facilities					
Government Community Clinics (KKom)	342	343	286	257	255
Government(MOH)	2,881	2,881	2,885	2,890	2,892
Private Practitioners (General Practitioners)	7,571	7,718	7,988	8,222	8,419
Total	10,794	10,942	11,159	11,369	11,566
Dental Clinics					
Government Dental Clinic	709	712	721	724	730
Dental Clinics in Other Institutions	20	21	21	21	20
Private Dental Clinics	2,137	2,311	2,507	2,798	3,053
Total	2,866	3,044	3,249	3,543	3,803

Medical Officers: Including House Officers

Private Hospitals: Private Hospitals, Private Maternity Home, Private Nursing Home And Hospice

Government (MOH) Health Clinics: Health Clinic, Rural Community Clinic, Maternal and Child Health Clinic

Government (non-MOH) Hospitals: Army Hospitals, University Hospitals,

Government Community Clinics (KKom) previously known as 1Msia clinic

Government Dental Clinics: Standalone Dental Clinics, Dental Clinics in Health Clinics and Dental Clinics in Hospitals

NA: Not Available

Source: Health Facts, Health Informatics Centre, Planning Division, Ministry of Health Malaysia 2017-2021

1.2.2 Cancer Death Certification

In Malaysia, all deaths are legally required to be reported to the National Registration Department (NRD). DOSM compiles and publishes national mortality statistics on an annual basis. Between 2017 and 2021, a total of 97,906 cancer deaths were recorded, encompassing both medically certified and non-medically certified deaths (Figure 4). Overall, 78.3% of the reported cancer deaths were medically certified, while 21.7% were uncertified (Figure 5).




Figure 4. Number of medically certified and non-medically certified cancer death, 2017-2021

Source: Department of Statistics Malaysia (DOSM), (Statistic on Causes of Death Malaysia, 2017-2021)




Figure 5. Certified and uncertified cancer death, 2017-2021

Source: Department of Statistics Malaysia (DOSM), (Statistic on Causes of Death Malaysia, 2017-2021)

2.0 METHODOLOGY

2.1 Sources of data

Since 2007, Malaysia has maintained a Nationwide Population Based Cancer Registry, which was established when all 15 states and federal territories instituted their own Regional Cancer Registries. Initially, data collection relied on a paper-based NCR-02 form, voluntarily submitted to the State Health Office. These records were then entered into the CanReg5 database, developed by the International Agency for Research on Cancer (IARC). The M2b module, which digitizes cancer notifications using the Malaysian Health Data Warehouse (MyHDW), was implemented in 2018 to improve data coverage and integration across several sources. The M2b module facilitates standardized online notifications from all data source providers in government and private health facilities.

In April 2020, a circular order issued by the Director General of Health mandated the reporting of all cancer cases by registered medical officers and medical support officers in government healthcare facilities, while strongly encouraging reporting from their counterparts in private healthcare facilities. The directive emphasized the importance of capturing comprehensive data for Malaysian citizens and residents to facilitate better cancer management and public health interventions. These combined efforts, including the circular order and the digitization of cancer notification processes, aim to improve the collection of essential epidemiological and clinical data regarding cancer cases diagnosed and treated across Malaysia.

Comprehensive cancer registration is achieved through a combination of passive and active case finding methods:

1. Passive Notification: This method entails healthcare professionals completing online notification forms and submitting them for registry review.

2. Active Case Finding: This approach involves making direct contact with pathology labs, medical facilities and other pertinent organizations in order to locate and document information on diagnosed cancer cases.

To maintain data integrity, active search activities may include routine assessments of pathology reports, hospital discharge records, and mortality information to identify any cases that may have been overlooked and confirm the accuracy of the data. Any discrepancies or missing data are resolved by additional inquiries with the relevant healthcare facilities. Patient confidentiality was maintained at all times.

The implementation of the M2b module and its combination with the active case-finding method has significantly enhanced the collection of cancer data in Malaysia. Additionally, continuous training and support for registry staff promotes compliance with cancer registry standards and complete data reporting.

2.2 Registration procedure

Flow of cancer registration

MyHDW, proposed in 2011 and operational since August 2016, serves as a centralized repository for comprehensive healthcare data from diverse sources, including government, private, university and military hospitals, as well as public and private clinics. Developed collaboratively by the Health Informatics Centre, Ministry of Health (HIC) and MIMOS Berhad, MyHDW integrates data from systems such as the Client Treatment Information System (SMRP), Patient Registry Information System (PRIS) and e-Reporting system. This integration supports evidence-based planning, decision-making and healthcare analysis by enabling access to extensive and real-time datasets. The SMRP compiles patient demographics, diagnoses and procedures from healthcare facilities, while the PRIS focuses on data related to specific diseases, including cancer and other non-communicable diseases.




Figure 6. Outline of registration procedure

The online cancer registration process in Malaysia's healthcare system is supported by the MyHDW platform (<https://myhdw.moh.gov.my>), as shown in Figure 6. Before a confirmed malignant case is reported, the patient's demographic details and visit information must first be recorded in the SMRP. Once diagnostic investigations are completed and a malignancy is confirmed, the attending physician submits a cancer notification through the M2b module in the SMRP system. Before the notification is transferred to the PRIS, the data must be coded using ICD-10 and ICD-O-3.2 to ensure consistency and accuracy.

The system is integrated with the NRD to verify the patient's National Registration Identity Card (NRIC) number before inclusion in the database. This verification step helps maintain data accuracy and prevents errors in patient identification.

At regular intervals, the HIC extracts the M2b data for the NCR team to review and abstract. The team compiles and updates patient and cancer-related information from all sources to ensure data completeness, followed by quality checks and analyses to maintain high standards of accuracy and reliability according to international standards (Table 4).

Continuous efforts are made to ensure that notifiers and coders are well-trained in completing the M2b form accurately and according to standards. If information is incomplete or incorrect, the form will not be coded. Coders will contact the data providers for clarification and if necessary, the inaccurate M2b form may be deleted and replaced with a corrected submission.

Table 4. MNCR Data Variables and Operational Definitions

No	Demographic Data	Definition / Reference
1	National Identity Number / Other ID	Malaysian NRIC / Official Passport
2	Date of birth	Malaysian NRIC / Official Passport/ conveyed verbally
3	Gender	Malaysian NRIC / Official Passport/ conveyed verbally
4	Citizenship	Malaysian NRIC / Official Passport/ conveyed verbally
5	Ethnic	Malaysian NRIC / Official Passport/ conveyed verbally
6	Address	Residence more than 6 month
Neoplasm Data		Definition / Reference
7	Date of diagnosis (incidence date)	European Network of Cancer Registries (ENCR) criteria
8	Most valid basis of diagnosis	ENCR criteria for basis of diagnosis
9	Topography	Exact anatomical site of primary cancer (ICD-10/ICD-11)
10	Morphology & Grade	Cancer histology as describe by pathologist
11	Behavior	Malignant(3)
12	Stage at diagnosis (at initial diagnosis of cancer)	American Joint Committee for Cancer Staging (AJCC)/TNM
13	Metastasis Site	Site of distant spread

2.3 Quality control

The data are used for epidemiological research and to monitor disease incidence and survival, and it is imperative that they be accurate as possible, so as to provide a true reflection of patterns and trends in cancer occurrence.

To ensure the comparability and accuracy of data, all cases reported to the registry adhere to the recommended standards outlined by the IARC. The facilitation of this process is supported by the utilization of the CanReg5, a software developed by the IARC in collaboration with the International Association for Cancer Registries (IACR).

Definition of Incidence Date: Refers to the guidelines established by the European Network of Cancer Registries (ENCR), as detailed by Tyczynski et al. (2003).

Coding: Topography and morphology conforms to the International Classification of Diseases for Oncology (ICD-O-3), as specified by Fritz et al. (2013).

Multiple Primaries: Registration of multiple primary cancers adheres to the rules delineated by the IARC, International Association of Cancer Registries (IACR) and ENCR (IARC, IACR & ENCR, 2004).

Consistency Check: Internal consistency checks are conducted utilizing the IARC/IACR Check application, originally documented in "Comparability and Quality Control in Cancer Registration" by Parkin et al. (1994). The IARC/IACR Check was developed with the specific purpose of evaluating data submitted for Volume VI of Cancer Incidence in Five Continents (CI5), as detailed by Parkin et al. (1992). This programme encompasses a comprehensive array of data checks typically conducted within registries, focusing on the validity of codes, consistency between gender and site, accuracy of age relative to date of birth, coherence between site and morphology, and alignment of site/histology with age. Notably, the programme's extensive examination of site/morphology combinations serves to promptly identify and reject outright errors, while also flagging improbable or unlikely combinations for further scrutiny.

Morphology verification: Morphology verification involves examining the proportion of cancer records with verified diagnoses, obtained through histology, cytology, imaging, biomarkers, or other diagnostic modalities, including tumours with a specific morphology code.

In addition to the extracted M2b data, pathology reports, hospital discharge records, and mortality records sourced from the NRD are also incorporated. Quality assurance procedures entail a meticulous comparison between the extracted data and the original documents to assess the precision with which information has been abstracted.

The acquisition of death certificate lists from the NRD, as well as from government and private hospitals, is conducted using identical procedures outlined earlier. Cases wherein cancer is noted on the death certificate are meticulously identified, with transcripts of associated reports or certificates being utilized by the registry for validation purposes. In instances where no pertinent information is obtainable, the case is duly registered as Death Certificate Only (DCO), thereby ensuring comprehensive documentation within the registry.

All data provided for this report undergo coding to ICD-O-3 standards, subsequently converted to ICD-10 format utilizing the IARC/IACR Check for subsequent analysis and report generation.

2.4 Data Analysis

All results presented exclusively pertain to Malaysian citizens and residents. Population denominators for the corresponding years were sourced from the DOSM and utilized to compute the rates. For the calculation of age-standardized incidence rates (ASR), Segi's World Population (1960) was employed for direct standardization.

Ethnicity-based analysis was conducted for the three major ethnic groups: Malays, Chinese and Indians, utilizing population denominators provided by DOSM for the respective years. Data analysis was performed using the R statistical software integrated within the CanReg5 software provided by the IARC.

2.4.1 Description of statistical methods

i. Crude incidence rates (CR)

The incidence rates of cancer refers to the count of new cancer cases observed within a given population during a specified period, divided by the corresponding population at risk within the same timeframe. This rate is typically expressed as the number of cases per 100,000 individuals.

$$CR = N / P \times 100,000$$

N - Total number of new cancer cases

P - Mid-period population

ii. Age-specific incidence rates (ASIR)

AR denotes the incidence rates within a specified five-year age group. It is computed by dividing the number of cancer cases occurring within the designated age bracket by the corresponding Malaysian population within that particular age group, and subsequently multiplying by 100,000.

$$AR = N_i / P_i \times 100,000$$

N_i - Number of new cancer occurring in the i^{th} age group

P_i - Population at risk in the i^{th} age group

iii. Age-standardised incidence rates (ASR)

The age-standardised incidence rates (ASR) serves as a vital measure in comparative analysis, compensating for variations in cancer incidence attributable to differences in population age structures. This summary indicator reflects the incidence rates that a given population would exhibit if it possessed a standard age distribution.

To compute the ASR, age-specific rates are aggregated and weighted according to a predetermined world standard population. The resulting calculated incidence rate is then termed the World Standardised incidence rate. Similar to other incidence rates, it is expressed per 100,000 individuals.

$$ASR = \sum (AR_i \times P_{i.std}) / \text{total world standard population}$$

AR_i - Age specific rate in the i^{th} age class

$P_{i.std}$ - The number in the i^{th} age class of world standard population

iv. Standard error (SE)

In the context of population measurements, including incidence rates, inherent variability is expected due to chance factors. This variability is quantified by a statistical metric known as the standard error. It serves as the primary index of the extent of this variability and is calculated according to established statistical methods.

$$SE = \sqrt{\sum_i d_i (w_i / y_i)^2}$$

d_i - Number of cases of the cancer of interest in the age class i

w_i - Standard world population for age class i

y_i - Person-years at risk for age class i

v. 95% Confidence Limit of ASR (95% CL)

Age-standardised incidence rates (ASRs) are susceptible to random fluctuations around the actual underlying rate. To provide a measure of certainty regarding the estimated rate, 95% confidence limits (95% CLs) are employed. These limits delineate the endpoints of a range within which the true incidence rate is anticipated to lie 95% of the time. The computation of 95% CLs entails the utilization of the standard error of the ASR, following a prescribed formula.

$$95\% \text{ CL} = \text{ASR} \pm (1.96 \times \text{SE})$$

vi. Cumulative rate (CR74)

The cumulative rate (CR) is derived from the weighted summation of ASIR up to the attainment of 74 years of age. The weighting methodology applied in this computation is straightforward, entailing the multiplication of the five-year age-gender specific rates per individual by a factor of 5. Subsequently, these products are aggregated across age groups ranging from 0-4 to 70-74. The CR74 serves as an indispensable metric for assessing cumulative risk and is expressed as a percentage.

$$\text{CR74} = 5 \times \sum_i (d_i / y_i) \times 100$$

i - 5-year age groups

d_i - Number of cases in age class i

y_i - Population at risk of age class i

vii. Cumulative risk (CumR)

Cumulative risk is defined as a probability that an individual would develop cancer during a certain age period, in the absence of any competing cause of death. The age period over which the risk is accumulated in this report is 0-74 years. The precise mathematical relationship between the cumulative rate and the cumulative risk is:

$$\text{CumR} = 100 \times [1 - \exp(-\text{CR74}/100)]$$

exp - exponential

viii. Lifetime risk

Lifetime risk is defined as the likelihood that a person who is free of a certain type of cancer will develop or die from that type of cancer during his or her lifetime. Lifetime risk estimates are usually expressed as the odds of developing cancer ('1 in x') or as a percentage.

3.0 RESULTS

3.1 Overall Cancer Incidence

A total of 168,823 new cancer cases were diagnosed in Malaysia for the period of 2017-2021. Of this total, females comprised a significant proportion, accounting for 54% of the cases.

The current database draws from multiple sources, including notifications to the National Cancer Registry up to December 31st, 2023 (accounting for 64.4% of cases), records from pathology departments (16.4%), the hospital discharge records (13.7%), and death records alone (5.5%). Approximately 5% of cases originate from university hospitals, while private hospitals contribute around 10%.

The Age-Standardized Incidence rates (ASR) demonstrated an upward trend during the period 2017-2021. Among the male population, the ASR increased from 86 cases per 100,000 male populations in 2012-2016 to 107 cases per 100,000 male populations in 2017-2021. A similar pattern was observed among females, with the ASR rising from 102 to 120 cases per 100,000 female populations over the same comparative periods.

The cumulative risk (CumR) was 11.9 for male and 12.7 for female, representing the probability of being diagnosed with a cancer before the age of 75, in the absence of other causes of death. The gender gap in cancer incidence is also narrowing, with the latest data showing that both genders now have the same lifetime risk, namely 1 in 8 individuals compared to 1 in 10 men and 1 in 9 women during the period 2012-2016 (Table 5).

Table 5. Incidence summary of new cancer cases by gender, Malaysia, 2017-2021

Gender	No.	%	CR	ASR	CR74	CumR	Lifetime risk
Males	77,692	46.0	103.9	107.3	12.7	11.9	1 in 8
Females	91,131	54.0	125.6	120.8	13.6	12.7	1 in 8
Total	168,823	100.0					

Table 6. Incidence summary by major ethnicity and gender, Malaysia, 2017-2021

Ethnicity	Male				Female			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
Malay	32,010	75.7	84.4	9.4	42,763	103.7	105.9	11.1
Chinese	31,801	181.7	147.9	16.3	30,301	180.9	141.7	15.0
Indian	4,895	97.4	98.2	11.1	7,749	156.6	139.7	15.1
Other Bumiputera	7,300	78.0	87.4	9.8	8,345	91.2	99.7	10.5

Ethnicity-based analysis indicates that the Chinese population has the highest likelihood of being diagnosed with cancer, followed by the Indian and Malay populations. Among the Chinese, the estimated lifetime risk of developing cancer is 1 in 6 for men and 1 in 7 for women. In the Indian population, the lifetime risk is 1 in 9 for men and 1 in 7 for women, while in the Malay population the risk is 1 in 11 for men and 1 in 9 for women. The Other Bumiputera ethnic group have a lifetime risk of 1 in 10 for both men and women. Overall, comparison with previous reporting periods demonstrates an increasing trend in lifetime cancer risk across all major ethnic groups and for both genders in Malaysia.




Figure 7. Comparison of incidence rates by ethnicity and gender, 2007-2021




Figure 8. Number of cases by age group and gender, 2017-2021

Number of cancer cases increased with age with the highest age at diagnosis was within age group of 60-69 years old in males and 55-64 years old in females.

3.1.1 Cancer Trends

The annual cancer incidence in Malaysia during the period 2017-2021 was higher compared to the preceding period of 2007-2016 for both genders, as illustrated in Figure 9. This increase is partly attributed to improvements in cancer case reporting following the introduction of the online notification system in 2018 and the issuance of the Director General of Health's administrative order in 2020 requiring cancer notification. In both periods, the incidence among females consistently exceeded that of males. The lower incidence observed in 2021 may have been influenced by temporary disruptions in routine health services and changes in health-seeking behaviour during the COVID-19 pandemic period.




Figure 9. Annual number and incidence rates by gender, 2007-2021

3.2 Age-specific Incidence rates

Cancer incidence increased with age for both males and females, beginning after 30 years of age (Figure 10). While females experienced higher rates in middle age, males showed a steeper and more pronounced rise in incidence after 60 years, especially in the advanced age groups.




Figure 10. Age-specific incidence rates by gender, all sites, 2017-2021




Figure 11. Age-specific incidence rates for five most common cancers, males, 2017-2021




Figure 12. Age-specific incidence rates for five most common cancers, females, 2017-2021

3.3 Incidence of Ten Most Common Cancers

The ten most common cancers among Malaysian were breast, colorectal, lung, lymphoma, liver, prostate, leukaemia, nasopharynx, corpus uteri and ovary (Table 7 and Figure 13). The top five most common cancers collectively represent more than half of the total cases.

Table 7. Ten most common cancers, all residents, Malaysia, 2017-2021

ICD-10	Sites	No.	%
C50	Breast	29,719	17.6
C18-21	Colorectal	23,871	14.1
C33-34	Lung, Trachea and Bronchus	17,028	10.1
C81-85, C96	Lymphoma	8,793	5.2
C22	Liver	8,256	4.9
C61	Prostate	6,441	3.8
C91-95	Leukaemia	6,265	3.7
C11	Nasopharynx	5,186	3.1
C54	Corpus Uteri	5,087	3.0
C56	Ovary	4,714	2.8
	Others	53,463	31.7
	Total	168,823	100.0




Figure 13. Comparison of ten most common cancers, all residents, 2012-2021

Table 8. Ten most common cancers by gender, all residents, Malaysia, 2017-2021

ICD-10	Sites	No.	%	CR	ASR	CumR	CR74
Male							
C18-21	Colorectal	13,610	17.5	18.2	18.8	2.3	2.3
C33-34	Lung, T&B	11,474	14.8	15.4	16.0	2.0	2.0
C61	Prostate	6,441	8.3	8.6	9.3	1.2	1.2
C22	Liver	6,101	7.9	8.2	8.4	1.1	1.1
C81-85, C96	Lymphoma	5,116	6.6	6.8	6.9	0.7	0.7
C11	Nasopharynx	3,877	5.0	5.2	5.1	0.6	0.6
C91-95	Leukaemia	3,529	4.5	4.7	4.9	0.4	0.4
C44	Non-Melanoma Skin	2,471	3.2	3.3	3.5	0.4	0.4
C16	Stomach	2,444	3.1	3.3	3.4	0.4	0.4
C25	Pancreas	2,162	2.8	2.9	3.0	0.4	0.4
Total all cancers		77,692	100.0	103.9	107.3	11.9	12.7
Female							
C50	Breast	29,534	32.4	40.7	38.9	4.3	4.4
C18-21	Colorectal	10,261	11.3	14.1	13.7	1.6	1.6
C33-34	Lung, T&B	5,554	6.1	7.7	7.4	0.9	0.9
C54	Corpus Uteri	5,087	5.6	7.0	6.7	0.8	0.8
C56	Ovary	4,714	5.2	6.5	6.2	0.7	0.7
C53	Cervix Uteri	4,573	5.0	6.3	6.0	0.6	0.7
C81-85,C96	Lymphoma	3,677	4.0	5.1	4.9	0.5	0.5
C73	Thyroid	3,258	3.6	4.5	4.2	0.4	0.4
C91-95	Leukaemia	2,736	3.0	3.8	3.9	0.3	0.3
C22	Liver	2,155	2.4	3.0	2.9	0.4	0.4
Total all cancers		91,131	100.0	125.6	120.8	12.7	13.6




Figure 14. Incidence rates for ten most common cancers by gender, 2017-2021

3.4 Ethnic Variations

The ASR per 100,000 populations for the ten most common cancers by ethnic group are presented in Table 9 and Table 10. Among males, the incidence rates of most cancers were highest among the Chinese population. In contrast, lymphoma was more commonly observed among Malays and stomach cancer was more common among Indians.

Among females, Indian women showed higher incidence rates of breast cancer, corpus uteri cancer, and leukaemia. Colorectal and lung cancers were more commonly reported among Chinese females, while Malays had higher incidence of lymphoma and thyroid cancer. The highest incidence of cervical cancer was observed among females from the Other Bumiputera group.

Table 9. Incidence rates for ten most common cancers: males by ethnicity, 2017-2021

Sites	ASR per 100,000 population by Ethnicity			
	Malay	Chinese	Indian	Other Bumiputera
Colorectal	14.5	*27.9	17.4	11.4
Lung, Trachea & Bronchus	13.1	*21.9	10.4	13.4
Prostate	6.3	*15.3	9.2	5.5
Liver	6.8	*12.0	6.4	6.2
Lymphoma	*7.3	6.3	5.5	5.7
Nasopharynx	2.6	*9.0	0.8	8.9
Leukaemia	4.7	*5.2	4.7	4.0
Non-Melanoma Skin	2.3	*5.6	1.9	3.1
Stomach	1.6	5.0	*5.1	5.0
Pancreas	1.9	*5.1	3.4	1.4

Note: *Highest ASR observed across ethnic groups for the respective cancer site

Table 10. Incidence rates for ten most common cancers: females by ethnicity, 2017-2021

Sites	ASR per 100,000 population by Ethnicity			
	Malay	Chinese	Indian	Other Bumiputera
Breast	35.8	45.6	*51.3	20.4
Colorectal	11.3	*19.1	12.2	8.7
Lung, Trachea & Bronchus	5.5	*10.7	4.5	8.9
Corpus Uteri	6.3	7.0	*9.3	4.4
Ovary	6.3	*6.4	6.3	4.4
Cervix Uteri	4.5	6.9	5.3	*9.3
Lymphoma	*5.2	4.0	4.3	4.7
Thyroid	*4.8	2.6	3.8	4.3
Leukaemia	3.7	3.8	*4.3	3.4
Liver	2.4	*3.7	2.7	2.8

Note: *Highest ASR observed across ethnic groups for the respective cancer site

Among Malay males, the most common cancers were colorectal, lung, lymphoma, liver and prostate, whereas among Malay females were breast, colorectal, corpus uteri, ovary, cervix uteri and lung cancers.

Table 11. Incidence rates for ten most common cancers: Malay by gender, 2017-2021

ICD-10	Sites	No.	%	CR	ASR	CumR	CR74
Male							
C18-21	Colorectal	5,422	16.9	12.8	14.5	1.8	1.8
C33-34	Lung, Trachea & Bronchus	4,846	15.1	11.5	13.1	1.7	1.7
C81-85,C96	Lymphoma	2,899	9.1	6.9	7.3	0.8	0.8
C22	Liver	2,541	7.9	6.0	6.8	0.9	0.9
C61	Prostate	2,166	6.8	5.1	6.3	0.8	0.8
C91-95	Leukaemia	1,871	5.8	4.4	4.7	0.4	0.4
C67	Bladder	955	3.0	2.3	2.7	0.3	0.3
C11	Nasopharynx	1,035	3.2	2.4	2.6	0.3	0.3
C44	Non-Melanoma Skin	824	2.6	1.9	2.3	0.2	0.2
C25	Pancreas	727	2.3	1.7	1.9	0.2	0.2
Total all cancers		32,010	100.0	75.7	84.4	9.4	9.9
Female							
C50	Breast	14,552	34.0	35.3	35.8	3.9	4.0
C18-21	Colorectal	4,454	10.4	10.8	11.3	1.3	1.4
C54	Corpus Uteri	2,595	6.1	6.3	6.3	0.7	0.7
C56	Ovary	2,548	6.0	6.2	6.3	0.7	0.7
C33-34	Lung, Trachea & Bronchus	2,166	5.1	5.3	5.5	0.7	0.7
C81-85,C96	Lymphoma	2,150	5.0	5.2	5.2	0.6	0.6
C73	Thyroid	2,058	4.8	5.0	4.8	0.5	0.5
C53	Cervix Uteri	1,843	4.3	4.5	4.5	0.5	0.5
C91-95	Leukaemia	1,470	3.4	3.6	3.7	0.3	0.3
C22	Liver	921	2.2	2.2	2.4	0.3	0.3
Total all cancers		42,763	100.0	103.7	105.9	11.1	11.8




Figure 15. Incidence rates for ten most common cancers among Malays by gender, 2017-2021

Among Chinese males, the most common cancers were colorectal, lung, prostate, liver and nasopharynx, whereas among Chinese females were breast, colorectal, lung, corpus uteri and cervix uteri.

Table 12. Incidence rates for ten most common cancers: Chinese by gender, 2017-2021

ICD-10	Sites	No.	%	CR	ASR	CumR	CR74
Male							
C18-21	Colorectal	6,082	19.1	34.8	27.9	3.4	3.4
C33-34	Lung, Trachea & Bronchus	4,762	15.0	27.2	21.9	2.7	2.7
C61	Prostate	3,297	10.4	18.8	15.3	2.0	2.0
C22	Liver	2,600	8.2	14.9	12.0	1.5	1.5
C11	Nasopharynx	1,959	6.2	11.2	9.0	1.0	1.0
C81-85,C96	Lymphoma	1,310	4.1	7.5	6.3	0.7	0.7
C44	Non-Melanoma Skin	1,227	3.9	7.0	5.6	0.6	0.6
C91-95	Leukaemia	998	3.1	5.7	5.2	0.5	0.5
C25	Pancreas	1,111	3.5	6.3	5.1	0.7	0.7
C16	Stomach	1,092	3.4	6.2	5.0	0.6	0.6
Total all cancers		31,801	100.0	181.7	147.9	16.3	17.9
Female							
C50	Breast	9,704	32.0	57.9	45.6	5.2	5.3
C18-21	Colorectal	4,192	13.8	25.0	19.1	2.2	2.2
C33-34	Lung, Trachea & Bronchus	2,351	7.8	14.0	10.7	1.3	1.3
C54	Corpus Uteri	1,491	4.9	8.9	7.0	0.8	0.8
C53	Cervix Uteri	1,471	4.9	8.8	6.9	0.8	0.8
C56	Ovary	1,330	4.4	7.9	6.4	0.7	0.7
C81-85,C96	Lymphoma	812	2.7	4.8	4.0	0.4	0.4
C25	Pancreas	842	2.8	5.0	3.9	0.5	0.5
C91-95	Leukaemia	711	2.3	4.2	3.8	0.4	0.4
C22	Liver	820	2.7	4.9	3.7	0.4	0.4
Total all cancers		30,301	100.0	180.9	141.7	15.0	16.2




Figure 16. Incidence rates for ten most common cancers among Chinese by gender, 2017-2021

Among Indian males, the most common cancers were colorectal, lung, prostate, liver and lymphoma, whereas among Indian females were breast, colorectal, corpus uteri, ovary and cervix uteri.

Table 13. Incidence rates for ten most common cancers: Indian by gender, 2017-2021

ICD-10	Sites	No.	%	CR	ASR	CumR	CR74
Male							
C18-21	Colorectal	866	17.7	17.2	17.4	2.1	2.2
C33-34	Lung, Trachea & Bronchus	514	10.5	10.2	10.4	1.4	1.4
C61	Prostate	424	8.7	8.4	9.2	1.2	1.2
C22	Liver	317	6.5	6.3	6.4	0.8	0.8
C81-85,C96	Lymphoma	290	5.9	5.8	5.5	0.6	0.6
C16	Stomach	261	5.3	5.2	5.1	0.6	0.6
C91-95	Leukaemia	230	4.7	4.6	4.7	0.4	0.4
C25	Pancreas	172	3.5	3.4	3.4	0.4	0.4
C64	Kidney	172	3.5	3.4	3.4	0.4	0.4
C32	Larynx	146	3.0	2.9	2.9	0.4	0.4
	Total all cancers	4,895	100.0	97.4	98.2	11.1	11.8
Female							
C50	Breast	2,896	37.4	58.5	51.3	5.9	6.1
C18-21	Colorectal	670	8.6	13.5	12.2	1.5	1.5
C54	Corpus uteri	526	6.8	10.6	9.3	1.1	1.1
C56	Ovary	354	4.6	7.2	6.3	0.7	0.7
C53	Cervix uteri	297	3.8	6.0	5.3	0.6	0.6
C33-34	Lung, Trachea & Bronchus	248	3.2	5.0	4.5	0.5	0.5
C81-85,C96	Lymphoma	239	3.1	4.8	4.3	0.4	0.4
C91-95	Leukaemia	217	2.8	4.4	4.3	0.4	0.4
C16	Stomach	228	2.9	4.6	4.1	0.5	0.5
C03-06	Mouth	216	2.8	4.4	4.0	0.5	0.5
	Total all cancers	7,749	100.0	156.6	139.7	15.1	16.3




Figure 17. Incidence rates for ten most common cancers among Indians by gender, 2017-2021

Among Other Bumiputera males, the most common cancers were lung, colorectal, nasopharynx, liver and lymphoma, whereas among Other Bumiputera females were breast, cervix uteri, lung, colorectal and lymphoma.

Table 14. Incidence rates for ten most common cancers: Other Bumiputera by gender, 2017-2021

ICD-10	Sites	No.	%	CR	ASR	CumR	CR74
Male							
C33-34	Lung, Trachea & Bronchus	1,087	14.9	11.6	13.4	1.6	1.6
C18-21	Colorectal	945	12.9	10.1	11.4	1.4	1.4
C11	Nasopharynx	779	10.7	8.3	8.9	1.0	1.0
C22	Liver	508	7.0	5.4	6.2	0.8	0.8
C81-85,C96	Lymphoma	500	6.8	5.3	5.7	0.6	0.6
C61	Prostate	426	5.8	4.6	5.5	0.8	0.8
C16	Stomach	414	5.7	4.4	5.0	0.6	0.6
C91-95	Leukaemia	346	4.7	3.7	4.0	0.3	0.3
C44	Non-Melanoma Skin	258	3.5	2.8	3.1	0.3	0.3
C67	Bladder	121	1.7	1.3	1.5	0.2	0.2
Total all cancers		7,300	100.0	78.0	87.4	9.8	10.3
Female							
C50	Breast	1,755	21.0	19.2	20.4	2.2	2.2
C53	Cervix Uteri	800	9.6	8.7	9.3	1.0	1.0
C33-34	Lung, Trachea & Bronchus	698	8.4	7.6	8.9	1.1	1.1
C18-21	Colorectal	709	8.5	7.7	8.7	1.0	1.0
C81-85,C96	Lymphoma	397	4.8	4.3	4.7	0.5	0.5
C54	Corpus Uteri	375	4.5	4.1	4.4	0.5	0.5
C56	Ovary	379	4.5	4.1	4.4	0.5	0.5
C73	Thyroid	387	4.6	4.2	4.3	0.5	0.5
C11	Nasopharynx	339	4.1	3.7	3.9	0.4	0.4
C91-95	Leukaemia	284	3.4	3.1	3.4	0.3	0.3
Total all cancers		8,345	100.0	91.2	99.7	10.5	11.1




Figure 18. Incidence rates for ten most common cancers among Other Bumiputera by gender, 2017-2021

3.5 Staging

Staging was available for 58,635 cases (52.8%) in 2012-2016 and 76,125 cases (45.1%) in 2017-2021. In the first period, 15.5% were stage I, 20.8% stage II, 22.8% stage III and 40.9% stage IV, with 63.7% diagnosed at advanced stages (III-IV). In the latter period, 15.5% were stage I, 19.7% stage II, 24.6% stage III and 40.2% stage IV, with 64.8% diagnosed at advanced stages. While the proportion of stage IV declined slightly, stage III increased, and overall advanced-stage diagnosis remained high. Table 15 summarised the recorded staging for cancers that may be detected by early screening.

Table 15. Stage Distribution of Screen-Detectable Cancers, Malaysia 2012-2021

ICD10	SITES	GENDER	STAGE I (%)		STAGE II (%)		STAGE III (%)		STAGE IV (%)	
			2012-2016	2017-2021	2012-2016	2017-2021	2012-2016	2017-2021	2012-2016	2017-2021
C50	Breast	F	17.5	15.8	34.5	34.5	25.1	28.0	22.8	21.7
C18-C21	Colorectal	M	7.4	7.0	20.2	19.2	32.8	35.7	39.6	38.0
		F	6.6	6.8	20.3	19.7	32.9	38.6	40.2	34.9
C11	Nasopharynx	M	10.1	8.2	20.6	15.6	29.5	29.5	39.8	46.7
		F	9.9	9.0	25.0	18.3	31.1	31.0	33.9	41.6
C61	Prostate	M	13.4	13.8	18.0	22.9	15.4	14.7	53.2	48.6
C53	Cervix Uteri	F	23.7	23.1	35.3	30.3	22.3	25.2	18.7	21.4
C01-C02	Tongue	M	17.4	13.5	19.7	14.7	21.1	18.4	41.9	53.4
		F	16.3	17.3	24.4	18.1	18.4	23.7	41.0	40.8
C03-C06	Mouth	M	10.5	10.3	19.0	16.3	19.0	18.2	51.5	55.2
		F	14.7	6.8	21.0	13.8	18.9	21.2	45.5	58.2
C62	Testis	M	30.8	38.0	21.0	21.0	16.3	18.6	31.9	22.3

3.5.1 Validity

Data quality in this report was assessed based on completeness, comparability, and validity. Validity refers to the proportion of cases in the dataset that genuinely possess the reported attributes. MNCR applied the five standard validity indicators recommended in Cancer Incidence in CI5, as outlined below:

- a) **Internal consistency:** The IARC/IACR Check application was utilised to perform logical and consistency checks on all submitted cases. Queries generated by the software were verified by registry staff prior to incorporating the relevant items into the database.
- b) **Histological verification:** Diagnostic validity is strengthened when supported by histopathology, cytology, or haematology confirmation. MNCR uses morphological verification as the indicator, with **87.6%** of cases (for cancers with specified sites) confirmed morphologically.
- c) **Death Certificate Only (DCO):** In Malaysia, all deaths must be notified to the NRD. Medically certified cancer deaths are cross-checked with health facility records by cancer registrars. Cases with no additional medical record found (DCO) accounted for 8,904 cases, representing 5.3% of all recorded cancers.
- d) **Unknown and ill-defined cases:** Consistent with IARC reporting standards, this indicator reflects the percentage of cancers coded to ill-defined or unspecified primary sites (ICD-10 codes C76–C80). In this report, the proportion was **2.4% (2.8% among males, 2.1% among females)**, indicating good diagnostic precision in identifying the primary site.
- e) **Age unknown:** Accurate age data are essential for valid statistical analyses and interpretation. In this report, all cases had complete age information.

3.6 Age Groups and Cancers

Figures 19–23 present the five most common cancers by gender across age groups. In children (<14 years), leukaemia remained the most frequent cancer (41.0% males, 39.8% females), followed by brain and nervous system tumours (13.7% males, 15.6% females) and lymphoma (13.2% males, 7.4% females), consistent with 2012–2016 patterns.

Among adolescents and young adults (15–24 years), lymphoma continued to predominate in both genders (21.9% males, 20.1% females), with leukaemia, testicular, thyroid and ovarian cancers maintaining similar proportions as in the previous period.

In adults (25–59 years), epithelial cancers dominated; colorectal (17.1%), lung (13.2%) and nasopharynx (8.7%) remained the top cancers in males. In females, breast cancer accounted for nearly two-fifths (39.9%), followed by colorectal (8.4%). A notable change compared to 2012–2016 was the increase in corpus uteri cancer (6.5%) overtaking cervix uteri (6.3%), with cervical cancer showing a slight proportional decline from 7.6% previously.

Among those aged 60–74 years, the leading cancers remained similar: colorectal (19.0%), lung (17.1%) and prostate (11.7%) in males; breast (28.7%), colorectal (14.2%) and lung (8.0%) in females.

In those aged ≥75 years, colorectal cancer continued to lead in both genders (19.1% males, 18.6% females), followed by prostate and lung in males, and breast and lung in females, with breast cancer proportions lower than in younger age groups.

Overall, cancer patterns across age groups have remained broadly consistent over time, with only modest shifts, notably the rising corpus uteri and declining cervical cancer proportions among middle-aged women.




Figure 19. Most common cancers among 0-14 years age group by gender, 2017-2021



Figure 20. Most common cancers among 15-24 years age group by gender, 2017-2021




Figure 21. Most common cancers among 25-59 years age group by gender, 2017-2021




Figure 22. Most common cancers among 60-74 years age group by gender, 2017-2021




Figure 23. Most common cancers among 75 years and above age group by gender, 2017-2021

3.7 International Comparisons




Figure 24. All Sites: International comparisons - Age-standardised incidence rates

Source: **The highest incidence from CI5, Volume XII; *The lowest incidence from CI5, Volume XII; Singapore Cancer Registry Annual Report 2021, National Registry of Diseases Office August 2023

4.0 SUMMARY TABLES

4.1 Incidence Summary Table

Table 16. Incidence summary of all cancer sites by year, ethnicity and state, Malaysia

Year	Total	Male					Female				
		NO.	CR	ASR	(95% CL)	CumR	NO.	CR	ASR	(95% CL)	CumR
2007	20,004	8,969	70.8	89.7	87.8, 91.6	10.1	11,035	89.5	102.6	100.6, 104.5	10.8
2008	20,727	9,383	72.5	90.2	88.3, 92.0	10.1	11,344	89.7	102.3	100.4, 104.2	10.9
2009	20,711	9,495	72.5	87.9	86.1, 89.7	9.9	11,216	88.0	98.4	96.5, 100.2	10.6
2010	21,243	9,571	71.9	85.4	83.7, 87.2	9.7	11,672	90.1	98.8	97.0, 100.6	10.6
2011	20,822	9,376	68.6	80.9	79.2, 82.5	9.3	11,446	87.2	93.8	92.0, 95.5	10.0
2012	22,057	9,728	71.2	81.4	79.7, 83.0	9.2	12,329	92.7	97.9	96.2, 99.7	10.4
2013	22,455	10,211	73.8	82.6	81.0, 84.2	9.5	12,244	90.8	94.3	92.6, 96.0	10.0
2014	23,134	10,450	75.5	84.1	82.5, 85.7	9.6	12,684	94.1	98.0	96.3, 99.7	10.4
2015	23,482	10,436	74.4	81.2	79.6, 82.8	9.2	13,046	95.4	97.6	95.9, 99.2	10.4
2016	24,110	10,680	76.2	83.5	81.9, 85.1	9.5	13,430	98.2	100.5	98.8, 102.2	10.7
2017	34,585	16,121	110.2	117.7	115.9, 119.5	13.1	18,464	130.1	129.0	127.2, 130.9	13.5
2018	33,940	15,627	105.6	111.0	109.2, 112.7	12.2	18,313	127.5	124.6	122.8, 126.4	13.0
2019	34,278	15,647	104.7	108.0	106.3, 109.7	11.9	18,631	128.3	123.4	121.6, 125.2	12.9
2020	34,332	15,729	104.2	104.9	103.2, 106.5	11.7	18,603	126.9	119.1	117.4, 120.9	12.6
2021	31,688	14,568	95.7	94.0	92.5, 95.5	10.5	17,120	115.7	106.7	105.1, 108.3	11.4
Ethnic group (2017-2021)											
Malay	74,773	32,010	75.7	84.4	83.5, 85.4	9.4	42,763	103.7	105.9	104.9, 106.9	11.1
Chinese	62,102	31,801	181.7	147.9	146.2, 149.5	16.3	30,301	180.9	141.7	140.1, 143.4	15.0
Indian	12,644	4,895	97.4	98.2	95.4, 101.0	11.1	7,749	156.6	139.7	136.5, 142.8	15.1
Other Bumiputera	15,645	7,300	78.0	87.4	85.3, 89.4	9.8	8,345	91.2	99.7	97.5, 101.9	10.5
Ethnic group (2012-2016)											
Malay	51,530	21,841	57.4	73.6	72.6, 74.6	8.4	29,689	79.4	90.9	89.8, 91.9	9.5
Chinese	43,825	21,385	127.6	106.1	104.7, 107.6	11.9	22,440	142.1	117.3	115.8, 118.9	12.5
Indian	8,038	2,842	58.1	66.7	64.2, 69.3	7.6	5,196	106.7	106.9	104.0, 109.9	11.7
Other Bumiputera	8,699	4,078	45.0	58.7	56.8, 60.5	6.8	4,621	52.3	65.3	63.4, 67.2	7.1
State (2017-2021)											
Selangor	28,134	12,630	78.5	81.6	80.1, 83.0	9.1	15,504	100.3	98.6	97.0, 100.2	10.3
Johor	22,079	9,963	107.4	114.1	111.8, 116.4	13.2	12,116	149.1	184.6	181.2, 188.0	19.5
Perak	18,248	8,738	147.2	128.3	125.6, 131.0	13.7	9,510	161.5	131.4	128.7, 134.1	13.6
Sarawak	15,650	7,810	131.2	123.8	121.0, 126.6	13.4	7,840	136.5	122.8	120.1, 125.5	12.6
W.P. KL&P	13,495	6,185	132.2	144.4	140.7, 148.1	15.9	7,310	159.6	167.7	163.7, 171.6	17.4
P. Pinang	13,044	5,979	148.6	145.1	141.4, 148.9	15.7	7,065	180.0	154.7	151.1, 158.4	16.2
Sabah	11,422	5,271	79.4	93.9	91.3, 96.4	10.4	6,151	97.0	112.3	109.4, 115.1	11.7
Kedah	11,071	5,058	99.8	96.7	94.0, 99.4	10.8	6,013	118.8	107.2	104.5, 110.0	11.2
Pahang	7,907	3,732	96.7	105.3	101.9, 108.7	11.9	4,175	113.8	117.7	114.1, 121.3	12.5
N. Sembilan	7,322	3,239	113.5	118.3	114.2, 122.4	12.9	4,083	148.3	140.9	136.5, 145.2	14.8
Kelantan	6,918	3,098	71.3	80.2	77.4, 83.1	8.9	3,820	87.8	91.4	88.5, 94.3	9.3
Melaka	6,467	2,907	125.8	140.1	135.0, 145.2	14.8	3,560	157.7	156.3	151.1, 161.5	16.2
Terengganu	5,533	2,459	87.5	107.4	103.1, 111.8	11.6	3,074	111.0	118.6	114.4, 122.8	12.3
Perlis	1,498	668	97.7	101.1	93.3, 108.9	11.2	830	121.3	114.3	106.4, 122.2	12.3
W.P. Labuan	326	139	64.7	89.0	73.9, 104.1	9.6	187	91.4	119.6	101.4, 137.8	13.7

4.2 Staging by Cancer Sites

Table 17. Staging for all cancer types, Malaysia, 2017-2021

ICD-10	SITES	GENDER	TOTAL	No. with recorded stage	% recorded stage	STAGE							
						1	%	2	%	3	%	4	%
C00	Lip	M	25	16	64.0	3	18.8	2	12.5	4	25.0	7	43.8
		F	56	40	71.4	11	27.5	8	20.0	5	12.5	16	40.0
C01-02	Tongue	M	784	511	65.2	69	13.5	75	14.7	94	18.4	273	53.4
		F	583	375	64.3	65	17.3	68	18.1	89	23.7	153	40.8
C03-06	Mouth	M	522	319	61.1	33	10.3	52	16.3	58	18.2	176	55.2
		F	523	340	65.0	23	6.8	47	13.8	72	21.2	198	58.2
C07-08	Salivary Glands	M	393	219	55.7	26	11.9	29	13.2	52	23.7	112	51.1
		F	312	176	56.4	14	8.0	43	24.4	39	22.2	80	45.5
C09	Tonsil	M	182	121	66.5	5	4.1	12	9.9	36	29.8	68	56.2
		F	51	28	54.9	6	21.4	2	7.1	5	17.9	15	53.6
C10	Other Oropharynx	M	113	73	64.6	3	4.1	6	8.2	14	19.2	50	68.5
		F	33	19	57.6	1	5.3	4	21.1	3	15.8	11	57.9
C11	Nasopharynx	M	3,877	2,467	63.6	203	8.2	384	15.6	727	29.5	1,153	46.7
		F	1,309	819	62.6	74	9.0	150	18.3	254	31.0	341	41.6
C12-13	Hypopharynx	M	186	117	62.9	2	1.7	9	7.7	28	23.9	78	66.7
		F	90	58	64.4	0	0	8	13.8	10	17.2	40	69.0
C14	Pharynx Unspecified	M	62	35	56.5	2	5.7	2	5.7	11	31.4	20	57.1
		F	33	17	51.5	1	5.9	5	29.4	3	17.6	8	47.1
C15	Oesophagus	M	1,066	392	36.8	18	4.6	41	10.5	123	31.4	210	53.6
		F	416	155	37.3	5	3.2	25	16.1	46	29.7	79	51.0
C16	Stomach	M	2,444	903	36.9	42	4.7	92	10.2	268	29.7	501	55.5
		F	1,563	657	42.0	37	5.6	69	10.5	177	26.9	374	56.9
C17	Small Intestine	M	378	148	39.2	11	7.4	28	18.9	36	24.3	73	49.3
		F	224	88	39.3	11	12.5	12	13.6	23	26.1	42	47.7
C18-21	Colorectal	M	13,610	7,061	51.9	494	7.0	1,358	19.2	2,524	35.7	2,685	38.0
		F	10,261	5,400	52.6	369	6.8	1,064	19.7	2,082	38.6	1,885	34.9
C22	Liver	M	6,101	1,225	20.1	65	5.3	107	8.7	193	15.8	860	70.2
		F	2,155	440	20.4	31	7.0	44	10.0	74	16.8	291	66.1
C23-24	Gallbladder etc	M	830	293	35.3	27	9.2	43	14.7	61	20.8	162	55.3
		F	751	296	39.4	30	10.1	43	14.5	45	15.2	178	60.1
C25	Pancreas	M	2,162	746	34.5	39	5.2	95	12.7	130	17.4	482	64.6
		F	1,635	611	37.4	41	6.7	80	13.1	105	17.2	385	63.0
C30-31	Nose, Sinuses etc	M	374	193	51.6	20	10.4	19	9.8	40	20.7	114	59.1
		F	193	96	49.7	7	7.3	13	13.5	20	20.8	56	58.3
C32	Larynx	M	1,114	719	64.5	138	19.2	93	12.9	197	27.4	291	40.5
		F	87	49	56.3	9	18.4	3	6.1	11	22.4	26	53.1
C33-34	Lung, Trachea & Bronchus	M	11,474	5,119	44.6	91	1.8	140	2.7	880	17.2	4,008	78.3
		F	5,554	2,804	50.5	64	2.3	82	2.9	349	12.4	2,309	82.3
C37-38	Other Thoracic Organs	M	454	148	32.6	10	6.8	12	8.1	38	25.7	88	59.5
		F	224	109	48.7	12	11.0	14	12.8	15	13.8	68	62.4
C40-41	Bone	M	507	180	35.5	24	13.3	36	20.0	27	15.0	93	51.7
		F	380	140	36.8	18	12.9	26	18.6	22	15.7	74	52.9
C43	Melanoma Of Skin	M	266	104	39.1	8	7.7	15	14.4	29	27.9	52	50.0
		F	242	94	38.8	14	14.9	18	19.1	19	20.2	43	45.7
C44	Non-Melanoma Skin	M	2,471	611	24.7	342	56.0	99	16.2	62	10.1	108	17.7
		F	1,881	482	25.6	308	63.9	74	15.4	43	8.9	57	11.8
C45	Mesothelioma	M	64	29	45.3	0	0	1	3.4	5	17.2	23	79.3
		F	30	14	46.7	0	0	1	7.1	5	35.7	8	57.1
C46	Kaposi Sarcoma	M	109	21	19.3	5	23.8	0	0	3	14.3	13	61.9
		F	12	4	33.3	0	0	1	25.0	0	0	3	75.0
C47,C49	Connective, Soft Tissue	M	875	272	31.1	38	14.0	54	19.9	48	17.6	132	48.5
		F	706	233	33.0	44	18.9	50	21.5	47	20.2	92	39.5
C50	Breast	M	185	94	50.8	13	13.8	27	28.7	19	20.2	35	37.2
		F	29,534	17,101	57.9	2,705	15.8	5,902	34.5	4,783	28.0	3,711	21.7
C51	Vulva	M	190	101	53.2	33	32.7	12	11.9	29	28.7	27	26.7
		F	168	74	44.0	10	13.5	13	17.6	17	23.0	34	45.9
C52	Vagina	M	4,573	2,738	59.9	632	23.1	830	30.3	689	25.2	587	21.4
		F	5,087	3,021	59.4	1,483	49.1	357	11.8	735	24.3	446	14.8
C53	Cervix Uteri	M	1,215	760	62.6	374	49.2	82	10.8	141	18.6	163	21.4
		F	4,714	2,731	57.9	931	34.1	322	11.8	807	29.5	671	24.6
C54	Corpus Uteri	M	409	187	45.7	42	22.5	24	12.8	55	29.4	66	35.3
		F	31	10	32.3	4	40.0	1	10.0	1	10.0	4	40.0
C55	Uterus Unspecified	M	149	52	34.9	12	23.1	16	30.8	13	25.0	11	21.2
		F	6,441	2,922	45.4	403	13.8	669	22.9	429	14.7	1,421	48.6
C56	Ovary	M	898	537	59.8	204	38.0	113	21.0	100	18.6	120	22.3
		F	49	19	38.8	2	10.5	6	31.6	3	15.8	8	42.1
C57	Other Female Genital	M	1,997	900	45.1	219	24.3	129	14.3	117	13.0	435	48.3
		F	889	402	45.2	85	21.1	54	13.4	65	16.2	198	49.3
C58	Placenta	M	53	27	50.9	2	7.4	6	22.2	4	14.8	15	55.6
		F	27	13	48.1	2	15.4	2	15.4	2	15.4	7	53.8
C59	Ureter	M	65	23	35.4	6	26.1	5	21.7	6	26.1	6	26.1
		F	34	19	55.9	2	10.5	5	26.3	3	15.8	9	47.4
C60	Bladder	M	1,933	741	38.3	221	29.8	175	23.6	115	15.5	230	31.0
		F	479	179	37.4	51	28.5	40	22.3	32	17.9	56	31.3
C61	Other Urinary Organs	M	50	18	36.0	4	22.2	2	11.1	4	22.2	8	44.4
		F	25	5	20.0	1	20.0	1	20.0	0	0	3	60.0
C62	Eye	M	127	58	45.7	27	46.6	11	19.0	7	12.1	13	22.4
		F	92	45	48.9	15	33.3	9	20.0	8	17.8	13	28.9
C63	Brain, Nervous System	M	1,300	362	27.8	50	13.8	54	14.9	71	19.6	187	51.7
		F	1,085	278	25.6	45	16.2	52	18.7	43	15.5	138	49.6
C64	Thyroid	M	1,035	459	44.3	135	29.4	74	16.1	85	18.5	165	35.9
		F	3,258	1,380	42.4	662	48.0	293	21.2	152	11.0	273	19.8
C65	Adrenal Gland	M	125	50	40.0	3	6.0	2	4.0	5	10.0	40	80.0
		F	103	38	36.9	2	5.3	4	10.5	5	13.2	27	71.1
C66	Other Endocrine	M	104	20	19.2	6	30.0	2	10.0	3	15.0	9	45.0
		F	48	12	25.0	3	25.0	2	16.7	4	33.3	3	25.0
C67	Lymphoma	M	5,116	1,518	29.7	186	12.3	397	26.2	289	19.0	646	42.6
		F	3,677	1,112	30.2	146	13.1	328	29.5	226	20.3	412	37.1
C68	Immunoproliferative Diseases	M	108	30	27.8	17	56.7	5	16.7	1	3.3	7	23.3
		F	40	19	47.5	10	52.6	4	21.1	1	5.3	4	21.1
C69	Multiple Myeloma	M	767	70	9.1	8	11.4	12	17.1	25	35.7	25	35.7
		F	646	78	12.1	10	12.8	16	20.5	31	39.7	21	26.9
C70-72	Others	M	6,747	1,211	17.9	87	7.2	73	6.0	174	14.4	877	72.4
		F	5503	1,125	20.4	76	6.8	88	7.8	173	15.4	788	70.0
ALL SITES			168,823	76,125	45.1	11,842	15.6	14,977	19.7	18,723	24.6	30,583	40.2

4.3 Quality Indicators

Table 18. Quality indicators for all cancer types, Malaysia, 2017-2021

ICD-10	SITES	TOTAL	QUALITY INDICATOR			
			MV	% MV	DCO	% DCO
C00	Lip	81	80	98.8	0	0.0
C01-02	Tongue	1,367	1,295	94.7	33	2.4
C03-06	Mouth	1,045	1,003	96.0	19	1.8
C07-08	Salivary Glands	705	649	92.1	23	3.3
C09	Tonsil	233	222	95.3	7	3.0
C10	Other Oropharynx	146	138	94.5	3	2.1
C11	Nasopharynx	5,186	4,779	92.2	165	3.2
C12-13	Hypopharynx	276	248	89.9	12	4.3
C14	Pharynx Unspecified	95	88	92.6	3	3.2
C15	Oesophagus	1,482	1,263	85.2	96	6.5
C16	Stomach	4,007	3,439	85.8	245	6.1
C17	Small Intestine	602	543	90.2	32	5.3
C18-21	Colorectal	23,871	21,544	90.3	851	3.6
C22	Liver	8,256	5,687	68.9	1,415	17.1
C23-24	Gallbladder etc	1,581	1,282	81.1	125	7.9
C25	Pancreas	3,797	2,319	61.1	512	13.5
C30-31	Nose, Sinuses etc	567	539	95.1	15	2.6
C32	Larynx	1,201	1,137	94.7	27	2.2
C33-34	Lung, Trachea & Bronchus	17,028	12,453	73.1	1,635	9.6
C37-38	Other Thoracic Organs	678	603	88.9	35	5.2
C40-41	Bone	887	827	93.2	32	3.6
C43	Melanoma Of Skin	508	496	97.6	13	2.6
C44	Non-Melanoma Skin	4,352	4,286	98.5	34	0.8
C45	Mesothelioma	94	87	92.6	7	7.4
C46	Kaposi Sarcoma	121	115	95.0	6	5.0
C47,C49	Connective, Soft Tissue	1,581	1,467	92.8	82	5.2
C50	Breast	29,719	27,608	92.9	736	2.5
C51	Vulva	190	176	92.6	7	3.7
C52	Vagina	168	160	95.2	2	1.2
C53	Cervix Uteri	4,573	4,222	92.3	132	2.9
C54	Corpus Uteri	5,087	4,884	96.0	90	1.8
C55	Uterus Unspecified	1,215	1,105	90.9	53	4.4
C56	Ovary	4,714	4,028	85.4	265	5.6
C57	Other Female Genital	409	378	92.4	14	3.4
C58	Placenta	31	27	87.1	2	6.5
C60	Penis	149	137	91.9	4	2.7
C61	Prostate	6,441	5,665	88.0	263	4.1
C62	Testis	898	829	92.3	36	4.0
C63	Other Male Genital	49	49	100.0	0	0.0
C64	Kidney	2,886	2,643	91.6	135	4.7
C65	Renal Pelvis	80	70	87.5	0	0.0
C66	Ureter	99	89	89.9	4	4.0
C67	Bladder	2,412	2,182	90.5	87	3.6
C68	Other Urinary Organs	75	72	96.0	1	1.3
C69	Eye	219	219	100.0	5	2.3
C70-72	Brain, Nervous System	2,385	2,058	86.3	107	4.5
C73	Thyroid	4,293	4,095	95.4	90	2.1
C74	Adrenal Gland	228	186	81.6	14	6.1
C75	Other Endocrine	152	143	94.1	1	0.7
C81-85,C96	Lymphoma	8,793	8,461	96.2	325	3.7
C88	Immunoproliferative Diseases	148	147	99.3	0	0.0
C90	Multiple Myeloma	1,413	1,317	93.2	93	6.6
C91-95	Leukaemia	6,265	5,918	94.5	405	6.5
	Others	5,985	4,452	74.4	606	10.1
	ALL SITES	168,823	147,909	87.6	8,904	5.3

* Percentage of cases registered on the basis of information from a death certificate only (DCO) and morphological verification (MV) which is based on cytology or histology (of the primary tumor, or a metastasis).

5.0 COMMENTARY ON SELECTED CANCER SITES

This section provides an in-depth review of ten selected cancers, focusing on ethnic variations, stage at diagnosis, ASIRs, and annual trends. International comparisons are included where possible, based on the most recent and available standardised and comparable sources: the Singapore Cancer Registry Annual Report 2021 (National Registry of Diseases Office, August 2023) and the Cancer Incidence in Five Continents, Volume XII (International Agency for Research on Cancer, 2024). These references were used as they offer internationally validated data that enable meaningful benchmarking of Malaysia's cancer burden against other populations. The ten cancers discussed are the most common sites combined for males and females.

5.1 Female Breast (ICD-10: C50)

A total of 29,534 female breast cancer cases were registered during the period 2017-2021, reaffirming breast cancer as the most common malignancy in Malaysia. It accounted for 32.4% of all cancers among females. The ASR increased from 34.1 to 38.9 per 100,000 population compared to the previous report. The ASIR began to increase from age 25 years, peaked at 65-69 years, and declined thereafter. The incidence was highest among Indians, followed by Chinese and Malays.

The overall lifetime risk of developing breast cancer was 1 in 23, compared to 1 in 27 previously. The highest lifetime risk was observed among Indians (1 in 17), followed by Chinese (1 in 19), Malays (1 in 26), and Other Bumiputera (1 in 45). Among cases with available staging information, 49.7% were diagnosed at late stages (Stage III and IV).

Table 19. Female Breast: Cancer incidence summary by year, Malaysia

All residents	No.	CR	ASR	CumR
2007-2011	18,206	28.6	31.1	3.4
2012-2016	21,634	32.5	34.1	3.7
2017-2021	29,534	40.7	38.9	4.3
2017	6,034	42.5	41.8	4.6
2018	6,004	41.8	40.6	4.5
2019	5,870	40.4	38.6	4.3
2020	6,053	41.3	38.4	4.3
2021	5,573	37.7	34.5	3.9

Table 20. Female Breast: Incidence summary by year and ethnicity, Malaysia

Year	No.	CR	ASR	CumR					
					No.	CR	ASR	CumR	
					Malay		Indian		
2007-2011	8,225	23.6	27.2	2.9	1,705	36.0	37.1	4.2	
2012-2016	10,455	28.0	31.5	3.4	1,910	39.2	38.1	4.4	
2017-2021	14,552	35.3	35.8	3.9	2,896	58.5	51.3	5.9	
					Chinese		Other Bumiputera		
2007-2011	7,333	47.5	41.5	4.5	651	8.1	10.5	1.1	
2012-2016	7,759	49.1	40.7	4.5	1,027	11.6	14.0	1.5	
2017-2021	9,704	57.9	45.6	5.2	1,755	19.2	20.4	2.2	




Figure 25. Female Breast: Comparison of age-standardised incidence rates by year and ethnicity




Figure 26. Female Breast: Comparison of age-specific incidence rates by year




Figure 27. Female Breast: Comparison of staging percentage by year




Figure 28. Female Breast: International comparisons – Age-standardised incidence rates

Source: **The highest incidence from CI5, Volume XII; *The lowest incidence from CI5, Volume XII;
 ^^Singapore Cancer Registry Annual Report 2021, National Registry of Diseases Office August 2023

5.2 Colorectal (ICD-10: C18-C21)

A total of 23,871 colorectal cancer cases were registered during the period 2017-2021, compared to 15,515 cases reported in 2012-2016. Of these, 57.0% occurred among males and 43.0% among females. Colorectal cancer ranked as the most common cancer among males and the second most common among females. The incidence was highest among Chinese, followed by Indians, for both genders. In both genders, the ASIR increased progressively with advancing age and consistently higher compared to previous report.

The overall lifetime risk for males was 1 in 43, with the highest risk among Chinese (1 in 29), followed by Indians (1 in 48), Malays (1 in 56), and Other Bumiputera (1 in 71). Among females, the lifetime risk was 1 in 63, with Chinese (1 in 45) having the highest risk, followed by Indians (1 in 67), Malays (1 in 77), and Other Bumiputera (1 in 100). Among cases with available staging information, 73.8% of males and 73.5% of females were diagnosed at late stages (Stage III and IV).

Table 21. Colorectal: Cancer incidence summary by year, Malaysia

All residents	Male				Female			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
2007-2011	7,646	11.7	14.6	1.8	6,047	9.5	11.1	1.3
2012-2016	8,701	12.7	14.8	1.8	6,814	10.2	11.1	1.3
2017-2021	13,610	18.2	18.8	2.3	10,261	14.1	13.7	1.6
2017	2,801	19.1	20.5	2.5	2,040	14.4	14.5	1.7
2018	2,764	18.7	19.7	2.4	2,065	14.4	14.2	1.6
2019	2,756	18.4	19.0	2.3	2,110	14.5	14.0	1.6
2020	2,664	17.6	17.8	2.2	2,044	13.9	13.1	1.5
2021	2,625	17.2	16.9	2.1	2,002	13.5	12.4	1.5

Table 22. Colorectal: Incidence summary by gender, year and ethnicity, Malaysia

Ethnic	Year	Male				Female			
		No.	CR	ASR	CumR	No.	CR	ASR	CumR
Malay	2007-2011	2,872	8.1	11.3	1.4	2,231	6.4	8.1	1.0
	2012-2016	3,493	9.2	12.2	1.5	2,912	7.8	9.4	1.1
	2017-2021	5,422	12.8	14.5	1.8	4,454	10.8	11.3	1.3
Chinese	2007-2011	3,825	23.3	21.1	2.5	3,023	19.6	17.1	2.0
	2012-2016	4,008	23.9	19.6	2.3	2,990	18.9	15.2	1.8
	2017-2021	6,082	34.8	27.9	3.4	4,192	25.0	19.1	2.2
Indian	2007-2011	389	8.1	10.3	1.2	364	7.7	8.7	1.1
	2012-2016	470	9.6	11.0	1.4	401	8.2	8.5	1.1
	2017-2021	866	17.2	17.4	2.1	670	13.5	12.2	1.5
Other Bumi	2007-2011	380	4.6	6.8	0.8	313	3.9	5.7	0.7
	2012-2016	492	5.4	7.3	0.9	353	4.0	5.3	0.7
	2017-2021	945	10.1	11.4	1.4	709	7.7	8.7	1.0





Figure 29. Colorectal: Comparison of age-standardised incidence rates by year, ethnicity and gender




Figure 30. Colorectal: Comparison of age-specific incidence rates by year in males




Figure 31. Colorectal: Comparison of age-specific incidence rates by year in females





Figure 32. Colorectal: Comparison of staging percentage by year and gender





Figure 33. Colorectal: International comparisons - Age-standardised incidence rates

Source: **The highest incidence from CI5, Volume XI; *The lowest incidence from CI5, Volume XI;
 ^^Singapore Cancer Registry Annual Report 2021, National Registry of Diseases Office August 2023

5.3 Lung, Trachea and Bronchus (ICD-10: C33-C34)

A total of 17,028 cases of lung, trachea, and bronchus cancers were registered during the period 2017-2021, compared to 11,256 cases reported in 2012-2016. Of these, 67.4% occurred among males and 32.6% among females. Lung cancer ranked as the second most common cancer among males and the third most common among females. The overall lifetime risk for males was 1 in 50, with the highest risk observed among Chinese (1 in 37), followed by Malays (1 in 59), Other Bumiputera (1 in 63), and Indians (1 in 71). For females, the lifetime risk was 1 in 111, with Chinese (1 in 77) having the highest risk, followed by Other Bumiputera (1 in 91), Malays (1 in 143) and Indians (1 in 200). The ASIR increased progressively with advancing age. Among cases with available staging information, 95% were diagnosed at late stages (Stage III and IV).

Table 23. Lung, Trachea and Bronchus: Cancer incidence summary by year, Malaysia

All residents	Male				Female			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
2007-2011	7,415	11.3	14.4	1.8	3,193	5.0	6.0	0.7
2012-2016	7,686	11.3	13.2	1.7	3,570	5.4	5.9	0.7
2017-2021	11,474	15.4	16.0	2.0	5,554	7.7	7.4	0.9
2017	2,314	15.8	17.1	2.1	1,108	7.8	7.9	1.0
2018	2,335	15.8	16.8	2.1	1,137	7.9	7.8	0.9
2019	2,388	16.0	16.6	2.0	1,177	8.1	7.9	0.9
2020	2,357	15.6	15.8	2.0	1,169	8.0	7.5	0.9
2021	2,080	13.7	13.4	1.7	963	6.5	6.0	0.7

Table 24. Lung, Trachea and Bronchus: Incidence summary by gender, year and ethnicity, Malaysia

Ethnic	Year	Male				Female			
		No.	CR	ASR	CumR	No.	CR	ASR	CumR
Malay	2007-2011	3,094	8.8	12.6	1.6	1,187	3.4	4.4	0.5
	2012-2016	3,500	9.2	12.5	1.6	1,492	4.0	4.9	0.6
	2017-2021	4,846	11.5	13.1	1.7	2,166	5.3	5.5	0.7
Chinese	2007-2011	3,390	20.6	18.8	2.3	1,486	9.6	8.5	1.0
	2012-2016	3,258	19.4	16.0	2.0	1,537	9.7	7.8	0.9
	2017-2021	4,762	27.2	21.9	2.7	2,351	14.0	10.7	1.3
Indian	2007-2011	270	5.6	7.6	1.0	127	2.7	3.1	0.4
	2012-2016	239	4.9	5.7	0.7	135	2.8	3.0	0.4
	2017-2021	514	10.2	10.4	1.4	248	5.0	4.5	0.5
Other Bumi	2007-2011	486	5.9	9.4	1.2	329	4.1	6.6	0.9
	2012-2016	514	5.7	7.9	1.0	321	3.6	5.1	0.7
	2017-2021	1087	11.6	13.4	1.6	698	7.6	8.9	1.1





Figure 34. Lung, Trachea and Bronchus: Comparison of age-standardised incidence rates by year, ethnicity and gender





Figure 35. Lung, Trachea and Bronchus: Age-specific incidence rates by year and gender





Figure 36. Lung, Trachea and Bronchus: Staging percentage by year and gender





Figure 37. Lung, Trachea and Bronchus: International comparisons - Age-standardised incidence rates

Source: **The highest incidence from CI5, Volume XII ; *The lowest incidence from CI5, Volume XI; ^^Singapore Cancer Registry Annual Report 2021, National Registry of Diseases Office August 2023

5.4 Lymphoma (ICD-10: C81-C85, C96)

A total of 8,793 lymphoma cases were registered during the period 2017-2021, compared to 5,830 cases reported in 2012-2016. Of these, 58.2% occurred among males and 41.8% among females. Lymphoma ranked as the fifth most common cancer among males and the seventh among females. The incidence was highest among Malays for both genders. The overall lifetime risk for males was 1 in 143, with Malays (1 in 125) having the highest risk, followed by Chinese (1 in 143), Indians (1 in 167), and Other Bumiputera (1 in 167). For females, the lifetime risk was 1 in 200, with Malays (1 in 200) and Other Bumiputera (1 in 200) showing higher risk compared to Chinese (1 in 250) and Indians (1 in 250). The ASIR gradually increased up to 50 years of age, followed with prominent rise in advanced age. Among cases with available staging information, 61.6% of males and 57.4% of females were diagnosed at late stages (Stage III and IV).

Table 25. Lymphoma: Cancer incidence summary by year, Malaysia

All residents	Male				Female			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
2007-2011	3,171	4.8	5.5	0.6	2,203	3.5	3.8	0.4
2012-2016	3,412	5.0	5.3	0.6	2,418	3.6	3.8	0.4
2017-2021	5,116	6.8	6.9	0.7	3,677	5.1	4.9	0.5
2017	1,122	7.7	7.9	0.9	729	5.1	5.1	0.5
2018	966	6.5	6.6	0.7	686	4.8	4.6	0.5
2019	1,031	6.9	6.9	0.8	701	4.8	4.6	0.5
2020	1,021	6.8	6.7	0.7	821	5.6	5.3	0.6
2021	938	6.2	6.0	0.6	720	4.9	4.5	0.5

Table 26. Lymphoma: Incidence summary by gender, year and ethnicity, Malaysia

Ethnic	Year	Male				Female			
		No.	CR	ASR	CumR	No.	CR	ASR	CumR
Malay	2007-2011	1,639	4.6	5.6	0.6	1,412	3.3	3.7	0.4
	2012-2016	1,866	4.9	5.6	0.6	1,354	3.6	3.9	0.4
	2017-2021	2,899	6.9	7.3	0.8	2,150	5.2	5.2	0.5
Chinese	2007-2011	908	5.5	5.0	0.6	639	4.1	3.7	0.4
	2012-2016	943	5.6	4.8	0.5	602	3.8	3.2	0.4
	2017-2021	1,310	7.5	6.3	0.7	812	4.8	4.0	0.4
Indian	2007-2011	187	3.9	4.2	0.4	130	2.7	3.0	0.4
	2012-2016	178	3.6	3.7	0.4	151	3.1	3.0	0.3
	2017-2021	290	5.8	5.5	0.6	239	4.8	4.3	0.4
Other Bumi	2007-2011	319	3.9	5.3	0.6	215	2.7	3.6	0.4
	2012-2016	303	3.3	4.0	0.4	234	2.6	3.2	0.4
	2017-2021	500	5.3	5.7	0.6	397	4.3	4.7	0.5





Figure 38. Lymphoma: Comparison of age-standardised incidence rates by year, ethnicity and gender





Figure 39. Lymphoma: Staging percentage by year and gender

Table 27. Lymphoma: Incidence summary by type, gender, year and ethnicity, Malaysia

Ethnic	Year	Male			Female		
		Hodgkin Disease					
		No.	CR	ASR	No.	CR	ASR
All Residents	2007-2011	379	0.6	0.6	279	0.4	0.4
	2012-2016	586	0.9	0.8	409	0.6	0.6
	2017-2021	840	1.1	1.1	646	0.9	0.8
Malay	2007-2011	226	0.6	0.6	164	0.5	0.4
	2012-2016	336	0.9	0.9	255	0.7	0.6
	2017-2021	534	1.3	1.2	441	1.1	1.0
Chinese	2007-2011	78	0.5	0.4	70	0.5	0.4
	2012-2016	125	0.8	0.7	67	0.4	0.4
	2017-2021	141	0.8	0.7	81	0.5	0.5
Indian	2007-2011	31	0.6	0.7	25	0.5	0.5
	2012-2016	61	1.3	1.2	39	0.8	0.7
	2017-2021	80	1.6	1.5	69	1.4	1.3
Other Bumi	2007-2011	31	0.4	0.4	13	0.2	0.2
	2012-2016	50	0.6	0.6	36	0.4	0.4
	2017-2021	71	0.8	0.7	47	0.5	0.5

Ethnic	Year	Non-Hodgkin Lymphoma					
		No.	CR	ASR	No.	CR	ASR
All Residents	2007-2011	2,792	4.3	4.9	1,924	3.0	3.3
	2012-2016	2,826	4.1	4.5	2,009	3.0	3.2
	2017-2021	4,276	5.7	5.8	3,031	4.2	4.0
Malay	2007-2011	1,413	4.0	5.0	978	2.8	3.3
	2012-2016	1,530	4.0	4.8	1,099	2.9	3.3
	2017-2021	2,365	5.6	6.1	1,709	4.1	4.2
Chinese	2007-2011	830	5.1	4.5	569	3.7	3.3
	2012-2016	818	4.9	4.1	535	3.4	2.9
	2017-2021	1,169	6.7	5.5	731	4.4	3.5
Indian	2007-2011	156	3.3	3.5	105	2.2	2.5
	2012-2016	117	2.4	2.5	112	2.3	2.3
	2017-2021	210	4.2	4.0	170	3.4	3.1
Other Bumi	2007-2011	288	3.5	4.8	202	2.5	3.5
	2012-2016	253	2.8	3.4	198	2.2	2.8
	2017-2021	429	4.6	5.0	350	3.8	4.2




Figure 40. Hodgkin Disease: Age-specific incidence rates by year and gender




Figure 41. Non-Hodgkin Lymphoma: Age-specific incidence rates by year and gender





Figure 42. Hodgkin lymphoma: International comparisons - Age-standardised incidence rates

Source: **The highest incidence from CI5, Volume XII; *The lowest incidence from CI5, Volume XII;





Figure 43. Non-Hodgkin lymphoma: International comparisons - Age-standardised incidence rates

Source: **The highest incidence from CI5, Volume XII ; *The lowest incidence from CI5, Volume XII;

5.5 Leukaemia (ICD-10: C91-C95)

A total of 6,265 leukaemia cases were registered during the period 2017-2021, compared to 4,273 cases reported in 2012-2016. Of these, 56.3% occurred among males and 43.7% among females. Leukaemia ranked as the seventh most common cancer in Malaysia and among males, and the ninth among females. The incidence was highest among Chinese males and Indian females. The overall lifetime risk for males was 1 in 250, with Chinese (1 in 200) having the highest risk, followed by Indians and Malays (1 in 250) and Other Bumiputera (1 in 333). For females, the lifetime risk was 1 in 333, with Chinese and Indians showing higher risk (1 in 250), compared to Malays and Other Bumiputera (1 in 333).

The ASIR demonstrated a bimodal pattern, with a higher incidence observed in childhood (0-9 years), followed by a decline in young adults and a steady increase from middle age onward, reaching the highest rates among individuals aged 70 years and above. The incidence was higher among males than females across most age groups. The overall incidence during 2017-2021 was higher than that observed in 2012-2016.

Table 28. Leukaemia: Cancer incidence summary by year, Malaysia

All residents	Male				Female			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
2007-2011	2,549	3.9	4.2	0.4	2,024	3.2	3.4	0.3
2012-2016	2,414	3.5	3.8	0.3	1,859	2.8	3.0	0.3
2017-2021	3,529	4.7	4.9	0.4	2,736	3.8	3.9	0.3
2017	809	5.5	5.8	0.6	627	4.4	4.5	0.4
2018	678	4.6	4.8	0.4	526	3.7	3.8	0.3
2019	633	4.2	4.4	0.4	509	3.5	3.6	0.3
2020	680	4.5	4.6	0.4	510	3.5	3.5	0.3
2021	729	4.8	5.0	0.4	564	3.8	3.8	0.3

Table 29. Leukaemia: Incidence summary by gender, year and ethnicity, Malaysia

Ethnic	Year	Male				Female			
		No.	CR	ASR	CumR	No.	CR	ASR	CumR
Malay	2007-2011	1,419	4.0	4.4	0.4	1,119	3.2	3.5	0.3
	2012-2016	1,352	3.6	3.9	0.3	1,019	2.7	2.9	0.2
	2017-2021	1,871	4.4	4.7	0.4	1,470	3.6	3.7	0.3
Chinese	2007-2011	657	4.0	4.0	0.3	527	3.4	3.4	0.3
	2012-2016	661	3.9	3.8	0.3	492	3.1	2.9	0.3
	2017-2021	998	5.7	5.2	0.5	711	4.2	3.8	0.4
Indian	2007-2011	171	3.6	3.8	0.3	137	2.9	3.0	0.3
	2012-2016	129	2.6	2.8	0.2	123	2.5	2.6	0.3
	2017-2021	230	4.6	4.7	0.4	217	4.4	4.3	0.4
Other Bumi	2007-2011	217	2.6	3.0	0.3	166	2.1	2.4	0.2
	2012-2016	187	2.1	2.2	0.2	162	1.8	2.1	0.2
	2017-2021	346	3.7	4.0	0.3	284	3.1	3.4	0.3





Figure 44. Leukaemia: Comparison of age-standardised incidence rates by year, ethnicity and gender

Table 30. Leukaemia: Incidence summary by type, gender, year and ethnicity, Malaysia

Ethnic	Year	Male			Female		
		Lymphoid Leukaemia					
		No.	CR	ASR	No.	CR	ASR
All Residents	2007-2011	779	1.2	1.3	524	0.8	0.9
	2012-2016	771	1.1	1.2	542	0.8	0.9
	2017-2021	1,081	1.4	1.6	795	1.1	1.2
Malay	2007-2011	381	1.1	1.1	259	0.7	0.8
	2012-2016	441	1.2	1.2	289	0.8	0.8
	2017-2021	601	1.4	1.5	459	1.1	1.2
Chinese	2007-2011	204	1.2	1.4	133	0.9	1.0
	2012-2016	181	1.1	1.2	135	0.9	0.9
	2017-2021	256	1.5	1.5	177	1.1	1.1
Indian	2007-2011	67	1.4	1.5	45	0.9	1.0
	2012-2016	43	0.9	1.1	39	0.8	0.9
	2017-2021	84	1.7	1.9	59	1.2	1.3
Other Bumi	2007-2011	93	1.1	1.2	55	0.7	0.7
	2012-2016	74	0.8	0.9	58	0.7	0.7
	2017-2021	116	1.2	1.4	87	1.0	1.1

Ethnic	Year	Myeloid Leukaemia					
		No.	CR	ASR	No.	CR	ASR
All Residents	2007-2011	1,328	2.0	2.2	1,149	1.8	1.9
	2012-2016	1,279	1.9	2.0	1,080	1.6	1.7
	2017-2021	2,034	2.7	2.7	1,646	2.3	2.2
Malay	2007-2011	704	2.0	2.3	626	1.8	2.0
	2012-2016	654	1.7	1.9	560	1.5	1.6
	2017-2021	1,033	2.4	2.6	847	2.1	2.1
Chinese	2007-2011	383	2.3	2.2	314	2.0	1.9
	2012-2016	405	2.4	2.2	313	2.0	1.7
	2017-2021	619	3.5	3.1	461	2.8	2.3
Indian	2007-2011	89	1.9	2.0	72	1.5	1.5
	2012-2016	71	1.5	1.4	71	1.5	1.4
	2017-2021	128	2.5	2.4	133	2.7	2.5
Other Bumi	2007-2011	108	1.3	1.6	98	1.2	1.5
	2012-2016	105	1.2	1.3	96	1.1	1.3
	2017-2021	205	2.2	2.3	172	1.9	2.0

Ethnic	Year	Leukaemia Unspecified					
		No.	CR	ASR	No.	CR	ASR
All Residents	2007-2011	442	0.7	0.7	351	0.6	0.6
	2012-2016	364	0.5	0.6	237	0.4	0.4
	2017-2021	414	0.6	0.6	295	0.4	0.4
Malay	2007-2011	334	0.9	1.0	234	0.7	0.7
	2012-2016	257	0.7	0.8	170	0.5	0.5
	2017-2021	237	0.6	0.6	164	0.4	0.4
Chinese	2007-2011	70	0.4	0.5	80	0.5	0.5
	2012-2016	75	0.5	0.5	44	0.3	0.3
	2017-2021	123	0.7	0.6	73	0.4	0.4
Indian	2007-2011	15	0.3	0.3	20	0.4	0.5
	2012-2016	15	0.3	0.3	13	0.3	0.3
	2017-2021	18	0.4	0.4	25	0.5	0.5
Other Bumi	2007-2011	16	0.2	0.2	13	0.2	0.2
	2012-2016	8	0.1	0.1	8	0.1	0.1
	2017-2021	25	0.3	0.3	25	0.3	0.3

Myeloid Leukaemia




Figure 45. Myeloid Leukaemia: Age-specific incidence rates by year and gender

Lymphoid Leukaemia




Figure 46. Lymphoid Leukaemia: Age-specific incidence rates by year and gender





Figure 47. Leukaemia: International comparisons - Age-standardised incidence rates

Source: **The highest incidence from CI5, Volume XII ; *The lowest incidence from CI5, Volume XII;

5.6 Nasopharynx (ICD-10: C11)

A total of 5,186 nasopharynx cancer cases were registered during the period 2017-2021, compared to 4,597 cases reported in 2012-2016. Of these, 74.8% occurred among males and 25.2% among females. Nasopharynx cancer ranked as the sixth most common cancer among males. The overall lifetime risk for males was 1 in 167, with the highest risk observed among Chinese and Other Bumiputera (1 in 100). For females, the lifetime risk was 1 in 500, with the highest risk observed among Other Bumiputera females (1 in 250). The ASIR among males began to increase after 25 years of age, peaking at the 60-64 years age group. Among cases with available staging information, 76.2% of males and 72.6% of females were diagnosed at late stages (Stage III and IV).

Table 31. Nasopharynx: Cancer incidence summary by year, Malaysia

All residents	Male				Female			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
2007-2011	3,785	5.8	6.4	0.7	1,305	2.0	2.2	0.2
2012-2016	3,359	4.9	5.2	0.6	1,238	1.9	1.9	0.2
2017-2021	3,877	5.2	5.1	0.6	1,309	1.8	1.7	0.2
2017	837	5.7	5.8	0.7	299	2.1	2.0	0.2
2018	873	5.9	5.9	0.6	275	1.9	1.8	0.2
2019	782	5.2	5.2	0.6	261	1.8	1.7	0.2
2020	711	4.7	4.5	0.5	255	1.7	1.6	0.2
2021	674	4.4	4.2	0.5	219	1.5	1.4	0.1

Table 32. Nasopharynx: Incidence summary by gender, year and ethnicity, Malaysia

Ethnic	Year	Male				Female			
		No.	CR	ASR	CumR	No.	CR	ASR	CumR
Malay	2007-2011	959	2.7	3.3	0.4	401	1.2	1.3	0.1
	2012-2016	862	2.3	2.7	0.3	383	1.0	1.1	0.1
	2017-2021	1,035	2.4	2.6	0.3	408	1.0	1.0	0.1
Chinese	2007-2011	2,104	12.8	11.0	1.2	611	4.0	3.5	0.4
	2012-2016	1,748	10.4	8.6	0.9	549	3.5	2.9	0.3
	2017-2021	1,959	11.2	9.0	1.0	525	3.1	2.5	0.3
Indian	2007-2011	44	0.9	1.1	0.1	25	0.5	0.6	0.1
	2012-2016	25	0.5	0.6	0.1	18	0.4	0.4	<0.1
	2017-2021	40	0.8	0.8	0.1	12	0.2	0.2	<0.1
Other Bumi	2007-2011	591	7.2	9.2	1.0	242	3.0	3.8	0.4
	2012-2016	659	7.3	8.6	0.9	256	2.9	3.5	0.4
	2017-2021	779	8.3	8.9	1.0	339	3.7	3.9	0.4





Figure 48. Nasopharynx: Comparison of age-standardised incidence rates by year, ethnicity and gender





Figure 49. Nasopharynx: Age-specific incidence rates by year and gender





Figure 50. Nasopharynx: Staging percentage by year and gender





Figure 51. Nasopharynx: International comparisons - Age-standardised incidence rates

Source: **The highest incidence from CI5, Volume XII; *The lowest incidence from CI5, Volume XII;

5.7 Liver (ICD-10: C22)

A total of 8,256 liver cancer cases were registered during the period 2017-2021, compared to 4,033 cases reported in 2012-2016. Of these, 73.9% occurred among males and 26.1% among females. Liver cancer ranked as the fifth most common cancer in Malaysia, the fourth among males, and the tenth among females.

The ASIR increased progressively with advancing age, peaking at the 70-74 years age group. The incidence was consistently higher among males compared to females, with Chinese showing the highest rates among all ethnic groups. The overall lifetime risk was 1 in 91 for males and 1 in 250 for females. Among the Chinese, the lifetime risk was 1 in 67 for males and 1 in 250 for females. Among cases with available staging information, 86.0% of males and 82.90% of females were diagnosed at late stages (Stage III and IV).

Table 33. Liver: Cancer incidence summary by year, Malaysia

All residents	Male				Female			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
2007-2011	3,054	4.7	5.6	0.7	1,074	1.7	2.0	0.2
2012-2016	2,949	4.3	4.9	0.6	1,084	1.6	1.8	0.2
2017-2021	6,101	8.2	8.4	1.1	2,155	3.0	2.9	0.4
2017	1,160	7.9	8.5	1.1	398	2.8	2.9	0.3
2018	1,248	8.4	8.8	1.1	431	3.0	3.0	0.4
2019	1,185	7.9	8.2	1.0	455	3.1	3.1	0.4
2020	1,307	8.7	8.7	1.1	459	3.1	3.0	0.4
2021	1,201	7.9	7.8	1.0	412	2.8	2.6	0.3

Table 34. Liver: Incidence summary by gender, year and ethnicity, Malaysia

Ethnic	Year	Male				Female			
		No.	CR	ASR	CumR	No.	CR	ASR	CumR
Malay	2007-2011	1,195	3.4	4.5	0.5	477	1.4	1.7	0.2
	2012-2016	1,263	3.3	4.3	0.5	517	1.4	1.7	0.2
	2017-2021	2,541	6.0	6.8	0.9	921	2.2	2.4	0.3
Chinese	2007-2011	1,416	8.6	7.7	0.9	411	2.7	2.3	0.3
	2012-2016	1,284	7.7	6.3	0.8	411	2.6	2.2	0.3
	2017-2021	2,600	14.9	12.0	1.5	820	4.9	3.7	0.4
Indian	2007-2011	114	2.4	3.1	0.4	58	1.2	1.5	0.2
	2012-2016	147	3.0	3.5	0.4	63	1.3	1.4	0.2
	2017-2021	317	6.3	6.4	0.8	147	3.0	2.7	0.3
Other Bumi	2007-2011	228	2.8	4.3	0.6	86	1.1	1.7	0.2
	2012-2016	183	2.0	2.7	0.3	67	0.8	1.1	0.1
	2017-2021	508	5.4	6.2	0.8	219	2.4	2.8	0.4





Figure 52. Liver: Comparison of age-standardised incidence rates by year, ethnicity and gender





Figure 53. Liver: Age-specific incidence rates by year and gender





Figure 54. Liver: Staging percentage by year and gender




Figure 55. Liver: International comparisons - Age-standardised incidence rates

Source: **The highest incidence from CI5, Volume XII; *The lowest incidence from CI5, Volume XII;

^^Singapore Cancer Registry Annual Report 2021, National Registry of Diseases Office August 2023; NA: Not Available

5.8 Stomach and Oesophagus (ICD-10: C15-C16)

A total of 4,007 stomach cancer cases were registered during the period 2017-2021, compared to 3,006 cases reported in 2012-2016. Stomach cancer ranked as the ninth most common cancer among males. The highest incidence was observed among Indians for both genders, followed by Chinese and Other Bumiputera populations. During the same period, a total of 1,482 oesophageal cancer cases were registered compared to 1,125 cases reported in 2012-2016. The incidence of oesophageal cancer was highest among Indian males and females, and Chinese males.

The ASIR for both stomach and oesophageal cancers began to rise noticeably after 40 years of age, with a sharper increase observed for stomach cancer after 60 years of age in both genders. The overall lifetime risk of developing stomach cancer was 1 in 250 for males and 1 in 500 for females. The risk was higher among Indian, Chinese, and Other Bumiputera males, with a lifetime risk of 1 in 167.

Among cases with available staging information, a large proportion was diagnosed at late stages (Stage III and IV). Among male stomach cancer patients, 85.2% presented at late stage, compared to 83.8% among females. Similarly, for oesophageal cancer, 85.0% of males and 80.7% of females were diagnosed at late stage.

Table 35. Stomach: Cancer incidence summary by year, Malaysia

All residents	Male				Female			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
2007-2011	2,014	3.1	3.9	0.5	1,447	2.3	2.6	0.3
2012-2016	1,818	2.7	3.1	0.4	1,188	1.8	1.9	0.2
2017-2021	2,444	3.3	3.4	0.4	1,563	2.2	2.1	0.2
2017	527	3.6	3.9	0.4	339	2.4	2.4	0.3
2018	475	3.2	3.4	0.4	324	2.3	2.2	0.2
2019	469	3.1	3.2	0.4	316	2.2	2.1	0.2
2020	481	3.2	3.2	0.4	286	2.0	1.8	0.2
2021	492	3.2	3.1	0.4	298	2.0	1.9	0.2

Table 36. Stomach: Incidence summary by gender, year and ethnicity, Malaysia

Ethnic	Year	Male				Female			
		No.	CR	ASR	CumR	No.	CR	ASR	CumR
Malay	2007-2011	429	1.2	1.7	0.2	312	0.9	1.1	0.1
	2012-2016	454	1.2	1.6	0.2	277	0.7	0.9	0.1
	2017-2021	626	1.5	1.6	0.2	339	0.8	0.8	0.1
Chinese	2007-2011	1,001	6.1	5.6	0.6	725	4.7	4.1	0.4
	2012-2016	862	5.1	4.2	0.5	551	3.5	2.8	0.3
	2017-2021	1,092	6.2	5.0	0.6	719	4.3	3.3	0.3
Indian	2007-2011	187	3.9	5.2	0.6	137	2.9	3.2	0.4
	2012-2016	143	2.9	3.5	0.4	155	3.2	3.3	0.4
	2017-2021	261	5.2	5.1	0.6	228	4.6	4.1	0.5
Other Bumi	2007-2011	341	4.1	6.6	0.8	237	2.9	4.6	0.6
	2012-2016	309	3.4	4.9	0.6	173	2.0	2.7	0.3
	2017-2021	414	4.4	5.0	0.6	260	2.8	3.2	0.4


Table 37. Oesophagus: Cancer incidence summary by year, Malaysia

All residents	Male				Female			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
2007-2011	737	1.1	1.4	0.2	429	0.7	0.8	0.1
2012-2016	788	1.2	1.4	0.2	337	0.5	0.5	0.1
2017-2021	1,066	1.4	1.5	0.2	416	0.6	0.6	0.1
2017	217	1.5	1.6	0.2	98	0.7	0.7	0.1
2018	234	1.6	1.6	0.2	85	0.6	0.6	0.1
2019	217	1.5	1.5	0.2	96	0.7	0.6	0.1
2020	210	1.4	1.4	0.2	71	0.5	0.5	0.1
2021	188	1.2	1.2	0.2	66	0.4	0.4	<0.1

Table 38. Oesophagus: Incidence summary by gender, year and ethnicity, Malaysia

Ethnic	Year	Male				Female			
		No.	CR	ASR	CumR	No.	CR	ASR	CumR
Malay	2007-2011	258	0.7	1.1	0.1	149	0.4	0.6	0.1
	2012-2016	294	0.8	1.1	0.1	116	0.3	0.4	<0.1
	2017-2021	375	0.9	1.0	0.1	136	0.3	0.3	<0.1
Chinese	2007-2011	305	1.9	1.7	0.2	82	0.5	0.5	<0.1
	2012-2016	321	1.9	1.6	0.2	77	0.5	0.4	<0.1
	2017-2021	468	2.7	2.2	0.3	95	0.6	0.4	<0.1
Indian	2007-2011	98	2.0	2.7	0.4	145	3.1	3.6	0.5
	2012-2016	98	2.0	2.4	0.3	97	2.0	2.1	0.2
	2017-2021	110	2.2	2.2	0.3	122	2.5	2.2	0.3
Other Bumi	2007-2011	52	0.6	1.0	0.1	38	0.5	0.8	0.1
	2012-2016	55	0.6	0.9	0.1	31	0.4	0.5	0.1
	2017-2021	81	0.9	1.0	0.1	50	0.5	0.6	0.1

Stomach Male



Stomach Female




Figure 56. Stomach: Comparison of age-standardised incidence rates by year, ethnicity and gender






Figure 57. Oesophagus: Comparison of age-standardised incidence rates by year, ethnicity and gender

Male



Female





Figure 58. Stomach and Oesophagus: Age-specific incidence rates by year and gender

Stomach Male



Stomach Female




Figure 59. Stomach: Comparison of staging percentage by year and gender





Figure 60. Oesophagus: Comparison of staging percentage by year and gender





Figure 61. Stomach: International comparisons - Age-standardised incidence rates

Source: **The highest incidence from CI5, Volume XII; *The lowest incidence from CI5, Volume XII; ^^Singapore Cancer Registry Annual Report 2021, National Registry of Diseases Office August 2023





Figure 62. Oesophagus: International comparisons - Age-standardised incidence rates

Source: **The highest incidence from CI5, Volume XII; *The lowest incidence from CI5, Volume XII;
 ^^Singapore Cancer Registry Annual Report 2021, National Registry of Diseases Office August 2023; NA: Not Available

5.9 Cervix Uteri (ICD-10: C53)

A total of 4573 cases of cervix uteri cancer were diagnosed for the period of 2017-2021 compared with 3,981 cases in 2012-2016 report. Cancer of the cervix uteri was the 6th most common cancer in females. The incidence rates have decreased from 7.6 to 6.0 per 100,000 populations over the ten years. Other Bumiputera had highest incidence rates followed by Chinese and Indians. The lifetime risk was 1 in 167 among Malaysian females. The lifetime risk for Other Bumiputera was 1 in 100, Chinese was 1 in 125, Indians 1 in 167 and Malays 1 in 200.

The trend for ASIR was similar in both reports. The ASIRs (ASIR) of cervical cancer began to rise steadily from the 25-29 age group. After the age of 60 the incidence rates are relatively stable. The overall pattern was similar in both reporting periods (2012-2016 and 2017-2021), with the latter period showed slightly lower incidence rates across most age groups. 46.6% from the total cases reported with staging were detected at late stage (III & IV).

Table 39. Cervix Uteri: Cancer incidence summary by year, Malaysia

All residents	No.	CR	ASR	CumR
2007-2011	4,325	6.8	7.6	0.9
2012-2016	3,981	6.0	6.2	0.7
2017-2021	4,573	6.3	6.0	0.6
2017	932	6.6	6.4	0.7
2018	948	6.6	6.3	0.7
2019	940	6.5	6.1	0.7
2020	873	6.0	5.5	0.6
2021	880	5.9	5.4	0.6

Table 40. Cervix Uteri: Incidence summary by year and ethnicity, Malaysia

Year	No.	CR	ASR	CumR	No.	CR	ASR	CumR
		Malay				Indian		
2007-2011	1,502	4.3	5.1	0.6	327	6.9	7.6	0.9
2012-2016	1,531	4.1	4.6	0.5	273	5.6	5.5	0.6
2017-2021	1,843	4.5	4.5	0.5	297	6.0	5.3	0.6
		Chinese				Other Bumiputera		
2007-2011	1,732	11.2	9.8	1.2	598	7.4	9.7	1.0
2012-2016	1,316	8.3	6.8	0.8	638	7.2	8.6	0.9
2017-2021	1,471	8.8	6.9	0.8	800	8.7	9.3	1.0




Figure 63. Cervix Uteri: Comparison of age-standardised incidence rates by year and ethnicity




Figure 64. Cervix Uteri: Age-specific incidence rates by year




Figure 65. Cervix Uteri: Comparison of staging percentage by year




Figure 66. Cervix Uteri: International comparisons - Age-standardised incidence rates

Source: **The highest incidence from CI5, Volume XII; *The lowest incidence from CI5, Volume XII;
^^Singapore Cancer Registry Annual Report 2021, National Registry of Diseases Office August 2023

5.10 Ovary (ICD-10: C56)

A total of 4,714 cases of ovarian cancer were registered for the period of 2017-2021 compared with 3,575 cases in 2012-2016 report. Cancer of ovary ranked tenth in Malaysia and fifth in females. The trend for ASIR were similar in both reports with the highest incidence was at the age of 65-69. The overall lifetime risk was 1 in 143, consistent across Malays, Indians, and Chinese. In contrast, Other Bumiputera had a lower lifetime risk of 1 in 200. 54.1% from the total cases reported with staging were detected at late stage (III & IV).

Table 41. Ovary: Cancer incidence summary by year, Malaysia

All residents	No.	CR	ASR	CumR
2007-2011	3,472	5.4	5.9	0.6
2012-2016	3,575	5.4	5.6	0.6
2017-2021	4,714	6.5	6.2	0.7
2017	981	6.9	6.8	0.7
2018	990	6.9	6.7	0.7
2019	934	6.4	6.1	0.7
2020	946	6.5	6.0	0.7
2021	863	5.8	5.4	0.6

Table 42. Ovary: Incidence summary by year and ethnicity, Malaysia

Year	No.	CR	ASR	CumR	No.	CR	ASR	CumR	
Malay					Indian				
2007-2011	1,754	5.0	5.8	0.6	277	5.8	6.1	0.7	
2012-2016	1,984	5.3	5.9	0.6	272	5.6	5.4	0.6	
2017-2021	2,548	6.2	6.3	0.7	354	7.2	6.3	0.7	
Chinese					Other Bumiputera				
2007-2011	1,107	7.2	6.3	0.7	237	2.9	3.7	0.4	
2012-2016	1,006	6.4	5.4	0.6	205	2.3	2.7	0.3	
2017-2021	1,330	7.9	6.4	0.7	379	4.1	4.4	0.5	




Figure 67. Ovary: Comparison of age-standardised incidence rates by year and ethnicity




Figure 68. Ovary: Comparison of age-specific incidence rates by year




Figure 69. Ovary: Comparison of staging percentage by year




Figure 70. Ovary: International comparisons - Age-standardised incidence rates

Source: **The highest incidence from CI5, Volume XII; *The lowest incidence from CI5, Volume XII;
 ^^Singapore Cancer Registry Annual Report 2021, National Registry of Diseases Office August 2023

5.11 Corpus Uteri (ICD-10: C54)

A total of 5,087 cases of corpus uteri cancer were registered during 2017-2021, compared to 3,575 cases reported in 2012-2016. Corpus uteri cancer ranked ninth overall in Malaysia and fourth among females. The ASIR showed a persistently higher trend across all age groups compared to the previous reporting period, with the highest incidence observed among women aged 65-69 years. The overall lifetime risk was 1 in 125. By ethnicity, the highest lifetime risk was observed among Indians (1 in 91), followed by Chinese (1 in 125), Malays (1 in 143), and Other Bumiputera (1 in 200). Among cases with staging information, 39.1% were diagnosed at late stages (Stage III & IV).

Table 43. Corpus Uteri: Cancer incidence summary by year, Malaysia

All residents	No.	CR	ASR	CumR
2007-2011	2,181	3.4	3.8	0.4
2012-2016	2,898	4.4	4.6	0.5
2017-2021	5,087	7.0	6.7	0.8
2017	940	6.6	6.6	0.8
2018	934	6.5	6.3	0.7
2019	1,069	7.4	7.0	0.8
2020	1,088	7.4	6.9	0.8
2021	1,056	7.1	6.5	0.8

Table 44. Corpus Uteri: Incidence summary by year and ethnicity, Malaysia

Year	No.	CR	ASR	CumR	No.	CR	ASR	CumR
		Malay			Indian			
2007-2011	964	2.8	3.3	0.4	204	4.3	4.8	0.6
2012-2016	1,409	3.8	4.4	0.5	265	5.4	5.5	0.7
2017-2021	2,595	6.3	6.3	0.7	526	10.6	9.3	1.1
		Chinese			Other Bumiputera			
2007-2011	853	5.5	4.9	0.6	116	1.4	2.0	0.2
2012-2016	977	6.2	5.1	0.6	179	2.0	2.5	0.3
2017-2021	1,491	8.9	7.0	0.8	375	4.1	4.4	0.5




Figure 71. Corpus Uteri: Comparison of age-standardised incidence rates by year and ethnicity




Figure 72. Corpus Uteri: Comparison of age-specific incidence rates by year




Figure 73. Corpus Uteri: Comparison of staging percentage by year




Figure 74. Corpus Uteri: International comparisons - Age-standardised incidence rates

Source: **The highest incidence from CI5, Volume XII ; *The lowest incidence from CI5, Volume XI;
 ^^Singapore Cancer Registry Annual Report 2021, National Registry of Diseases Office August 2023

5.12 Prostate (ICD-10: C61)

A total of 6,441 prostate cancer cases were registered during the period 2017-2021, compared to 4,189 cases reported in 2012-2016. Prostate cancer ranked as the sixth most common cancer in Malaysia and the third most common cancer among males. The ASIR begins to increase from age 50 years old and rises markedly with advancing age. The incidence was highest among Chinese, followed by Indians and Other Bumiputera. The overall lifetime risk of developing prostate cancer was 1 in 83. By ethnicity, the highest lifetime risk was observed among Chinese (1 in 50), followed by Indians (1 in 83) and consistent among Malays and Other Bumiputeras (1 in 125). Among cases with available staging information, 63.3% were diagnosed at late stages (Stage III and IV).

Table 45. Prostate: Cancer incidence summary by year, Malaysia

All residents	No.	CR	ASR	CumR
2007-2011	3,132	4.8	6.6	0.9
2012-2016	4,189	6.1	7.7	1.1
2017-2021	6,441	8.6	9.3	1.2
2017	1,413	9.7	11.0	1.5
2018	1,339	9.0	10.0	1.3
2019	1,198	8.0	8.7	1.1
2020	1,379	9.1	9.5	1.2
2021	1,112	7.3	7.3	1.0

Table 46. Prostate: Incidence summary by year and ethnicity, Malaysia

Year	No.	CR	ASR	CumR	No.	CR	ASR	CumR	
Malay					Indian				
2007-2011	1,163	3.3	5.3	0.7	188	3.9	6.1	0.8	
2012-2016	1,577	4.1	6.3	0.9	245	5.0	6.8	0.9	
2017-2021	2,166	5.1	6.3	0.8	424	8.4	9.2	1.2	
Chinese					Other Bumiputera				
2007-2011	1,589	9.7	9.0	1.2	128	1.5	2.7	0.3	
2012-2016	2,040	12.2	10.1	1.4	254	2.8	4.3	0.6	
2017-2021	3,297	18.8	15.3	2.0	426	4.6	5.5	0.8	




Figure 75. Prostate: Comparison of age-standardised incidence rates by year and ethnicity




Figure 76. Prostate: Comparison of age-specific incidence rates by year




Figure 77. Prostate: Comparison of staging percentage by year




Figure 78. Prostate: International comparisons - Age-standardised incidence rates


Source: **The highest incidence from CI5, Volume XI; *The lowest incidence from CI5, Volume XI;
 ^^Singapore Cancer Registry Annual Report 2021, National Registry of Diseases Office August 2023

REFERENCES

1. Azizah AM., Hashimah B., Nirmal K., Siti Zubaidah AR., Puteri NA., Nabihah A., Sukumaran R., Balqis B., Nadia SMR., Sharifah SSS., Rahayu O., Nur Alham O., Azlina AA. *Malaysian National Cancer Registry Report (MNCR) 2012-2016*. Available from: <https://nci.moh.gov.my/images/Laporan/MNCR_2012-2016_FINAL_PUBLISHED_2019.pdf>
2. Bray F, Colombet M, Aitken JF, Bardot A, Eser S, Galceran J, et al., editors. (2024). *Cancer Incidence in Five Continents, Vol. XII*. IARC Scientific Publication No. 169. Lyon, France: International Agency for Research on Cancer. Available from: <<https://publications.iarc.who.int/641>. Licence: CC BY-NC-ND 3.0 IGO.>
3. Department of Statistic, Malaysia (2017-2021). *Intercensal Mid-Year Population Estimates, Malaysia, 2011-2019 based on Population and Housing Census of Malaysia 2020*.
4. Fritz, A.G. ed. 2013. *International classification of diseases for oncology: ICD-O*. World Health Organization.
5. *International Classification of Diseases for Oncology (ICD-O), Third Edition, Second Revision Morphology*. World Health Organisation. Available from: <http://www.iacr.com.fr/images/Newsflash/ICD-O-3.2_final_update09102020.xls>
6. Health Informatics Centre. *Health Facts 2018-2022*. Health Informatics Centre, Planning Division, Ministry of Health Malaysia. Available from <<https://www.moh.gov.my/index.php/pages/view/58>>
7. IARC, IACR & ENCR. 2004. *International Rules for Multiple Primary Cancers (ICD-O Third Edition)*. World Health Organization. International Agency for Research on Cancer. Lyon. Available from <https://www.enr.eu/sites/default/files/pdf/MPrules_july2004.pdf>
8. Jensen, O.M. ed. 1991. *Cancer registration: principles and methods (Vol. 95)*. IARC. Available from <<https://publications.iarc.who.int/Book-And-Report-Series/Iarc-Scientific-Publications/Cancer-Registration-Principles-And-Methods-1991>>
9. *Singapore Cancer Registry Annual Report 2021, National Registry of Diseases Office, 2023*. Available from <<https://www.nrdo.gov.sg/docs/librariesprovider3/default-document-library/scr-ar-2021-web-report>>
10. Parkin, DM., Chen, V.W., Ferlay, J., Galceran, J., Storm, H.H. & Whelan, S.L. 1994. *Comparability and Quality Control in Cancer Registration, IARC Technical Report No. 19*, Lyon, France.
11. Segi, M. 1960. *Cancer Mortality for Selected Sites in 24 Countries (1950-1957)*, Sendai Japan, Tohoku University School of Medicine, Department of Public Health.
12. Tyczynski, J.E., Démareé, E. and Parkin, D.M. 2003. *Standards and Guidelines for Cancer Registration in Europe: the ENCR recommendations. Volume I. European Network of Cancer Registries*. World Health Organization. International Agency for Research on Cancer. Lyon.
13. Rajappa, et al. 2023. *Cancer incidence and mortality trends in Asia based on regions and human development index levels: an analyses from GLOBOCAN 2020*. Available from <<https://doi.org/10.1080/03007995.2023.2231761>>
14. WHO. 3rd Feb 2025. *Cancer Factsheet*. Available from <<https://www.who.int/news-room/factsheets/detail/cancer>>
15. Huang, et al. 2022. *Cancer Incidence and Mortality in Asian Countries: A Trend Analysis*. Available from <<https://doi.org/10.1177/10732748221095955>>

APPENDICES

Appendix 1. Population at risk (mid-period population), all Malaysian, 2017-2021



AGE GROUP	MALAYSIAN POPULATION		WORLD STANDARD POPULATION
	MALE	FEMALE	
0-4	6,110,500	5,853,500	12,000
5-9	6,539,000	6,077,500	10,000
10-14	6,593,000	6,145,000	9,000
15-19	6,953,000	6,479,000	9,000
20-24	6,261,500	5,991,000	8,000
25-29	6,224,000	6,153,000	8,000
30-34	6,226,000	6,247,500	6,000
35-39	6,049,500	5,801,000	6,000
40-44	4,804,000	4,652,000	6,000
45-49	4,246,500	4,177,500	6,000
50-54	3,732,500	3,739,500	5,000
55-59	3,525,500	3,442,500	4,000
60-64	2,725,000	2,734,000	4,000
65-69	2,055,500	2,082,000	3,000
70-74	1,314,000	1,405,000	2,000
75+	1,383,000	1,603,500	2,000
TOTAL	74,742,500	72,583,500	100,000

Appendix 2. Incidence summary table, all residents, males, 2017-2021

ICD-10	SITE	NO.	%	CR	CR74	ASR	(95%CL)		CumR
C18	Colorectal	13,610	17.5	18.2	2.3	18.8	18.5	19.1	2.3
C33-34	Lung, Trachea & Bronchus	11,474	14.8	15.4	2.0	16.0	15.7	16.3	2.0
C61	Prostate	6,441	8.3	8.6	1.2	9.3	9.1	9.6	1.2
C22	Liver	6,101	7.9	8.2	1.1	8.4	8.2	8.6	1.1
C81-85,C96	Lymphoma	5,116	6.6	6.8	0.7	6.9	6.7	7.1	0.7
C11	Nasopharynx	3,877	5.0	5.2	0.6	5.1	4.9	5.3	0.6
C91	Leukaemia	3,529	4.5	4.7	0.4	4.9	4.8	5.1	0.4
C44	Non-Melanoma Skin	2,471	3.2	3.3	0.4	3.5	3.3	3.6	0.4
C16	Stomach	2,444	3.1	3.3	0.4	3.4	3.2	3.5	0.4
C25	Pancreas	2,162	2.8	2.9	0.4	3.0	2.9	3.1	0.4
C64	Kidney	1,997	2.6	2.7	0.3	2.7	2.6	2.9	0.3
C67	Bladder	1,933	2.5	2.6	0.3	2.7	2.6	2.9	0.3
C70-72	Brain, Nervous System	1,300	1.7	1.7	0.2	1.8	1.7	1.9	0.2
C32	Larynx	1,114	1.4	1.5	0.2	1.6	1.5	1.7	0.2
C15	Oesophagus	1,066	1.4	1.4	0.2	1.5	1.4	1.6	0.2
C73	Thyroid	1,035	1.3	1.4	0.2	1.4	1.3	1.5	0.2
C47,C49	Connective, Soft Tissue	875	1.1	1.2	0.1	1.2	1.1	1.2	0.1
C23-24	Gallbladder etc	830	1.1	1.1	0.1	1.2	1.1	1.2	0.1
C62	Testis	898	1.2	1.2	0.1	1.1	1.0	1.2	0.1
C90	Multiple Myeloma	767	1.0	1.0	0.1	1.1	1.0	1.1	0.1
C01-02	Tongue	784	1.0	1.0	0.1	1.1	1.0	1.1	0.1
C03-06	Mouth	522	0.7	0.7	0.1	0.7	0.7	0.8	0.1
C40-41	Bone	507	0.7	0.7	0.1	0.7	0.6	0.7	0.1
C37-38	Other Thoracic Organs	454	0.6	0.6	0.1	0.6	0.5	0.6	0.1
C07-08	Salivary Glands	393	0.5	0.5	0.1	0.5	0.5	0.6	0.1
C17	Small Intestine	378	0.5	0.5	0.1	0.5	0.5	0.6	0.1
C30-31	Nose, Sinuses etc	374	0.5	0.5	0.1	0.5	0.5	0.6	0.1
MPD	Myeloproliferative Disorders	287	0.4	0.4	0.1	0.4	0.3	0.4	0.1
MDS	Myelodysplastic Syndromes	269	0.3	0.4	0.1	0.4	0.3	0.4	0.1
C43	Melanoma of Skin	266	0.3	0.4	0.0	0.4	0.3	0.4	0.0
C12-13	Hypopharynx	186	0.2	0.2	0.0	0.3	0.2	0.3	0.0
C50	Breast	185	0.2	0.2	0.0	0.3	0.2	0.3	0.0
C09	Tonsil	182	0.2	0.2	0.0	0.2	0.2	0.3	0.0
C69	Eye	127	0.2	0.2	0.0	0.2	0.2	0.2	0.0
C60	Penis	149	0.2	0.2	0.0	0.2	0.2	0.2	0.0
C74	Adrenal Gland	125	0.2	0.2	0.0	0.2	0.2	0.2	0.0
C10	Other Oropharynx	113	0.1	0.2	0.0	0.2	0.1	0.2	0.0
C88	Immunoproliferative Diseases	108	0.1	0.1	0.0	0.1	0.1	0.2	0.0
C75	Other Endocrine	104	0.1	0.1	0.0	0.1	0.1	0.2	0.0
C46	Kaposi Sarcoma	109	0.1	0.1	0.0	0.1	0.1	0.2	0.0
C66	Ureter	65	0.1	0.1	0.0	0.1	0.1	0.1	0.0
C45	Mesothelioma	64	0.1	0.1	0.0	0.1	0.1	0.1	0.0
C14	Pharynx Unspecified	62	0.1	0.1	0.0	0.1	0.1	0.1	0.0
C65	Renal Pelvis	53	0.1	0.1	0.0	0.1	0.1	0.1	0.0
C68	Other Urinary Organs	50	0.1	0.1	0.0	0.1	0.1	0.1	0.0
C63	Other Male Genital	49	0.1	0.1	0.0	0.1	0.0	0.1	0.0
C00	Lip	25	0.0	0.0	0.0	0.0	0.0	0.0	0.0
O&U	Others & Unspecified	2,662	3.4	3.6	0.4	3.7	3.5	3.8	0.4
All	All sites total	77,692	100.0	103.9	12.7	107.3	106.5	108.1	11.9

Note: all 0.0 = Value <0.1; presented as 0.0 due to rounding.

Appendix 3. Incidence summary table, all residents, females, 2017-2021

ICD-10	SITE	NO.	%	CR	CR74	ASR	(95%CL)		CumR
C50	Breast	29,534	32.4	40.7	4.4	38.9	38.4	39.3	4.3
C18	Colorectal	10,261	11.3	14.1	1.6	13.7	13.4	13.9	1.6
C33-34	Lung, Trachea & Bronchus	5,554	6.1	7.7	0.9	7.4	7.2	7.6	0.9
C54	Corpus Uteri	5,087	5.6	7.0	0.8	6.7	6.5	6.9	0.8
C56	Ovary	4,714	5.2	6.5	0.7	6.2	6.0	6.4	0.7
C53	Cervix Uteri	4,573	5.0	6.3	0.7	6.0	5.8	6.1	0.6
C81-85,C96	Lymphoma	3,677	4.0	5.1	0.5	4.9	4.7	5.0	0.5
C73	Thyroid	3,258	3.6	4.5	0.4	4.2	4.0	4.3	0.4
C91	Leukaemia	2,736	3.0	3.8	0.3	3.9	3.7	4.0	0.3
C22	Liver	2,155	2.4	3.0	0.4	2.9	2.8	3.0	0.4
C44	Non-Melanoma Skin	1,881	2.1	2.6	0.3	2.5	2.4	2.6	0.3
C25	Pancreas	1,635	1.8	2.3	0.3	2.2	2.1	2.3	0.3
C16	Stomach	1,563	1.7	2.2	0.2	2.1	2.0	2.2	0.2
C11	Nasopharynx	1,309	1.4	1.8	0.2	1.7	1.6	1.8	0.2
C55	Uterus Unspecified	1,215	1.3	1.7	0.2	1.6	1.5	1.7	0.2
C70-72	Brain, Nervous System	1,085	1.2	1.5	0.1	1.5	1.4	1.6	0.1
C64	Kidney	889	1.0	1.2	0.1	1.2	1.1	1.3	0.1
C23-24	Gallbladder etc	751	0.8	1.0	0.1	1.0	0.9	1.1	0.1
C47,C49	Connective, Soft Tissue	706	0.8	1.0	0.1	0.9	0.9	1.0	0.1
C90	Multiple Myeloma	646	0.7	0.9	0.1	0.9	0.8	0.9	0.1
C01-02	Tongue	583	0.6	0.8	0.1	0.8	0.7	0.8	0.1
C03-06	Mouth	523	0.6	0.7	0.1	0.7	0.6	0.8	0.1
C67	Bladder	479	0.5	0.7	0.1	0.6	0.6	0.7	0.1
C15	Oesophagus	416	0.5	0.6	0.1	0.6	0.5	0.6	0.1
C57	Other Female Genital	409	0.4	0.6	0.1	0.5	0.5	0.6	0.1
C40-41	Bone	380	0.4	0.5	0.0	0.5	0.5	0.6	0.0
C07-08	Salivary Glands	312	0.3	0.4	0.0	0.4	0.4	0.5	0.0
C43	Melanoma of Skin	242	0.3	0.3	0.0	0.3	0.3	0.4	0.0
C17	Small Intestine	224	0.2	0.3	0.0	0.3	0.3	0.3	0.0
C37-38	Other Thoracic Organs	224	0.2	0.3	0.0	0.3	0.3	0.3	0.0
MPD	Myeloproliferative Disorders	192	0.2	0.3	0.0	0.3	0.2	0.3	0.0
C30-31	Nose, Sinuses etc	193	0.2	0.3	0.0	0.3	0.2	0.3	0.0
C51	Vulva	190	0.2	0.3	0.0	0.3	0.2	0.3	0.0
MDS	Myelodysplastic Syndromes	171	0.2	0.2	0.0	0.2	0.2	0.3	0.0
C52	Vagina	168	0.2	0.2	0.0	0.2	0.2	0.3	0.0
C74	Adrenal Gland	103	0.1	0.1	0.0	0.2	0.1	0.2	0.0
C69	Eye	92	0.1	0.1	0.0	0.2	0.1	0.2	0.0
C12-13	Hypopharynx	90	0.1	0.1	0.0	0.1	0.1	0.1	0.0
C32	Larynx	87	0.1	0.1	0.0	0.1	0.1	0.1	0.0
C00	Lip	56	0.1	0.1	0.0	0.1	0.1	0.1	0.0
C09	Tonsil	51	0.1	0.1	0.0	0.1	0.0	0.1	0.0
C75	Other Endocrine	48	0.1	0.1	0.0	0.1	0.0	0.1	0.0
C88	Immunoproliferative Diseases	40	0.0	0.1	0.0	0.1	0.0	0.1	0.0
C66	Ureter	34	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C10	Other Oropharynx	33	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C14	Pharynx Unspecified	33	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C45	Mesothelioma	30	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C58	Placenta	31	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C65	Renal Pelvis	27	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C68	Other Urinary Organs	25	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C46	Kaposi Sarcoma	12	0.0	0.0	0.0	0.0	0.0	0.0	0.0
O&U	Others & Unspecified	2,404	2.6	3.3	0.4	3.2	3.1	3.3	0.4
All	All sites total	91,131	100.0	125.6	13.6	120.8	120.0	121.6	12.7

Appendix 4. Incidence summary table, Malay males, 2017-2021

ICD-10	SITE	NO.	%	CR	CR74	ASR	(95%CL)		CumR
C18-21	Colorectal	5,422	16.9	12.8	1.8	14.5	14.1	14.8	1.8
C33-34	Lung, Trachea & Bronchus	4,846	15.1	11.5	1.7	13.1	12.8	13.5	1.7
C81-85,C96	Lymphoma	2,899	9.1	6.9	0.8	7.3	7.0	7.5	0.8
C22	Liver	2,541	7.9	6.0	0.9	6.8	6.5	7.0	0.9
C61	Prostate	2,166	6.8	5.1	0.8	6.3	6.0	6.5	0.8
C91-95	Leukaemia	1,871	5.8	4.4	0.4	4.7	4.5	4.9	0.4
C67	Bladder	955	3.0	2.3	0.3	2.7	2.5	2.8	0.3
C11	Nasopharynx	1,035	3.2	2.4	0.3	2.6	2.4	2.8	0.3
C44	Non-Melanoma Skin	824	2.6	1.9	0.2	2.3	2.1	2.4	0.2
C25	Pancreas	727	2.3	1.7	0.2	1.9	1.8	2.1	0.2
C64	Kidney	735	2.3	1.7	0.2	1.9	1.8	2.1	0.2
C70-72	Brain, Nervous System	692	2.2	1.6	0.2	1.7	1.6	1.8	0.2
C16	Stomach	626	2.0	1.5	0.2	1.6	1.5	1.8	0.2
C73	Thyroid	610	1.9	1.4	0.2	1.5	1.4	1.7	0.2
C62	Testis	610	1.9	1.4	0.1	1.3	1.2	1.4	0.1
C90	Multiple Myeloma	407	1.3	1.0	0.1	1.1	1.0	1.2	0.1
C47,C49	Connective, Soft Tissue	422	1.3	1.0	0.1	1.0	0.9	1.1	0.1
C15	Oesophagus	375	1.2	0.9	0.1	1.0	0.9	1.1	0.1
C23-24	Gallbladder etc	336	1.0	0.8	0.1	0.9	0.8	1.0	0.1
C32	Larynx	319	1.0	0.8	0.1	0.9	0.8	1.0	0.1
C40-41	Bone	281	0.9	0.7	0.1	0.7	0.6	0.8	0.1
C01-02	Tongue	265	0.8	0.6	0.1	0.7	0.6	0.8	0.1
C37-38	Other Thoracic Organs	262	0.8	0.6	0.1	0.6	0.5	0.7	0.1
C07-08	Salivary Glands	161	0.5	0.4	0.0	0.4	0.3	0.5	0.0
C03-06	Mouth	150	0.5	0.4	0.0	0.4	0.3	0.5	0.0
C17	Small Intestine	152	0.5	0.4	0.0	0.4	0.3	0.5	0.0
MPD	Myeloproliferative Disorders	145	0.5	0.3	0.0	0.4	0.3	0.4	0.0
C30-31	Nose, Sinuses etc	144	0.4	0.3	0.0	0.4	0.3	0.4	0.0
MDS	Myelodysplastic Syndromes	109	0.3	0.3	0.0	0.3	0.2	0.4	0.0
C43	Melanoma of Skin	104	0.3	0.2	0.0	0.3	0.2	0.3	0.0
C50	Breast	80	0.2	0.2	0.0	0.2	0.2	0.3	0.0
C74	Adrenal Gland	72	0.2	0.2	0.0	0.2	0.2	0.2	0.0
C69	Eye	57	0.2	0.1	0.0	0.2	0.1	0.2	0.0
C88	Immunoproliferative Diseases	55	0.2	0.1	0.0	0.2	0.1	0.2	0.0
C75	Other Endocrine	64	0.2	0.2	0.0	0.1	0.1	0.2	0.0
C09	Tonsil	45	0.1	0.1	0.0	0.1	0.1	0.2	0.0
C46	Kaposi Sarcoma	45	0.1	0.1	0.0	0.1	0.1	0.1	0.0
C12-13	Hypopharynx	30	0.1	0.1	0.0	0.1	0.1	0.1	0.0
C68	Other Urinary Organs	29	0.1	0.1	0.0	0.1	0.1	0.1	0.0
C45	Mesothelioma	21	0.1	0.0	0.0	0.1	0.0	0.1	0.0
C66	Ureter	19	0.1	0.0	0.0	0.1	0.0	0.1	0.0
C65	Renal Pelvis	19	0.1	0.0	0.0	0.1	0.0	0.1	0.0
C10	Other Oropharynx	18	0.1	0.0	0.0	0.0	0.0	0.1	0.0
C60	Penis	18	0.1	0.0	0.0	0.0	0.0	0.1	0.0
C63	Other Male Genital	17	0.1	0.0	0.0	0.0	0.0	0.1	0.0
C14	Pharynx Unspecified	15	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C00	Lip	12	0.0	0.0	0.0	0.0	0.0	0.0	0.0
O&U	Others & Unspecified	1,203	3.8	2.8	0.4	3.2	3.0	3.4	0.4
All	All sites total	32,010	100.0	75.7	9.9	84.4	83.5	85.4	9.4

Note: all 0.0 = Value <0.1; presented as 0.0 due to rounding.

Appendix 5. Incidence summary table, Malay females, 2017-2021

ICD-10	SITE	NO.	%	CR	CR74	ASR	(95%CL)		CumR
C50	Breast	14,552	34.0	35.3	4.0	35.8	35.3	36.4	3.9
C18-21	Colorectal	4,454	10.4	10.8	1.4	11.3	10.9	11.6	1.3
C54	Corpus Uteri	2,595	6.1	6.3	0.7	6.3	6.1	6.6	0.7
C56	Ovary	2,548	6.0	6.2	0.7	6.3	6.0	6.5	0.7
C33-34	Lung, Trachea & Bronchus	2,166	5.1	5.3	0.7	5.5	5.3	5.7	0.7
C81-85,C96	Lymphoma	2,150	5.0	5.2	0.6	5.2	5.0	5.4	0.6
C73	Thyroid	2,058	4.8	5.0	0.5	4.8	4.6	5.1	0.5
C53	Cervix Uteri	1,843	4.3	4.5	0.5	4.5	4.3	4.7	0.5
C91-95	Leukaemia	1,470	3.4	3.6	0.3	3.7	3.5	3.9	0.3
C22	Liver	921	2.2	2.2	0.3	2.4	2.2	2.5	0.3
C44	Non-Melanoma Skin	699	1.6	1.7	0.2	1.8	1.6	1.9	0.2
C70-72	Brain, Nervous System	604	1.4	1.5	0.1	1.5	1.4	1.6	0.1
C55	Uterus Unspecified	608	1.4	1.5	0.2	1.5	1.4	1.6	0.2
C25	Pancreas	562	1.3	1.4	0.2	1.4	1.3	1.6	0.2
C11	Nasopharynx	408	1.0	1.0	0.1	1.0	0.9	1.1	0.1
C64	Kidney	354	0.8	0.9	0.1	0.9	0.8	1.0	0.1
C47,C49	Connective, Soft Tissue	366	0.9	0.9	0.1	0.9	0.8	1.0	0.1
C23-24	Gallbladder etc	346	0.8	0.8	0.1	0.9	0.8	1.0	0.1
C16	Stomach	339	0.8	0.8	0.1	0.8	0.8	0.9	0.1
C90	Multiple Myeloma	319	0.7	0.8	0.1	0.8	0.7	0.9	0.1
C01-02	Tongue	239	0.6	0.6	0.1	0.6	0.5	0.7	0.1
C40-41	Bone	222	0.5	0.5	0.0	0.5	0.5	0.6	0.0
C57	Other Female Genital	219	0.5	0.5	0.1	0.5	0.5	0.6	0.1
C67	Bladder	192	0.4	0.5	0.1	0.5	0.4	0.6	0.1
C15	Oesophagus	136	0.3	0.3	0.0	0.3	0.3	0.4	0.0
C03-06	Mouth	124	0.3	0.3	0.0	0.3	0.3	0.4	0.0
C07-08	Salivary Glands	129	0.3	0.3	0.0	0.3	0.3	0.4	0.0
MPD	Myeloproliferative Disorders	112	0.3	0.3	0.0	0.3	0.2	0.3	0.0
C17	Small Intestine	104	0.2	0.3	0.0	0.3	0.2	0.3	0.0
C37-38	Other Thoracic Organs	104	0.2	0.3	0.0	0.3	0.2	0.3	0.0
C43	Melanoma of Skin	92	0.2	0.2	0.0	0.2	0.2	0.3	0.0
C30-31	Nose, Sinuses etc	87	0.2	0.2	0.0	0.2	0.2	0.3	0.0
C52	Vagina	69	0.2	0.2	0.0	0.2	0.1	0.2	0.0
C51	Vulva	68	0.2	0.2	0.0	0.2	0.1	0.2	0.0
C74	Adrenal Gland	57	0.1	0.1	0.0	0.2	0.1	0.2	0.0
MDS	Myelodysplastic Syndromes	63	0.1	0.2	0.0	0.2	0.1	0.2	0.0
C69	Eye	53	0.1	0.1	0.0	0.1	0.1	0.2	0.0
C75	Other Endocrine	31	0.1	0.1	0.0	0.1	0.0	0.1	0.0
C32	Larynx	27	0.1	0.1	0.0	0.1	0.0	0.1	0.0
C12-13	Hypopharynx	26	0.1	0.1	0.0	0.1	0.0	0.1	0.0
C58	Placenta	20	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C09	Tonsil	16	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C00	Lip	16	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C88	Immunoproliferative Diseases	16	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C45	Mesothelioma	13	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C65	Renal Pelvis	11	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C10	Other Oropharynx	10	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C68	Other Urinary Organs	9	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C66	Ureter	6	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C46	Kaposi Sarcoma	5	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C14	Pharynx Unspecified	5	0.0	0.0	0.0	0.0	0.0	0.0	0.0
O&U	Others & Unspecified	1,120	2.6	2.7	0.3	2.8	2.7	3.0	0.3
All	All sites total	42,763	100.0	103.7	11.8	105.9	104.9	106.9	11.1

Note: all 0.0 = Value <0.1; presented as 0.0 due to rounding.

Appendix 6. Incidence summary table, Chinese males, 2017-2021

ICD-10	SITE	NO.	%	CR	CR74	ASR	(95%CL)		CumR
C18-21	Colorectal	6,082	19.1	34.8	3.4	27.9	27.2	28.6	3.4
C33-34	Lung, Trachea & Bronchus	4,762	15.0	27.2	2.7	21.9	21.3	22.6	2.7
C61	Prostate	3,297	10.4	18.8	2.0	15.3	14.8	15.8	2.0
C22	Liver	2,600	8.2	14.9	1.5	12.0	11.5	12.4	1.5
C11	Nasopharynx	1,959	6.2	11.2	1.0	9.0	8.6	9.4	1.0
C81-85,C96	Lymphoma	1,310	4.1	7.5	0.7	6.3	5.9	6.6	0.7
C44	Non-Melanoma Skin	1,227	3.9	7.0	0.6	5.6	5.2	5.9	0.6
C91	Leukaemia	998	3.1	5.7	0.5	5.2	4.8	5.5	0.5
C25	Pancreas	1,111	3.5	6.3	0.7	5.1	4.8	5.4	0.7
C16	Stomach	1,092	3.4	6.2	0.6	5.0	4.7	5.3	0.6
C64	Kidney	946	3.0	5.4	0.6	4.4	4.1	4.7	0.6
C67	Bladder	687	2.2	3.9	0.4	3.2	2.9	3.4	0.4
C32	Larynx	521	1.6	3.0	0.3	2.4	2.2	2.6	0.3
C15	Oesophagus	468	1.5	2.7	0.3	2.2	2.0	2.4	0.3
C70-72	Brain, Nervous System	354	1.1	2.0	0.2	1.9	1.7	2.1	0.2
C23-24	Gallbladder etc	328	1.0	1.9	0.2	1.5	1.3	1.7	0.2
C01-02	Tongue	317	1.0	1.8	0.2	1.5	1.3	1.6	0.2
C47,C49	Connective, Soft Tissue	273	0.9	1.6	0.1	1.3	1.1	1.5	0.1
C73	Thyroid	250	0.8	1.4	0.1	1.2	1.0	1.3	0.1
C90	Multiple Myeloma	198	0.6	1.1	0.1	0.9	0.8	1.0	0.1
C62	Testis	166	0.5	0.9	0.1	0.9	0.7	1.0	0.1
C03-06	Mouth	189	0.6	1.1	0.1	0.9	0.8	1.0	0.1
C07-08	Salivary Glands	159	0.5	0.9	0.1	0.7	0.6	0.9	0.1
C17	Small Intestine	154	0.5	0.9	0.1	0.7	0.6	0.8	0.1
C40-41	Bone	126	0.4	0.7	0.1	0.7	0.5	0.8	0.1
C30-31	Nose, Sinuses etc	136	0.4	0.8	0.1	0.6	0.5	0.7	0.1
C37-38	Other Thoracic Organs	131	0.4	0.7	0.1	0.6	0.5	0.7	0.1
MDS	Myelodysplastic Syndromes	119	0.4	0.7	0.1	0.6	0.5	0.7	0.1
C43	Melanoma of Skin	107	0.3	0.6	0.1	0.5	0.4	0.6	0.1
MPD	Myeloproliferative Disorders	96	0.3	0.5	0.1	0.5	0.4	0.5	0.1
C12-13	Hypopharynx	94	0.3	0.5	0.1	0.4	0.3	0.5	0.1
C09	Tonsil	90	0.3	0.5	0.0	0.4	0.3	0.5	0.0
C60	Penis	71	0.2	0.4	0.0	0.3	0.2	0.4	0.0
C50	Breast	66	0.2	0.4	0.0	0.3	0.2	0.4	0.0
C10	Other Oropharynx	50	0.2	0.3	0.0	0.2	0.2	0.3	0.0
C69	Eye	38	0.1	0.2	0.0	0.2	0.1	0.3	0.0
C74	Adrenal Gland	30	0.1	0.2	0.0	0.2	0.1	0.3	0.0
C66	Ureter	41	0.1	0.2	0.0	0.2	0.1	0.2	0.0
C45	Mesothelioma	35	0.1	0.2	0.0	0.2	0.1	0.2	0.0
C65	Renal Pelvis	30	0.1	0.2	0.0	0.1	0.1	0.2	0.0
C75	Other Endocrine	22	0.1	0.1	0.0	0.1	0.1	0.2	0.0
C88	Immunoproliferative Diseases	28	0.1	0.2	0.0	0.1	0.1	0.2	0.0
C14	Pharynx Unspecified	24	0.1	0.1	0.0	0.1	0.1	0.2	0.0
C46	Kaposi Sarcoma	21	0.1	0.1	0.0	0.1	0.1	0.1	0.0
C63	Other Male Genital	18	0.1	0.1	0.0	0.1	0.0	0.1	0.0
C68	Other Urinary Organs	15	0.0	0.1	0.0	0.1	0.0	0.1	0.0
C00	Lip	7	0.0	0.0	0.0	0.0	0.0	0.1	0.0
O&U	Others & Unspecified	958	3.0	5.5	0.5	4.4	4.2	4.7	0.5
All	All sites total	31,801	100.0	181.7	17.9	147.9	146.2	149.5	16.3

Note: all 0.0 = Value <0.1; presented as 0.0 due to rounding.

Appendix 7. Incidence summary table, Chinese females, 2017-2021

ICD-10	SITE	NO.	%	CR	CR74	ASR	(95%CL)		CumR
C50	Breast	9,704	32.0	57.9	5.3	45.6	44.7	46.5	5.2
C18-21	Colorectal	4,192	13.8	25.0	2.2	19.1	18.6	19.7	2.2
C33-34	Lung, Trachea & Bronchus	2,351	7.8	14.0	1.3	10.7	10.3	11.1	1.3
C54	Corpus Uteri	1,491	4.9	8.9	0.8	7.0	6.6	7.3	0.8
C53	Cervix Uteri	1,471	4.9	8.8	0.8	6.9	6.5	7.2	0.8
C56	Ovary	1,330	4.4	7.9	0.7	6.4	6.0	6.7	0.7
C81-85,C96	Lymphoma	812	2.7	4.8	0.4	4.0	3.7	4.3	0.4
C25	Pancreas	842	2.8	5.0	0.5	3.9	3.6	4.1	0.5
C91	Leukaemia	711	2.3	4.2	0.4	3.8	3.5	4.1	0.4
C22	Liver	820	2.7	4.9	0.4	3.7	3.5	4.0	0.4
C44	Non-Melanoma Skin	797	2.6	4.8	0.3	3.5	3.2	3.7	0.3
C16	Stomach	719	2.4	4.3	0.3	3.3	3.0	3.5	0.3
C73	Thyroid	532	1.8	3.2	0.3	2.6	2.4	2.9	0.3
C11	Nasopharynx	525	1.7	3.1	0.3	2.5	2.3	2.7	0.3
C64	Kidney	388	1.3	2.3	0.2	1.8	1.7	2.0	0.2
C55	Uterus Unspecified	359	1.2	2.1	0.2	1.7	1.5	1.9	0.2
C70-72	Brain, Nervous System	272	0.9	1.6	0.1	1.4	1.3	1.6	0.1
C23-24	Gallbladder etc	257	0.8	1.5	0.2	1.2	1.1	1.3	0.2
C47,C49	Connective, Soft Tissue	202	0.7	1.2	0.1	1.0	0.9	1.1	0.1
C67	Bladder	203	0.7	1.2	0.1	0.9	0.8	1.0	0.1
C90	Multiple Myeloma	177	0.6	1.1	0.1	0.8	0.7	1.0	0.1
C01-02	Tongue	146	0.5	0.9	0.1	0.7	0.6	0.8	0.1
C07-08	Salivary Glands	112	0.4	0.7	0.1	0.5	0.4	0.6	0.1
C57	Other Female Genital	101	0.3	0.6	0.1	0.5	0.4	0.6	0.1
C43	Melanoma of Skin	100	0.3	0.6	0.1	0.5	0.4	0.5	0.1
C40-41	Bone	78	0.3	0.5	0.0	0.4	0.3	0.5	0.0
C15	Oesophagus	95	0.3	0.6	0.0	0.4	0.3	0.5	0.0
C03-06	Mouth	89	0.3	0.5	0.0	0.4	0.3	0.5	0.0
C37-38	Other Thoracic Organs	83	0.3	0.5	0.0	0.4	0.3	0.5	0.0
MDS	Myelodysplastic Syndromes	83	0.3	0.5	0.0	0.4	0.3	0.5	0.0
C52	Vagina	68	0.2	0.4	0.0	0.3	0.2	0.4	0.0
C51	Vulva	69	0.2	0.4	0.0	0.3	0.2	0.4	0.0
C17	Small Intestine	66	0.2	0.4	0.0	0.3	0.2	0.4	0.0
C30-31	Nose, Sinuses etc	61	0.2	0.4	0.0	0.3	0.2	0.4	0.0
MPD	Myeloproliferative Disorders	34	0.1	0.2	0.0	0.2	0.1	0.2	0.0
C74	Adrenal Gland	27	0.1	0.2	0.0	0.2	0.1	0.2	0.0
C69	Eye	19	0.1	0.1	0.0	0.1	0.1	0.2	0.0
C32	Larynx	21	0.1	0.1	0.0	0.1	0.1	0.1	0.0
C09	Tonsil	20	0.1	0.1	0.0	0.1	0.1	0.1	0.0
C66	Ureter	20	0.1	0.1	0.0	0.1	0.0	0.1	0.0
C88	Immunoproliferative Diseases	18	0.1	0.1	0.0	0.1	0.0	0.1	0.0
C65	Renal Pelvis	13	0.0	0.1	0.0	0.1	0.0	0.1	0.0
C68	Other Urinary Organs	12	0.0	0.1	0.0	0.1	0.0	0.1	0.0
C10	Other Oropharynx	11	0.0	0.1	0.0	0.1	0.0	0.1	0.0
C75	Other Endocrine	10	0.0	0.1	0.0	0.0	0.0	0.1	0.0
C14	Pharynx Unspecified	9	0.0	0.1	0.0	0.0	0.0	0.1	0.0
C12-13	Hypopharynx	9	0.0	0.1	0.0	0.0	0.0	0.1	0.0
C45	Mesothelioma	7	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C58	Placenta	3	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C46	Kaposi Sarcoma	3	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C00	Lip	3	0.0	0.0	0.0	0.0	0.0	0.0	0.0
O&U	Others & Unspecified	756	2.5	4.5	0.4	3.4	3.2	3.7	0.4
All	All sites total	30,301	100.0	180.9	16.2	141.7	140.1	143.4	15.0

Appendix 8. Incidence summary table, Indian males, 2017-2021

ICD-10	SITE	NO.	%	CR	CR74	ASR	(95%CL)		CumR
C18-21	Colorectal	866	17.7	17.2	2.2	17.4	16.2	18.5	2.1
C33-34	Lung, Trachea & Bronchus	514	10.5	10.2	1.4	10.4	9.5	11.3	1.4
C61	Prostate	424	8.7	8.4	1.2	9.2	8.3	10.1	1.2
C22	Liver	317	6.5	6.3	0.8	6.4	5.7	7.1	0.8
C81-85,C96	Lymphoma	290	5.9	5.8	0.6	5.5	4.9	6.1	0.6
C16	Stomach	261	5.3	5.2	0.6	5.1	4.5	5.8	0.6
C91-95	Leukaemia	230	4.7	4.6	0.4	4.7	4.1	5.3	0.4
C25	Pancreas	172	3.5	3.4	0.4	3.4	2.9	3.9	0.4
C64	Kidney	172	3.5	3.4	0.4	3.4	2.9	3.9	0.4
C32	Larynx	146	3.0	2.9	0.4	2.9	2.5	3.4	0.4
C67	Bladder	125	2.6	2.5	0.3	2.6	2.2	3.1	0.3
C15	Oesophagus	110	2.2	2.2	0.3	2.2	1.8	2.6	0.3
C01-02	Tongue	112	2.3	2.2	0.3	2.2	1.8	2.6	0.3
C70-72	Brain, Nervous System	111	2.3	2.2	0.2	2.1	1.7	2.6	0.2
C44	Non-melanoma skin	94	1.9	1.9	0.2	1.9	1.5	2.3	0.2
C03-06	Mouth	93	1.9	1.9	0.2	1.9	1.5	2.2	0.2
C90	Multiple myeloma	68	1.4	1.4	0.2	1.3	1.0	1.7	0.2
C23-24	Gallbladder etc	63	1.3	1.3	0.1	1.3	1.0	1.6	0.1
C73	Thyroid	67	1.4	1.3	0.1	1.2	0.9	1.5	0.1
C62	Testis	67	1.4	1.3	0.1	1.2	0.9	1.5	0.1
C47,C49	Connective, soft tissue	49	1.0	1.0	0.1	0.9	0.7	1.2	0.1
C40-41	Bone	38	0.8	0.8	0.1	0.8	0.5	1.0	0.1
C11	Nasopharynx	40	0.8	0.8	0.1	0.8	0.5	1.0	0.1
C12-13	Hypopharynx	34	0.7	0.7	0.1	0.7	0.4	0.9	0.1
C09	Tonsil	34	0.7	0.7	0.1	0.7	0.4	0.9	0.1
C17	Small intestine	30	0.6	0.6	0.1	0.6	0.4	0.8	0.1
C10	Other oropharynx	28	0.6	0.6	0.1	0.5	0.3	0.7	0.1
C50	Breast	27	0.6	0.5	0.1	0.5	0.3	0.7	0.1
C30-31	Nose, sinuses etc	24	0.5	0.5	0.1	0.5	0.3	0.7	0.1
C60	Penis	23	0.5	0.5	0.0	0.4	0.3	0.6	0.0
C07-08	Salivary glands	21	0.4	0.4	0.0	0.4	0.2	0.6	0.0
MPD	Myeloproliferative disorders	19	0.4	0.4	0.0	0.4	0.2	0.5	0.0
C37-38	Other thoracic organs	16	0.3	0.3	0.0	0.3	0.2	0.5	0.0
MDS	Myelodysplastic syndromes	13	0.3	0.3	0.0	0.3	0.1	0.4	0.0
C69	Eye	10	0.2	0.2	0.0	0.3	0.1	0.4	0.0
C46	Kaposi sarcoma	12	0.2	0.2	0.0	0.2	0.1	0.3	0.0
C74	Adrenal gland	7	0.1	0.1	0.0	0.2	0.0	0.3	0.0
C43	Melanoma of skin	8	0.2	0.2	0.0	0.2	0.0	0.3	0.0
C14	Pharynx unspecified	7	0.1	0.1	0.0	0.1	0.0	0.3	0.0
C63	Other male genital	7	0.1	0.1	0.0	0.1	0.0	0.2	0.0
C66	Ureter	4	0.1	0.1	0.0	0.1	0.0	0.2	0.0
C45	Mesothelioma	4	0.1	0.1	0.0	0.1	0.0	0.2	0.0
C75	Other endocrine	4	0.1	0.1	0.0	0.1	0.0	0.2	0.0
C88	Immunoproliferative diseases	3	0.1	0.1	0.0	0.1	0.0	0.1	0.0
C00	Lip	2	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C68	Other urinary organs	2	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C65	Renal pelvis	2	0.0	0.0	0.0	0.0	0.0	0.1	0.0
O&U	Others & unspecified	125	2.6	2.5	0.3	2.5	2.1	3.0	0.3
All	All sites total	4,895	100.0	97.4	11.8	98.2	95.4	101.0	11.1

Note: all 0.0 = Value <0.1; presented as 0.0 due to rounding.

Appendix 9. Incidence summary table, Indian females, 2017-2021

SITE	ICD-10	NO.	%	CR	CR74	ASR	(95%CL)		CumR
C50	Breast	2,896	37.4	58.5	6.1	51.3	49.4	53.1	5.9
C18-21	Colorectal	670	8.6	13.5	1.5	12.2	11.2	13.1	1.5
C54	Corpus Uteri	526	6.8	10.6	1.1	9.3	8.5	10.1	1.1
C56	Ovary	354	4.6	7.2	0.7	6.3	5.7	7.0	0.7
C53	Cervix Uteri	297	3.8	6.0	0.6	5.3	4.7	5.9	0.6
C33-34	Lung, Trachea & Bronchus	248	3.2	5.0	0.5	4.5	4.0	5.1	0.5
C81-85,C96	Lymphoma	239	3.1	4.8	0.4	4.3	3.8	4.9	0.4
C91-95	Leukaemia	217	2.8	4.4	0.4	4.3	3.7	4.9	0.4
C16	Stomach	228	2.9	4.6	0.5	4.1	3.6	4.7	0.5
C03-06	Mouth	216	2.8	4.4	0.5	4.0	3.4	4.5	0.5
C73	Thyroid	213	2.7	4.3	0.4	3.8	3.3	4.3	0.4
C22	Liver	147	1.9	3.0	0.3	2.7	2.3	3.1	0.3
C55	Uterus Unspecified	149	1.9	3.0	0.3	2.6	2.2	3.0	0.3
C15	Oesophagus	122	1.6	2.5	0.3	2.2	1.8	2.6	0.3
C01-02	Tongue	113	1.5	2.3	0.3	2.0	1.7	2.4	0.3
C25	Pancreas	109	1.4	2.2	0.2	2.0	1.6	2.4	0.2
C44	Non-Melanoma Skin	96	1.2	1.9	0.2	1.8	1.4	2.2	0.2
C70-72	Brain, Nervous System	73	0.9	1.5	0.1	1.5	1.2	1.9	0.1
C64	Kidney	78	1.0	1.6	0.2	1.5	1.1	1.8	0.2
C90	Multiple Myeloma	69	0.9	1.4	0.2	1.2	0.9	1.5	0.2
C23-24	Gallbladder etc	48	0.6	1.0	0.1	0.9	0.6	1.1	0.1
C47,C49	Connective, Soft Tissue	44	0.6	0.9	0.1	0.8	0.6	1.0	0.1
C57	Other Female Genital	44	0.6	0.9	0.1	0.8	0.5	1.0	0.1
C67	Bladder	38	0.5	0.8	0.1	0.7	0.5	1.0	0.1
C12-13	Hypopharynx	34	0.4	0.7	0.1	0.6	0.4	0.8	0.1
C40-41	Bone	29	0.4	0.6	0.0	0.6	0.4	0.8	0.0
C07-08	Salivary Glands	26	0.3	0.5	0.1	0.5	0.3	0.7	0.1
C51	Vulva	23	0.3	0.5	0.0	0.4	0.2	0.6	0.0
C00	Lip	21	0.3	0.4	0.0	0.4	0.2	0.6	0.0
C30-31	Nose, Sinuses etc	19	0.2	0.4	0.0	0.4	0.2	0.5	0.0
C32	Larynx	19	0.2	0.4	0.0	0.3	0.2	0.5	0.0
C17	Small Intestine	18	0.2	0.4	0.1	0.3	0.2	0.5	0.1
C52	Vagina	16	0.2	0.3	0.0	0.3	0.2	0.4	0.0
C14	Pharynx Unspecified	14	0.2	0.3	0.0	0.3	0.1	0.4	0.0
C11	Nasopharynx	12	0.2	0.2	0.0	0.2	0.1	0.4	0.0
MDS	Myelodysplastic Syndromes	11	0.1	0.2	0.0	0.2	0.1	0.3	0.0
MPD	Myeloproliferative Disorders	10	0.1	0.2	0.0	0.2	0.1	0.3	0.0
C43	Melanoma of Skin	11	0.1	0.2	0.0	0.2	0.1	0.3	0.0
C37-38	Other Thoracic Organs	9	0.1	0.2	0.0	0.2	0.1	0.3	0.0
C69	Eye	6	0.1	0.1	0.0	0.2	0.0	0.3	0.0
C74	Adrenal Gland	4	0.1	0.1	0.0	0.1	0.0	0.2	0.0
C09	Tonsil	6	0.1	0.1	0.0	0.1	0.0	0.2	0.0
C10	Other Oropharynx	5	0.1	0.1	0.0	0.1	0.0	0.2	0.0
C66	Ureter	5	0.1	0.1	0.0	0.1	0.0	0.2	0.0
C45	Mesothelioma	4	0.1	0.1	0.0	0.1	0.0	0.1	0.0
C68	Other Urinary Organs	2	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C88	Immunoproliferative Diseases	2	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C65	Renal Pelvis	2	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C58	Placenta	2	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C75	Other Endocrine	2	0.0	0.0	0.0	0.0	0.0	0.1	0.0
O&U	Others & Unspecified	203	2.6	4.1	0.4	3.7	3.1	4.2	0.4
All	All sites total	7,749	100.0	156.6	16.3	139.7	136.5	142.8	15.1

Note: all 0.0 = Value <0.1; presented as 0.0 due to rounding.

Appendix 10. Incidence summary table, Other Bumiputera males, 2017-2021

SITE	ICD-10	NO.	%	CR	CR74	ASR	(95%CL)	CumR
C33-34	Lung, Trachea & Bronchus	1,087	14.9	11.6	1.6	13.4	12.6 14.2	1.6
C18-21	Colorectal	945	12.9	10.1	1.4	11.4	10.7 12.1	1.4
C11	Nasopharynx	779	10.7	8.3	1.0	8.9	8.3 9.5	1.0
C22	Liver	508	7.0	5.4	0.8	6.2	5.7 6.8	0.8
C81-85,C96	Lymphoma	500	6.8	5.3	0.6	5.7	5.2 6.2	0.6
C61	Prostate	426	5.8	4.6	0.8	5.5	5.0 6.1	0.8
C16	Stomach	414	5.7	4.4	0.6	5.0	4.5 5.5	0.6
C91-95	Leukaemia	346	4.7	3.7	0.3	4.0	3.6 4.4	0.3
C44	Non-Melanoma Skin	258	3.5	2.8	0.3	3.1	2.7 3.4	0.3
C67	Bladder	121	1.7	1.3	0.2	1.5	1.2 1.8	0.2
C64	Kidney	124	1.7	1.3	0.2	1.5	1.2 1.8	0.2
C70-72	Brain, Nervous System	124	1.7	1.3	0.1	1.4	1.2 1.7	0.1
C25	Pancreas	117	1.6	1.3	0.2	1.4	1.1 1.6	0.2
C47,C49	Connective, Soft Tissue	110	1.5	1.2	0.1	1.3	1.0 1.5	0.1
C32	Larynx	88	1.2	0.9	0.1	1.1	0.9 1.3	0.1
C23-24	Gallbladder etc	88	1.2	0.9	0.1	1.1	0.8 1.3	0.1
C73	Thyroid	91	1.2	1.0	0.1	1.0	0.8 1.3	0.1
C15	Oesophagus	81	1.1	0.9	0.1	1.0	0.8 1.2	0.1
C90	Multiple Myeloma	76	1.0	0.8	0.1	0.9	0.7 1.2	0.1
C01-02	Tongue	80	1.1	0.9	0.1	0.9	0.7 1.1	0.1
C03-06	Mouth	77	1.1	0.8	0.1	0.9	0.7 1.1	0.1
C30-31	Nose, Sinuses etc	57	0.8	0.6	0.1	0.7	0.5 0.9	0.1
C40-41	Bone	51	0.7	0.5	0.0	0.5	0.4 0.7	0.0
C07-08	Salivary Glands	45	0.6	0.5	0.1	0.5	0.4 0.7	0.1
C43	Melanoma of Skin	39	0.5	0.4	0.1	0.5	0.3 0.6	0.1
C62	Testis	45	0.6	0.5	0.0	0.5	0.3 0.6	0.0
C37-38	Other Thoracic Organs	41	0.6	0.4	0.0	0.5	0.3 0.6	0.0
C60	Penis	35	0.5	0.4	0.0	0.4	0.3 0.6	0.0
C17	Small Intestine	32	0.4	0.3	0.0	0.4	0.2 0.5	0.0
MDS	Myelodysplastic Syndromes	27	0.4	0.3	0.1	0.3	0.2 0.5	0.1
C46	Kaposi Sarcoma	31	0.4	0.3	0.0	0.3	0.2 0.4	0.0
C12-13	Hypopharynx	23	0.3	0.2	0.0	0.3	0.2 0.4	0.0
MPD	Myeloproliferative Disorders	21	0.3	0.2	0.0	0.3	0.2 0.4	0.0
C88	Immunoproliferative Diseases	18	0.2	0.2	0.0	0.2	0.1 0.3	0.0
C69	Eye	15	0.2	0.2	0.0	0.2	0.1 0.3	0.0
C74	Adrenal Gland	14	0.2	0.1	0.0	0.2	0.1 0.3	0.0
C14	Pharynx Unspecified	15	0.2	0.2	0.0	0.2	0.1 0.3	0.0
C10	Other Oropharynx	14	0.2	0.1	0.0	0.2	0.1 0.3	0.0
C09	Tonsil	11	0.2	0.1	0.0	0.1	0.1 0.2	0.0
C75	Other Endocrine	11	0.2	0.1	0.0	0.1	0.0 0.2	0.0
C50	Breast	8	0.1	0.1	0.0	0.1	0.0 0.2	0.0
C63	Other Male Genital	6	0.1	0.1	0.0	0.1	0.0 0.1	0.0
C45	Mesothelioma	3	0.0	0.0	0.0	0.0	0.0 0.1	0.0
C00	Lip	3	0.0	0.0	0.0	0.0	0.0 0.1	0.0
C68	Other Urinary Organs	2	0.0	0.0	0.0	0.0	0.0 0.1	0.0
C65	Renal Pelvis	1	0.0	0.0	0.0	0.0	0.0 0.0	0.0
O&U	Others & Unspecified	292	4.0	3.1	0.4	3.5	3.1 3.9	0.4
All	All sites total	7,300	100.0	78.0	10.3	87.4	85.3 89.4	9.8

Note: all 0.0 = Value <0.1; presented as 0.0 due to rounding.

Appendix 11. Incidence summary table, Other Bumiputera females, 2017-2021

SITE	ICD-10	NO.	%	CR	CR74	ASR	(95%CL)		CumR
C50	Breast	1,755	21.0	19.2	2.2	20.4	19.4	21.4	2.2
C53	Cervix Uteri	800	9.6	8.7	1.0	9.3	8.6	9.9	1.0
C33-34	Lung, Trachea & Bronchus	698	8.4	7.6	1.1	8.9	8.2	9.5	1.1
C18-21	Colorectal	709	8.5	7.7	1.0	8.7	8.1	9.4	1.0
C81-85,C96	Lymphoma	397	4.8	4.3	0.5	4.7	4.2	5.1	0.5
C54	Corpus Uteri	375	4.5	4.1	0.5	4.4	3.9	4.8	0.5
C56	Ovary	379	4.5	4.1	0.5	4.4	3.9	4.8	0.5
C73	Thyroid	387	4.6	4.2	0.5	4.3	3.9	4.7	0.5
C11	Nasopharynx	339	4.1	3.7	0.4	3.9	3.5	4.4	0.4
C91-95	Leukaemia	284	3.4	3.1	0.3	3.4	3.0	3.8	0.3
C16	Stomach	260	3.1	2.8	0.4	3.2	2.8	3.6	0.4
C44	Non-Melanoma Skin	247	3.0	2.7	0.4	3.1	2.7	3.5	0.4
C22	Liver	219	2.6	2.4	0.4	2.8	2.4	3.2	0.4
C25	Pancreas	109	1.3	1.2	0.2	1.4	1.1	1.6	0.2
C70-72	Brain, Nervous System	110	1.3	1.2	0.1	1.3	1.0	1.5	0.1
C23-24	Gallbladder etc	86	1.0	0.9	0.1	1.1	0.8	1.3	0.1
C03-06	Mouth	83	1.0	0.9	0.1	1.0	0.8	1.3	0.1
C47,C49	Connective, Soft Tissue	81	1.0	0.9	0.1	0.9	0.7	1.1	0.1
C90	Multiple Myeloma	70	0.8	0.8	0.1	0.9	0.7	1.1	0.1
C55	Uterus Unspecified	72	0.9	0.8	0.1	0.8	0.6	1.0	0.1
C01-02	Tongue	64	0.8	0.7	0.1	0.7	0.6	0.9	0.1
C64	Kidney	58	0.7	0.6	0.1	0.7	0.5	0.9	0.1
C15	Oesophagus	50	0.6	0.5	0.1	0.6	0.5	0.8	0.1
C40-41	Bone	45	0.5	0.5	0.0	0.5	0.3	0.6	0.0
C67	Bladder	38	0.5	0.4	0.1	0.5	0.3	0.6	0.1
C57	Other Female Genital	36	0.4	0.4	0.0	0.4	0.3	0.6	0.0
C07-08	Salivary Glands	36	0.4	0.4	0.0	0.4	0.3	0.6	0.0
C17	Small Intestine	33	0.4	0.4	0.0	0.4	0.3	0.5	0.0
MPD	Myeloproliferative Disorders	30	0.4	0.3	0.0	0.4	0.2	0.5	0.0
C43	Melanoma of Skin	31	0.4	0.3	0.0	0.4	0.2	0.5	0.0
C30-31	Nose, Sinuses etc	25	0.3	0.3	0.0	0.3	0.2	0.4	0.0
C37-38	Other Thoracic Organs	25	0.3	0.3	0.0	0.3	0.2	0.4	0.0
C51	Vulva	21	0.3	0.2	0.0	0.3	0.1	0.4	0.0
C12-13	Hypopharynx	17	0.2	0.2	0.0	0.2	0.1	0.3	0.0
C32	Larynx	15	0.2	0.2	0.0	0.2	0.1	0.3	0.0
C00	Lip	15	0.2	0.2	0.0	0.2	0.1	0.3	0.0
C69	Eye	13	0.2	0.1	0.0	0.2	0.1	0.3	0.0
MDS	Myelodysplastic Syndromes	13	0.2	0.1	0.0	0.2	0.1	0.3	0.0
C74	Adrenal Gland	12	0.1	0.1	0.0	0.2	0.1	0.2	0.0
C52	Vagina	11	0.1	0.1	0.0	0.1	0.1	0.2	0.0
C09	Tonsil	8	0.1	0.1	0.0	0.1	0.0	0.2	0.0
C10	Other Oropharynx	6	0.1	0.1	0.0	0.1	0.0	0.1	0.0
C75	Other Endocrine	5	0.1	0.1	0.0	0.1	0.0	0.1	0.0
C46	Kaposi Sarcoma	4	0.0	0.0	0.0	0.1	0.0	0.1	0.0
C14	Pharynx Unspecified	4	0.0	0.0	0.0	0.1	0.0	0.1	0.0
C45	Mesothelioma	4	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C58	Placenta	4	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C88	Immunoproliferative Diseases	3	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C66	Ureter	2	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C68	Other Urinary Organs	2	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C65	Renal Pelvis	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0
O&U	Others & Unspecified	254	3.0	2.8	0.4	3.1	2.8	3.5	0.4
All	All sites total	8,345	100.0	91.2	11.1	99.7	97.5	101.9	10.5

Appendix 12. Population table by gender and ethnicity (all residents), 2017-2021

AGE GROUP	ETHNIC GROUPS					TOTAL
	MALAY	CHINESE	INDIAN	OTHER BUMIPUTERA	OTHERS	
Male						
0-4	3,874,000	1,085,500	324,500	776,000	50,500	6,110,500
5-9	3,911,500	1,346,000	407,000	823,000	52,000	6,539,000
10-14	3,743,000	1,411,000	428,500	963,500	46,500	6,593,000
15-19	4,215,500	1,336,000	434,500	906,000	61,000	6,953,000
20-24	3,696,500	1,242,500	410,500	856,000	56,500	6,261,500
25-29	3,585,500	1,291,000	419,000	863,500	65,000	6,224,000
30-34	3,608,000	1,336,000	434,000	781,500	66,000	6,226,000
35-39	3,358,000	1,469,000	449,500	724,000	48,500	6,049,500
40-44	2,576,000	1,297,000	364,000	532,000	34,500	4,804,000
45-49	2,209,000	1,216,500	308,000	487,500	25,500	4,246,500
50-54	1,912,500	1,086,500	274,500	437,000	22,500	3,732,500
55-59	1,797,000	1,072,000	264,000	372,500	20,500	3,525,500
60-64	1,374,000	838,000	196,000	299,000	17,500	2,725,000
65-69	1,087,500	583,000	141,500	228,000	15,500	2,055,500
70-74	670,000	416,000	85,500	133,500	8,500	1,314,000
75+	643,000	471,500	83,000	176,000	8,500	1,383,000
Total	42,261,000	17,497,500	5,024,000	9,359,000	599,000	74,742,500
Female						
0-4	3,703,500	1,055,000	322,500	726,000	47,000	5,853,500
5-9	3,644,500	1,231,500	373,500	780,000	47,000	6,077,500
10-14	3,489,500	1,299,000	404,000	913,000	39,500	6,145,000
15-19	3,928,000	1,232,500	400,000	871,000	47,000	6,479,000
20-24	3,523,500	1,172,000	389,500	859,500	46,500	5,991,000
25-29	3,546,500	1,263,000	417,500	877,000	49,000	6,153,000
30-34	3,627,000	1,351,000	421,000	799,500	49,500	6,247,500
35-39	3,218,500	1,410,000	420,500	709,500	42,000	5,801,000
40-44	2,512,000	1,223,500	349,500	536,000	31,000	4,652,000
45-49	2,193,500	1,150,000	313,000	494,000	27,000	4,177,500
50-54	1,954,500	1,054,500	283,500	425,500	22,000	3,739,500
55-59	1,803,000	982,500	272,500	365,500	18,500	3,442,500
60-64	1,423,500	804,500	218,000	273,500	15,000	2,734,000
65-69	1,127,500	578,000	158,500	204,500	14,000	2,082,000
70-74	734,000	420,500	102,000	139,500	9,000	1,405,000
75+	795,000	519,000	101,500	177,000	10,500	1,603,500
Total	41,224,000	16,746,500	4,947,000	9,151,000	514,500	72,583,500
Both genders						
0-4	7,577,500	2,140,000	646,500	1,502,000	97,500	11,964,000
5-9	7,556,000	2,577,500	780,500	1,603,000	99,500	12,616,000
10-14	7,233,000	2,710,000	832,500	1,876,500	86,000	12,738,000
15-19	8,144,000	2,569,000	834,500	1,777,000	107,500	13,432,000
20-24	7,220,500	2,414,500	800,000	1,715,500	102,500	12,252,500
25-29	7,132,000	2,553,500	836,000	1,741,000	114,500	12,377,000
30-34	7,235,000	2,687,000	855,000	1,580,500	115,000	12,473,000
35-39	6,576,500	2,879,500	870,000	1,433,500	91,000	11,850,000
40-44	5,088,000	2,520,500	713,500	1,068,000	65,500	9,456,000
45-49	4,402,500	2,367,000	621,000	981,500	52,000	8,423,500
50-54	3,867,000	2,141,000	558,000	862,500	44,500	7,472,500
55-59	3,600,500	2,054,500	536,500	738,000	39,000	6,968,000
60-64	2,798,000	1,642,500	414,000	572,500	32,500	5,459,000
65-69	2,215,000	1,160,500	300,000	432,500	29,500	4,137,500
70-74	1,404,000	836,500	187,500	273,000	17,500	2,719,000
75+	1,438,500	991,000	185,000	353,500	19,000	2,986,500
TOTAL	83,488,000	34,244,500	9,970,500	18,510,500	1,113,000	147,324,500

Note: all 0.0 = Value <0.1; presented as 0.0 due to rounding.

Appendix 13. Population table by gender, state and age group (all residents), 2017-2021

AGE GROUP	STATE				
	PERLIS	KEDAH	P. PINANG	PERAK	SELANGOR
Male					
0-4	50,000	447,500	267,000	454,000	1,215,500
5-9	51,000	453,500	290,500	554,500	1,263,500
10-14	63,000	432,500	301,000	515,000	1,217,500
15-19	86,000	491,500	319,000	588,000	1,306,000
20-24	72,000	533,000	357,000	489,000	1,203,500
25-29	53,000	438,000	349,500	427,500	1,332,500
30-34	50,500	346,000	328,000	421,500	1,629,500
35-39	46,500	303,000	333,000	415,500	1,521,500
40-44	53,000	281,000	285,000	360,500	1,196,000
45-49	27,000	267,000	276,000	310,000	1,030,500
50-54	29,500	260,500	249,500	304,500	867,500
55-59	30,500	247,000	221,000	332,000	737,000
60-64	24,000	203,000	189,500	266,000	567,500
65-69	20,000	151,000	120,500	210,000	456,000
70-74	13,000	102,000	69,500	140,000	282,000
75+	15,000	112,500	68,000	149,500	259,500
Total	684,000	5,069,000	4,024,000	5,937,500	16,085,500
Female					
0-4	46,500	422,500	244,000	429,000	1,179,000
5-9	47,000	430,500	252,500	510,500	1,170,000
10-14	57,500	413,000	270,500	469,500	1,176,500
15-19	82,000	452,500	305,500	549,000	1,207,000
20-24	70,500	491,500	333,000	476,000	1,139,000
25-29	49,500	424,000	352,500	411,500	1,360,000
30-34	49,000	356,500	344,500	416,500	1,680,500
35-39	41,000	310,500	323,500	400,500	1,480,000
40-44	58,000	281,500	271,000	364,500	1,073,500
45-49	34,500	290,000	269,500	324,000	953,500
50-54	31,500	283,000	253,500	331,000	805,000
55-59	32,000	260,500	218,500	346,500	671,000
60-64	26,500	225,000	195,500	280,500	530,000
65-69	24,500	163,500	125,500	229,500	438,000
70-74	14,000	110,500	75,500	153,500	321,000
75+	20,000	147,000	90,000	198,000	273,000
Total	684,000	5,062,000	3,925,000	5,890,000	15,457,000
Both genders					
0-4	96,500	870,000	511,000	883,500	2,394,500
5-9	97,500	884,000	543,000	1,065,000	2,433,500
10-14	120,500	845,500	571,500	984,500	2,394,000
15-19	168,500	944,000	624,500	1,136,500	2,512,500
20-24	142,000	1,024,500	690,000	964,500	2,342,500
25-29	103,000	862,000	702,000	838,500	2,692,000
30-34	99,500	702,000	672,000	838,500	3,310,000
35-39	88,000	613,000	657,000	816,500	3,001,500
40-44	111,000	563,000	556,000	724,500	2,269,000
45-49	61,500	556,500	545,500	633,000	1,984,000
50-54	61,000	543,000	503,000	635,000	1,672,500
55-59	63,000	507,500	439,500	677,500	1,408,000
60-64	51,000	427,500	385,000	547,000	1,097,500
65-69	44,500	314,500	246,000	440,500	894,000
70-74	27,500	212,500	145,000	293,500	603,000
75+	34,500	259,500	157,500	348,500	533,000
TOTAL	1,369,500	10,129,000	7,948,500	11,827,000	31,541,500

Appendix 13. Population table by gender, state and age group (all residents), 2017-2021

AGE GROUP	STATE				
	W.P.KL&P	N. SEMBILAN	MELAKA	JOHOR	PAHANG
Male					
0-4	345,500	266,000	217,500	763,500	347,500
5-9	362,000	285,500	207,500	858,000	360,000
10-14	398,500	246,000	177,500	803,000	414,000
15-19	344,500	259,000	278,500	853,500	379,500
20-24	281,000	217,000	205,000	817,500	300,000
25-29	426,000	245,500	193,000	742,500	297,500
30-34	468,000	240,000	166,500	749,500	296,500
35-39	541,500	222,000	192,000	711,500	337,000
40-44	384,500	165,000	154,000	602,000	232,000
45-49	306,000	145,000	104,500	544,500	204,500
50-54	197,500	125,000	93,000	499,000	164,500
55-59	193,500	149,000	106,000	455,500	165,000
60-64	128,000	106,000	78,000	346,000	117,500
65-69	122,000	87,500	61,500	211,000	97,500
70-74	87,000	48,500	37,500	145,500	71,000
75+	93,000	47,500	39,500	176,500	77,000
Total	4,678,500	2,854,500	2,311,500	9,279,000	3,861,000
Female					
0-4	331,000	247,500	203,000	773,000	338,500
5-9	327,000	258,000	190,500	804,000	342,000
10-14	372,000	216,500	165,500	753,000	370,000
15-19	304,500	242,500	242,000	803,000	350,000
20-24	282,500	213,000	196,000	762,500	272,500
25-29	458,000	231,500	197,000	717,500	280,000
30-34	498,500	233,000	162,500	699,500	289,500
35-39	547,500	204,000	160,000	681,000	292,000
40-44	367,000	167,500	175,500	551,000	252,000
45-49	276,000	143,500	113,000	532,000	194,500
50-54	194,000	139,000	102,500	492,000	162,000
55-59	190,000	150,500	107,500	427,000	162,000
60-64	126,000	113,500	82,000	354,500	119,000
65-69	125,500	87,000	68,500	213,000	95,500
70-74	88,500	49,000	40,500	149,500	71,500
75+	92,000	58,000	51,000	184,500	78,000
Total	4,580,000	2,754,000	2,257,000	8,897,000	3,669,000
Both genders					
0-4	676,500	514,000	420,500	1,536,500	685,500
5-9	689,000	543,500	398,000	1,662,000	701,500
10-14	771,000	462,000	343,000	1,555,500	784,000
15-19	649,500	501,500	520,500	1,656,500	730,000
20-24	563,500	430,000	401,000	1,580,000	572,000
25-29	884,500	477,000	390,500	1,459,500	577,500
30-34	966,500	473,000	329,000	1,449,000	586,000
35-39	1,089,000	426,000	352,000	1,392,500	629,000
40-44	751,500	332,500	329,500	1,152,500	484,000
45-49	582,500	288,500	217,500	1,076,500	398,500
50-54	391,000	264,000	195,500	991,000	326,500
55-59	383,500	299,500	213,000	882,000	327,500
60-64	254,000	219,500	160,500	700,500	236,500
65-69	247,500	174,500	130,500	424,000	193,000
70-74	175,500	98,000	78,000	295,000	142,500
75+	185,500	106,000	90,000	361,500	155,500
TOTAL	9,260,500	5,609,500	4,569,000	18,174,500	7,529,500

Appendix 13. Population table by gender, state and age group (all residents), 2017-2021

AGE GROUP	STATE				
	TERENGGANU	KELANTAN	SABAH	SARAWAK	W.P. LABUAN
Male					
0-4	278,000	446,500	567,000	419,000	25,000
5-9	290,500	481,000	579,500	483,000	20,000
10-14	283,500	463,000	724,500	535,000	19,000
15-19	296,000	505,000	678,000	549,500	18,500
20-24	251,000	396,500	613,500	510,000	16,500
25-29	237,500	330,000	611,500	522,500	18,500
30-34	217,000	282,000	547,000	462,500	21,000
35-39	204,500	251,500	523,000	423,500	22,500
40-44	151,500	204,500	361,000	362,000	11,500
45-49	136,000	197,500	322,000	367,500	9,500
50-54	121,000	190,000	288,500	335,000	9,000
55-59	118,500	195,000	250,000	317,500	9,000
60-64	89,500	149,500	216,000	238,000	6,000
65-69	62,500	107,500	158,000	185,500	4,000
70-74	39,500	75,000	85,500	115,500	2,500
75+	34,000	68,000	113,000	126,000	2,500
Total	2,810,500	4,342,500	6,638,000	5,952,000	215,000
Female					
0-4	271,500	432,500	519,000	395,500	21,500
5-9	273,500	447,000	559,000	449,000	17,000
10-14	265,500	433,000	672,500	493,500	17,500
15-19	281,500	508,500	607,000	521,500	22,500
20-24	248,000	406,000	591,500	491,500	18,000
25-29	223,500	312,000	617,500	500,000	19,000
30-34	210,000	273,000	568,000	447,000	20,000
35-39	188,500	238,500	508,000	407,500	17,500
40-44	151,500	208,000	358,500	362,500	11,000
45-49	142,500	217,500	315,500	362,500	10,000
50-54	130,500	210,000	270,500	326,500	9,000
55-59	126,500	211,000	227,500	304,500	7,500
60-64	95,500	163,000	185,500	231,500	5,000
65-69	66,500	117,500	144,500	178,500	4,000
70-74	42,000	78,500	88,000	120,500	1,500
75+	53,500	97,000	107,500	150,500	3,500
Total	2,770,500	4,353,000	6,340,000	5,742,500	204,500
Both genders					
0-4	549,000	879,000	1,086,000	814,500	46,500
5-9	564,000	928,000	1,138,500	931,500	37,500
10-14	548,000	896,000	1,397,000	1,028,500	36,000
15-19	578,000	1,013,500	1,285,500	1,071,000	41,000
20-24	499,500	802,500	1,205,500	1,001,500	34,500
25-29	460,500	642,000	1,229,000	1,022,000	37,500
30-34	426,500	555,000	1,115,000	909,500	41,000
35-39	393,500	490,000	1,031,000	831,500	40,000
40-44	302,000	412,500	719,500	725,000	22,500
45-49	277,500	415,000	637,000	730,000	19,500
50-54	252,000	400,000	559,000	661,500	18,500
55-59	245,000	406,000	477,000	622,000	16,500
60-64	185,500	312,500	401,500	469,500	11,500
65-69	129,500	225,000	302,500	364,000	8,000
70-74	81,500	153,500	174,000	236,000	4,000
75+	87,000	163,500	221,000	276,500	6,000
TOTAL	5,579,000	8,694,000	12,979,000	11,694,500	420,500

**Appendix 14. Incidence summary for 13 selected cancers by state and gender, 2017-2021
(State-Level Data Updated to 31st August 2024)**

STATE	TOTAL	MALE							FEMALE						
		NO.	CR	CR74	ASR	(95% CL)	CumR	NO.	CR	CR74	ASR	(95% CL)	CumR		
1. Breast															
Selangor	5,584	52	0.3	0.0	0.3	0.2	0.4	0.0	5,532	35.8	3.9	34.3	33.4	35.2	3.8
Johor	4,211	23	0.2	0.0	0.3	0.2	0.4	0.0	4,188	51.6	7.2	60.6	58.7	62.6	7.0
Perak	2,890	16	0.3	0.0	0.2	0.1	0.3	0.0	2,874	48.8	4.6	40.6	39.1	42.1	4.5
W.P. KL&P	2,648	13	0.3	0.0	0.3	0.1	0.5	0.0	2,635	57.5	6.9	59.4	57.1	61.8	6.6
P. Pinang	2,425	13	0.3	0.0	0.3	0.1	0.5	0.0	2,412	61.5	6.0	51.5	49.5	53.6	5.8
Kedah	1,990	18	0.4	0.0	0.3	0.2	0.5	0.0	1,972	39.0	4.0	35.7	34.1	37.3	3.9
Sarawak	1,796	9	0.2	0.0	0.1	0.0	0.2	0.0	1,787	31.1	3.0	27.8	26.5	29.1	3.0
Sabah	1,612	9	0.1	0.0	0.2	0.1	0.3	0.0	1,603	25.3	3.1	28.6	27.1	30.0	3.1
N. Sembilan	1,379	4	0.1	0.0	0.1	0.0	0.2	0.0	1,375	49.9	5.4	47.2	44.7	49.8	5.2
Pahang	1,366	7	0.2	0.0	0.2	0.1	0.4	0.0	1,359	37.0	4.3	38.3	36.2	40.3	4.3
Melaka	1,293	7	0.3	0.0	0.4	0.1	0.6	0.0	1,286	57.0	6.3	56.3	53.2	59.5	6.1
Kelantan	1,153	12	0.3	0.0	0.3	0.1	0.5	0.0	1,141	26.2	2.9	27.8	26.2	29.4	2.9
Terengganu	963	3	0.1	0.0	0.2	0.0	0.3	0.0	960	34.7	3.9	36.6	34.3	38.9	3.8
Perlis	283	0	0.0	0.0	0.0	0.0	0.0	0.0	283	41.4	4.6	39.3	34.7	44.0	4.5
W.P. Labuan	48	0	0.0	0.0	0.0	0.0	0.0	0.0	48	23.5	3.2	29.4	20.8	38.0	3.1
2. Colorectal															
Selangor	3,953	2249	14.0	1.7	14.6	14.0	15.2	1.7	1,704	11.0	1.3	11.1	10.6	11.6	1.3
Johor	3,240	1836	19.8	2.7	21.2	20.2	22.2	2.7	1,404	17.3	2.9	23.8	22.5	25.1	2.9
Perak	2,740	1590	26.8	2.7	23.1	21.9	24.2	2.6	1,150	19.5	1.8	15.2	14.3	16.1	1.7
W.P. KL&P	2,069	1179	25.2	3.4	27.6	26.0	29.2	3.3	890	19.4	2.4	20.6	19.2	22.0	2.4
P. Pinang	1,996	1147	28.5	3.4	27.6	26.0	29.2	3.3	849	21.6	2.2	18.7	17.4	20.0	2.1
Sarawak	1,882	1102	18.5	2.2	17.4	16.3	18.4	2.1	780	13.6	1.4	12.0	11.2	12.8	1.4
Kedah	1,542	890	17.6	2.2	17.0	15.9	18.1	2.1	652	12.9	1.3	11.2	10.3	12.1	1.3
Sabah	1,510	890	13.4	2.0	16.0	15.0	17.1	2.0	620	9.8	1.3	11.7	10.8	12.7	1.3
Pahang	1,170	673	17.4	2.4	19.1	17.7	20.6	2.4	497	13.5	1.7	13.9	12.7	15.2	1.7
N. Sembilan	1,085	578	20.2	2.6	21.4	19.6	23.1	2.6	507	18.4	2.1	17.6	16.1	19.2	2.1
Kelantan	893	464	10.7	1.5	12.2	11.1	13.3	1.4	429	9.9	1.2	10.2	9.2	11.2	1.2
Melaka	860	489	21.2	2.8	23.8	21.7	25.9	2.7	371	16.4	2.0	16.4	14.7	18.0	1.9
Terengganu	738	403	14.3	2.2	17.8	16.0	19.5	2.1	335	12.1	1.7	13.4	11.9	14.8	1.7
Perlis	215	127	18.6	2.1	19.3	15.9	22.6	2.1	88	12.9	1.4	11.8	9.3	14.3	1.4
W.P. Labuan	40	23	10.7	1.8	15.4	9.0	21.8	1.8	17	8.3	1.9	12.6	6.1	19.1	1.8
3. Lung, Trachea and Bronchus															
Selangor	2,752	1836	11.4	1.5	12.0	11.4	12.5	1.5	916	5.9	0.7	6.0	5.6	6.4	0.7
Johor	2,094	1469	15.8	2.2	16.9	16.1	17.8	2.2	625	7.7	1.2	10.4	9.6	11.2	1.2
Perak	1,980	1350	22.7	2.4	19.5	18.5	20.6	2.3	630	10.7	0.9	8.1	7.4	8.7	0.9
Sarawak	1,878	1197	20.1	2.2	18.8	17.7	19.8	2.2	681	11.9	1.3	10.5	9.8	11.3	1.3
W.P. KL&P	1,406	938	20.0	2.9	22.4	21.0	23.9	2.9	468	10.2	1.3	11.0	10.0	12.0	1.3
P. Pinang	1,284	834	20.7	2.4	20.1	18.7	21.5	2.4	450	11.5	1.1	9.9	9.0	10.8	1.1
Kedah	1,105	743	14.7	1.8	14.2	13.2	15.2	1.8	362	7.2	0.8	6.2	5.6	6.9	0.8
Sabah	1,168	730	11.0	1.6	13.3	12.3	14.2	1.6	438	6.9	1.0	8.6	7.7	9.4	1.0
Kelantan	722	514	11.8	1.8	13.5	12.3	14.7	1.7	208	4.8	0.6	4.9	4.2	5.6	0.6
Pahang	698	503	13.0	1.9	14.5	13.2	15.8	1.9	195	5.3	0.7	5.6	4.8	6.4	0.7
N. Sembilan	688	494	17.3	2.3	18.1	16.5	19.8	2.3	194	7.0	0.9	6.7	5.8	7.7	0.9
Melaka	543	384	16.6	2.3	18.8	16.9	20.7	2.3	159	7.0	0.9	7.0	5.9	8.1	0.9
Terengganu	547	368	13.1	2.2	17.0	15.2	18.8	2.1	179	6.5	0.9	7.2	6.1	8.2	0.8
Perlis	146	107	15.6	2.1	15.9	12.9	19.0	2.1	39	5.7	0.6	5.3	3.6	7.0	0.6
W.P. Labuan	32	17	7.9	1.7	12.1	6.3	17.9	1.7	15	7.3	1.4	10.6	4.9	16.3	1.4

Note: all 0.0 = Value <0.1; presented as 0.0 due to rounding.

**Appendix 14. Incidence summary for 13 selected cancers by state and gender, 2017-2021
(State-Level Data Updated to 31st August 2024)(continue)**

STATE	TOTAL	Male							Female						
		NO.	CR	CR74	ASR	(95% CL)	CumR	NO.	CR	CR74	ASR	(95% CL)	CumR		
4. Lymphoma															
Selangor	1,385	814	5.1	0.5	5.1	4.7	5.4	0.5	571	3.7	0.4	3.7	3.4	4.0	0.4
Johor	1,271	731	7.9	0.9	8.1	7.5	8.7	0.9	540	6.6	1.0	8.1	7.4	8.8	1.0
Sarawak	982	567	9.5	1.0	9.0	8.2	9.7	1.0	415	7.2	0.7	6.5	5.9	7.1	0.7
Perak	853	495	8.3	0.8	7.5	6.8	8.1	0.8	358	6.1	0.5	5.0	4.5	5.6	0.5
W.P. KL&P	656	402	8.6	1.0	9.0	8.1	9.9	1.0	254	5.5	0.7	5.9	5.1	6.6	0.7
Kedah	596	351	6.9	0.7	6.7	6.0	7.4	0.7	245	4.8	0.5	4.4	3.8	4.9	0.5
P. Pinang	559	311	7.7	0.8	7.1	6.3	7.9	0.8	248	6.3	0.6	5.6	4.9	6.3	0.6
Sabah	488	272	4.1	0.5	4.5	4.0	5.1	0.5	216	3.4	0.4	3.8	3.3	4.3	0.4
Kelantan	437	246	5.7	0.7	6.2	5.4	7.0	0.6	191	4.4	0.4	4.5	3.8	5.1	0.4
Pahang	428	266	6.9	0.8	7.2	6.4	8.1	0.8	162	4.4	0.5	4.6	3.8	5.3	0.5
N. Sembilan	397	236	8.3	0.9	8.3	7.2	9.3	0.9	161	5.8	0.6	5.5	4.6	6.3	0.6
Terengganu	332	202	7.2	0.9	8.0	6.9	9.2	0.9	130	4.7	0.5	4.8	3.9	5.6	0.5
Melaka	306	168	7.3	0.9	7.7	6.6	8.9	0.9	138	6.1	0.6	6.0	5.0	7.0	0.6
Perlis	83	45	6.6	0.8	6.6	4.7	8.6	0.8	38	5.6	0.6	5.4	3.6	7.1	0.6
W.P. Labuan	13	6	2.8	0.2	3.2	0.6	5.7	0.2	7	3.4	0.6	4.3	0.8	7.9	0.6
5. Leukaemia															
Selangor	1,002	570	3.5	0.3	3.7	3.4	4.0	0.3	432	2.8	0.3	3.0	2.7	3.2	0.3
Johor	871	476	5.1	0.5	5.4	4.9	5.9	0.5	395	4.9	0.6	5.8	5.2	6.4	0.6
Perak	637	371	6.2	0.6	6.0	5.4	6.6	0.5	266	4.5	0.4	4.5	3.9	5.0	0.4
Sarawak	579	325	5.5	0.5	5.6	5.0	6.2	0.5	254	4.4	0.4	4.5	4.0	5.1	0.4
Kedah	453	259	5.1	0.4	5.1	4.5	5.7	0.4	194	3.8	0.3	3.8	3.3	4.4	0.3
W.P. KL&P	470	254	5.4	0.5	6.0	5.2	6.7	0.5	216	4.7	0.5	5.1	4.4	5.8	0.5
P. Pinang	440	246	6.1	0.6	6.4	5.5	7.2	0.6	194	4.9	0.4	4.9	4.1	5.6	0.4
Sabah	425	239	3.6	0.3	4.0	3.5	4.6	0.3	186	2.9	0.2	3.2	2.7	3.7	0.2
Kelantan	328	173	4.0	0.4	4.2	3.6	4.9	0.4	155	3.6	0.3	3.7	3.1	4.3	0.3
Pahang	303	169	4.4	0.4	4.6	3.9	5.3	0.4	134	3.7	0.3	3.7	3.1	4.3	0.3
N. Sembilan	259	146	5.1	0.5	5.2	4.4	6.1	0.5	113	4.1	0.4	4.1	3.3	4.8	0.4
Terengganu	239	143	5.1	0.4	5.6	4.7	6.6	0.4	96	3.5	0.3	3.7	3.0	4.5	0.3
Melaka	232	134	5.8	0.6	6.3	5.2	7.4	0.6	98	4.3	0.4	4.4	3.5	5.3	0.4
Perlis	60	38	5.6	0.6	6.0	4.1	8.0	0.6	22	3.2	0.3	3.2	1.8	4.6	0.3
W.P. Labuan	25	18	8.4	0.9	10.1	5.3	14.9	0.9	7	3.4	0.2	3.6	0.9	6.3	0.2
6. Nasopharynx															
Sarawak	936	685	11.5	1.2	10.6	9.8	11.4	1.2	251	4.4	0.4	3.9	3.5	4.4	0.4
Johor	716	537	5.8	0.7	5.7	5.3	6.2	0.7	179	2.2	0.3	2.5	2.1	2.9	0.3
Selangor	707	533	3.3	0.3	3.1	2.9	3.4	0.3	174	1.1	0.1	1.1	0.9	1.2	0.1
Perak	559	441	7.4	0.7	6.8	6.1	7.4	0.7	118	2.0	0.2	1.7	1.4	2.0	0.2
Sabah	558	394	5.9	0.7	6.6	5.9	7.2	0.7	164	2.6	0.3	2.9	2.5	3.4	0.3
W.P. KL&P	372	283	6.0	0.7	6.1	5.4	6.8	0.7	89	1.9	0.2	1.9	1.5	2.3	0.2
P. Pinang	311	237	5.9	0.6	5.1	4.4	5.7	0.6	74	1.9	0.2	1.6	1.2	1.9	0.2
Pahang	217	166	4.3	0.5	4.7	4.0	5.4	0.5	51	1.4	0.2	1.4	1.0	1.8	0.2
Kedah	214	168	3.3	0.4	3.2	2.8	3.7	0.4	46	0.9	0.1	0.8	0.6	1.1	0.1
Melaka	162	113	4.9	0.6	5.3	4.3	6.3	0.6	49	2.2	0.3	2.1	1.5	2.7	0.3
N. Sembilan	155	120	4.2	0.5	4.3	3.6	5.1	0.5	35	1.3	0.1	1.2	0.8	1.6	0.1
Kelantan	146	110	2.5	0.3	2.8	2.3	3.3	0.3	36	0.8	0.1	0.9	0.6	1.1	0.1
Terengganu	73	50	1.8	0.2	2.0	1.5	2.6	0.2	23	0.8	0.1	0.9	0.5	1.2	0.1
Perlis	23	14	2.0	0.2	2.0	0.9	3.1	0.2	9	1.3	0.1	1.3	0.4	2.1	0.1
W.P. Labuan	17	12	5.6	0.7	7.6	3.3	12.0	0.7	5	2.4	0.6	3.7	0.2	7.2	0.6

Note: all 0.0 = Value <0.1; presented as 0.0 due to rounding.

**Appendix 14. Incidence summary for 13 selected cancers by state and gender, 2017-2021
(State-Level Data Updated to 31st August 2024)(continue)**

STATE	TOTAL	Male							Female						
		NO.	CR	CR74	ASR	(95% CL)	CumR	NO.	CR	CR74	ASR	(95% CL)	CumR		
7. Liver															
Selangor	1,362	1026	6.4	0.8	6.6	6.2	7.0	0.8	336	2.2	0.3	2.3	2.0	2.5	0.3
Johor	1,035	791	8.5	1.2	9.0	8.4	9.7	1.2	244	3.0	0.5	4.2	3.7	4.8	0.5
Perak	910	662	11.1	1.2	9.6	8.8	10.3	1.2	248	4.2	0.4	3.3	2.9	3.7	0.4
Sarawak	756	557	9.4	1.1	8.7	8.0	9.5	1.1	199	3.5	0.4	3.1	2.7	3.5	0.4
P. Pinang	670	482	12.0	1.5	11.3	10.3	12.4	1.5	188	4.8	0.6	4.3	3.7	4.9	0.6
W.P. KL&P	662	490	10.5	1.5	11.9	10.8	13.0	1.5	172	3.8	0.4	4.0	3.4	4.6	0.4
Sabah	562	405	6.1	0.9	7.4	6.7	8.1	0.9	157	2.5	0.4	3.0	2.6	3.5	0.4
Kedah	511	368	7.3	0.9	7.1	6.3	7.8	0.9	143	2.8	0.3	2.4	2.0	2.8	0.3
Pahang	433	313	8.1	1.1	9.0	8.0	10.0	1.0	120	3.3	0.4	3.4	2.8	4.0	0.4
N. Sembilan	341	257	9.0	1.2	9.2	8.1	10.4	1.2	84	3.1	0.4	2.9	2.3	3.6	0.4
Terengganu	335	248	8.8	1.4	10.7	9.3	12.0	1.4	87	3.1	0.4	3.5	2.7	4.2	0.4
Melaka	327	245	10.6	1.5	11.9	10.4	13.4	1.5	82	3.6	0.4	3.6	2.8	4.4	0.4
Kelantan	284	212	4.9	0.7	5.5	4.7	6.2	0.7	72	1.7	0.2	1.7	1.3	2.1	0.2
Perlis	71	45	6.6	0.9	7.1	5.0	9.2	0.9	26	3.8	0.5	3.6	2.2	5.0	0.5
W.P. Labuan	16	12	5.6	1.0	7.6	3.3	12.0	1.0	4	2.0	0.2	2.4	0.0	4.8	0.2
8. Stomach															
Selangor	664	413	2.6	0.3	2.7	2.4	2.9	0.3	251	1.6	0.2	1.6	1.4	1.8	0.2
Sarawak	558	348	5.8	0.6	5.5	4.9	6.1	0.6	210	3.7	0.4	3.2	2.8	3.7	0.4
Johor	540	319	3.4	0.5	3.7	3.3	4.1	0.5	221	2.7	0.4	3.8	3.2	4.3	0.4
Sabah	412	257	3.9	0.5	4.6	4.0	5.2	0.5	155	2.4	0.3	2.9	2.4	3.4	0.3
Perak	406	231	3.9	0.4	3.3	2.9	3.7	0.4	175	3.0	0.2	2.3	1.9	2.6	0.2
P. Pinang	347	211	5.2	0.5	5.2	4.5	5.9	0.5	136	3.5	0.3	3.0	2.5	3.5	0.3
W.P. KL&P	290	175	3.7	0.5	4.1	3.5	4.7	0.5	115	2.5	0.3	2.6	2.1	3.1	0.3
Kedah	203	128	2.5	0.3	2.4	2.0	2.8	0.3	75	1.5	0.1	1.3	1.0	1.6	0.1
N. Sembilan	174	97	3.4	0.4	3.6	2.9	4.3	0.4	77	2.8	0.2	2.6	2.1	3.2	0.2
Pahang	138	87	2.3	0.3	2.4	1.9	3.0	0.3	51	1.4	0.2	1.4	1.0	1.8	0.2
Melaka	135	83	3.6	0.5	4.0	3.1	4.9	0.5	52	2.3	0.3	2.3	1.7	3.0	0.3
Kelantan	75	54	1.2	0.2	1.4	1.0	1.8	0.2	21	0.5	0.1	0.5	0.3	0.7	0.1
Terengganu	44	27	1.0	0.2	1.2	0.8	1.7	0.2	17	0.6	0.1	0.7	0.3	1.0	0.1
Perlis	16	9	1.3	0.2	1.4	0.5	2.3	0.2	7	1.0	0.1	1.0	0.2	1.7	0.1
W.P. Labuan	8	5	2.3	0.3	3.3	0.4	6.3	0.3	3	1.5	0.2	1.6	-0.3	3.6	0.2
9. Oesophagus															
Selangor	262	197	1.2	0.2	1.3	1.1	1.5	0.2	65	0.4	0.0	0.4	0.3	0.5	0.0
Perak	169	113	1.9	0.2	1.6	1.3	1.9	0.2	56	1.0	0.1	0.7	0.5	0.9	0.1
Johor	166	127	1.4	0.2	1.5	1.2	1.7	0.2	39	0.5	0.1	0.7	0.5	0.9	0.1
W.P. KL&P	131	101	2.2	0.3	2.5	2.0	2.9	0.3	30	0.7	0.1	0.7	0.4	0.9	0.1
Kedah	124	81	1.6	0.2	1.5	1.2	1.9	0.2	43	0.8	0.1	0.7	0.5	0.9	0.1
P. Pinang	110	78	1.9	0.2	2.0	1.5	2.4	0.2	32	0.8	0.1	0.7	0.5	1.0	0.1
Sarawak	100	67	1.1	0.1	1.0	0.8	1.3	0.1	33	0.6	0.1	0.5	0.3	0.7	0.1
Sabah	97	68	1.0	0.2	1.2	0.9	1.5	0.2	29	0.5	0.1	0.6	0.4	0.8	0.1
N. Sembilan	80	54	1.9	0.2	2.0	1.5	2.5	0.2	26	0.9	0.1	0.9	0.5	1.2	0.1
Pahang	80	60	1.6	0.2	1.7	1.3	2.2	0.2	20	0.5	0.1	0.6	0.3	0.9	0.1
Melaka	52	38	1.6	0.3	1.8	1.2	2.4	0.3	14	0.6	0.1	0.6	0.3	0.9	0.1
Terengganu	52	37	1.3	0.2	1.7	1.2	2.3	0.2	15	0.5	0.1	0.6	0.3	0.9	0.1
Kelantan	48	37	0.9	0.1	1.0	0.7	1.3	0.1	11	0.3	0.0	0.3	0.1	0.4	0.0
Perlis	17	12	1.8	0.2	2.0	0.8	3.1	0.2	5	0.7	0.0	0.5	0.1	1.0	0.0
Selangor	262	197	1.2	0.2	1.3	1.1	1.5	0.2	65	0.4	0.0	0.4	0.3	0.5	0.0

Note: all 0.0 = Value <0.1; presented as 0.0 due to rounding.

**Appendix 14. Incidence summary for 13 selected cancers by state and gender, 2017-2021
(State-Level Data Updated to 31st August 2024)(continue)**

STATE	FEMALE						CumR
	NO.	CR	CR74	ASR	(95% CL)		
10. Cervix Uteri							
Sarawak	629	11.0	1.0	9.7	9.0	10.5	1.0
Selangor	621	4.0	0.4	3.8	3.5	4.1	0.4
Johor	592	7.3	1.0	8.4	7.7	9.2	0.9
Sabah	563	8.9	1.1	10.1	9.2	10.9	1.1
Perak	363	6.2	0.5	5.1	4.5	5.6	0.5
P. Pinang	326	8.3	0.8	6.9	6.1	7.6	0.8
W.P. KL&P	296	6.5	0.8	6.6	5.8	7.3	0.8
Kedah	282	5.6	0.6	5.0	4.4	5.6	0.6
Pahang	218	5.9	0.6	6.1	5.3	6.9	0.6
N. Sembilan	198	7.2	0.7	6.8	5.8	7.7	0.7
Kelantan	186	4.3	0.5	4.5	3.8	5.1	0.5
Melaka	134	5.9	0.6	5.8	4.8	6.8	0.6
Terengganu	121	4.4	0.5	4.7	3.9	5.5	0.5
Perlis	39	5.7	0.7	5.4	3.7	7.2	0.7
W.P. Labuan	16	7.8	1.0	9.5	4.7	14.2	1.0
11. Ovary							
Selangor	782	5.1	0.5	4.9	4.5	5.2	0.5
Johor	626	7.7	1.0	8.7	8.0	9.4	1.0
Perak	496	8.4	0.8	7.1	6.4	7.7	0.8
P. Pinang	365	9.3	0.9	7.8	7.0	8.6	0.9
W.P. KL&P	349	7.6	0.9	8.0	7.1	8.8	0.9
Sarawak	347	6.0	0.6	5.5	4.9	6.0	0.6
Kedah	347	6.9	0.7	6.3	5.6	6.9	0.7
Sabah	316	5.0	0.6	5.6	5.0	6.2	0.6
Kelantan	244	5.6	0.6	5.8	5.0	6.5	0.6
Terengganu	235	8.5	1.0	9.0	7.9	10.2	1.0
N. Sembilan	218	7.9	0.8	7.5	6.5	8.5	0.8
Pahang	201	5.5	0.6	5.6	4.9	6.4	0.6
Melaka	175	7.8	0.9	7.7	6.5	8.8	0.9
Perlis	33	4.8	0.5	4.6	3.0	6.2	0.5
W.P. Labuan	7	3.4	0.4	3.9	0.9	7.0	0.4
12. Corpus Uteri							
Selangor	876	5.7	0.7	5.5	5.1	5.8	0.6
Johor	761	9.4	1.4	11.2	10.4	12.1	1.4
Perak	541	9.2	0.9	7.5	6.8	8.1	0.9
Sarawak	418	7.3	0.7	6.5	5.9	7.1	0.7
Kedah	386	7.6	0.8	7.0	6.3	7.7	0.8
W.P. KL&P	359	7.8	1.1	8.5	7.6	9.4	1.1
P. Pinang	358	9.1	0.9	7.6	6.8	8.3	0.9
Sabah	282	4.4	0.6	5.1	4.5	5.7	0.6
Melaka	254	11.3	1.3	11.1	9.7	12.4	1.3
Pahang	229	6.2	0.8	6.4	5.6	7.3	0.8
N. Sembilan	207	7.5	0.9	7.0	6.0	8.0	0.8
Kelantan	197	4.5	0.5	4.7	4.0	5.4	0.5
Terengganu	179	6.5	0.8	6.9	5.9	7.9	0.8
Perlis	53	7.7	0.8	7.2	5.2	9.2	0.8
W.P. Labuan	11	5.4	0.9	6.9	2.5	11.2	0.9

Note: all 0.0 = Value <0.1; presented as 0.0 due to rounding.

**Appendix 14. Incidence summary for 13 selected cancers by state and gender, 2017-2021
(State-Level Data Updated to 31st August 2024)(continue)**

DISTRICT	MALE					
	NO.	CR	CR74	ASR	(95% CL)	CumR
13. Prostate						
Selangor	1,109	6.9	1.0	7.8	7.3 8.2	1.0
Perak	715	12.0	1.2	10.0	9.3 10.7	1.2
Johor	685	7.4	1.2	8.5	7.8 9.1	1.2
Sarawak	676	11.4	1.4	11.0	10.2 11.8	1.4
P. Pinang	567	14.1	2.0	15.1	13.8 16.3	1.9
W.P. KL&P	557	11.9	1.8	13.2	12.1 14.4	1.8
Kedah	428	8.4	1.1	8.1	7.3 8.9	1.1
Sabah	382	5.8	1.0	7.4	6.6 8.1	1.0
Melaka	334	14.4	2.0	16.7	14.9 18.5	2.0
Pahang	325	8.4	1.3	9.3	8.3 10.4	1.2
N. Sembilan	260	9.1	1.2	10.0	8.8 11.2	1.2
Kelantan	214	4.9	0.8	5.8	5.0 6.6	0.8
Terengganu	148	5.3	0.9	7.4	6.2 8.6	0.9
Perlis	50	7.3	1.1	7.4	5.4 9.5	1.1
W.P. Labuan	11	5.1	0.8	7.5	3.0 12.0	0.8

Note: all 0.0 = Value <0.1; presented as 0.0 due to rounding.




Notes:

Appendix 14 and 15 summarize the cancer burden data by individual states in Malaysia for 2017-2021, updated as of 31st August 2024.

This reflects the most recent information, in contrast to the national data for all residents, which is based on figures up to 31st December 2023.




**Appendix 15. Age-standardised incidence rates for 13 selected cancers, 2017-2021
(updated as of 31st August 2024)**

■ Male ■ Female






Appendix 15. Age-standardised incidence rates for 13 selected cancers, 2017-2021
(updated as of 31st August 2024)(continue)

Male Female






Appendix 15. Age-standardised incidence rates for 13 selected cancers, 2017-2021
(updated as of 31st August 2024)(continue)


Male Female



Appendix 15. Age-standardised incidence rates for 13 selected cancers, 2017-2021
(updated as of 31st August 2024)(continue)



**Appendix 15. Age-standardised incidence rates for 13 selected cancers, 2017-2021
(updated as of 31st August 2024)(continue)**



Notes:

Appendix 12 and 13 summarize the cancer burden data by individual states in Malaysia for 2017-2021, updated as of 31st August 2024.

This reflects the most recent information, in contrast to the national data for all residents, which is based on figures up to 31st December 2023.

Appendix 16. Number of new cancer cases by site and age group, all residents, males, 2017-2021

SITE	TOTAL	AGE U	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	(%)	ICD-10
Lip	25	0	0	0	0	0	0	1	0	0	2	1	1	5	7	1	4	3	0.0	C00
Tongue	784	0	1	0	0	0	5	17	28	44	53	84	92	103	116	98	75	68	1.0	C01-02
Mouth	522	0	0	2	1	4	4	8	5	13	27	34	68	75	85	83	60	53	0.7	C03-06
Salivary glands	393	0	0	0	6	7	9	11	16	19	18	44	36	58	45	48	35	41	0.5	C07-08
Tonsil	182	0	0	0	0	0	0	0	2	5	15	4	25	29	40	28	17	17	0.2	C09
Other oropharynx	113	0	1	0	0	0	0	1	2	3	3	8	18	17	22	10	12	16	0.1	C10
Nasopharynx	3,877	0	0	5	33	38	55	59	147	251	364	534	575	532	539	350	212	183	5.0	C11
Hypopharynx	186	0	0	0	0	0	0	0	1	1	3	9	16	33	30	32	30	31	0.2	C12-13
Pharynx unspecified	62	0	0	0	1	0	0	1	0	4	4	8	7	5	10	13	4	5	0.1	C14
Oesophagus	1,066	0	0	0	0	0	2	7	12	17	32	62	92	157	198	198	126	163	1.4	C15
Stomach	2,444	0	0	1	0	7	6	19	46	72	99	124	216	274	375	377	326	502	3.1	C16
Small intestine	378	0	0	0	0	1	0	4	12	14	25	18	40	62	51	58	38	55	0.5	C17
Colon	6,904	0	0	0	7	10	39	69	100	175	241	346	538	868	1,086	1,159	981	1,285	8.9	C18
Rectum	6,364	0	0	0	2	3	20	39	86	146	215	372	605	886	1,139	1,088	867	896	8.2	C19-20
Anus	342	0	0	0	0	0	1	5	13	7	20	21	50	37	51	41	41	55	0.4	C21
Liver	6,101	0	33	6	4	5	7	7	33	83	176	342	690	1,096	1,233	1,056	700	630	7.9	C22
Gallbladder etc	830	0	1	0	0	0	0	3	5	18	25	39	80	115	144	154	111	135	1.1	C23-24
Pancreas	2,162	0	0	0	0	1	4	5	21	32	64	115	221	332	371	387	301	308	2.8	C25
Nose, sinuses etc	374	0	6	0	0	3	2	12	15	16	25	29	33	54	60	52	37	30	0.5	C30-31
Larynx	1,114	0	0	0	0	1	1	0	2	4	19	36	83	163	207	218	165	215	1.4	C32
Lung, trachea & bronchus	11,474	0	1	0	4	8	26	20	79	159	336	596	970	1,579	2,059	2,044	1,701	1,892	14.8	C33-34
Other thoracic organs	454	0	5	0	10	38	45	30	28	27	25	39	29	47	39	32	27	33	0.6	C37-38
Bone	507	0	9	23	61	86	37	38	16	21	22	21	27	31	36	29	25	25	0.7	C40-41
Melanoma of skin	266	0	0	1	3	1	1	3	5	7	14	15	18	20	47	34	46	51	0.3	C43
Non-melanoma skin	2,471	0	1	2	3	5	14	15	30	53	67	98	136	242	291	353	371	790	3.2	C44
Mesothelioma	64	0	0	0	0	0	0	1	0	1	0	5	5	9	11	12	16	4	0.1	C45
Kaposi sarcoma	109	0	0	0	0	0	9	14	24	27	8	5	6	4	6	3	3	0	0.1	C46
Connective, soft tissue	875	0	24	13	18	32	42	45	50	53	59	58	71	87	84	103	56	80	1.1	C47,C49
Breast	185	0	0	0	0	0	1	0	3	4	5	22	10	30	25	28	21	36	0.2	C50
Peris	149	0	0	0	0	0	0	1	0	6	9	14	30	22	19	10	29	0.2	C60	
Prostate	6,441	0	2	1	0	1	1	1	1	5	7	38	114	402	876	1,451	1,632	1,909	8.3	C61
Testis	898	0	34	2	6	80	176	204	161	78	57	36	25	12	6	7	7	7	1.2	C62
Other male genital	49	0	0	0	0	0	3	4	1	0	2	1	6	5	3	7	8	9	0.1	C63
Kidney	1,997	0	40	14	5	2	9	11	40	62	96	150	225	309	332	292	231	179	2.6	C64
Renal pelvis	53	0	0	0	0	0	1	0	0	1	1	4	5	11	9	7	9	5	0.1	C65
Ureter	65	0	0	0	0	0	0	0	0	2	0	1	7	8	10	13	8	16	0.1	C66
Bladder	1,933	0	2	1	1	0	1	9	13	18	31	64	133	180	293	373	342	472	2.5	C67
Other urinary organs	50	0	0	0	0	0	0	0	1	1	0	4	2	3	14	6	8	11	0.1	C68
Eye	127	0	51	3	0	4	2	0	3	3	3	9	3	9	7	8	6	16	0.2	C69
Brain, nervous system	1,300	0	96	82	67	60	62	59	64	83	77	87	90	117	118	125	68	45	1.7	C70-72
Thyroid	1,035	0	2	1	2	16	33	41	67	60	83	84	100	119	157	99	90	81	1.3	C73
Adrenal gland	125	0	49	10	4	1	1	3	3	1	3	6	5	9	12	10	5	3	0.2	C74
Other endocrine	104	0	2	9	20	18	13	3	6	3	3	5	7	4	5	3	2	1	0.1	C75
Hodgkin lymphoma	840	0	2	19	31	80	119	132	117	50	47	39	34	49	46	37	21	17	1.1	C81
Non-hodgkin lymphoma	4,276	0	67	65	52	88	133	150	168	186	223	298	354	480	565	532	454	461	5.5	C82-85,C96
Immunoproliferative diseases	108	0	1	0	0	0	0	1	0	2	4	10	16	16	16	12	14	14	0.1	C88
Multiple myeloma	767	0	0	0	0	1	0	3	5	13	30	47	77	127	153	134	94	83	1.0	C90
Lymphoid leukaemia	1,081	0	209	154	86	91	49	36	35	41	30	30	49	43	52	65	56	55	1.4	C91
Myeloid leukaemia	2,034	0	85	42	61	98	91	128	128	87	120	115	154	214	171	210	148	182	2.6	C92-94
Leukaemia unspecified	414	0	42	29	25	17	18	15	17	8	9	13	23	31	32	41	42	52	0.5	C95
Myelodysplastic syndromes	269	0	1	0	1	1	5	4	2	3	6	11	20	23	38	51	64	39	0.3	MDS
Myeloproliferative disorders	287	0	0	0	0	1	5	3	10	7	12	20	32	39	50	44	42	22	0.4	MPD
Others & unspecified	2,662	0	9	6	8	17	41	46	49	78	91	176	228	327	417	432	325	412	3.4	O&U
ALL SITES	77,692	0	776	491	522	826	1,093	1,288	1,672	2,074	2,910	4,346	6,481	9,517	11,811	12,071	10,092	11,722	100.0	ALL

Note: all 0.0 = Value <0.1; presented as 0.0 due to rounding. Age U = Age Unknown

Appendix 17. Cancer incidence by site and age group, all residents, males, 2017-2021

SITE	TOTAL	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	CR	CR74	ASR	ASR(95% CL)	CumR
Lip	25	0	0	0	0	0	0.0	0	0	0.0	0.0	0.0	0.1	0.3	0.0	0.3	0.2	0.0	0.0	0.0	0.0	0.0
Tongue	784	0.0	0	0	0	0.1	0.3	0.4	0.7	1.1	2.0	2.5	2.9	4.3	4.8	5.7	4.9	1.0	0.1	1.1	1.0	1.1
Mouth	522	0	0.0	0.0	0.1	0.1	0.1	0.1	0.2	0.6	0.8	1.8	2.1	3.1	4.0	4.6	3.8	0.7	0.1	0.7	0.7	0.8
Salivary Glands	393	0	0	0.1	0.1	0.1	0.2	0.3	0.3	0.4	1.0	1.0	1.6	1.7	2.3	2.7	3.0	0.5	0.1	0.5	0.5	0.6
Tonsil	182	0	0	0	0	0	0	0.0	0.1	0.3	0.1	0.7	0.8	1.5	1.4	1.3	1.2	0.2	0.0	0.2	0.2	0.3
Other Oropharynx	113	0.0	0	0	0	0	0.0	0.0	0.0	0.1	0.2	0.5	0.5	0.8	0.5	0.9	1.2	0.2	0.0	0.2	0.1	0.2
Nasopharynx	3,877	0	0.1	0.5	0.5	0.9	0.9	2.4	4.1	7.6	12.6	15.4	15.1	19.8	17.0	16.1	13.2	5.2	0.6	5.1	4.9	5.3
Hypopharynx	186	0	0	0	0	0	0	0.0	0.0	0.1	0.2	0.4	0.9	1.1	1.6	2.3	2.2	0.2	0.0	0.3	0.2	0.3
Pharynx Unspecified	62	0	0	0.0	0	0	0.0	0	0.1	0.1	0.2	0.2	0.1	0.4	0.6	0.3	0.4	0.1	0.0	0.1	0.1	0.1
Oesophagus	1,066	0	0	0	0	0.0	0.1	0.2	0.3	0.7	1.5	2.5	4.5	7.3	9.6	9.6	11.8	1.4	0.2	1.5	1.4	1.6
Stomach	2,444	0	0.0	0	0.1	0.1	0.3	0.7	1.2	2.1	2.9	5.8	7.8	13.8	18.3	24.8	36.3	3.3	0.4	3.4	3.2	3.5
Small Intestine	378	0	0	0	0.0	0	0.1	0.2	0.2	0.5	0.4	1.1	1.8	1.9	2.8	2.9	4.0	0.5	0.1	0.5	0.5	0.6
Colon	6,904	0	0	0.1	0.1	0.6	1.1	1.6	2.9	5.0	8.1	14.4	24.6	39.9	56.4	74.7	92.9	9.2	1.1	9.6	9.3	9.8
Rectum	6,364	0	0	0.0	0.0	0.3	0.6	1.4	2.4	4.5	8.8	16.2	25.1	41.8	52.9	66.0	64.8	8.5	1.1	8.8	8.6	9.0
Anus	342	0	0	0	0	0.0	0.1	0.2	0.1	0.4	0.5	1.3	1.0	1.9	2.0	3.1	4.0	0.5	0.1	0.5	0.4	0.5
Liver	6,101	0.5	0.1	0.1	0.1	0.1	0.1	0.5	1.4	3.7	8.1	18.5	31.1	45.2	51.4	53.3	45.6	8.2	1.1	8.4	8.2	8.6
Gallbladder etc	830	0.0	0	0	0	0	0.0	0.1	0.3	0.5	0.9	2.1	3.3	5.3	7.5	8.4	9.8	1.1	0.1	1.2	1.1	1.2
Pancreas	2,162	0	0	0	0.0	0.1	0.1	0.3	0.5	1.3	2.7	5.9	9.4	13.6	18.8	22.9	22.3	2.9	0.4	3.0	2.9	3.1
Nose, Sinuses etc	374	0.1	0	0	0.0	0.0	0.2	0.2	0.3	0.5	0.7	0.9	1.5	2.2	2.5	2.8	2.2	0.5	0.1	0.5	0.5	0.6
Larynx	1,114	0	0	0	0.0	0.0	0	0.0	0.1	0.4	0.8	2.2	4.6	7.6	10.6	12.6	15.5	1.5	0.2	1.6	1.5	1.7
Lung, Trachea & Bronchus	11,474	0.0	0	0.1	0.1	0.4	0.3	1.3	2.6	7.0	14.0	26.0	44.8	75.6	99.4	129.5	136.8	15.4	2.0	16.0	15.7	16.3
Other Thoracic Organs	454	0.1	0	0.2	0.5	0.7	0.5	0.4	0.4	0.5	0.9	0.8	1.3	1.4	1.6	2.1	2.4	0.6	0.1	0.6	0.5	0.6
Bone	507	0.1	0.4	0.9	1.2	0.6	0.6	0.3	0.3	0.5	0.5	0.7	0.9	1.3	1.4	1.9	1.8	0.7	0.1	0.7	0.6	0.7
Melanoma of Skin	266	0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.3	0.4	0.5	0.6	1.7	1.7	3.5	3.7	0.4	0.0	0.4	0.3	0.4
Non-Melanoma Skin	2,471	0.0	0.0	0.0	0.1	0.2	0.2	0.5	0.9	1.4	2.3	3.6	6.9	10.7	17.2	28.2	57.1	3.3	0.4	3.5	3.3	3.6
Mesothelioma	64	0	0	0	0	0	0.0	0	0.0	0	0.1	0.1	0.3	0.4	0.6	1.2	0.3	0.1	0.0	0.1	0.1	0.1
Kaposi Sarcoma	109	0	0	0	0	0.1	0.2	0.4	0.4	0.2	0.1	0.2	0.1	0.2	0.1	0.2	0	0.1	0.0	0.1	0.1	0.2
Connective, Soft Tissue	875	0.4	0.2	0.3	0.5	0.7	0.7	0.8	0.9	1.2	1.4	1.9	2.5	3.1	5.0	4.3	5.8	1.2	0.1	1.2	1.1	1.2
Breast	185	0	0	0	0	0.0	0	0.0	0.1	0.1	0.5	0.3	0.9	0.9	1.4	1.6	2.6	0.2	0.0	0.3	0.2	0.3
Penis	149	0	0	0	0	0	0.0	0	0.1	0.2	0.2	0.4	0.9	0.8	0.9	0.8	2.1	0.2	0.0	0.2	0.2	0.2
Prostate	6,441	0.0	0.0	0	0.0	0.0	0.0	0.0	0.1	0.1	0.9	3.1	11.4	32.1	70.6	124.2	138.0	8.6	1.2	9.3	9.1	9.6
Testis	898	0.6	0.0	0.1	1.2	2.8	3.3	2.6	1.3	1.2	0.8	0.7	0.3	0.2	0.3	0.5	0.5	1.2	0.1	1.1	1.0	1.2
Other Male Genital	49	0	0	0	0	0.0	0.1	0.0	0	0.0	0.0	0.2	0.1	0.1	0.3	0.6	0.7	0.1	0.0	0.1	0.0	0.1
Kidney	1,997	0.7	0.2	0.1	0.0	0.1	0.2	0.6	1.0	2.0	3.5	6.0	8.8	12.2	14.2	17.6	12.9	2.7	0.3	2.7	2.6	2.9
Renal Pelvis	53	0	0	0	0	0.0	0	0	0.0	0.0	0.1	0.1	0.3	0.3	0.3	0.7	0.4	0.1	0.0	0.1	0.1	0.1
Ureter	65	0	0	0	0	0	0	0	0.0	0	0.0	0.2	0.2	0.4	0.6	0.6	1.2	0.1	0.0	0.1	0.1	0.1
Bladder	1,933	0.0	0.0	0.0	0	0.0	0.1	0.2	0.3	0.6	1.5	3.6	5.1	10.8	18.1	26.0	34.1	2.6	0.3	2.7	2.6	2.9
Other Urinary Organs	50	0	0	0	0	0	0	0.0	0.0	0	0.1	0.1	0.1	0.5	0.3	0.6	0.8	0.1	0.0	0.1	0.1	0.1
Eye	127	0.8	0.0	0	0.1	0.0	0	0.0	0.0	0.1	0.2	0.1	0.3	0.3	0.4	0.5	1.2	0.2	0.0	0.2	0.2	0.2
Brain, Nervous System	1,300	1.6	1.3	1.0	0.9	1.0	0.9	1.0	1.4	1.6	2.0	2.4	3.3	4.3	6.1	5.2	3.3	1.7	0.2	1.8	1.7	1.9
Thyroid	1,035	0.0	0.0	0.0	0.2	0.5	0.7	1.1	1.0	1.7	2.0	2.7	3.4	5.8	4.8	6.8	5.9	1.4	0.2	1.4	1.3	1.5
Adrenal Gland	125	0.8	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.3	0.4	0.5	0.4	0.2	0.2	0.0	0.2	0.2	0.2
Other Endocrine	104	0.0	0.1	0.3	0.3	0.2	0.0	0.1	0.0	0.1	0.1	0.2	0.1	0.2	0.1	0.2	0.1	0.1	0.0	0.1	0.1	0.2
Hodgkin Lymphoma	840	0.0	0.3	0.5	1.2	1.9	2.1	1.9	0.8	1.0	0.9	0.9	1.4	1.7	1.8	1.6	1.2	1.1	0.1	1.1	1.0	1.1
Non-Hodgkin Lymphoma	4,276	1.1	1.0	0.8	1.3	2.1	2.4	2.7	3.1	4.6	7.0	9.5	13.6	20.7	25.9	34.6	33.3	5.7	0.7	5.8	5.6	6.0
Immunoproliferative Diseases	108	0.0	0	0	0	0	0.0	0	0.0	0.1	0.2	0.4	0.5	0.6	0.8	0.9	1.0	0.1	0.0	0.1	0.1	0.2
Multiple Myeloma	767	0	0	0	0.0	0	0.0	0.1	0.2	0.6	1.1	2.1	3.6	5.6	6.5	7.2	6.0	1.0	0.1	1.1	1.0	1.1
Lymphoid Leukaemia	1,081	3.4	2.4	1.3	1.3	0.8	0.6	0.6	0.7	0.6	0.7	1.3	1.2	1.9	3.2	4.3	4.0	1.4	0.1	1.6	1.5	1.7
Myeloid Leukaemia	2,034	1.4	0.6	0.9	1.4	1.5	2.1	2.1	1.4	2.5	2.7	4.1	6.1	6.3	10.2	11.3	13.2	2.7	0.3	2.7	2.6	2.9
Leukaemia Unspecified	414	0.7	0.4	0.4	0.2	0.3	0.2	0.3	0.1	0.2	0.3	0.6	0.9	1.2	2.0	3.2	3.8	0.6	0.1	0.6	0.5	0.6
Myelodysplastic Syndromes	269	0.0	0	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.3	0.5	0.7	1.4	2.5	4.9	2.8	0.4	0.1	0.4	0.3	0.4
Myeloproliferative Disorders	287	0	0	0	0.0	0.1	0.0	0.2	0.1	0.2	0.5	0.9	1.1	1.8	2.1	3.2	1.6	0.4	0.1	0.4	0.3	0.4
Others & Unspecified	2,662	0.1	0.1	0.1	0.2	0.7	0.7	0.8	1.3	1.9	4.1	6.1	9.3	15.3	21.0	24.7	29.8	3.6	0.4	3.7	3.5	3.8
ALL SITES	77,692	12.7	7.5	7.9	11.9	17.5	20.7	26.9	34.3	60.6	102.3	173.6	269.9	433.4	587.3	768.0	847.6	103.9	12.7	107.3	106.5	108.1

Note: 0.0 = Value <0.1; presented as 0.0 due to rounding

Appendix 18. Number of new cancer cases by site and age group, all residents, females, 2017-2021

SITE	TOTAL	AGE U	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	(%)	ICD-10
Lip	56	0	0	0	0	0	1	0	0	1	4	2	2	5	7	11	8	15	0.1	C00
Tongue	583	0	0	1	1	1	2	4	20	41	50	63	67	87	82	59	49	56	0.6	C01-02
Mouth	523	0	2	2	1	4	4	10	3	10	21	21	37	59	85	78	72	114	0.6	C03-06
Salivary Glands	312	0	0	0	7	4	12	14	22	17	22	27	28	27	40	34	23	35	0.3	C07-08
Tonsil	51	0	0	1	0	0	1	0	1	0	0	3	7	10	10	4	8	6	0.1	C09
Other Oropharynx	33	0	0	0	0	0	0	0	0	1	0	3	5	5	4	7	4	4	0.0	C10
Nasopharynx	1,309	0	0	2	10	19	26	23	57	93	126	152	199	187	146	113	82	74	1.4	C11
Hypopharynx	90	0	0	0	0	0	1	1	1	2	8	7	15	7	16	13	12	7	0.1	C12-13
Pharynx Unspecified	33	0	0	0	0	0	0	1	0	1	1	1	3	6	7	3	1	9	0.0	C14
Oesophagus	416	0	0	0	0	0	1	1	5	8	19	17	37	42	73	59	60	94	0.5	C15
Stomach	1,563	0	0	0	1	5	10	21	37	53	69	95	118	155	211	232	186	370	1.7	C16
Small Intestine	224	0	0	0	0	1	2	4	6	11	6	14	21	32	30	39	21	37	0.2	C17
Anus	251	0	0	0	0	0	2	2	7	8	17	16	19	34	35	41	24	46	0.3	C21
Colon	5,825	0	0	0	4	15	37	58	116	158	256	363	548	697	832	887	725	1,129	6.4	C18
Rectum	4,185	0	0	0	0	5	12	27	71	114	161	267	416	574	666	695	502	675	4.6	C19-20
Liver	2,155	0	26	5	7	6	6	8	23	38	47	75	146	253	364	394	311	446	2.4	C22
Gallbladder etc	751	0	1	0	0	1	1	2	8	8	22	34	58	104	137	130	101	144	0.8	C23-24
Pancreas	1,635	0	0	0	4	4	7	13	16	19	41	56	129	210	254	297	247	338	1.8	C25
Nose, Sinuses etc	193	0	2	1	1	2	4	2	8	10	15	15	25	30	20	22	20	16	0.2	C30-31
Larynx	87	0	0	0	0	0	0	1	1	2	3	4	9	11	20	11	7	18	0.1	C32
Lung, Trachea & Bronchus	5,554	0	0	1	4	3	8	30	54	124	198	318	540	714	884	833	758	1,085	6.1	C33-34
Other Thoracic Organs	224	0	2	1	1	5	3	7	12	15	12	19	28	27	28	30	15	19	0.2	C37-38
Bone	380	0	8	21	45	55	25	22	18	16	20	16	25	27	26	27	14	15	0.4	C40-41
Melanoma of Skin	242	0	0	3	1	2	6	6	1	10	11	15	21	31	39	26	28	42	0.3	C43
Non-Melanoma Skin	1,881	0	2	3	1	6	18	29	39	45	65	102	140	231	262	280	656	2.1	C44	
Mesothelioma	30	0	0	0	0	1	1	1	0	3	1	2	5	6	2	4	0	4	0.0	C45
Kaposi Sarcoma	12	0	1	0	0	0	0	0	0	2	0	3	2	0	1	0	2	0.0	C46	
Connective, Soft Tissue	706	0	27	16	15	32	27	26	36	42	46	48	71	74	53	75	42	76	0.8	C47,C49
Breast	29,534	0	0	0	0	6	70	317	926	1,823	2,924	3,939	4,284	4,555	3,985	3,119	1,797	1,789	32.4	C50
Vulva	190	0	0	0	0	1	0	0	2	4	9	14	18	28	29	28	14	43	0.2	C51
Vagina	168	0	1	0	0	0	2	0	2	4	4	12	20	26	26	24	22	25	0.2	C52
Cervix Uteri	4,573	0	0	0	0	1	25	74	221	344	441	573	663	651	565	389	279	347	5.0	C53
Corpus Uteri	5,087	0	0	0	0	1	12	50	200	315	390	532	662	907	769	635	348	266	5.6	C54
Uterus Unspecified	1,215	0	0	0	0	1	5	15	37	75	121	130	164	218	192	127	63	67	1.3	C55
Ovary	4,714	0	6	14	35	90	130	144	193	238	370	579	698	669	590	456	264	238	5.2	C56
Other Female Genital	409	0	0	0	3	5	9	7	11	26	22	33	66	60	64	44	36	23	0.4	C57
Placenta	31	0	0	0	0	0	2	5	5	7	3	2	6	1	0	0	0	0	0.0	C58
Kidney	889	0	43	8	6	3	4	14	16	18	42	54	83	129	162	108	88	111	1.0	C64
Renal Pelvis	27	0	0	0	0	0	0	1	1	1	0	2	4	2	4	5	3	4	0.0	C65
Ureter	34	0	0	0	0	0	0	0	0	0	0	1	1	3	4	5	8	12	0.0	C66
Bladder	479	0	0	0	0	0	0	2	8	6	9	12	26	47	75	72	70	152	0.5	C67
Other Urinary Organs	25	0	0	0	0	0	0	0	0	0	1	1	1	2	5	4	3	8	0.0	C68
Eye	92	0	37	7	2	1	0	3	2	3	0	3	5	6	1	8	6	8	0.1	C69
Brain, Nervous System	1,085	0	80	81	59	35	45	42	59	64	58	72	84	111	103	83	51	58	1.2	C70-72
Thyroid	3,258	0	0	3	22	82	174	258	288	309	313	297	312	300	318	258	171	153	3.6	C73
Adrenal Gland	103	0	35	6	3	5	2	2	3	1	5	1	7	7	12	5	5	4	0.1	C74
Other Endocrine	48	0	3	2	4	3	1	1	2	3	8	2	1	7	2	4	3	2	0.1	C75
Hodgkin Lymphoma	646	0	0	6	17	85	107	121	96	51	30	25	16	20	34	19	10	9	0.7	C81
Non-Hodgkin Lymphoma	3,031	0	38	19	24	56	97	125	117	126	154	201	279	351	407	418	286	333	3.3	C82-85,C96
Immunoproliferative Diseases	40	0	0	0	0	0	0	0	0	2	3	0	4	9	4	11	3	4	0.0	C88
Multiple Myeloma	646	0	0	0	2	0	2	2	8	10	28	36	82	97	110	120	82	67	0.7	C90
Leukaemia Unspecified	295	0	41	21	16	12	8	6	4	5	15	13	18	15	23	19	34	45	0.3	C95
Lymphoid Leukaemia	795	0	173	103	62	46	39	31	33	22	27	30	32	40	44	44	32	37	0.9	C91
Myeloid Leukaemia	1,646	0	74	27	44	70	66	83	100	112	96	131	149	148	138	150	106	152	1.8	C92-94
Myelodysplastic Syndromes	171	0	2	0	2	1	0	2	4	4	4	7	14	20	19	27	24	45	0.2	MDS
Myeloproliferative Disorders	192	0	1	1	0	3	2	8	3	10	11	9	24	25	34	26	21	14	0.2	MPD
Others & Unspecified	2,404	0	26	6	14	9	30	32	42	71	97	143	217	312	352	370	259	424	2.6	O&U
ALL SITES	91,131	0	631	360	420	682	1,037	1,645	2,933	4,500	6,406	8,575	10,623	12,320	12,374	10,965	7,688	9,972	100.0	ALL

Appendix 19. Cancer incidence by site and age group, all residents, females, 2017-2021

SITE	TOTAL	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	CR	CR74	ASR	ASR(95% CL)	CumR	
Lip	56	0	0	0	0	0.02	0	0	0.0	0.1	0.0	0.1	0.1	0.3	0.5	0.6	0.9	0.1	0.0	0.1	0.1	0.1	0.0
Tongue	583	0	0.0	0.0	0.0	0.0	0.1	0.3	0.7	1.1	1.5	1.8	2.5	3.0	2.8	3.5	3.5	0.8	0.1	0.8	0.7	0.8	0.1
Mouth	523	0.0	0.0	0.0	0.1	0.1	0.2	0.0	0.2	0.5	0.5	1.0	1.7	3.1	3.7	5.1	7.1	0.7	0.1	0.7	0.6	0.8	0.1
Salivary Glands	312	0	0	0.1	0.1	0.2	0.2	0.4	0.3	0.5	0.6	0.7	0.8	1.5	1.6	1.6	2.2	0.4	0.0	0.4	0.4	0.5	0.0
Tonsil	51	0	0.0	0	0	0.0	0	0.0	0	0	0.1	0.2	0.3	0.4	0.2	0.6	0.4	0.1	0.0	0.1	0.0	0.1	0.0
Other Oropharynx	33	0	0	0	0	0	0	0	0.0	0	0.1	0.1	0.1	0.1	0.3	0.3	0.2	0.0	0.0	0.0	0.0	0.1	0.0
Nasopharynx	1,309	0	0.0	0.2	0.3	0.4	0.4	0.9	1.6	2.7	3.6	5.3	5.4	5.3	5.4	5.8	4.6	1.8	0.2	1.7	1.6	1.8	0.2
Hypopharynx	90	0	0	0	0	0.0	0.0	0.0	0.0	0.2	0.2	0.4	0.2	0.6	0.6	0.9	0.4	0.1	0.0	0.1	0.1	0.1	0.0
Pharynx Unspecified	33	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.1	0.2	0.3	0.1	0.1	0.6	0.0	0.0	0.0	0.0	0.1	0.0
Oesophagus	416	0	0	0	0	0.0	0.0	0.1	0.1	0.4	0.4	1.0	1.2	2.7	2.8	4.3	5.9	0.6	0.1	0.6	0.5	0.6	0.1
Stomach	1,563	0	0	0.0	0.1	0.2	0.3	0.6	0.9	1.5	2.3	3.2	4.5	7.7	11.1	13.2	23.1	2.2	0.2	2.1	2.0	2.2	0.2
Small Intestine	224	0	0	0	0.0	0.0	0.1	0.1	0.2	0.1	0.3	0.6	0.9	1.1	1.9	1.5	2.3	0.3	0.0	0.3	0.3	0.3	0.0
Colon	5,825	0	0	0.1	0.2	0.6	0.9	1.9	2.7	5.5	8.7	14.7	20.2	30.4	42.6	51.6	70.4	8.0	0.9	7.8	7.6	8.0	0.9
Rectum	4,185	0	0	0	0.1	0.2	0.4	1.1	2.0	3.5	6.4	11.1	16.7	24.4	33.4	35.7	42.1	5.8	0.7	5.6	5.4	5.8	0.7
Anus	251	0	0	0	0	0.0	0.0	0.1	0.1	0.4	0.4	0.5	1.0	1.3	2.0	1.7	2.9	0.3	0.0	0.3	0.3	0.4	0.0
Liver	2,155	0.4	0.1	0.1	0.1	0.1	0.1	0.4	0.7	1.0	1.8	3.9	7.3	13.3	18.9	22.1	27.8	3.0	0.4	2.9	2.8	3.0	0.4
Gallbladder etc	751	0.0	0	0	0.0	0.0	0.0	0.1	0.1	0.5	0.8	1.6	3.0	5.0	6.2	7.2	9.0	1.0	0.1	1.0	0.9	1.1	0.1
Pancreas	1,635	0	0	0.1	0.1	0.1	0.2	0.3	0.3	0.9	1.3	3.4	6.1	9.3	14.3	17.6	21.1	2.3	0.3	2.2	2.1	2.3	0.3
Nose, Sinuses etc	193	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.2	0.3	0.4	0.7	0.9	0.7	1.1	1.4	1.0	0.3	0.0	0.3	0.2	0.3	0.0
Larynx	87	0	0	0	0	0	0	0.0	0.0	0.1	0.1	0.2	0.3	0.7	0.5	0.5	1.1	0.1	0.0	0.1	0.1	0.1	0.0
Lung, Trachea & Bronchus	5,554	0	0.0	0.1	0.0	0.1	0.5	0.9	2.1	4.3	7.6	14.4	20.7	32.3	40.0	54.0	67.7	7.7	0.9	7.4	7.2	7.6	0.9
Other Thoracic Organs	224	0.0	0.0	0.0	0.1	0.1	0.1	0.2	0.3	0.3	0.5	0.7	0.8	1.0	1.4	1.1	1.2	0.3	0.0	0.3	0.3	0.3	0.0
Bone	380	0.1	0.3	0.7	0.8	0.4	0.4	0.3	0.3	0.4	0.4	0.7	0.8	1.0	1.3	1.0	0.9	0.5	0.0	0.5	0.5	0.6	0.0
Melanoma of Skin	242	0	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.2	0.4	0.6	0.9	1.4	1.2	2.0	2.6	0.3	0.0	0.3	0.3	0.4	0.0
Non-Melanoma Skin	1,881	0.0	0.0	0.0	0.0	0.1	0.3	0.5	0.7	1.0	1.6	2.7	4.1	8.4	12.6	19.9	40.9	2.6	0.3	2.5	2.4	2.6	0.3
Mesothelioma	30	0	0	0	0.0	0.0	0.0	0	0.1	0.0	0.0	0.1	0.2	0.1	0.2	0	0.2	0.0	0.0	0.0	0.0	0.1	0.0
Kaposi Sarcoma	12	0.0	0	0	0	0	0	0	0.0	0	0.1	0.1	0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Connective, Soft Tissue	706	0.5	0.3	0.2	0.5	0.5	0.4	0.6	0.7	1.0	1.1	1.9	2.1	1.9	3.6	3.0	4.7	1.0	0.1	0.9	0.9	1.0	0.1
Breast	29,534	0	0	0	0.1	1.2	5.2	14.8	31.4	62.9	94.3	114.6	132.3	145.8	149.8	127.9	111.6	40.7	4.4	38.9	38.4	39.3	4.3
Vulva	190	0	0	0	0.0	0	0	0.0	0.1	0.2	0.3	0.5	0.8	1.1	1.3	1.0	2.7	0.3	0.0	0.3	0.2	0.3	0.0
Vagina	168	0.0	0	0	0	0.0	0	0.0	0.1	0.1	0.3	0.5	0.8	1.0	1.2	1.6	1.6	0.2	0.0	0.2	0.2	0.3	0.0
Cervix Uteri	4,573	0	0	0	0.0	0.4	1.2	3.5	5.9	9.5	13.7	17.7	18.9	20.7	18.7	19.9	21.6	6.3	0.7	6.0	5.8	6.1	0.6
Corpus Uteri	5,087	0	0	0	0.0	0.2	0.8	3.2	5.4	8.4	12.7	17.7	26.3	28.1	30.5	24.8	16.6	7.0	0.8	6.7	6.5	6.9	0.8
Uterus Unspecified	1,215	0	0	0	0.0	0.1	0.2	0.6	1.3	2.6	3.1	4.4	6.3	7.0	6.1	4.5	4.2	1.7	0.2	1.6	1.5	1.7	0.2
Ovary	4,714	0.1	0.2	0.6	1.4	2.2	2.3	3.1	4.1	8.0	13.9	18.7	19.4	21.6	21.9	18.8	14.8	6.5	0.7	6.2	6.0	6.4	0.7
Other Female Genital	409	0	0	0.0	0.1	0.2	0.1	0.2	0.4	0.5	0.8	1.8	1.7	2.3	2.1	2.6	1.4	0.6	0.1	0.5	0.5	0.6	0.1
Placenta	31	0	0	0	0	0.0	0.1	0.1	0.1	0.1	0.0	0.2	0.0	0	0	0	0	0.0	0.0	0.0	0.0	0.1	0.0
Kidney	889	0.7	0.1	0.1	0.0	0.1	0.2	0.3	0.3	0.9	1.3	2.2	3.7	5.9	5.2	6.3	6.9	1.2	0.1	1.2	1.1	1.3	0.1
Renal Pelvis	27	0	0	0	0	0	0.0	0.0	0.0	0	0.0	0.1	0.1	0.1	0.2	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0
Ureter	34	0	0	0	0	0	0	0	0	0	0.0	0.0	0.1	0.1	0.2	0.6	0.7	0.0	0.0	0.0	0.0	0.1	0.0
Bladder	479	0	0	0	0	0	0.0	0.1	0.1	0.2	0.3	0.7	1.4	2.7	3.5	5.0	9.5	0.7	0.1	0.6	0.6	0.7	0.1
Other Urinary Organs	25	0	0	0	0	0	0	0	0	0.0	0.0	0.0	0.1	0.2	0.2	0.2	0.5	0.0	0.0	0.0	0.0	0.0	0.0
Eye	92	0.6	0.1	0.0	0.0	0	0	0.0	0.0	0.1	0	0.1	0.2	0.0	0.4	0.4	0.5	0.1	0.0	0.2	0.1	0.2	0.0
Brain, Nervous System	1,085	1.4	1.3	1.0	0.5	0.8	0.7	0.9	1.1	1.2	1.7	2.2	3.2	3.8	4.0	3.6	3.6	1.5	0.1	1.5	1.4	1.6	0.1
Thyroid	3,258	0	0.0	0.4	1.3	2.9	4.2	4.6	5.3	6.7	7.1	8.3	8.7	11.6	12.4	12.2	9.5	4.5	0.4	4.2	4.0	4.3	0.4
Adrenal Gland	103	0.6	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.2	0.4	0.2	0.4	0.2	0.1	0.0	0.2	0.1	0.2	0.0
Other Endocrine	48	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.2	0.1	0.2	0.2	0.1	0.1	0.0	0.1	0.0	0.1	0.0
Hodgkin Lymphoma	646	0	0.1	0.3	1.3	1.8	2.0	1.5	0.9	0.6	0.6	0.4	0.6	1.2	0.9	0.7	0.6	0.9	0.1	0.8	0.8	0.9	0.1
Non-Hodgkin Lymphoma	3,031	0.6	0.3	0.4	0.9	1.6	2.0	1.9	2.2	3.3	4.8	7.5	10.2	14.9	20.1	20.4	20.8	4.2	0.5	4.0	3.9	4.2	0.5
Immunoproliferative Diseases	40	0	0	0	0	0	0	0	0.0	0.1	0	0.1	0.3	0.1	0.5	0.2	0.2	0.1	0.0	0.1	0.0	0.1	0.0
Multiple Myeloma	646	0	0	0.0	0	0.0	0.0	0.1	0.2	0.6	0.9	2.2	2.8	4.0	5.8	5.8	4.2	0.9	0.1	0.9	0.8	0.9	0.1
Lymphoid Leukaemia	795	3.0	1.7	1.0	0.7	0.7	0.5	0.4	0.6	0.7	0.9	1.2	1.6	2.1	2.3	2.3	1.1	0.1	1.2	1.1	1.3	0.1	0.1
Myeloid Leukaemia	1,646	1.3	0.4	0.7	1.1	1.1	1.3	1.6	1.9	2.1	3.1	4.0	4.3	5.0	7.2	7.5	9.5	2.3	0.2	2.2	2.1	2.3	0.2
Leukaemia Unspecified	295	0.7	0.3	0.3	0.2	0.1	0.1	0.1	0.1	0.3	0.3	0.5	0.4	0.8	0.9	2.4	2.8	0.4	0.0	0.4	0.4	0.5	0.0
Myelodysplastic Syndromes	171	0.0	0	0.0	0.0	0	0	0.0	0.1	0.1	0.2	0.4	0.6	0.7	1.3	1.7	2.8	0.2	0.0	0.2	0.2	0.3	0.0
Myeloproliferative Disorders	192	0.0	0.0	0	0.0	0.0	0.1	0.0	0.2	0.2	0.2	0.6	0.7	1.2	1.2	1.5	0.9	0.3	0.0	0.3	0.2	0.3	0.0
Others & Unspecified	2,404	0.4	0.1	0.2	0.1	0.5	0.5	0.7	1.2	2.1	3.4	5.8	9.1	12.9	17.8	18.4	26.4	3.3	0.4	3.2	3.1	3.3	0.4
ALL SITES	91,131	10.8	5.9	6.8	10.5	17.3	26.7	46.9	77.6	137.7	205.3	284.1	357.9	452.6	526.7	547.2	621.9	125.6	13.6	120.8	120.0	121.6	12.7

Appendix 20. Number of new cancer cases by site and age group, Malay males, 2017-2021

SITE	TOTAL	AGE U	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	(%)	ICD-10
Lip	12	0	0	0	0	0	0	1	0	0	1	1	1	2	5	0	1	0	0.0	C00
Tongue	265	0	1	0	0	0	2	7	14	20	23	31	30	34	50	26	15	12	0.8	C01-02
Mouth	150	0	0	2	1	1	4	3	3	5	13	9	19	19	26	19	12	14	0.5	C03-06
Salivary Glands	161	0	0	0	3	4	5	5	10	10	9	20	10	23	18	15	11	18	0.5	C07-08
Tonsil	45	0	0	0	0	0	0	0	0	3	2	1	8	9	11	2	7	2	0.1	C09
Other Oropharynx	18	0	0	0	0	0	0	0	0	0	1	0	1	4	5	1	4	2	0.1	C10
Nasopharynx	1,035	0	0	1	11	16	28	20	44	77	97	120	153	138	138	84	67	41	3.2	C11
Hypopharynx	30	0	0	0	0	0	0	0	1	0	0	4	1	4	2	1	7	10	0.1	C12-13
Pharynx Unspecified	15	0	0	0	1	0	0	1	0	1	1	2	2	1	2	3	0	1	0.0	C14
Oesophagus	375	0	0	0	0	0	1	4	6	8	17	23	32	58	78	61	41	46	1.2	C15
Stomach	626	0	0	1	0	3	1	12	24	36	36	39	68	81	100	96	65	64	2.0	C16
Small Intestine	152	0	0	0	0	1	0	3	7	10	9	8	13	28	21	23	12	17	0.5	C17
Colon	2,595	0	0	0	2	7	27	50	69	108	126	161	233	361	409	428	299	315	8.1	C18
Rectum	2,682	0	0	0	2	1	11	25	58	83	109	155	276	391	490	448	341	292	8.4	C19-20
Anus	145	0	0	0	0	0	1	5	10	3	5	9	22	19	23	17	13	18	0.5	C21
Liver	2,541	0	23	4	2	5	3	4	17	37	98	163	340	505	526	402	254	158	7.9	C22
Gallbladder etc	336	0	1	0	0	0	0	1	2	9	12	15	38	52	62	64	40	40	1.0	C23-24
Pancreas	727	0	0	0	0	0	2	3	14	12	36	39	83	131	127	125	79	76	2.3	C25
Nose, Sinuses etc	144	0	4	0	0	1	0	7	6	10	10	13	16	18	20	13	18	8	0.4	C30-31
Larynx	319	0	0	0	0	0	0	0	2	3	8	9	24	52	62	65	42	52	1.0	C32
Lung, Trachea & Bronchus	4,846	0	1	0	1	8	13	13	48	95	186	270	458	742	883	868	666	594	15.1	C33-34
Other Thoracic Organs	262	0	4	0	6	27	41	23	19	13	17	24	15	25	14	9	11	14	0.8	C37-38
Bone	281	0	8	18	34	54	19	20	8	11	15	13	15	18	18	16	8	6	0.9	C40-41
Melanoma of Skin	104	0	0	0	2	1	1	0	2	5	8	3	11	7	21	14	14	15	0.3	C43
Non-Melanoma Skin	824	0	1	2	1	0	9	7	14	25	28	56	57	97	107	121	111	188	2.6	C44
Mesothelioma	21	0	0	0	0	0	0	0	0	0	0	5	2	4	4	4	2	0	0.1	C45
Kaposi Sarcoma	45	0	0	0	0	0	3	10	10	12	4	1	3	2	0	0	0	0	0.1	C46
Connective, Soft Tissue	422	0	18	10	8	20	27	25	29	32	27	29	33	40	40	39	22	23	1.3	C47,C49
Breast	80	0	0	0	0	0	1	0	0	2	4	12	7	11	9	15	5	14	0.2	C50
Penis	18	0	0	0	0	0	0	1	0	1	1	1	2	2	3	2	1	4	0.1	C60
Prostate	2,166	0	2	1	0	1	1	1	0	3	3	17	40	158	356	496	513	574	6.8	C61
Testis	610	0	24	1	5	61	132	147	122	53	25	17	8	5	2	3	2	3	1.9	C62
Other Male Genital	17	0	0	0	0	0	1	1	1	0	1	1	2	2	2	3	1	2	0.1	C63
Kidney	735	0	28	7	4	1	6	4	21	30	42	62	88	122	122	93	69	36	2.3	C64
Renal Pelvis	19	0	0	0	0	0	0	0	0	1	1	2	3	3	4	1	3	1	0.1	C65
Ureter	19	0	0	0	0	0	0	0	0	1	0	1	2	3	2	4	1	5	0.1	C66
Bladder	955	0	0	1	0	0	1	6	5	12	13	34	72	107	161	193	173	177	3.0	C67
Other Urinary Organs	29	0	0	0	0	0	0	0	1	1	0	1	1	1	9	2	6	7	0.1	C68
Eye	57	0	32	1	0	3	0	0	1	1	0	7	1	4	1	1	2	3	0.2	C69
Brain, Nervous System	692	0	65	48	36	42	40	31	41	43	43	55	43	61	53	52	27	12	2.2	C70-72
Thyroid	610	0	2	1	1	10	19	30	41	39	48	49	63	71	78	59	57	42	1.9	C73
Adrenal Gland	72	0	31	6	2	0	1	2	1	0	3	2	3	6	6	6	3	0	0.2	C74
Other Endocrine	64	0	2	5	12	13	7	2	5	3	2	3	4	2	3	1	0	0	0.2	C75
Hodgkin Lymphoma	534	0	2	13	26	60	79	97	71	36	30	21	16	26	25	22	7	3	1.7	C81
Non-Hodgkin Lymphoma	2,365	0	52	46	38	49	82	99	116	112	137	167	204	268	307	290	205	193	7.4	C82-85,C96
Immunoproliferative Diseases	55	0	1	0	0	0	0	0	0	1	2	5	8	6	11	10	4	7	0.2	C88
Multiple Myeloma	407	0	0	0	0	0	0	2	3	12	20	25	43	68	86	69	38	41	1.3	C90
Lymphoid Leukaemia	601	0	135	95	40	56	31	16	26	24	18	12	28	24	25	30	26	15	1.9	C91
Myeloid Leukaemia	1,033	0	57	22	34	47	53	76	84	45	62	54	83	108	91	96	63	58	3.2	C92-94
Leukaemia Unspecified	237	0	36	19	21	10	12	10	13	5	4	8	6	16	18	20	19	20	0.7	C95
Myelodysplastic Syndromes	109	0	1	0	1	1	2	3	1	0	4	4	10	11	19	18	26	8	0.3	MDS
Myeloproliferative Disorders	145	0	0	0	0	1	2	1	6	4	9	13	21	24	24	20	12	8	0.5	MPD
Others & Unspecified	1,203	0	7	3	5	9	23	30	27	38	54	101	112	158	197	187	125	127	3.8	O&U
ALL SITES	32,010	0	538	307	299	513	691	808	1,003	1,095	1,424	1,897	2,834	4,132	4,876	4,657	3,550	3,386	100.0	ALL

Note: all 0.0 = Value <0.1; presented as 0.0 due to rounding. Age U = Age Unknown

Appendix 21. Cancer incidence by site and age group, Malay males, 2017-2021

SITE	TOTAL	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	CR	CR74	ASR	ASR(95% CL)	CumR	
Lip	12	0	0	0	0	0	0.0	0	0	0.0	0.0	0.1	0.1	0.4	0	0.1	0	0.0	0.0	0.0	0.0	0.1	0.0
Tongue	265	0.0	0	0	0	0.1	0.2	0.4	0.6	0.9	1.4	1.6	1.9	3.6	2.4	2.2	1.9	0.6	0.1	0.7	0.6	0.8	0.1
Mouth	150	0	0.1	0.0	0.0	0.1	0.1	0.1	0.1	0.5	0.4	1.0	1.1	1.9	1.7	1.8	2.2	0.4	0.0	0.4	0.3	0.5	0.0
Salivary Glands	161	0	0	0.1	0.1	0.1	0.1	0.3	0.3	0.3	0.9	0.5	1.3	1.3	1.4	1.6	2.8	0.4	0.0	0.4	0.3	0.5	0.0
Tonsil	45	0	0	0	0	0	0	0	0.1	0.1	0.0	0.4	0.5	0.8	0.2	1.0	0.3	0.1	0.0	0.1	0.1	0.2	0.0
Other Oropharynx	18	0	0	0	0	0	0	0	0	0.0	0	0.1	0.2	0.4	0.1	0.6	0.3	0.0	0.0	0.0	0.0	0.1	0.0
Nasopharynx	1,035	0	0.0	0.3	0.4	0.8	0.6	1.2	2.3	3.8	5.4	8.0	7.7	10.0	7.7	10	6.4	2.4	0.3	2.6	2.4	2.8	0.3
Hypopharynx	30	0	0	0	0	0	0	0.0	0	0	0.2	0.1	0.2	0.1	0.1	1.0	1.6	0.1	0.0	0.1	0.1	0.1	0.0
Pharynx Unspecified	15	0	0	0.0	0	0	0.0	0	0.0	0.0	0.1	0.1	0.1	0.1	0.3	0	0.2	0.0	0.0	0.0	0.0	0.1	0.0
Oesophagus	375	0	0	0	0	0.0	0.1	0.2	0.2	0.7	1.0	1.7	3.2	5.7	5.6	6.1	7.2	0.9	0.1	1.0	0.9	1.1	0.1
Stomach	626	0	0.0	0	0.1	0.0	0.3	0.7	1.1	1.4	1.8	3.6	4.5	7.3	8.8	9.7	10.0	1.5	0.2	1.6	1.5	1.8	0.2
Small Intestine	152	0	0	0	0.0	0	0.1	0.2	0.3	0.3	0.4	0.7	1.6	1.5	2.1	1.8	2.6	0.4	0.0	0.4	0.3	0.5	0.0
Colon	2,595	0	0	0.1	0.2	0.7	1.4	1.9	3.2	4.9	7.3	12.2	20.1	29.8	39.4	44.6	49.0	6.1	0.8	6.9	6.6	7.2	0.8
Rectum	2,682	0	0	0.1	0.0	0.3	0.7	1.6	2.5	4.2	7.0	14.4	21.8	35.7	41.2	50.9	45.4	6.3	0.9	7.2	6.9	7.5	0.9
Anus	145	0	0	0	0	0.0	0.1	0.3	0.1	0.2	0.4	1.2	1.1	1.7	1.6	1.9	2.8	0.3	0.0	0.4	0.3	0.4	0.0
Liver	2,541	0.6	0.1	0.1	0.1	0.1	0.1	0.5	1.1	3.8	7.4	17.8	28.1	38.3	37.0	37.9	24.6	6.0	0.9	6.8	6.5	7.0	0.9
Gallbladder etc	336	0.0	0	0	0	0	0.0	0.1	0.3	0.5	0.7	2.0	2.9	4.5	5.9	6.0	6.2	0.8	0.1	0.9	0.8	1.0	0.1
Pancreas	727	0	0	0	0	0.1	0.1	0.4	0.4	1.4	1.8	4.3	7.3	9.2	11.5	11.8	11.8	1.7	0.2	1.9	1.8	2.1	0.2
Nose, Sinuses etc	144	0.1	0	0	0.0	0	0.2	0.2	0.3	0.4	0.6	0.8	1.0	1.5	1.2	2.7	1.2	0.3	0.0	0.4	0.3	0.4	0.0
Larynx	319	0	0	0	0	0	0	0.1	0.1	0.3	0.4	1.3	2.9	4.5	6.0	6.3	8.1	0.8	0.1	0.9	0.8	1.0	0.1
Lung, Trachea & Bronchus	4,846	0.0	0	0.0	0.2	0.4	0.4	1.3	2.8	7.2	12.2	23.9	41.3	64.3	79.8	99.4	92.4	11.5	1.7	13.1	12.8	13.5	1.7
Other Thoracic Organs	262	0.1	0	0.2	0.6	1.1	0.6	0.5	0.4	0.7	1.1	0.8	1.4	1.0	0.8	1.6	2.2	0.6	0.1	0.6	0.5	0.7	0.1
Bone	281	0.2	0.5	0.9	1.3	0.5	0.6	0.2	0.3	0.6	0.6	0.8	1.0	1.3	1.5	1.2	0.9	0.7	0.1	0.7	0.6	0.8	0.1
Melanoma of Skin	104	0	0	0.1	0.0	0.0	0	0.1	0.1	0.3	0.1	0.6	0.4	1.5	1.3	2.1	2.3	0.2	0.0	0.3	0.2	0.3	0.0
Non-Melanoma Skin	824	0.0	0.1	0.0	0	0.2	0.2	0.4	0.7	1.1	2.5	3.0	5.4	7.8	11.1	16.6	29.2	1.9	0.2	2.3	2.1	2.4	0.2
Mesothelioma	21	0	0	0	0	0	0	0	0	0.2	0.1	0.2	0.3	0.4	0.3	0	0	0.0	0.0	0.1	0.0	0.1	0.0
Kaposi Sarcoma	45	0	0	0	0	0.1	0.3	0.3	0.4	0.2	0.0	0.2	0.1	0	0	0	0	0.1	0.0	0.1	0.1	0.1	0.0
Connective, Soft Tissue	422	0.5	0.3	0.2	0.5	0.7	0.7	0.8	1.0	1.0	1.3	1.7	2.2	2.9	3.6	3.3	3.6	1.0	0.1	1.0	0.9	1.1	0.1
Breast	80	0	0	0	0	0.0	0	0	0.1	0.2	0.5	0.4	0.6	0.7	1.4	0.7	2.2	0.2	0.0	0.2	0.2	0.3	0.0
Peris	18	0	0	0	0	0	0.0	0	0.0	0.0	0.0	0.1	0.1	0.2	0.2	0.1	0.6	0.0	0.0	0.0	0.0	0.1	0.0
Prostate	2,166	0.1	0.0	0	0.0	0.0	0.0	0	0.1	0.1	0.8	2.1	8.8	25.9	45.6	76.6	89.3	5.1	0.8	6.3	6.0	6.5	0.8
Testis	610	0.6	0.0	0.1	1.4	3.6	4.1	3.4	1.6	1.0	0.8	0.4	0.3	0.1	0.3	0.3	0.5	1.4	0.1	1.3	1.2	1.4	0.1
Other Male Genital	17	0	0	0	0	0.0	0.0	0.0	0	0.0	0.0	0.1	0.1	0.1	0.3	0.1	0.3	0.0	0.0	0.0	0.0	0.1	0.0
Kidney	735	0.7	0.2	0.1	0.0	0.2	0.1	0.6	0.9	1.6	2.8	4.6	6.8	8.9	8.6	10.3	5.6	1.7	0.2	1.9	1.8	2.1	0.2
Renal Pelvis	19	0	0	0	0	0	0	0	0.0	0.0	0.1	0.2	0.2	0.3	0.1	0.4	0.2	0.0	0.0	0.1	0.0	0.1	0.0
Ureter	19	0	0	0	0	0	0	0	0.0	0	0.0	0.1	0.2	0.1	0.4	0.1	0.8	0.0	0.0	0.1	0.0	0.1	0.0
Bladder	955	0	0.0	0	0	0.0	0.2	0.1	0.4	0.5	1.5	3.8	6.0	11.7	17.7	25.8	27.5	2.3	0.3	2.7	2.5	2.8	0.3
Other Urinary Organs	29	0	0	0	0	0	0	0.0	0.0	0	0.0	0.1	0.1	0.7	0.2	0.9	1.1	0.1	0.0	0.1	0.1	0.1	0.0
Eye	57	0.8	0.0	0	0.1	0	0	0.0	0.0	0	0.3	0.1	0.2	0.1	0.1	0.3	0.5	0.1	0.0	0.2	0.1	0.2	0.0
Brain, Nervous System	692	1.7	1.2	1.0	1.0	1.1	0.9	1.1	1.3	1.7	2.5	2.2	3.4	3.9	4.8	4.0	1.9	1.6	0.2	1.7	1.6	1.8	0.2
Thyroid	610	0.1	0.0	0.0	0.2	0.5	0.8	1.1	1.2	1.9	2.2	3.3	4.0	5.7	5.4	8.5	6.5	1.4	0.2	1.5	1.4	1.7	0.2
Adrenal Gland	72	0.8	0.2	0.1	0	0.0	0.1	0.0	0	0.1	0.1	0.2	0.3	0.4	0.6	0.4	0	0.2	0.0	0.2	0.2	0.2	0.0
Other Endocrine	64	0.1	0.1	0.3	0.3	0.2	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.1	0	0	0.2	0.0	0.1	0.1	0.2	0.0
Hodgkin Lymphoma	534	0.1	0.3	0.7	1.4	2.1	2.7	2.0	1.1	1.2	1.0	0.8	1.4	1.8	2.0	1.0	0.5	1.3	0.1	1.2	1.1	1.3	0.1
Non-Hodgkin Lymphoma	2,365	1.3	1.2	1.0	1.2	2.2	2.8	3.2	3.3	5.3	7.6	10.7	14.9	22.3	26.7	30.6	30.0	5.6	0.7	6.1	5.8	6.3	0.7
Immunoproliferative Diseases	55	0.0	0	0	0	0	0	0	0.0	0.1	0.2	0.4	0.3	0.8	0.9	0.6	1.1	0.1	0.0	0.2	0.1	0.2	0.0
Multiple Myeloma	407	0	0	0	0	0	0.1	0.1	0.4	0.8	1.1	2.2	3.8	6.3	6.3	5.7	6.4	1.0	0.1	1.1	1.0	1.2	0.1
Lymphoid Leukaemia	601	3.5	2.4	1.1	1.3	0.8	0.4	0.7	0.7	0.7	0.5	1.5	1.3	1.8	2.8	3.9	2.3	1.4	0.1	1.5	1.4	1.7	0.1
Myeloid Leukaemia	1,033	1.5	0.6	0.9	1.1	1.4	2.1	2.3	1.3	2.4	2.4	4.3	6.0	6.6	8.8	9.4	9.0	2.4	0.3	2.6	2.4	2.7	0.3
Leukaemia Unspecified	237	0.9	0.5	0.6	0.2	0.3	0.3	0.4	0.1	0.2	0.4	0.3	0.9	1.3	1.8	2.8	3.1	0.6	0.1	0.6	0.5	0.7	0.1
Myelodysplastic Syndromes	109	0.0	0	0.0	0.0	0.1	0.1	0.0	0	0.2	0.2	0.5	0.6	1.4	1.7	3.9	1.2	0.3	0.0	0.3	0.2	0.4	0.0
Myeloproliferative Disorders	145	0	0	0	0.0	0.1	0.0	0.2	0.1	0.3	0.6	1.1	1.3	1.7	1.8	1.8	1.2	0.3	0.0	0.4	0.3	0.4	0.0
Others & Unspecified	1,203	0.2	0.1	0.1	0.2	0.6	0.8	0.7	1.1	2.1	4.6	5.9	8.8	14.3	17.2	18.7	19.8	2.8	0.4	3.2	3.0	3.4	0.4
ALL SITES	32,010	13.9	7.8	8.0	12.2	18.7	22.5	27.8	32.6	55.3	85.9	148.2	229.9	354.9	428.2	529.9	526.6	75.7	9.9	84.4	83.5	85.4	9.4

Note: all 0.0 = Value <0.1; presented as 0.0 due to rounding

Appendix 22. Number of new cancer cases by site and age group, Malay females, 2017-2021

SITE	TOTAL	AGE U	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	(%)	ICD-10
Lip	16	0	0	0	0	0	1	0	0	0	2	0	0	3	0	3	4	3	0.0	C00
Tongue	239	0	0	1	1	0	0	3	9	19	24	32	29	40	32	23	11	15	0.6	C01-02
Mouth	124	0	1	2	1	4	3	4	2	4	6	7	9	7	22	18	15	19	0.3	C03-06
Salivary Glands	129	0	0	0	4	2	7	7	12	10	6	10	14	13	12	12	10	10	0.3	C07-08
Tonsil	16	0	0	1	0	0	1	0	0	0	1	4	4	2	1	1	1	1	0.0	C09
Other Oropharynx	10	0	0	0	0	0	0	0	1	0	2	1	2	1	2	0	1	0.0	C10	
Nasopharynx	408	0	0	1	6	7	14	8	22	30	41	42	61	55	46	32	25	18	1.0	C11
Hypopharynx	26	0	0	0	0	0	1	0	2	2	2	5	5	2	4	2	1	0.1	C12-13	
Pharynx Unspecified	5	0	0	0	0	0	0	1	0	1	1	0	0	1	0	0	1	0.0	C14	
Oesophagus	136	0	0	0	0	0	1	1	3	2	6	1	18	14	18	20	23	29	0.3	C15
Stomach	339	0	0	0	0	3	4	8	17	21	11	24	28	38	51	49	39	46	0.8	C16
Small Intestine	104	0	0	0	0	0	2	3	6	5	2	6	11	21	14	15	7	12	0.2	C17
Colon	2,335	0	0	0	1	8	27	40	79	94	117	177	242	297	367	348	259	279	5.5	C18
Rectum	1,987	0	0	0	0	3	8	16	45	76	91	128	217	297	347	328	201	230	4.6	C19-20
Anus	132	0	0	0	0	0	1	1	5	4	8	11	16	17	23	21	11	14	0.3	C21
Liver	921	0	19	4	3	1	4	3	11	15	23	40	71	115	185	176	124	127	2.2	C22
Gallbladder etc	346	0	1	0	0	1	0	1	4	7	12	17	22	59	60	61	43	58	0.8	C23-24
Pancreas	562	0	0	0	2	3	2	7	9	9	17	25	65	79	99	103	67	75	1.3	C25
Nose, Sinuses etc	87	0	1	1	1	1	2	2	6	5	10	8	12	13	8	7	6	4	0.2	C30-31
Larynx	27	0	0	0	0	0	0	0	0	2	2	3	4	1	7	3	1	4	0.1	C32
Lung, Trachea & Bronchus	2,166	0	0	1	2	2	4	16	36	70	107	163	248	318	354	334	235	276	5.1	C33-34
Other Thoracic Organs	104	0	2	0	0	2	2	5	6	10	6	8	11	13	14	12	7	6	0.2	C37-38
Bone	222	0	4	11	31	35	15	13	11	7	12	11	16	16	11	14	10	5	0.5	C40-41
Melanoma of Skin	92	0	0	2	0	1	4	4	1	6	3	6	8	9	21	10	8	9	0.2	C43
Non-Melanoma Skin	699	0	1	2	2	1	4	13	15	25	25	37	45	68	101	100	95	165	1.6	C44
Mesothelioma	13	0	0	0	0	0	1	0	0	1	0	2	3	3	0	2	0	1	0.0	C45
Kaposi Sarcoma	5	0	0	0	0	0	0	0	0	1	0	1	1	0	0	1	0	1	0.0	C46
Connective, Soft Tissue	366	0	20	7	11	22	15	13	23	29	27	31	36	30	27	35	15	25	0.9	C47,C49
Breast	14,552	0	0	0	0	4	49	195	588	1,140	1,627	2,109	2,223	2,277	1,858	1,286	659	537	34.0	C50
Vulva	68	0	0	0	0	0	0	0	1	2	5	6	6	12	10	11	4	11	0.2	C51
Vagina	69	0	1	0	0	0	1	0	1	3	1	5	11	17	7	9	4	9	0.2	C52
Cervix Uteri	1,843	0	0	0	0	0	17	43	129	168	182	235	255	278	199	145	98	94	4.3	C53
Corpus Uteri	2,595	0	0	0	0	1	8	40	141	220	231	277	333	438	346	306	162	92	6.1	C54
Uterus Unspecified	608	0	0	0	0	1	4	12	28	49	71	77	83	105	79	61	18	20	1.4	C55
Ovary	2,548	0	2	7	27	51	92	94	128	142	206	324	387	354	316	223	111	84	6.0	C56
Other Female Genital	219	0	0	0	3	3	8	7	7	17	13	12	36	32	33	24	19	5	0.5	C57
Placenta	20	0	0	0	0	0	1	1	5	7	1	1	3	1	0	0	0	0	0.0	C58
Kidney	354	0	30	4	3	2	2	6	12	10	16	22	35	60	68	40	23	21	0.8	C64
Renal Pelvis	11	0	0	0	0	0	0	0	1	1	0	1	2	2	1	2	0	1	0.0	C65
Ureter	6	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	2	1	0.0	C66
Bladder	192	0	0	0	0	0	0	2	6	4	6	6	11	26	37	28	26	40	0.4	C67
Other Urinary Organs	9	0	0	0	0	0	0	0	0	0	1	0	0	0	3	1	0	4	0.0	C68
Eye	53	0	20	6	1	0	0	1	2	3	0	1	3	6	1	4	4	1	0.1	C69
Brain, Nervous System	604	0	48	57	38	19	26	21	39	43	34	41	41	60	55	42	17	23	1.4	C70-72
Thyroid	2,058	0	0	2	15	57	118	176	210	210	188	169	186	183	208	164	88	84	4.8	C73
Adrenal Gland	57	0	28	3	1	4	0	1	2	0	3	1	4	1	4	1	1	3	0.1	C74
Other Endocrine	31	0	2	2	3	3	0	1	2	3	6	1	1	4	1	1	1	0	0.1	C75
Hodgkin Lymphoma	441	0	0	5	8	58	81	91	74	38	16	14	10	14	18	10	2	2	1.0	C81
Non-Hodgkin Lymphoma	1,709	0	20	11	12	43	61	86	77	86	101	115	149	197	238	209	158	146	4.0	C82-85,C96
Immunoproliferative Diseases	16	0	0	0	0	0	0	0	0	1	0	0	1	7	2	3	1	1	0.0	C88
Multiple Myeloma	319	0	0	0	2	0	0	2	7	6	12	19	49	48	59	48	39	28	0.7	C90
Lymphoid Leukaemia	459	0	106	69	37	32	27	20	21	12	16	14	13	28	20	20	9	15	1.1	C91
Myeloid Leukaemia	847	0	53	14	28	42	34	46	66	57	52	61	77	75	66	78	41	57	2.0	C92-94
Leukaemia Unspecified	164	0	34	15	9	10	5	5	3	2	11	8	9	11	9	5	12	16	0.4	C95
Myelodysplastic Syndromes	63	0	2	0	1	0	0	0	1	3	2	2	8	10	8	9	8	9	0.1	MDS
Myeloproliferative Disorders	112	0	1	0	0	2	1	4	3	7	5	5	17	15	22	12	13	5	0.3	MPD
Others & Unspecified	1,120	0	17	6	10	4	19	19	19	40	51	75	116	150	175	175	111	133	2.6	O&U
ALL SITES	42,763	0	413	234	263	432	676	1,043	1,895	2,730	3,418	4,396	5,266	5,949	5,668	4,653	2,850	2,877	100.0	ALL

Appendix 23. Cancer incidence by site and age group, Malay females, 2017-2021

SITE	TOTAL	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	CR	CR74	ASR	ASR(95% CL)	CumR	
Lip	16	0	0	0	0	0.0	0	0	0	0.1	0	0	0.2	0	0.3	0.5	0.4	0.0	0.0	0.0	0.0	0.1	0.0
Tongue	239	0	0.0	0.0	0	0	0.1	0.2	0.6	1.0	1.5	1.5	2.2	2.2	2.0	1.5	1.9	0.6	0.1	0.6	0.5	0.7	0.1
Mouth	124	0.0	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.2	0.3	0.5	0.4	1.5	1.6	2.0	2.4	0.3	0.0	0.3	0.3	0.4	0.0
Salivary Glands	129	0	0	0.1	0.1	0.2	0.2	0.3	0.3	0.2	0.5	0.7	0.7	0.8	1.1	1.4	1.3	0.3	0.0	0.3	0.3	0.4	0.0
Tonsil	16	0	0.0	0	0	0.0	0	0	0	0	0.0	0.2	0.2	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.0
Other Oropharynx	10	0	0	0	0	0	0	0	0	0	0.1	0.1	0.1	0.1	0.2	0	0.1	0.0	0.0	0.0	0.0	0.0	0.0
Nasopharynx	408	0	0.0	0.2	0.2	0.4	0.2	0.6	0.9	1.6	1.9	3.1	3.1	3.2	2.8	3.4	2.3	1.0	0.1	1.0	0.9	1.1	0.1
Hypopharynx	26	0	0	0	0	0	0.0	0	0.1	0.1	0.1	0.3	0.3	0.1	0.4	0.3	0.1	0.1	0.0	0.1	0.0	0.1	0.0
Pharynx Unspecified	5	0	0	0	0	0	0.0	0	0.0	0.0	0	0	0.1	0	0	0	0.1	0.0	0.0	0.0	0.0	0.0	0.0
Oesophagus	136	0	0	0	0	0.0	0.0	0.1	0.1	0.2	0.0	0.9	0.8	1.3	1.8	3.1	3.6	0.3	0.0	0.3	0.3	0.4	0.0
Stomach	339	0	0	0	0.1	0.1	0.2	0.5	0.7	0.4	1.1	1.4	2.1	3.6	4.3	5.3	5.8	0.8	0.1	0.8	0.8	0.9	0.1
Small Intestine	104	0	0	0	0	0.1	0.1	0.2	0.2	0.1	0.3	0.6	1.2	1.0	1.3	1.0	1.5	0.3	0.0	0.3	0.2	0.3	0.0
Colon	2,335	0	0	0.0	0.2	0.8	1.1	2.2	2.9	4.7	8.1	12.4	16.5	25.8	30.9	35.3	35.1	5.7	0.7	5.9	5.6	6.1	0.7
Rectum	1,987	0	0	0	0.1	0.2	0.5	1.2	2.4	3.6	5.8	11.1	16.5	24.4	29.1	27.4	28.9	4.8	0.6	5.0	4.8	5.3	0.6
Anus	132	0	0	0	0	0.0	0.0	0.1	0.1	0.3	0.5	0.8	0.9	1.6	1.9	1.5	1.8	0.3	0.0	0.3	0.3	0.4	0.0
Liver	921	0.5	0.1	0.1	0.0	0.1	0.1	0.3	0.5	0.9	1.8	3.6	6.4	13.0	15.6	16.9	16.0	2.2	0.3	2.4	2.2	2.5	0.3
Gallbladder etc	346	0.0	0	0	0.0	0	0.0	0.1	0.2	0.5	0.8	1.1	3.3	4.2	5.4	5.9	7.3	0.8	0.1	0.9	0.8	1.0	0.1
Pancreas	562	0	0	0.1	0.1	0.1	0.2	0.2	0.3	0.7	1.1	3.3	4.4	7.0	9.1	9.1	9.4	1.4	0.2	1.4	1.3	1.6	0.2
Nose, Sinuses etc	87	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.2	0.4	0.4	0.6	0.7	0.6	0.6	0.8	0.5	0.2	0.0	0.2	0.2	0.3	0.0
Larynx	27	0	0	0	0	0	0	0	0.1	0.1	0.1	0.2	0.1	0.5	0.3	0.1	0.5	0.1	0.0	0.1	0.0	0.1	0.0
Lung, Trachea & Bronchus	2,166	0	0.0	0.1	0.1	0.1	0.5	1.0	2.2	4.3	7.4	12.7	17.6	24.9	29.6	32.0	34.7	5.3	0.7	5.5	5.3	5.7	0.7
Other Thoracic Organs	104	0.1	0	0	0.1	0.1	0.1	0.2	0.3	0.2	0.4	0.6	0.7	1.0	1.1	1.0	0.8	0.3	0.0	0.3	0.2	0.3	0.0
Bone	222	0.1	0.3	0.9	0.9	0.4	0.4	0.3	0.2	0.5	0.5	0.8	0.9	0.8	1.2	1.4	0.6	0.5	0.0	0.5	0.5	0.6	0.0
Melanoma of Skin	92	0	0.1	0	0.0	0.1	0.1	0.0	0.2	0.1	0.3	0.4	0.5	1.5	0.9	1.1	1.1	0.2	0.0	0.2	0.2	0.3	0.0
Non-Melanoma Skin	699	0.0	0.1	0.1	0.0	0.1	0.4	0.4	0.8	1.0	1.7	2.3	3.8	7.1	8.9	12.9	20.8	1.7	0.2	1.8	1.6	1.9	0.2
Mesothelioma	13	0	0	0	0	0.0	0	0	0.0	0	0.1	0.2	0.2	0	0.2	0	0.1	0.0	0.0	0.0	0.0	0.0	0.0
Kaposi Sarcoma	5	0	0	0	0	0	0	0	0.0	0	0.0	0.1	0	0	0.1	0	0.1	0.0	0.0	0.0	0.0	0.0	0.0
Connective, Soft Tissue	366	0.5	0.2	0.3	0.6	0.4	0.4	0.6	0.9	1.1	1.4	1.8	1.7	1.9	3.1	2.0	3.1	0.9	0.1	0.9	0.8	1.0	0.1
Breast	14,552	0	0	0	0.1	1.4	5.5	16.2	35.4	64.8	96.1	113.7	126.3	130.5	114.1	89.8	67.5	35.3	4.0	35.8	35.3	36.4	3.9
Vulva	68	0	0	0	0	0	0	0.0	0.1	0.2	0.3	0.3	0.7	0.7	1.0	0.5	1.4	0.2	0.0	0.2	0.1	0.2	0.0
Vagina	69	0.0	0	0	0	0.0	0	0.0	0.1	0.0	0.2	0.6	0.9	0.5	0.8	0.5	1.1	0.2	0.0	0.2	0.1	0.2	0.0
Cervix Uteri	1,843	0	0	0	0	0.5	1.2	3.6	5.2	7.2	10.7	13.0	15.4	14.0	12.9	13.4	11.8	4.5	0.5	4.5	4.3	4.7	0.5
Corpus Uteri	2,595	0	0	0	0.0	0.2	1.1	3.9	6.8	9.2	12.6	17.0	24.3	24.3	27.1	22.1	11.6	6.3	0.7	6.3	6.1	6.6	0.7
Uterus Unspecified	608	0	0	0	0.0	0.1	0.3	0.8	1.5	2.8	3.5	4.2	5.8	5.5	5.4	2.5	2.5	1.5	0.2	1.5	1.4	1.6	0.2
Ovary	2,548	0.1	0.2	0.8	1.3	2.6	2.7	3.5	4.4	8.2	14.8	19.8	19.6	22.2	19.8	15.1	10.6	6.2	0.7	6.3	6.0	6.5	0.7
Other Female Genital	219	0	0	0.1	0.1	0.2	0.2	0.2	0.5	0.5	0.5	1.8	1.8	2.3	2.1	2.6	0.6	0.5	0.1	0.5	0.5	0.6	0.1
Placenta	20	0	0	0	0	0.0	0.0	0.1	0.2	0.0	0.0	0.2	0.1	0	0	0	0	0.0	0.0	0.0	0.0	0.1	0.0
Kidney	354	0.8	0.1	0.1	0.1	0.1	0.2	0.3	0.3	0.6	1.0	1.8	3.3	4.8	3.5	3.1	2.6	0.9	0.1	0.9	0.8	1.0	0.1
Renal Pelvis	11	0	0	0	0	0	0	0.0	0.0	0	0	0.1	0.1	0.1	0.2	0	0.1	0.0	0.0	0.0	0.0	0.0	0.0
Ureter	6	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.2	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0
Bladder	192	0	0	0	0	0	0.1	0.2	0.1	0.2	0.3	0.6	1.4	2.6	2.5	3.5	5.0	0.5	0.1	0.5	0.4	0.6	0.1
Other Urinary Organs	9	0	0	0	0	0	0	0	0.0	0	0	0	0	0.2	0.1	0	0.5	0.0	0.0	0.0	0.0	0.0	0.0
Eye	53	0.5	0.2	0.0	0	0	0.0	0.1	0.1	0	0.0	0.2	0.3	0.1	0.4	0.5	0.1	0.1	0.0	0.1	0.1	0.2	0.0
Brain, Nervous System	604	1.3	1.6	1.1	0.5	0.7	0.6	1.1	1.3	1.4	1.9	2.1	3.3	3.9	3.7	2.3	2.9	1.5	0.1	1.5	1.4	1.6	0.1
Thyroid	2,058	0	0.1	0.4	1.5	3.3	5.0	5.8	6.5	7.5	7.7	9.5	10.1	14.6	14.5	12.0	10.6	5.0	0.5	4.8	4.6	5.1	0.5
Adrenal Gland	57	0.8	0.1	0.0	0.1	0	0.0	0.1	0	0.1	0.0	0.2	0.1	0.3	0.1	0.1	0.4	0.1	0.0	0.2	0.1	0.2	0.0
Other Endocrine	31	0.1	0.1	0.1	0.1	0	0.0	0.1	0.1	0.2	0.0	0.1	0.2	0.1	0.1	0.1	0	0.1	0.0	0.1	0.0	0.1	0.0
Hodgkin Lymphoma	441	0	0.1	0.2	1.5	2.3	2.6	2.0	1.2	0.6	0.6	0.5	0.8	1.3	0.9	0.3	0.3	1.1	0.1	1.0	0.9	1.1	0.1
Non-Hodgkin Lymphoma	1,709	0.5	0.3	0.3	1.1	1.7	2.4	2.1	2.7	4.0	5.2	7.6	10.9	16.7	18.5	21.5	18.4	4.1	0.5	4.2	4.0	4.4	0.5
Immunoproliferative Diseases	16	0	0	0	0	0	0	0	0.0	0	0	0.1	0.4	0.1	0.3	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.0
Multiple Myeloma	319	0	0	0.1	0	0	0.1	0.2	0.2	0.5	0.9	2.5	2.7	4.1	4.3	5.3	3.5	0.8	0.1	0.8	0.7	0.9	0.1
Lymphoid Leukaemia	459	2.9	1.9	1.1	0.8	0.8	0.6	0.6	0.4	0.6	0.6	0.7	1.6	1.4	1.8	1.2	1.9	1.1	0.1	1.2	1.1	1.3	0.1
Myeloid Leukaemia	847	1.4	0.4	0.8	1.1	1.0	1.3	1.8	1.8	2.1	2.8	3.9	4.2	4.6	6.9	5.6	7.2	2.1	0.2	2.1	1.9	2.2	0.2
Leukaemia Unspecified	164	0.9	0.4	0.3	0.3	0.1	0.1	0.1	0.1	0.4	0.4	0.5	0.6	0.6	0.4	1.6	2.0	0.4	0.0	0.4	0.4	0.5	0.0
Myelodysplastic Syndromes	63	0.1	0	0.0	0	0	0	0.0	0.1	0.1	0.1	0.4	0.6	0.6	0.8	1.1	1.1	0.2	0.0	0.2	0.1	0.2	0.0
Myeloproliferative Disorders	112	0.0	0	0	0.1	0.0	0.1	0.1	0.2	0.2	0.2	0.9	0.8	1.5	1.1	1.8	0.6	0.3	0.0	0.3	0.2	0.3	0.0
Others & Unspecified	1,120	0.5	0.2	0.3	0.1	0.5	0.5	0.5	1.2	2.0	3.4	5.9	8.3	12.3	15.5	15.1	16.7	2.7	0.3	2.8	2.7	3.0	0.3
ALL SITES	42,763	11.2	6.4	7.5	11.0	19.2	29.4	52.2	84.8	136.1	200.4	269.4	330.0	398.2	412.7	388.3	361.9	103.7	11.8	105.9	104.9	106.9	11.1

Appendix 24. Number of new cancer cases by site and age group, Chinese males, 2017-2021

SITE	TOTAL	AGE U	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	(%)	ICD-10
Lip	7	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	2	3	0.0	C00
Tongue	317	0	0	0	0	0	1	7	8	11	15	23	36	45	47	47	39	38	1.0	C01-02
Mouth	189	0	0	0	0	2	0	1	0	3	9	12	20	27	31	35	25	24	0.6	C03-06
Salivary Glands	159	0	0	0	0	1	3	3	2	5	5	17	17	20	20	26	20	20	0.5	C07-08
Tonsil	90	0	0	0	0	0	0	0	1	2	12	3	9	10	19	19	5	10	0.3	C09
Other Oropharynx	50	0	0	0	0	0	0	0	2	3	0	1	7	8	10	4	5	10	0.2	C10
Nasopharynx	1,959	0	0	0	1	2	4	24	68	110	190	314	290	282	271	194	104	105	6.2	C11
Hypopharynx	94	0	0	0	0	0	0	0	0	0	2	2	13	18	17	16	12	14	0.3	C12-13
Pharynx Unspecified	24	0	0	0	0	0	0	0	0	1	2	2	2	2	6	6	2	1	0.1	C14
Oesophagus	468	0	0	0	0	0	1	3	3	3	7	26	41	57	81	97	54	95	1.5	C15
Stomach	1,092	0	0	0	0	1	2	3	3	12	24	35	72	93	153	175	178	341	3.4	C16
Small Intestine	154	0	0	0	0	0	0	1	1	2	10	7	18	19	22	23	19	32	0.5	C17
Colon	3,315	0	0	0	2	0	7	12	15	35	69	114	207	347	524	568	566	849	10.4	C18
Rectum	2,637	0	0	0	0	1	2	4	17	33	59	133	216	337	450	478	416	491	8.3	C19-20
Anus	130	0	0	0	0	0	0	0	1	2	5	8	17	11	19	14	23	30	0.4	C21
Liver	2,600	0	3	2	0	0	1	1	9	23	54	125	249	423	492	508	347	363	8.2	C22
Gallbladder etc	328	0	0	0	0	0	0	2	0	4	7	13	21	38	58	61	56	68	1.0	C23-24
Pancreas	1,111	0	0	0	0	0	0	0	3	6	20	58	99	139	182	216	196	192	3.5	C25
Nose, Sinuses etc	136	0	0	0	0	0	0	1	6	5	8	11	21	25	24	12	15	0.4	C30-31	
Larynx	521	0	0	0	0	0	1	0	0	1	5	18	28	62	99	96	86	125	1.6	C32
Lung, Trachea & Bronchus	4,762	0	0	0	2	0	7	4	16	34	83	215	359	538	803	872	799	1,030	15.0	C33-34
Other Thoracic Organs	131	0	0	0	2	4	1	4	4	11	6	12	10	15	18	18	13	13	0.4	C37-38
Bone	126	0	0	2	7	13	8	11	4	8	4	4	5	8	9	12	16	15	0.4	C40-41
Melanoma of Skin	107	0	0	1	0	0	0	3	1	1	4	8	4	6	18	14	22	25	0.3	C43
Non-Melanoma Skin	1,227	0	0	0	2	2	4	3	6	13	18	17	43	100	118	179	212	510	3.9	C44
Mesothelioma	35	0	0	0	0	0	0	0	0	1	0	0	3	4	5	7	12	3	0.1	C45
Kaposi Sarcoma	21	0	0	0	0	0	2	1	3	6	2	3	0	1	3	0	0	0	0.1	C46
Connective, Soft Tissue	273	0	1	1	4	6	6	10	13	10	18	11	21	29	24	49	24	46	0.9	C47,C49
Breast	66	0	0	0	0	0	0	0	2	0	0	5	1	11	10	10	11	16	0.2	C50
Peris	71	0	0	0	0	0	0	0	0	3	4	4	4	13	7	12	7	17	0.2	C60
Prostate	3,297	0	0	0	0	0	0	0	0	2	2	13	44	164	365	738	890	1,079	10.4	C61
Testis	166	0	3	0	1	11	24	29	23	18	17	14	13	5	2	1	1	4	0.5	C62
Other Male Genital	18	0	0	0	0	0	1	1	0	0	0	0	1	2	1	0	6	6	0.1	C63
Kidney	946	0	4	2	0	0	0	5	12	22	39	66	97	132	151	159	136	121	3.0	C64
Renal Pelvis	30	0	0	0	0	0	1	0	0	0	0	0	2	8	4	5	6	4	0.1	C65
Ureter	41	0	0	0	0	0	0	0	0	1	0	0	3	5	7	9	5	11	0.1	C66
Bladder	687	0	0	0	0	0	0	2	3	4	10	15	26	46	90	132	125	234	2.2	C67
Other Urinary Organs	15	0	0	0	0	0	0	0	0	0	0	2	0	1	3	3	2	4	0.0	C68
Eye	38	0	7	1	0	0	1	0	2	1	1	2	2	2	3	4	3	9	0.1	C69
Brain, Nervous System	354	0	13	14	19	9	14	14	9	18	22	17	26	32	39	51	28	29	1.1	C70-72
Thyroid	250	0	0	0	1	3	10	6	12	12	17	24	19	25	46	22	27	26	0.8	C73
Adrenal Gland	30	0	9	2	2	1	0	0	2	1	0	1	2	1	4	2	1	2	0.1	C74
Other Endocrine	22	0	0	2	5	2	4	1	1	0	1	0	2	1	1	1	1	0	0.1	C75
Hodgkin Lymphoma	141	0	0	3	2	8	15	10	20	8	7	13	8	10	11	7	8	11	0.4	C81
Non-Hodgkin Lymphoma	1,169	0	3	7	4	16	25	22	24	30	49	72	85	115	177	168	182	190	3.7	C82-85,C96
Immunoproliferative Diseases	28	0	0	0	0	0	0	0	0	0	1	2	5	2	5	7	6	6	0.1	C88
Multiple Myeloma	198	0	0	0	0	0	0	1	1	0	5	7	18	26	40	36	39	25	0.6	C90
Lymphoid Leukaemia	256	0	24	21	20	14	5	9	4	13	8	11	12	9	24	27	20	35	0.8	C91
Myeloid Leukaemia	619	0	11	8	8	22	17	28	23	20	31	38	45	59	54	80	70	105	1.9	C92-94
Leukaemia Unspecified	123	0	6	9	2	3	3	1	4	1	3	5	10	11	8	14	17	26	0.4	C95
Myelodysplastic Syndromes	119	0	0	0	0	0	1	0	1	3	2	5	7	9	14	28	24	25	0.4	MDS
Myeloproliferative Disorders	96	0	0	0	0	0	3	1	2	3	2	5	6	5	16	18	22	13	0.3	MPD
Others & Unspecified	958	0	1	2	1	3	8	6	5	22	18	47	59	104	140	177	141	224	3.0	O&U
ALL SITES	31,801	0	85	77	85	124	182	234	336	527	876	1,556	2,312	3,462	4,744	5,467	5,044	6,690	100.0	ALL

Note: all 0.0 = Value <0.1; presented as 0.0 due to rounding. Age U = Age Unknown

Appendix 25. Cancer incidence by site and age group, Chinese males, 2017-2021

SITE	TOTAL	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	CR	CR74	ASR	ASR(95% CL)	CumR		
Lip	7	0	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0	0.5	0.6	0.0	0.0	0.0	0.0	0.1	0.0	
Tongue	317	0	0	0	0	0.1	0.5	0.6	0.7	1.2	1.9	3.3	4.2	5.6	8.1	9.4	8.1	1.8	0.2	1.5	1.3	1.6	0.2	
Mouth	189	0	0	0	0.1	0	0.1	0	0.2	0.7	1.0	1.8	2.5	3.7	6.0	6.0	5.1	1.1	0.1	0.9	0.8	1.0	0.1	
Salivary Glands	159	0	0	0	0.1	0.2	0.2	0.1	0.3	0.4	1.4	1.6	1.9	2.4	4.5	4.8	4.2	0.9	0.1	0.7	0.6	0.9	0.1	
Tonsil	90	0	0	0	0	0	0	0.1	0.1	0.9	0.2	0.8	0.9	2.3	3.3	1.2	2.1	0.5	0.0	0.4	0.3	0.5	0.0	
Other Oropharynx	50	0	0	0	0	0	0	0.1	0.2	0	0.1	0.6	0.7	1.2	0.7	1.2	2.1	0.3	0.0	0.2	0.2	0.3	0.0	
Nasopharynx	1,959	0	0	0.1	0.1	0.3	1.9	5.1	7.5	14.6	25.8	26.7	26.3	32.3	33.3	25.0	22.3	11.2	1.0	9.0	8.6	9.4	1.0	
Hypopharynx	94	0	0	0	0	0	0	0	0	0.2	0.2	1.2	1.7	2.0	2.7	2.9	3.0	0.5	0.1	0.4	0.3	0.5	0.1	
Pharynx Unspecified	24	0	0	0	0	0	0	0	0.1	0.2	0.2	0.2	0.2	0.7	1.0	0.5	0.2	0.1	0.0	0.1	0.1	0.2	0.0	
Oesophagus	468	0	0	0	0	0.1	0.2	0.2	0.2	0.5	2.1	3.8	5.3	9.7	16.6	13.0	20.1	2.7	0.3	2.2	2.0	2.4	0.3	
Stomach	1,092	0	0	0	0.1	0.2	0.2	0.2	0.8	1.9	2.9	6.6	8.7	18.3	30.0	42.8	72.3	6.2	0.6	5.0	4.7	5.3	0.6	
Small Intestine	154	0	0	0	0	0	0.1	0.1	0.1	0.8	0.6	1.7	1.8	2.6	3.9	4.6	6.8	0.9	0.1	0.7	0.6	0.8	0.1	
Colon	3,315	0	0	0.1	0	0.6	0.9	1.1	2.4	5.3	9.4	19.1	32.4	62.5	97.4	136.1	180.1	18.9	1.8	15.2	14.7	15.7	1.8	
Rectum	2,637	0	0	0	0.1	0.2	0.3	1.3	2.2	4.5	10.9	19.9	31.4	53.7	82.0	100.0	104.1	15.1	1.5	12.1	11.7	12.6	1.5	
Anus	130	0	0	0	0	0	0	0.1	0.1	0.4	0.7	1.6	1.0	2.3	2.4	5.5	6.4	0.7	0.1	0.6	0.5	0.7	0.1	
Liver	2,600	0.3	0.1	0	0	0.1	0.1	0.7	1.6	4.2	10.3	22.9	39.5	58.7	87.1	83.4	77.0	14.9	1.5	12.0	11.5	12.4	1.5	
Gallbladder etc	328	0	0	0	0	0	0.2	0	0.3	0.5	1.1	1.9	3.5	6.9	10.5	13.5	14.4	1.9	0.2	1.5	1.3	1.7	0.2	
Pancreas	1,111	0	0	0	0	0	0	0.2	0.4	1.5	4.8	9.1	13.0	21.7	37.0	47.1	40.7	6.3	0.7	5.1	4.8	5.4	0.7	
Nose, Sinuses etc	136	0	0	0	0	0	0.1	0.4	0.3	0.6	0.7	1.0	2.0	3.0	4.1	2.9	3.2	0.8	0.1	0.6	0.5	0.7	0.1	
Larynx	521	0	0	0	0	0.1	0	0	0.1	0.4	1.5	2.6	5.8	11.8	16.5	20.7	26.5	3.0	0.3	2.4	2.2	2.6	0.3	
Lung, Trachea & Bronchus	4,762	0	0	0.1	0	0.6	0.3	1.2	2.3	6.4	17.7	33.0	50.2	95.8	149.6	192.1	218.5	27.2	2.7	21.9	21.3	22.6	2.7	
Other Thoracic Organs	131	0	0	0.1	0.3	0.1	0.3	0.3	0.7	0.5	1.0	0.9	1.4	2.1	3.1	3.1	2.8	0.7	0.1	0.6	0.5	0.7	0.1	
Bone	126	0	0.1	0.5	1.0	0.6	0.9	0.3	0.5	0.3	0.3	0.5	0.7	1.1	2.1	3.8	3.2	0.7	0.1	0.7	0.5	0.8	0.1	
Melanoma of Skin	107	0	0.1	0	0	0	0.2	0.1	0.1	0.3	0.7	0.4	0.6	2.1	2.4	5.3	5.3	0.6	0.1	0.5	0.4	0.6	0.1	
Non-Melanoma Skin	1,227	0	0	0.1	0.1	0.3	0.2	0.4	0.9	1.4	1.4	4.0	9.3	14.1	30.7	51.0	108.2	7.0	0.6	5.6	5.2	5.9	0.6	
Mesothelioma	35	0	0	0	0	0	0	0	0.1	0	0	0.3	0.4	0.6	1.2	2.9	0.6	0.2	0.0	0.2	0.1	0.2	0.0	
Kaposi Sarcoma	21	0	0	0	0	0.2	0.1	0.2	0.4	0.2	0.2	0	0.1	0.4	0	0	0	0.1	0.0	0.1	0.1	0.1	0.0	
Connective, Soft Tissue	273	0.1	0.1	0.3	0.4	0.5	0.8	1.0	0.7	1.4	0.9	1.9	2.7	2.9	8.4	5.8	9.8	1.6	0.1	1.3	1.1	1.5	0.1	
Breast	66	0	0	0	0	0	0	0.1	0	0	0.4	0.1	1.0	1.2	1.7	2.6	3.4	0.4	0.0	0.3	0.2	0.4	0.0	
Peris	71	0	0	0	0	0	0	0	0.2	0.3	0.3	0.4	1.2	0.8	2.1	1.7	3.6	0.4	0.0	0.3	0.2	0.4	0.0	
Prostate	3,297	0	0	0	0	0	0	0	0.1	0.2	1.1	4.0	15.3	43.6	126.6	213.9	228.8	18.8	2.0	15.3	14.8	15.8	2.0	
Testis	166	0.3	0	0.1	0.8	1.9	2.2	1.7	1.2	1.3	1.2	1.2	0.5	0.2	0.2	0.2	0.8	0.9	0.1	0.9	0.7	1.0	0.1	
Other Male Genital	18	0	0	0	0	0.1	0.1	0	0	0	0	0.1	0.2	0.1	0	1.4	1.3	0.1	0.0	0.1	0.0	0.1	0.0	
Kidney	946	0.4	0.1	0	0	0	0.4	0.9	1.5	3.0	5.4	8.9	12.3	18.0	27.3	32.7	25.7	5.4	0.6	4.4	4.1	4.7	0.6	
Renal Pelvis	30	0	0	0	0	0.1	0	0	0	0	0	0.2	0.7	0.5	0.9	1.4	0.8	0.2	0.0	0.1	0.1	0.2	0.0	
Ureter	41	0	0	0	0	0	0	0	0.1	0	0	0	0.3	0.5	0.8	1.5	1.2	2.3	0.2	0.0	0.2	0.1	0.2	0.0
Bladder	687	0	0	0	0	0	0.2	0.2	0.3	0.8	1.2	2.4	4.3	10.7	22.6	30.0	49.6	3.9	0.4	3.2	2.9	3.4	0.4	
Other Urinary Organs	15	0	0	0	0	0	0	0	0	0	0.2	0.0	0.1	0.4	0.5	0.5	0.8	0.1	0.0	0.1	0.0	0.1	0.0	
Eye	38	0.6	0.1	0	0	0.1	0	0.1	0.1	0.1	0.2	0.2	0.2	0.4	0.7	0.7	1.9	0.2	0.0	0.2	0.1	0.3	0.0	
Brain, Nervous System	354	1.2	1.0	1.3	0.7	1.1	1.1	0.7	1.2	1.7	1.4	2.4	3.0	4.7	8.7	6.7	6.2	2.0	0.2	1.9	1.7	2.1	0.2	
Thyroid	250	0	0	0.1	0.2	0.8	0.5	0.9	0.8	1.3	2.0	1.7	2.3	5.5	3.8	6.5	5.5	1.4	0.1	1.2	1.0	1.3	0.1	
Adrenal Gland	30	0.8	0.1	0.1	0.1	0	0	0.1	0.1	0	0.1	0.2	0.1	0.5	0.3	0.2	0.4	0.2	0.0	0.2	0.1	0.3	0.0	
Other Endocrine	22	0	0.1	0.4	0.1	0.3	0.1	0.1	0	0.1	0	0.2	0.1	0.1	0.2	0.2	0	0.1	0.0	0.1	0.1	0.2	0.0	
Hodgkin Lymphoma	141	0	0.2	0.1	0.6	1.2	0.8	1.5	0.5	0.5	1.1	0.7	0.9	1.3	1.2	1.9	2.3	0.8	0.1	0.7	0.6	0.8	0.1	
Non-Hodgkin Lymphoma	1,169	0.3	0.5	0.3	1.2	2.0	1.7	1.8	2.0	3.8	5.9	7.8	10.7	21.1	28.8	43.8	40.3	6.7	0.7	5.5	5.2	5.9	0.7	
Immunoproliferative Diseases	28	0	0	0	0	0	0	0	0	0	0.1	0.2	0.5	0.2	0.9	1.7	1.3	0.2	0.0	0.1	0.1	0.2	0.0	
Multiple Myeloma	198	0	0	0	0	0	0.1	0.1	0	0.4	0.6	1.7	2.4	4.8	6.2	9.4	5.3	1.1	0.1	0.9	0.8	1.0	0.1	
Lymphoid Leukaemia	256	2.2	1.6	1.4	1.0	0.4	0.7	0.3	0.9	0.6	0.9	1.1	0.8	2.9	4.6	4.8	7.4	1.5	0.1	1.5	1.3	1.7	0.1	
Myeloid Leukaemia	619	1.0	0.6	0.6	1.6	1.4	2.2	1.7	1.4	2.4	3.1	4.1	5.5	6.4	13.7	16.8	22.3	3.5	0.3	3.1	2.8	3.3	0.3	
Leukaemia Unspecified	123	0.6	0.7	0.1	0.2	0.2	0.1	0.3	0.1	0.2	0.4	0.9	1.0	1.0	2.4	4.1	5.5	0.7	0.1	0.6	0.5	0.8	0.1	
Myelodysplastic Syndromes	119	0	0	0	0	0.1	0	0.1	0.2	0.2	0.4	0.6	0.8	1.7	4.8	5.8	5.3	0.7	0.1	0.6	0.5	0.7	0.1	
Myeloproliferative Disorders	96	0	0	0	0	0.2	0.1	0.1	0.2	0.2	0.4	0.6	0.5	1.9	3.1	5.3	2.8	0.5	0.1	0.5	0.4	0.5	0.1	
Others & Unspecified	958	0.1	0.1	0.1	0.2	0.6	0.5	0.4	1.5	1.4	3.9	5.4	9.7	16.7	30.4	33.9	47.5	5.5	0.5	4.4	4.2	4.7	0.5	
ALL SITES	31,801	7.8	5.7	6.0	9.3	14.6	18.1	25.1	35.9	67.5	127.9	212.8	322.9	566.1	937.7	1212.5	1418.9	181.7	17.9	147.9	146.2	149.5	16.3	

Note: all 0.0 = Value <0.1; presented as 0.0 due to rounding

Appendix 26. Number of new cancer cases by site and age group, Chinese females, 2017-2021

SITE	TOTAL	AGE U	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	(%)	ICD-10
Lip	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	0.0	C00
Tongue	146	0	0	0	0	1	1	0	3	12	16	10	18	19	16	15	18	17	0.5	C01-02
Mouth	89	0	0	0	0	0	1	1	0	1	6	4	5	11	9	10	14	27	0.3	C03-06
Salivary Glands	112	0	0	0	1	0	3	3	9	1	8	10	11	8	17	14	6	21	0.4	C07-08
Tonsil	20	0	0	0	0	0	0	0	0	0	0	2	2	5	4	2	4	1	0.1	C09
Other Oropharynx	11	0	0	0	0	0	0	0	0	0	0	1	2	1	2	2	1	2	0.0	C10
Nasopharynx	525	0	0	0	0	1	3	6	20	33	44	71	74	86	65	52	34	36	1.7	C11
Hypopharynx	9	0	0	0	0	0	0	0	0	0	1	0	3	1	0	0	1	3	0.0	C12-13
Pharynx Unspecified	9	0	0	0	0	0	0	0	0	0	0	1	1	3	2	0	0	2	0.0	C14
Oesophagus	95	0	0	0	0	0	0	0	1	1	3	5	7	8	16	10	14	30	0.3	C15
Stomach	719	0	0	0	0	1	3	6	8	17	24	40	43	54	87	108	86	242	2.4	C16
Small Intestine	66	0	0	0	0	1	0	0	0	3	0	5	5	4	9	13	8	18	0.2	C17
Colon	2,613	0	0	0	1	2	3	9	20	41	75	114	196	270	329	434	369	750	8.6	C18
Rectum	1,510	0	0	0	0	1	4	5	22	38	80	123	177	202	272	223	362	5.0	C19-20	
Anus	69	0	0	0	0	0	1	0	0	3	4	2	9	7	12	9	22	0.2	C21	
Liver	820	0	2	0	2	1	0	3	5	16	13	16	43	68	109	146	140	256	2.7	C22
Gallbladder etc	257	0	0	0	0	1	1	1	0	5	7	27	15	50	54	39	57	0.8	C23-24	
Pancreas	842	0	0	0	1	1	4	5	6	4	20	19	46	89	122	152	146	227	2.8	C25
Nose, Sinuses etc	61	0	0	0	0	0	0	0	0	4	4	2	5	12	5	10	11	8	0.2	C30-31
Larynx	21	0	0	0	0	0	0	0	1	0	0	0	3	2	2	4	3	6	0.1	C32
Lung, Trachea & Bronchus	2,351	0	0	0	1	0	2	7	10	37	52	88	186	252	365	338	378	635	7.8	C33-34
Other Thoracic Organs	83	0	0	0	0	1	1	2	3	3	6	14	11	10	12	8	12	0.3	C37-38	
Bone	78	0	2	1	7	8	5	4	2	4	6	1	4	8	9	9	3	5	0.3	C40-41
Melanoma of Skin	100	0	0	1	0	0	0	1	0	2	5	4	7	15	12	11	16	26	0.3	C43
Non-Melanoma Skin	797	0	0	0	1	0	1	1	8	7	11	15	27	39	70	101	133	383	2.6	C44
Mesothelioma	7	0	0	0	0	0	0	0	0	1	0	0	1	1	1	0	1	0.0	C45	
Kaposi Sarcoma	3	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	1	0.0	C46	
Connective, Soft Tissue	202	0	2	5	3	3	5	6	5	5	10	9	17	25	18	28	24	37	0.7	C47,C49
Breast	9,704	0	0	0	0	1	12	57	162	369	776	1,107	1,262	1,482	1,428	1,271	819	958	32.0	C50
Vulva	69	0	0	0	0	0	0	0	1	1	1	1	5	8	9	12	6	25	0.2	C51
Vagina	68	0	0	0	0	0	0	0	1	1	2	4	6	6	15	9	11	13	0.2	C52
Cervix Uteri	1,471	0	0	0	0	0	2	11	30	75	117	167	200	200	203	152	120	194	4.9	C53
Corpus Uteri	1,491	0	0	0	0	0	1	2	22	40	77	160	203	294	246	194	132	120	4.9	C54
Uterus Unspecified	359	0	0	0	0	0	1	1	4	13	31	26	57	61	65	41	27	32	1.2	C55
Ovary	1,330	0	1	5	2	12	19	23	36	51	86	159	189	205	164	155	106	117	4.4	C56
Other Female Genital	101	0	0	0	0	1	1	0	2	5	5	10	11	12	20	13	10	11	0.3	C57
Placenta	3	0	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0.0	C58
Kidney	388	0	5	2	1	0	1	2	4	5	17	24	34	46	61	55	53	78	1.3	C64
Renal Pelvis	13	0	0	0	0	0	0	1	0	0	0	1	2	0	2	2	2	3	0.0	C65
Ureter	20	0	0	0	0	0	0	0	0	0	0	1	1	0	2	2	5	9	0.1	C66
Bladder	203	0	0	0	0	0	0	0	1	1	0	4	11	9	23	33	31	90	0.7	C67
Other Urinary Organs	12	0	0	0	0	0	0	0	0	0	0	1	1	1	2	2	3	2	0.0	C68
Eye	19	0	7	1	0	1	0	0	0	0	0	2	0	0	0	2	1	5	0.1	C69
Brain, Nervous System	272	0	11	11	5	7	9	8	10	10	18	15	27	36	29	27	26	23	0.9	C70-72
Thyroid	532	0	0	1	4	13	26	32	29	36	44	49	51	54	49	44	50	50	1.8	C73
Adrenal Gland	27	0	2	1	2	1	1	1	1	1	2	0	2	4	4	2	3	0	0.1	C74
Other Endocrine	10	0	0	0	1	0	0	0	0	0	1	0	0	1	1	2	2	2	0.0	C75
Hodgkin Lymphoma	81	0	0	0	5	12	10	9	5	4	6	4	4	2	5	7	3	5	0.3	C81
Non-Hodgkin Lymphoma	731	0	6	3	2	4	18	15	16	16	25	38	74	69	96	131	89	129	2.4	C82-85,C96
Immunoproliferative Diseases	18	0	0	0	0	0	0	0	0	1	3	0	2	1	1	5	2	3	0.1	C88
Multiple Myeloma	177	0	0	0	0	1	0	0	2	3	12	17	18	29	37	29	29	29	0.6	C90
Lymphoid Leukaemia	177	0	29	13	9	5	9	4	6	4	6	10	8	8	17	17	15	17	0.6	C91
Myeloid Leukaemia	461	0	5	3	5	15	13	18	14	33	20	41	36	40	37	47	51	83	1.5	C92-94
Leukaemia Unspecified	73	0	2	3	4	2	2	0	0	1	2	2	6	1	9	6	12	21	0.2	C95
Myelodysplastic Syndromes	83	0	0	0	1	0	0	0	1	0	1	4	3	7	8	14	10	34	0.3	MDS
Myeloproliferative Disorders	34	0	0	0	0	0	1	0	0	2	2	2	3	6	6	4	5	3	0.1	MPD
Others & Unspecified	756	0	2	0	1	1	3	5	7	19	22	36	47	74	94	112	104	229	2.5	O&U
ALL SITES	30,301	0	76	50	59	95	164	249	458	905	1,615	2,395	3,136	3,838	4,164	4,208	3,415	5,474	100.0	ALL

Appendix 27. Cancer incidence by site and age group, Chinese females, 2017-2021

SITE	TOTAL	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	CR	CR74	ASR	ASR(95% CL)	CumR		
Lip	3	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0.4	0.0	0.0	0.0	0.0	0.0		
Tongue	146	0	0	0	0.1	0.1	0	0.2	0.9	1.3	0.9	1.7	1.9	2.0	2.6	4.3	3.3	0.9	0.1	0.7	0.6	0.8	0.1	
Mouth	89	0	0	0	0	0.1	0.1	0	0.1	0.5	0.3	0.5	1.1	1.1	1.7	3.3	5.2	0.5	0.0	0.4	0.3	0.5	0.0	
Salivary Glands	112	0	0	0.1	0	0.3	0.2	0.7	0.1	0.7	0.9	1.0	0.8	2.1	2.4	1.4	4.0	0.7	0.1	0.5	0.4	0.6	0.1	
Tonsil	20	0	0	0	0	0	0	0	0	0	0.2	0.2	0.5	0.5	0.3	1.0	0.2	0.1	0.0	0.1	0.1	0.1	0.0	
Other Oropharynx	11	0	0	0	0	0	0	0	0	0	0.1	0.2	0.1	0.2	0.3	0.2	0.4	0.1	0.0	0.1	0.0	0.1	0.0	
Nasopharynx	525	0	0	0	0.1	0.3	0.5	1.5	2.3	3.6	6.2	7.0	8.8	8.1	9.0	8.1	6.9	3.1	0.3	2.5	2.3	2.7	0.3	
Hypopharynx	9	0	0	0	0	0	0	0	0	0.1	0	0.3	0.1	0	0	0.2	0.6	0.1	0.0	0.0	0.0	0.1	0.0	
Pharynx Unspecified	9	0	0	0	0	0	0	0	0	0	0.1	0.1	0.3	0.2	0	0	0.4	0.1	0.0	0.0	0.0	0.1	0.0	
Oesophagus	95	0	0	0	0	0	0	0.1	0.1	0.2	0.4	0.7	0.8	2.0	1.7	3.3	5.8	0.6	0.0	0.4	0.3	0.5	0.0	
Stomach	719	0	0	0	0.1	0.3	0.5	0.6	1.2	2.0	3.5	4.1	5.5	10.8	18.7	20.5	46.6	4.3	0.3	3.3	3.0	3.5	0.3	
Small Intestine	66	0	0	0	0.1	0	0	0	0.2	0	0.4	0.5	0.4	1.1	2.2	1.9	3.5	0.4	0.0	0.3	0.2	0.4	0.0	
Colon	2,613	0	0	0.1	0.2	0.3	0.7	1.5	2.9	6.1	9.9	18.6	27.5	40.9	75.1	87.8	144.5	15.6	1.4	11.9	11.4	12.3	1.3	
Rectum	1,510	0	0	0	0.1	0.1	0.3	0.4	1.6	3.1	7.0	11.7	18.0	25.1	47.1	53.0	69.7	9.0	0.8	6.9	6.6	7.3	0.8	
Anus	69	0	0	0	0	0	0.1	0	0	0.2	0.3	0.2	0.9	0.9	2.1	2.1	4.2	0.4	0.0	0.3	0.2	0.4	0.0	
Liver	820	0.2	0	0.2	0.1	0	0.2	0.4	1.1	1.1	1.4	4.1	6.9	13.5	25.3	33.3	49.3	4.9	0.4	3.7	3.5	4.0	0.4	
Gallbladder etc	257	0	0	0	0	0.1	0.1	0.1	0	0.4	0.6	2.6	1.5	6.2	9.3	9.3	11.0	1.5	0.2	1.2	1.1	1.3	0.2	
Pancreas	842	0	0	0.1	0.1	0.3	0.4	0.4	0.3	1.6	1.7	4.4	9.1	15.2	26.3	34.7	43.7	5.0	0.5	3.9	3.6	4.1	0.5	
Nose, Sinuses etc	61	0	0	0	0	0	0	0	0.3	0.3	0.2	0.5	1.2	0.6	1.7	2.6	1.5	0.4	0.0	0.3	0.2	0.4	0.0	
Larynx	21	0	0	0	0	0	0	0.1	0	0	0	0.3	0.2	0.2	0.7	0.7	1.2	0.1	0.0	0.1	0.1	0.1	0.0	
Lung, Trachea & Bronchus	2,351	0	0	0.1	0	0.2	0.6	0.7	2.6	4.3	7.7	17.6	25.6	45.4	58.5	89.9	122.4	14.0	1.3	10.7	10.3	11.1	1.3	
Other Thoracic Organs	83	0	0	0	0	0.1	0.1	0.1	0.2	0.2	0.5	1.3	1.1	1.2	2.1	1.9	2.3	0.5	0.0	0.4	0.3	0.5	0.0	
Bone	78	0.2	0.1	0.5	0.6	0.4	0.3	0.1	0.3	0.5	0.1	0.4	0.8	1.1	1.6	0.7	1.0	0.5	0.0	0.4	0.3	0.5	0.0	
Melanoma of Skin	100	0	0.1	0	0	0	0.1	0	0.1	0.4	0.3	0.7	1.5	1.5	1.9	3.8	5.0	0.6	0.1	0.5	0.4	0.5	0.1	
Non-Melanoma Skin	797	0	0	0.1	0	0.1	0.1	0.6	0.5	0.9	1.3	2.6	4.0	8.7	17.5	31.6	73.8	4.8	0.3	3.5	3.2	3.7	0.3	
Mesothelioma	7	0	0	0	0	0	0	0	0.1	0.1	0	0.1	0.1	0.1	0.2	0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	
Kaposi Sarcoma	3	0	0	0	0	0	0	0	0.1	0	0	0.1	0	0	0	0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	
Connective, Soft Tissue	202	0.2	0.4	0.2	0.2	0.4	0.5	0.4	0.4	0.8	0.8	1.6	2.5	2.2	4.8	5.7	7.1	1.2	0.1	1.0	0.9	1.1	0.1	
Breast	9,704	0	0	0	0.1	1.0	4.5	12.0	26.2	63.4	96.3	119.7	150.8	177.5	219.9	194.8	184.6	57.9	5.3	45.6	44.7	46.5	5.2	
Vulva	69	0	0	0	0	0	0	0.1	0.1	0.1	0.1	0.5	0.8	1.1	2.1	1.4	4.8	0.4	0.0	0.3	0.2	0.4	0.0	
Vagina	68	0	0	0	0	0	0	0.1	0.1	0.2	0.3	0.6	0.6	1.9	1.6	2.6	2.5	0.4	0.0	0.3	0.2	0.4	0.0	
Cervix Uteri	1,471	0	0	0	0	0.2	0.9	2.2	5.3	9.6	14.5	19.0	20.4	25.2	26.3	28.5	37.4	8.8	0.8	6.9	6.5	7.2	0.8	
Corpus Uteri	1,491	0	0	0	0	0.1	0.2	1.6	2.8	6.3	13.9	19.3	29.9	30.6	33.6	31.4	23.1	8.9	0.8	7.0	6.6	7.3	0.8	
Uterus Unspecified	359	0	0	0	0	0.1	0.1	0.3	0.9	2.5	2.3	5.4	6.2	8.1	7.1	6.4	6.2	2.1	0.2	1.7	1.5	1.9	0.2	
Ovary	1,330	0.1	0.4	0.2	1.0	1.6	1.8	2.7	3.6	7.0	13.8	17.9	20.9	20.4	26.8	25.2	22.5	7.9	0.7	6.4	6.0	6.7	0.7	
Other Female Genital	101	0	0	0	0.1	0.1	0	0.1	0.4	0.4	0.9	1.0	1.2	2.5	2.2	2.4	2.1	0.6	0.1	0.5	0.4	0.6	0.1	
Placenta	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	
Kidney	388	0.5	0.2	0.1	0	0.1	0.2	0.3	0.4	1.4	2.1	3.2	4.7	7.6	9.5	12.6	15.0	2.3	0.2	1.8	1.7	2.0	0.2	
Renal Pelvis	13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.0	0.1	0.0	0.1	0.0	
Ureter	20	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.0	0.1	0.0	0.1	0.0	
Bladder	203	0	0	0	0	0	0	0.1	0.1	0	0.3	1.0	0.9	2.9	5.7	7.4	17.3	1.2	0.1	0.9	0.8	1.0	0.1	
Other Urinary Organs	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.0	0.1	0.0	0.1	0.0	
Eye	19	0.7	0.1	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0.3	0.2	1.0	0.1	0.1	0.2	0.0
Brain, Nervous System	272	1.0	0.9	0.4	0.6	0.8	0.6	0.7	0.7	1.5	1.3	2.6	3.7	3.6	4.7	6.2	4.4	1.6	0.1	1.4	1.3	1.6	0.1	
Thyroid	532	0	0.1	0.3	1.1	2.2	2.5	2.1	2.6	3.6	4.3	4.8	5.5	6.1	7.6	11.9	9.6	3.2	0.3	2.6	2.4	2.9	0.3	
Adrenal Gland	27	0.2	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.2	0	0.2	0.4	0.5	0.3	0.7	0	0.2	0.0	0.2	0.1	0.2	0.0	
Other Endocrine	10	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.0	0.0	0.0	0.1	0.0	
Hodgkin Lymphoma	81	0	0	0.4	1.0	0.9	0.7	0.4	0.3	0.5	0.3	0.4	0.2	0.6	1.2	0.7	1.0	0.5	0.0	0.5	0.4	0.6	0.0	
Non-Hodgkin Lymphoma	731	0.6	0.2	0.3	1.5	1.2	1.2	1.1	2.0	3.3	7.0	7.0	11.9	22.7	21.2	24.9	4.4	0.4	3.5	3.3	3.8	0.4	0.4	
Immunoproliferative Diseases	18	0	0	0	0	0	0	0	0.1	0.2	0	0.2	0.1	0.1	0.9	0.5	0.6	0.1	0.0	0.1	0.0	0.1	0.0	
Multiple Myeloma	177	0	0	0	0	0.1	0	0	0.1	0.2	1.0	1.6	1.8	3.6	6.4	6.9	5.6	1.1	0.1	0.8	0.7	1.0	0.1	
Lymphoid Leukaemia	177	2.7	1.1	0.7	0.4	0.8	0.3	0.4	0.3	0.5	0.9	0.8	0.8	2.1	2.9	3.6	3.3	1.1	0.1	1.1	0.9	1.3	0.1	
Myeloid Leukaemia	461	0.5	0.2	0.4	1.2	1.1	1.4	1.0	2.3	1.6	3.6	3.4	4.1	4.6	8.1	12.1	16.0	2.8	0.2	2.3	2.1	2.5	0.2	
Leukaemia Unspecified	73	0.2	0.2	0.3	0.2	0.2	0	0	0.1	0.2	0.2	0.6	0.1	1.1	1.0	2.9	4.0	0.4	0.0	0.4	0.3	0.5	0.0	
Myelodysplastic Syndromes	83	0	0	0.1	0	0	0	0.1	0	0.1	0.3	0.3	0.7	1.0	2.4	2.4	6.6	0.5	0.0	0.4	0.3	0.5	0.0	
Myeloproliferative Disorders	34	0	0	0	0	0.1	0	0	0.1	0.2	0.2	0.3	0.6	0.7	0.7	1.2	0.6	0.2	0.0	0.2	0.1	0.2	0.0	
Others & Unspecified	756	0.2	0	0.1	0.1	0.3	0.4	0.5	1.3	1.8	3.1	4.5	7.5	11.7	19.4	24.7	44.1	4.5	0.4	3.4	3.2	3.7	0.4	
ALL SITES	30,301	7.2	4.1	4.5	7.7	14.0	19.7	33.9	64.2	132.0	208.3	297.4	390.6	517.6	728.0	812.1	1054.7	180.9	16.2	141.7	140.1	143.4	15.0	

Appendix 28. Number of new cancer cases by site and age group, Indian males, 2017-2021

SITE	TOTAL	AGE U	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	(%)	ICD-10
Lip	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0.0	C00
Tongue	112	0	0	0	0	0	1	1	3	4	8	13	16	14	14	17	11	10	2.3	C01-02
Mouth	93	0	0	0	0	0	0	0	1	1	2	7	13	15	13	17	14	10	1.9	C03-06
Salivary Glands	21	0	0	0	0	1	1	0	2	1	1	2	3	4	2	1	1	2	0.4	C07-08
Tonsil	34	0	0	0	0	0	0	0	0	0	1	0	5	9	5	6	5	3	0.7	C09
Other Oropharynx	28	0	0	0	0	0	0	0	0	0	1	2	7	5	5	3	2	3	0.6	C10
Nasopharynx	40	0	0	0	2	1	0	0	1	1	4	3	6	6	8	3	2	3	0.8	C11
Hypopharynx	34	0	0	0	0	0	0	0	0	1	0	2	2	6	7	9	5	2	0.7	C12-13
Pharynx Unspecified	7	0	0	0	0	0	0	0	0	0	0	0	1	1	1	2	0	2	0.1	C14
Oesophagus	110	0	0	0	0	0	0	0	2	0	6	5	6	21	19	26	13	12	2.2	C15
Stomach	261	0	0	0	0	0	1	2	9	10	13	17	27	35	43	39	36	29	5.3	C16
Small Intestine	30	0	0	0	0	0	0	0	1	0	3	0	4	9	5	4	3	1	0.6	C17
Colon	427	0	0	0	0	0	1	3	4	12	17	27	27	56	70	80	61	69	8.7	C18
Rectum	407	0	0	0	0	0	1	3	6	9	17	25	37	55	83	83	46	42	8.3	C19-20
Anus	32	0	0	0	0	0	0	0	1	0	5	2	5	3	3	7	2	4	0.7	C21
Liver	317	0	2	0	0	0	1	0	2	3	2	14	27	55	73	56	34	48	6.5	C22
Gallbladder etc	63	0	0	0	0	0	0	0	0	2	2	1	6	11	7	14	7	13	1.3	C23-24
Pancreas	172	0	0	0	0	1	0	1	2	10	2	12	10	29	39	25	15	26	3.5	C25
Nose, Sinuses etc	24	0	0	0	0	2	0	0	0	0	2	1	0	6	1	6	2	4	0.5	C30-31
Larynx	146	0	0	0	0	1	0	0	0	0	4	6	15	26	27	28	22	17	3.0	C32
Lung, Trachea & Bronchus	514	0	0	0	1	0	2	0	5	7	20	28	29	74	109	86	85	68	10.5	C33-34
Other Thoracic Organs	16	0	0	0	0	1	1	1	3	0	1	1	0	2	2	1	0	3	0.3	C37-38
Bone	38	0	1	1	6	7	6	3	2	0	0	0	3	1	4	0	1	3	0.8	C40-41
Melanoma of Skin	8	0	0	0	1	0	0	0	0	1	0	0	0	1	2	1	1	1	0.2	C43
Non-Melanoma Skin	94	0	0	0	0	0	0	0	1	1	9	3	11	7	17	12	18	15	1.9	C44
Mesothelioma	4	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	1	0.1	C45
Kaposi Sarcoma	12	0	0	0	0	0	0	2	4	2	2	0	1	0	1	0	0	0	0.2	C46
Connective, Soft Tissue	49	0	0	0	1	2	3	1	0	4	4	1	9	3	8	5	3	5	1.0	C47,C49
Breast	27	0	0	0	0	0	0	0	1	1	0	4	1	5	5	2	4	4	0.6	C50
Penis	23	0	0	0	0	0	0	0	0	0	2	0	2	8	4	3	1	3	0.5	C60
Prostate	424	0	0	0	0	0	0	0	0	0	0	1	13	39	65	94	99	113	8.7	C61
Testis	67	0	0	1	0	4	12	17	9	5	5	3	4	1	2	1	3	0	1.4	C62
Other Male Genital	7	0	0	0	0	0	0	1	0	0	0	0	2	1	0	2	1	0	0.1	C63
Kidney	172	0	1	0	0	0	0	0	4	5	8	11	20	28	33	25	20	17	3.5	C64
Renal Pelvis	2	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0.0	C65
Ureter	4	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	2	0	0.1	C66
Bladder	125	0	0	0	0	0	0	0	1	0	2	4	12	12	22	25	16	31	2.6	C67
Other Urinary Organs	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0.0	C68
Eye	10	0	4	1	0	0	1	0	0	0	1	0	0	1	0	1	0	1	0.2	C69
Brain, Nervous System	111	0	3	5	4	2	3	7	5	9	5	6	11	14	14	15	5	3	2.3	C70-72
Thyroid	67	0	0	0	0	1	1	0	5	3	6	5	9	10	18	5	1	3	1.4	C73
Adrenal Gland	7	0	3	0	0	0	0	0	0	0	0	0	0	1	1	2	0	0	0.1	C74
Other Endocrine	4	0	0	0	0	0	1	0	0	0	0	1	0	1	0	0	1	0	0.1	C75
Hodgkin Lymphoma	80	0	0	0	1	7	15	13	12	2	4	2	3	7	5	4	4	1	1.6	C81
Non-Hodgkin Lymphoma	210	0	4	0	4	8	8	12	10	12	12	14	14	34	23	25	15	15	4.3	C82-85,C96
Immunoproliferative Diseases	3	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0.1	C88
Multiple Myeloma	68	0	0	0	0	0	0	0	0	1	0	5	6	15	13	12	8	8	1.4	C90
Lymphoid Leukaemia	84	0	12	12	6	6	8	7	1	2	1	5	3	3	2	5	6	5	1.7	C91
Myeloid Leukaemia	128	0	1	2	4	7	5	9	8	11	9	6	7	19	10	15	7	8	2.6	C92-94
Leukaemia Unspecified	18	0	0	1	2	1	0	2	0	0	0	0	3	1	2	3	2	1	0.4	C95
Myelodysplastic Syndromes	13	0	0	0	0	0	0	0	0	0	0	2	1	2	1	1	5	1	0.3	MDS
Myeloproliferative Disorders	19	0	0	0	0	0	0	0	1	0	0	0	4	5	4	2	2	1	0.4	MPD
Others & Unspecified	125	0	1	0	0	1	1	2	5	3	1	6	17	12	18	20	19	19	2.6	O&U
ALL SITES	4,895	0	32	23	32	53	73	87	111	123	182	250	404	675	813	795	612	630	100.0	ALL

Note: all 0.0 = Value <0.1; presented as 0.0 due to rounding. Age U = Age Unknown

Appendix 29. Cancer incidence by site and age group, Indian males, 2017-2021

SITE	TOTAL	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	CR	CR74	ASR	ASR(95% CL)	CumR	
Lip	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0.7	1.2	0	0.0	0.0	0.0	0.0	0.1	0.0
Tongue	112	0	0	0	0	0.2	0.2	0.7	0.9	2.2	4.2	5.8	5.3	7.1	12.0	12.9	12.0	2.2	0.3	2.2	1.8	2.6	0.3
Mouth	93	0	0	0	0	0	0	0.2	0.2	0.5	2.3	4.7	5.7	6.6	12.0	16.4	12.0	1.9	0.2	1.9	1.5	2.2	0.2
Salivary Glands	21	0	0	0	0.2	0.2	0	0.5	0.2	0.3	0.6	1.1	1.5	1.0	0.7	1.2	2.4	0.4	0.0	0.4	0.2	0.6	0.0
Tonsil	34	0	0	0	0	0	0	0	0	0.3	0	1.8	3.4	2.6	4.2	5.8	3.6	0.7	0.1	0.7	0.4	0.9	0.1
Other Oropharynx	28	0	0	0	0	0	0	0	0	0.3	0.6	2.6	1.9	2.6	2.1	2.3	3.6	0.6	0.1	0.5	0.3	0.7	0.1
Nasopharynx	40	0	0	0.5	0.2	0	0	0.2	0.2	1.1	1.0	2.2	2.3	4.1	2.1	2.3	3.6	0.8	0.1	0.8	0.5	1.0	0.1
Hypopharynx	34	0	0	0	0	0	0	0	0.2	0	0.6	0.7	2.3	3.6	6.4	5.8	2.4	0.7	0.1	0.7	0.4	0.9	0.1
Pharynx Unspecified	7	0	0	0	0	0	0	0	0	0	0	0.4	0.4	0.5	1.4	0	2.4	0.1	0.0	0.1	0.0	0.3	0.0
Oesophagus	110	0	0	0	0	0	0	0.5	0	1.6	1.6	2.2	8.0	9.7	18.4	15.2	14.5	2.2	0.3	2.2	1.8	2.6	0.3
Stomach	261	0	0	0	0	0.2	0.5	2.1	2.2	3.6	5.5	9.8	13.3	21.9	27.6	42.1	34.9	5.2	0.6	5.1	4.5	5.8	0.6
Small Intestine	30	0	0	0	0	0	0	0.2	0	0.8	0	1.5	3.4	2.6	2.8	3.5	1.2	0.6	0.1	0.6	0.4	0.8	0.1
Colon	427	0	0	0	0	0.2	0.7	0.9	2.7	4.7	8.8	9.8	21.2	35.7	56.5	71.3	83.1	8.5	1.1	8.7	7.8	9.5	1.1
Rectum	407	0	0	0	0	0.2	0.7	1.4	2.0	4.7	8.1	13.5	20.8	42.3	58.7	53.8	50.6	8.1	1.0	8.1	7.3	8.9	1.0
Anus	32	0	0	0	0	0	0	0.2	0	1.4	0.6	1.8	1.1	1.5	4.9	2.3	4.8	0.6	0.1	0.6	0.4	0.8	0.1
Liver	317	0.6	0	0	0	0.2	0	0.5	0.7	0.5	4.5	9.8	20.8	37.2	39.6	39.8	57.8	6.3	0.8	6.4	5.7	7.1	0.8
Gallbladder etc	63	0	0	0	0	0	0	0	0.4	0.5	0.3	2.2	4.2	3.6	9.9	8.2	15.7	1.3	0.1	1.3	1.0	1.6	0.1
Pancreas	172	0	0	0	0.2	0	0.2	0.5	2.2	0.5	3.9	3.6	11.0	19.9	17.7	17.5	31.3	3.4	0.4	3.4	2.9	3.9	0.4
Nose, Sinuses etc	24	0	0	0	0.5	0	0	0	0	0.5	0.3	0	2.3	0.5	4.2	2.3	4.8	0.5	0.1	0.5	0.3	0.7	0.1
Larynx	146	0	0	0	0.2	0	0	0	0	1.1	1.9	5.5	9.8	13.8	19.8	25.7	20.5	2.9	0.4	2.9	2.5	3.4	0.4
Lung, Trachea & Bronchus	514	0	0	0.2	0	0.5	0	1.2	1.6	5.5	9.1	10.6	28.0	55.6	60.8	99.4	81.9	10.2	1.4	10.4	9.5	11.3	1.4
Other Thoracic Organs	16	0	0	0	0.2	0.2	0.7	0	0.3	0.3	0	0	0.8	1.0	0.7	0	3.6	0.3	0.0	0.3	0.2	0.5	0.0
Bone	38	0.3	0.2	1.4	1.6	1.5	0.7	0.5	0	0	0	1.1	0.4	2.0	0	1.2	3.6	0.8	0.1	0.8	0.5	1.0	0.1
Melanoma of Skin	8	0	0	0.2	0	0	0	0	0.2	0	0	0	0.4	1.0	0.7	1.2	1.2	0.2	0.0	0.2	0.0	0.3	0.0
Non-Melanoma Skin	94	0	0	0	0	0	0	0.2	0.2	2.5	1.0	4.0	2.7	8.7	8.5	21.1	18.1	1.9	0.2	1.9	1.5	2.3	0.2
Mesothelioma	4	0	0	0	0	0	0	0	0	0	0	0	0.4	0.5	0	1.2	1.2	0.1	0.0	0.1	0.0	0.2	0.0
Kaposi Sarcoma	12	0	0	0	0	0	0.5	0.9	0.4	0.5	0	0.4	0	0.5	0	0	0	0.2	0.0	0.2	0.1	0.3	0.0
Connective, Soft Tissue	49	0	0	0.2	0.5	0.7	0.2	0	0.9	1.1	0.3	3.3	1.1	4.1	3.5	6.0	6.0	1.0	0.1	0.9	0.7	1.2	0.1
Breast	27	0	0	0	0	0	0	0.2	0.2	0	1.3	0.4	1.9	2.6	1.4	4.7	4.8	0.5	0.1	0.5	0.3	0.7	0.1
Peris	23	0	0	0	0	0	0	0	0	0.5	0	0.7	3.0	2.0	2.1	1.2	3.6	0.5	0.0	0.4	0.3	0.6	0.0
Prostate	424	0	0	0	0	0	0	0	0	0	0.3	4.7	14.8	33.2	66.4	115.8	136.1	8.4	1.2	9.2	8.3	10.1	1.2
Testis	67	0	0.2	0	0.9	2.9	4.1	2.1	1.1	1.4	1.0	1.5	0.4	1.0	0.7	3.5	0	1.3	0.1	1.2	0.9	1.5	0.1
Other Male Genital	7	0	0	0	0	0	0.2	0	0	0	0	0.7	0.4	0	1.4	1.2	0	0.1	0.0	0.1	0.0	0.2	0.0
Kidney	172	0.3	0	0	0	0	0	0.9	1.1	2.2	3.6	7.3	10.6	16.8	17.7	23.4	20.5	3.4	0.4	3.4	2.9	3.9	0.4
Renal Pelvis	2	0	0	0	0	0	0	0	0	0	0.6	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.1	0.0
Ureter	4	0	0	0	0	0	0	0	0	0	0	0.4	0	0.5	0	2.3	0	0.1	0.0	0.1	0.0	0.2	0.0
Bladder	125	0	0	0	0	0	0	0.2	0	0.5	1.3	4.4	4.5	11.2	17.7	18.7	37.3	2.5	0.3	2.6	2.2	3.1	0.3
Other Urinary Organs	2	0	0	0	0	0	0	0	0	0	0	0	0	0.5	0.7	0	0	0.0	0.0	0.0	0.0	0.1	0.0
Eye	10	1.2	0.2	0	0	0.2	0	0	0	0.3	0	0	0.4	0	0.7	0	1.2	0.2	0.0	0.3	0.1	0.4	0.0
Brain, Nervous System	111	0.9	1.2	0.9	0.5	0.7	1.7	1.2	2.0	1.4	1.9	4.0	5.3	7.1	10.6	5.8	3.6	2.2	0.2	2.1	1.7	2.6	0.2
Thyroid	67	0	0	0	0.2	0.2	0	1.2	0.7	1.6	1.6	3.3	3.8	9.2	3.5	1.2	3.6	1.3	0.1	1.2	0.9	1.5	0.1
Adrenal Gland	7	0.9	0	0	0	0	0	0	0	0	0	0	0.4	0.5	1.4	0	0	0.1	0.0	0.2	0.0	0.3	0.0
Other Endocrine	4	0	0	0	0	0.2	0	0	0	0	0.3	0	0.4	0	1.2	0	0	0.1	0.0	0.1	0.0	0.2	0.0
Hodgkin Lymphoma	80	0	0	0.2	1.6	3.7	3.1	2.8	0.4	1.1	0.6	1.1	2.7	2.6	2.8	4.7	1.2	1.6	0.1	1.5	1.1	1.8	0.1
Non-Hodgkin Lymphoma	210	1.2	0	0.9	1.8	1.9	2.9	2.3	2.7	3.3	4.5	5.1	12.9	11.7	17.7	17.5	18.1	4.2	0.4	4.0	3.5	4.6	0.4
Immunoproliferative Diseases	3	0	0	0	0	0	0	0	0	0	0.3	0.4	0.4	0	0	0	0	0.1	0.0	0.1	0.0	0.1	0.0
Multiple Myeloma	68	0	0	0	0	0	0	0	0.2	0	1.6	2.2	5.7	6.6	8.5	9.4	9.6	1.4	0.2	1.3	1.0	1.7	0.2
Lymphoid Leukaemia	84	3.7	2.9	1.4	1.4	1.9	1.7	0.2	0.4	0.3	1.6	1.1	1.1	1.0	3.5	7.0	6.0	1.7	0.1	1.9	1.5	2.4	0.1
Myeloid Leukaemia	128	0.3	0.5	0.9	1.6	1.2	2.1	1.8	2.4	2.5	1.9	2.6	7.2	5.1	10.6	8.2	9.6	2.5	0.2	2.4	2.0	2.8	0.2
Leukaemia Unspecified	18	0	0.2	0.5	0.2	0	0.5	0	0	0	0	1.1	0.4	1.0	2.1	2.3	1.2	0.4	0.0	0.4	0.2	0.5	0.0
Myelodysplastic Syndromes	13	0	0	0	0	0	0	0	0	0	0.6	0.4	0.8	0.5	0.7	5.8	1.2	0.3	0.0	0.3	0.1	0.4	0.0
Myeloproliferative Disorders	19	0	0	0	0	0	0	0.2	0	0	0	1.5	1.9	2.0	1.4	2.3	1.2	0.4	0.0	0.4	0.2	0.5	0.0
Others & Unspecified	125	0.3	0	0	0.2	0.2	0.5	1.2	0.7	0.3	1.9	6.2	4.5	9.2	14.1	22.2	22.9	2.5	0.3	2.5	2.1	3.0	0.3
ALL SITES	4,895	9.9	5.7	7.5	12.2	17.8	20.8	25.6	27.4	50	81.2	147.2	255.7	414.8	561.8	715.8	759.0	97.4	11.8	98.2	95.4	101.0	11.1

Note: all 0.0 = Value <0.1; presented as 0.0 due to rounding

Appendix 30. Number of new cancer cases by site and age group, Indian females, 2017-2021

SITE	TOTAL	AGE U	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	(%)	ICD-10
Lip	21	0	0	0	0	0	0	0	0	1	1	0	1	0	5	6	0	7	0.3	C00
Tongue	113	0	0	0	0	0	0	0	3	3	2	6	13	14	25	19	14	14	1.5	C01-02
Mouth	216	0	0	0	0	0	0	1	0	2	5	6	13	28	38	38	36	49	2.8	C03-06
Salivary Glands	26	0	0	0	0	1	0	2	0	3	4	0	1	0	4	6	2	3	0.3	C07-08
Tonsil	6	0	0	0	0	0	0	0	0	0	0	0	0	0	4	0	1	1	0.1	C09
Other Oropharynx	5	0	0	0	0	0	0	0	0	0	0	0	1	0	1	2	1	0	0.1	C10
Nasopharynx	12	0	0	0	0	2	0	0	0	0	1	0	0	1	3	2	2	1	0.2	C11
Hypopharynx	34	0	0	0	0	0	0	0	1	0	4	2	2	1	10	5	6	3	0.4	C12-13
Pharynx Unspecified	14	0	0	0	0	0	0	0	0	0	0	0	0	2	4	2	1	5	0.2	C14
Oesophagus	122	0	0	0	0	0	0	0	1	3	8	7	7	15	25	22	14	20	1.6	C15
Stomach	228	0	0	0	0	0	1	1	3	7	21	19	22	27	35	35	23	34	2.9	C16
Small Intestine	18	0	0	0	0	0	0	0	0	0	0	0	0	3	4	6	4	1	0.2	C17
Colon	388	0	0	0	1	3	2	1	5	7	26	29	40	48	69	51	56	50	5.0	C18
Rectum	269	0	0	0	0	0	1	0	6	4	12	20	25	31	51	43	41	35	3.5	C19-20
Anus	13	0	0	0	0	0	0	0	0	1	2	1	0	3	1	1	2	2	0.2	C21
Liver	147	0	1	0	0	2	0	1	1	1	3	6	10	23	27	27	15	30	1.9	C22
Gallbladder etc	48	0	0	0	0	0	0	0	0	0	1	2	3	10	9	11	5	7	0.6	C23-24
Pancreas	109	0	0	0	0	0	0	0	1	1	4	3	10	14	18	23	16	19	1.4	C25
Nose, Sinuses etc	19	0	0	0	0	0	2	0	0	0	1	0	3	2	2	4	2	3	0.2	C30-31
Larynx	19	0	0	0	0	0	0	0	0	0	0	0	1	5	7	0	2	4	0.2	C32
Lung, Trachea & Bronchus	248	0	0	0	0	0	1	3	0	6	3	13	25	32	41	41	37	46	3.2	C33-34
Other Thoracic Organs	9	0	0	0	0	0	0	0	2	1	0	3	0	0	0	2	0	1	0.1	C37-38
Bone	29	0	1	2	2	3	3	2	0	1	0	2	1	2	5	2	1	2	0.4	C40-41
Melanoma of Skin	11	0	0	0	0	0	0	0	0	0	0	1	3	3	1	0	1	2	0.1	C43
Non-Melanoma Skin	96	0	1	0	0	0	0	2	1	2	3	0	9	4	16	15	16	27	1.2	C44
Mesothelioma	4	0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	0	0	0.1	C45
Connective, Soft Tissue	44	0	1	1	0	1	3	0	1	4	3	2	5	7	5	5	0	6	0.6	C47,C49
Breast	2,896	0	0	0	0	0	3	22	57	128	196	334	396	468	454	392	236	210	37.4	C50
Vulva	23	0	0	0	0	0	0	0	0	0	1	1	1	3	7	4	2	4	0.3	C51
Vagina	16	0	0	0	0	0	0	0	0	0	0	2	1	1	4	4	5	1	0.2	C52
Cervix Uteri	297	0	0	0	0	0	1	6	4	17	30	33	42	48	32	29	22	3.8	C53	
Corpus Uteri	526	0	0	0	0	0	1	2	8	22	24	33	49	96	110	99	40	42	6.8	C54
Uterus Unspecified	149	0	0	0	0	0	0	0	2	5	9	12	14	30	35	20	11	11	1.9	C55
Ovary	354	0	0	1	1	5	2	7	10	12	28	37	50	48	61	48	26	18	4.6	C56
Other Female Genital	44	0	0	0	0	0	0	0	2	1	2	5	7	7	7	4	5	4	0.6	C57
Placenta	2	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0.0	C58
Kidney	78	0	2	1	0	1	0	3	0	1	5	3	9	10	18	9	7	9	1.0	C64
Renal Pelvis	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0.0	C65
Ureter	5	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	2	0.1	C66
Bladder	38	0	0	0	0	0	0	0	0	0	0	0	2	2	5	7	6	16	0.5	C67
Other Urinary Organs	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0.0	C68
Eye	6	0	2	0	0	0	0	0	0	0	0	0	0	0	0	2	0	2	0.1	C69
Brain, Nervous System	73	0	7	2	4	4	2	6	1	0	2	4	4	7	14	4	5	7	0.9	C70-72
Thyroid	213	0	0	0	2	4	13	11	14	16	25	29	19	18	25	22	9	6	2.7	C73
Adrenal Gland	4	0	2	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0.1	C74
Other Endocrine	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0.0	C75
Hodgkin Lymphoma	69	0	0	1	1	9	7	10	7	6	4	5	2	3	7	2	3	2	0.9	C81
Non-Hodgkin Lymphoma	170	0	1	1	3	0	5	7	8	8	6	9	17	24	24	29	11	17	2.2	C82-85,C96
Immunoproliferative Diseases	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0.0	C88
Multiple Myeloma	69	0	0	0	0	0	0	0	0	1	5	2	4	17	9	21	6	4	0.9	C90
Lymphoid Leukaemia	59	0	8	4	5	3	1	2	1	4	2	4	7	2	4	4	7	1	0.8	C91
Myeloid Leukaemia	133	0	4	6	0	5	3	5	7	9	10	10	14	11	18	17	9	5	1.7	C92-94
Leukaemia Unspecified	25	0	2	1	3	0	1	0	0	0	0	1	1	1	2	6	4	3	0.3	C95
Myelodysplastic Syndromes	11	0	0	0	0	0	0	0	0	0	1	0	2	1	3	1	2	1	0.1	MDS
Myeloproliferative Disorders	10	0	0	0	0	1	0	0	0	0	0	2	0	0	2	2	1	2	0.1	MPD
Others & Unspecified	203	0	1	0	1	1	0	3	8	3	7	7	15	34	39	38	19	27	2.6	O&U
ALL SITES	7,749	0	33	20	23	45	52	98	154	280	463	655	842	1,103	1,307	1,143	742	789	100.0	ALL

Note: all 0.0 = Value <0.1; presented as 0.0 due to rounding. Age U = Age Unknown

Appendix 31. Cancer incidence by site and age group, Indian females, 2017-2021

SITE	TOTAL	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	CR	CR74	ASR	ASR(95% CL)	CumR	
Lip	21	0	0	0	0	0	0	0	0.2	0.3	0	0.4	0	2.3	3.8	0	6.9	0.4	0.0	0.4	0.2	0.6	0.0
Tongue	113	0	0	0	0	0	0	0.7	0.7	0.6	1.9	4.6	5.1	11.5	12.0	13.7	13.8	2.3	0.3	2.0	1.7	2.4	0.3
Mouth	216	0	0	0	0	0	0.2	0	0.5	1.4	1.9	4.6	10.3	17.4	24.0	35.3	48.3	4.4	0.5	4.0	3.4	4.5	0.5
Salivary Glands	26	0	0	0	0.3	0	0.5	0	0.7	1.1	0	0.4	0	1.8	3.8	2.0	3.0	0.5	0.1	0.5	0.3	0.7	0.1
Tonsil	6	0	0	0	0	0	0	0	0	0	0	0	0	1.8	0	1.0	1.0	0.1	0.0	0.1	0.0	0.2	0.0
Other Oropharynx	5	0	0	0	0	0	0	0	0	0	0	0.4	0	0.5	1.3	1.0	0	0.1	0.0	0.1	0.0	0.2	0.0
Nasopharynx	12	0	0	0	0.5	0	0	0	0	0.3	0	0	0.4	1.4	1.3	2.0	1.0	0.2	0.0	0.2	0.1	0.4	0.0
Hypopharynx	34	0	0	0	0	0	0	0.2	0	1.1	0.6	0.7	0.4	4.6	3.2	5.9	3.0	0.7	0.1	0.6	0.4	0.8	0.1
Pharynx Unspecified	14	0	0	0	0	0	0	0	0	0	0	0	0.7	1.8	1.3	1.0	4.9	0.3	0.0	0.3	0.1	0.4	0.0
Oesophagus	122	0	0	0	0	0	0	0.2	0.7	2.3	2.2	2.5	5.5	11.5	13.9	13.7	19.7	2.5	0.3	2.2	1.8	2.6	0.3
Stomach	228	0	0	0	0	0.3	0.2	0.7	1.7	6.0	6.1	7.8	9.9	16.1	22.1	22.5	33.5	4.6	0.5	4.1	3.6	4.7	0.5
Small Intestine	18	0	0	0	0	0	0	0	0	0	0	0	1.1	1.8	3.8	3.9	1.0	0.4	0.1	0.3	0.2	0.5	0.1
Colon	388	0	0	0.2	0.8	0.5	0.2	1.2	1.7	7.4	9.3	14.1	17.6	31.7	32.2	54.9	49.3	7.8	0.9	7.0	6.3	7.8	0.9
Rectum	269	0	0	0	0	0.3	0	1.4	1.0	3.4	6.4	8.8	11.4	23.4	27.1	40.2	34.5	5.4	0.6	4.9	4.3	5.5	0.6
Anus	13	0	0	0	0	0	0	0	0.2	0.6	0.3	0	1.1	0.5	0.6	2.0	2.0	0.3	0.0	0.2	0.1	0.4	0.0
Liver	147	0.3	0	0	0.5	0	0.2	0.2	0.2	0.9	1.9	3.5	8.4	12.4	17.0	14.7	29.6	3.0	0.3	2.7	2.3	3.1	0.3
Gallbladder etc	48	0	0	0	0	0	0	0	0	0.3	0.6	1.1	3.7	4.1	6.9	4.9	6.9	1.0	0.1	0.9	0.6	1.1	0.1
Pancreas	109	0	0	0	0	0	0	0.2	0.2	1.1	1.0	3.5	5.1	8.3	14.5	15.7	18.7	2.2	0.2	2.0	1.6	2.4	0.2
Nose, Sinuses etc	19	0	0	0	0	0.5	0	0	0	0.3	0	1.1	0.7	0.9	2.5	2.0	3.0	0.4	0.0	0.4	0.2	0.5	0.0
Larynx	19	0	0	0	0	0	0	0	0	0	0	0.4	1.8	3.2	0	2.0	3.9	0.4	0.0	0.3	0.2	0.5	0.0
Lung, Trachea & Bronchus	248	0	0	0	0	0.3	0.7	0	1.4	0.9	4.2	8.8	11.7	18.8	25.9	36.3	45.3	5.0	0.5	4.5	4.0	5.1	0.5
Other Thoracic Organs	9	0	0	0	0	0	0	0.5	0.2	0	1.0	0	0	0	1.3	0	1.0	0.2	0.0	0.2	0.1	0.3	0.0
Bone	29	0.3	0.5	0.5	0.8	0.8	0.5	0	0.2	0	0.6	0.4	0.7	2.3	1.3	1.0	2.0	0.6	0.0	0.6	0.4	0.8	0.0
Melanoma of Skin	11	0	0	0	0	0	0	0	0	0	0.3	1.1	1.1	0.5	0	1.0	2.0	0.2	0.0	0.2	0.1	0.3	0.0
Non-Melanoma Skin	96	0.3	0	0	0	0	0.5	0.2	0.5	0.9	0	3.2	1.5	7.3	9.5	15.7	26.6	1.9	0.2	1.8	1.4	2.2	0.2
Mesothelioma	4	0	0	0	0	0	0.2	0	0	0	0	0	0.4	0.5	0.6	0	0	0.1	0.0	0.1	0.0	0.1	0.0
Connective, Soft Tissue	44	0.3	0.3	0	0.3	0.8	0	0.2	1.0	0.9	0.6	1.8	2.6	2.3	3.2	0	5.9	0.9	0.1	0.8	0.6	1.0	0.1
Breast	2,896	0	0	0	0	0.8	5.3	13.5	30.4	56.1	106.7	139.7	171.7	208.3	247.3	231.4	206.9	58.5	6.1	51.3	49.4	53.1	5.9
Vulva	23	0	0	0	0	0	0	0	0	0.3	0.3	0.4	1.1	3.2	2.5	2.0	3.9	0.5	0.0	0.4	0.2	0.6	0.0
Vagina	16	0	0	0	0	0	0	0	0	0	0.6	0.4	0.4	0.9	2.5	4.9	1.0	0.3	0.0	0.3	0.2	0.4	0.0
Cervix Uteri	297	0	0	0	0	0.3	1.4	1.0	4.0	8.6	10.5	11.6	15.4	22.0	20.2	28.4	21.7	6.0	0.6	5.3	4.7	5.9	0.6
Corpus Uteri	526	0	0	0	0	0.3	0.5	1.9	5.2	6.9	10.5	17.3	35.2	50.5	62.5	39.2	41.4	10.6	1.1	9.3	8.5	10.1	1.1
Uterus Unspecified	149	0	0	0	0	0	0	0.5	1.2	2.6	3.8	4.9	11.0	16.1	12.6	10.8	10.8	3.0	0.3	2.6	2.2	3.0	0.3
Ovary	354	0	0.3	0.2	1.3	0.5	1.7	2.4	2.9	8.0	11.8	17.6	17.6	28.0	30.3	25.5	17.7	7.2	0.7	6.3	5.7	7.0	0.7
Other Female Genital	44	0	0	0	0	0	0	0.5	0.2	0.6	1.6	2.5	2.6	3.2	2.5	4.9	3.9	0.9	0.1	0.8	0.5	1.0	0.1
Placenta	2	0	0	0	0	0	0	0	0	0.6	0	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.1	0.0
Kidney	78	0.6	0.3	0	0.3	0	0.7	0	0.2	1.4	1.0	3.2	3.7	8.3	5.7	6.9	8.9	1.6	0.2	1.5	1.1	1.8	0.2
Renal Pelvis	2	0	0	0	0	0	0	0	0	0	0	0	0	0.5	0.6	0	0	0.0	0.0	0.0	0.0	0.1	0.0
Ureter	5	0	0	0	0	0	0	0	0	0	0	0	0.4	0.5	0.6	0	2.0	0.1	0.0	0.1	0.0	0.2	0.0
Bladder	38	0	0	0	0	0	0	0	0	0	0	0.7	0.7	2.3	4.4	5.9	15.8	0.8	0.1	0.7	0.5	1.0	0.1
Other Urinary Organs	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6	0	1.0	0.0	0.0	0.0	0.0	0.1	0.0
Eye	6	0.6	0	0	0	0	0	0	0	0	0	0	0	0	1.3	0	2.0	0.1	0.0	0.2	0.0	0.3	0.0
Brain, Nervous System	73	2.2	0.5	1.0	1	0.5	1.4	0.2	0	0.6	1.3	1.4	2.6	6.4	2.5	4.9	6.9	1.5	0.1	1.5	1.2	1.9	0.1
Thyroid	213	0	0	0.5	1	3.3	2.6	3.3	3.8	7.2	9.3	6.7	6.6	11.5	13.9	8.8	5.9	4.3	0.4	3.8	3.3	4.3	0.4
Adrenal Gland	4	0.6	0	0	0	0	0	0	0	0	0	0	0	0	0.6	1.0	0	0.1	0.0	0.1	0.0	0.2	0.0
Other Endocrine	2	0	0	0	0	0	0	0	0	0	0	0	0.4	0	0.6	0	0	0.0	0.0	0.0	0.0	0.1	0.0
Hodgkin Lymphoma	69	0	0.3	0.2	2.3	1.8	2.4	1.7	1.4	1.1	1.6	0.7	1.1	3.2	1.3	2.9	2.0	1.4	0.1	1.3	1.0	1.6	0.1
Non-Hodgkin Lymphoma	170	0.3	0.3	0.7	0	1.3	1.7	1.9	1.9	1.7	2.9	6.0	8.8	11.0	18.3	10.8	16.7	3.4	0.3	3.1	2.6	3.5	0.3
Immunoproliferative Diseases	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1.3	0	0	0.0	0.0	0.0	0.0	0.1	0.0
Multiple Myeloma	69	0	0	0	0	0	0	0	0.2	1.4	0.6	1.4	6.2	4.1	13.2	5.9	3.9	1.4	0.2	1.2	0.9	1.5	0.2
Lymphoid Leukaemia	59	2.5	1.1	1.2	0.8	0.3	0.5	0.2	1.0	0.6	1.3	2.5	0.7	1.8	2.5	6.9	1.0	1.2	0.1	1.3	0.9	1.6	0.1
Myeloid Leukaemia	133	1.2	1.6	0	1.3	0.8	1.2	1.7	2.1	2.9	3.2	4.9	4.0	8.3	10.7	8.8	4.9	2.7	0.3	2.5	2.1	2.9	0.3
Leukaemia Unspecified	25	0.6	0.3	0.7	0	0.3	0	0	0	0	0.3	0.4	0.4	0.9	3.8	3.9	3.0	0.5	0.1	0.5	0.3	0.7	0.1
Myelodysplastic Syndromes	11	0	0	0	0	0	0	0	0	0.3	0	0.7	0.4	1.4	0.6	2.0	1.0	0.2	0.0	0.2	0.1	0.3	0.0
Myeloproliferative Disorders	10	0	0	0	0.3	0	0	0	0	0	0.6	0	0	0.9	1.3	1.0	2.0	0.2	0.0	0.2	0.1	0.3	0.0
Others & Unspecified	203	0.3	0	0.2	0.3	0	0.7	1.9	0.7	2.0	2.2	5.3	12.5	17.9	24.0	18.6	26.6	4.1	0.4	3.7	3.1	4.2	0.4
ALL SITES	7,749	10.2	5.4	5.7	11.3	13.4	23.5	36.6	66.6	132.5	209.3	297.0	404.8	599.5	721.1	727.5	777.3	156.6	16.3	139.7	136.5	142.8	15.1

Note: all 0.0 = Value <0.1; presented as 0.0 due to rounding

Appendix 32. Number of new cancer cases by site and age group, Other Bumiputera males, 2017-2021

SITE	TOTAL	AGE U	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	(%)	ICD-10
Lip	3	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	0.0	C00
Tongue	80	0	0	0	0	0	1	1	3	9	6	16	7	8	5	7	9	8	1.1	C01-02
Mouth	77	0	0	0	0	1	0	2	1	3	3	3	16	13	12	9	9	5	1.1	C03-06
Salivary Glands	45	0	0	0	3	1	0	3	2	2	3	5	6	9	3	4	3	1	0.6	C07-08
Tonsil	11	0	0	0	0	0	0	0	1	0	0	0	3	1	3	1	0	2	0.2	C09
Other Oropharynx	14	0	1	0	0	0	0	1	0	0	0	4	2	0	2	1	1	0.2	C10	
Nasopharynx	779	0	0	4	17	19	22	14	33	61	68	89	113	94	112	63	36	34	10.7	C11
Hypopharynx	23	0	0	0	0	0	0	0	0	0	1	0	0	5	3	4	5	5	0.3	C12-13
Pharynx Unspecified	15	0	0	0	0	0	0	0	0	2	1	3	2	1	1	2	2	1	0.2	C14
Oesophagus	81	0	0	0	0	0	0	0	0	5	2	7	10	15	12	9	12	9	1.1	C15
Stomach	414	0	0	0	0	3	2	2	10	10	25	32	44	56	66	62	41	61	5.7	C16
Small Intestine	32	0	0	0	0	0	0	0	3	2	3	3	3	4	1	6	4	3	0.4	C17
Colon	428	0	0	0	3	3	3	2	8	16	25	36	55	80	62	60	41	34	5.9	C18
Rectum	488	0	0	0	0	1	6	5	3	14	26	54	54	69	83	62	49	62	6.7	C19-20
Anus	29	0	0	0	0	0	0	0	1	2	5	2	6	3	3	2	2	3	0.4	C21
Liver	508	0	5	0	2	0	2	2	3	18	20	31	57	78	104	76	57	53	7.0	C22
Gallbladder etc	88	0	0	0	0	0	0	0	3	3	3	10	12	10	14	13	7	13	1.2	C23-24
Pancreas	117	0	0	0	0	0	1	1	2	4	6	4	22	25	19	14	10	9	1.6	C25
Nose, Sinuses etc	57	0	2	0	0	0	2	3	2	1	3	5	6	8	11	7	4	3	0.8	C30-31
Larynx	88	0	0	0	0	0	0	0	0	0	2	2	14	15	10	18	13	14	1.2	C32
Lung, Trachea & Bronchus	1,087	0	0	0	0	0	4	3	7	20	39	74	102	173	189	177	123	176	14.9	C33-34
Other Thoracic Organs	41	0	1	0	2	5	2	2	2	3	1	2	4	5	4	3	3	2	0.6	C37-38
Bone	51	0	0	2	13	8	2	4	2	2	2	4	4	4	2	1	0	1	0.7	C40-41
Melanoma of Skin	39	0	0	0	0	0	0	0	1	0	2	3	2	4	6	5	8	8	0.5	C43
Non-Melanoma Skin	258	0	0	0	0	1	0	3	8	12	11	17	19	30	34	35	21	67	3.5	C44
Mesothelioma	3	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	0	0	0.0	C45
Kaposi Sarcoma	31	0	0	0	0	0	4	1	7	7	0	1	2	1	2	3	3	0	0.4	C46
Connective, Soft Tissue	110	0	5	2	5	3	4	8	7	6	8	16	6	9	10	10	6	5	1.5	C47,C49
Breast	8	0	0	0	0	0	0	0	0	0	1	1	1	3	1	0	0	1	0.1	C50
Peris	35	0	0	0	0	0	0	0	0	2	2	4	6	6	8	2	1	4	0.5	C60
Prostate	426	0	0	0	0	0	0	0	1	0	2	6	14	24	65	95	111	108	5.8	C61
Testis	45	0	7	0	0	2	8	9	5	2	10	0	0	0	0	2	0	0	0.6	C62
Other Male Genital	6	0	0	0	0	0	0	1	0	0	1	0	1	0	0	2	0	1	0.1	C63
Kidney	124	0	6	4	1	1	3	2	0	5	7	11	18	24	20	14	5	3	1.7	C64
Renal Pelvis	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.0	C65
Bladder	121	0	2	0	0	0	0	1	4	1	5	9	19	8	13	17	18	24	1.7	C67
Other Urinary Organs	2	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0.0	C68
Eye	15	0	5	0	0	1	0	0	0	1	1	0	0	2	2	0	1	2	0.2	C69
Brain, Nervous System	124	0	14	14	6	7	4	6	8	10	7	8	8	8	8	7	8	1	1.7	C70-72
Thyroid	91	0	0	0	0	1	3	4	8	4	11	6	8	10	10	12	5	9	1.2	C73
Adrenal Gland	14	0	6	1	0	0	0	1	0	0	0	2	0	1	1	0	1	1	0.2	C74
Other Endocrine	11	0	0	2	2	3	0	0	0	0	0	1	1	0	0	1	0	1	0.2	C75
Hodgkin Lymphoma	71	0	0	3	2	5	7	9	11	4	5	3	6	4	5	4	1	2	1.0	C81
Non-Hodgkin Lymphoma	429	0	7	8	5	13	16	13	14	30	21	38	40	46	38	36	46	58	5.9	C82-85,C96
Immunoproliferative Diseases	18	0	0	0	0	0	0	1	0	1	1	3	4	3	2	1	1	1	0.2	C88
Multiple Myeloma	76	0	0	0	0	1	0	0	1	0	4	10	8	13	12	15	8	4	1.0	C90
Lymphoid Leukaemia	116	0	36	20	18	11	3	3	2	2	3	2	4	5	1	3	3	0	1.6	C91
Myeloid Leukaemia	205	0	8	10	15	15	14	11	8	11	15	15	13	24	12	16	7	11	2.8	C92-94
Leukaemia Unspecified	25	0	0	0	0	1	2	1	0	2	2	0	2	2	3	3	2	5	0.3	C95
Myelodysplastic Syndromes	27	0	0	0	0	0	2	1	0	0	0	0	2	1	4	4	8	5	0.4	MDS
Myeloproliferative Disorders	21	0	0	0	0	0	0	0	1	0	1	2	1	4	3	4	5	0	0.3	MPD
Others & Unspecified	292	0	0	0	1	3	5	5	8	14	16	17	32	40	43	40	31	37	4.0	O&U
ALL SITES	7,300	0	105	70	95	109	122	126	180	291	380	561	760	950	1,028	934	731	858	100.0	ALL

Note: all 0.0 = Value <0.1; presented as 0.0 due to rounding. Age U = Age Unknown

Appendix 33. Cancer incidence by site and age group, Other Bumiputera males, 2017-2021

SITE	TOTAL	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	CR	CR74	ASR	ASR(95% CL)	CumR	
Lip	3	0	0	0	0	0	0	0	0	0	0	0	0.5	0.3	0	0	0	0.0	0.0	0.0	0.0	0.1	0.0
Tongue	80	0	0	0	0	0.1	0.1	0.4	1.2	1.1	3.3	1.6	2.1	1.7	3.1	6.7	4.5	0.9	0.1	0.9	0.7	1.1	0.1
Mouth	77	0	0	0	0.1	0	0.2	0.1	0.4	0.6	0.6	3.7	3.5	4.0	3.9	6.7	2.8	0.8	0.1	0.9	0.7	1.1	0.1
Salivary Glands	45	0	0	0.3	0.1	0	0.3	0.3	0.3	0.6	1.0	1.4	2.4	1.0	1.8	2.2	0.6	0.5	0.1	0.5	0.4	0.7	0.1
Tonsil	11	0	0	0	0	0	0	0.1	0	0	0	0.7	0.3	1.0	0.4	0	1.1	0.1	0.0	0.1	0.1	0.2	0.0
Other Oropharynx	14	0.1	0	0	0	0	0.1	0	0	0	0.8	0.5	0	0.7	0.9	0.7	0.6	0.1	0.0	0.2	0.1	0.3	0.0
Nasopharynx	779	0	0.5	1.8	2.1	2.6	1.6	4.2	8.4	12.8	18.3	25.9	25.2	37.5	27.6	27.0	19.3	8.3	1.0	8.9	8.3	9.5	1.0
Hypopharynx	23	0	0	0	0	0	0	0	0	0.2	0	0	1.3	1.0	1.8	3.7	2.8	0.2	0.0	0.3	0.2	0.4	0.0
Pharynx Unspecified	15	0	0	0	0	0	0	0	0.3	0.2	0.6	0.5	0.3	0.3	0.9	1.5	0.6	0.2	0.0	0.2	0.1	0.3	0.0
Oesophagus	81	0	0	0	0	0	0	0	0.7	0.4	1.4	2.3	4.0	4.0	3.9	9.0	5.1	0.9	0.1	1.0	0.8	1.2	0.1
Stomach	414	0	0	0	0.3	0.2	0.2	1.3	1.4	4.7	6.6	10.1	15.0	22.1	27.2	30.7	34.7	4.4	0.6	5.0	4.5	5.5	0.6
Small Intestine	32	0	0	0	0	0	0	0.4	0.3	0.6	0.6	0.7	1.1	0.3	2.6	3.0	1.7	0.3	0.0	0.4	0.2	0.5	0.0
Colon	428	0	0	0.3	0.3	0.4	0.2	1.0	2.2	4.7	7.4	12.6	21.5	20.7	26.3	30.7	19.3	4.6	0.6	5.1	4.6	5.6	0.6
Rectum	488	0	0	0	0.1	0.7	0.6	0.4	1.9	4.9	11.1	12.4	18.5	27.8	27.2	36.7	35.2	5.2	0.7	5.9	5.4	6.5	0.7
Anus	29	0	0	0	0	0	0	0.1	0.3	0.9	0.4	1.4	0.8	1.0	0.9	1.5	1.7	0.3	0.0	0.3	0.2	0.5	0.0
Liver	508	0.6	0	0.2	0	0.2	0.2	0.4	2.5	3.8	6.4	13.0	20.9	34.8	33.3	42.7	30.1	5.4	0.8	6.2	5.7	6.8	0.8
Gallbladder etc	88	0	0	0	0	0	0	0.4	0.4	0.6	2.1	2.7	2.7	4.7	5.7	5.2	7.4	0.9	0.1	1.1	0.8	1.3	0.1
Pancreas	117	0	0	0	0	0.1	0.1	0.3	0.6	1.1	0.8	5.0	6.7	6.4	6.1	7.5	5.1	1.3	0.2	1.4	1.1	1.6	0.2
Nose, Sinuses etc	57	0.3	0	0	0	0.2	0.3	0.3	0.1	0.6	1.0	1.4	2.1	3.7	3.1	3.0	1.7	0.6	0.1	0.7	0.5	0.9	0.1
Larynx	88	0	0	0	0	0	0	0	0	0.4	0.4	3.2	4.0	3.3	7.9	9.7	8.0	0.9	0.1	1.1	0.9	1.3	0.1
Lung, Trachea & Bronchus	1,087	0	0	0	0	0.5	0.3	0.9	2.8	7.3	15.2	23.3	46.4	63.2	77.6	92.1	100.0	11.6	1.6	13.4	12.6	14.2	1.6
Other Thoracic Organs	41	0.1	0	0.2	0.6	0.2	0.2	0.3	0.4	0.2	0.4	0.9	1.3	1.3	1.3	2.2	1.1	0.4	0.0	0.5	0.3	0.6	0.0
Bone	51	0	0.2	1.3	0.9	0.2	0.5	0.3	0.3	0.4	0.8	0.9	1.1	0.7	0.4	0	0.6	0.5	0.0	0.5	0.4	0.7	0.0
Melanoma Of Skin	39	0	0	0	0	0	0	0.1	0	0.4	0.6	0.5	1.1	2.0	2.2	6.0	4.5	0.4	0.1	0.5	0.3	0.6	0.1
Non-Melanoma Skin	258	0	0	0	0.1	0	0.3	1.0	1.7	2.1	3.5	4.3	8.1	11.4	15.4	15.7	38.1	2.8	0.3	3.1	2.7	3.4	0.3
Mesothelioma	3	0	0	0	0	0	0.1	0	0	0	0	0	0	0.3	0.4	0	0	0.0	0.0	0.0	0.0	0.1	0.0
Kaposi Sarcoma	31	0	0	0	0	0.5	0.1	0.9	1.0	0	0.2	0.5	0.3	0.7	1.3	2.2	0	0.3	0.0	0.3	0.2	0.4	0.0
Connective, Soft Tissue	110	0.6	0.2	0.5	0.3	0.5	0.9	0.9	0.8	1.5	3.3	1.4	2.4	3.3	4.4	4.5	2.8	1.2	0.1	1.3	1.0	1.5	0.1
Breast	8	0	0	0	0	0	0	0	0	0.2	0.2	0.2	0.8	0.3	0	0	0.6	0.1	0.0	0.1	0.0	0.2	0.0
Peris	35	0	0	0	0	0	0	0	0.3	0.4	0.8	1.4	1.6	2.7	0.9	0.7	2.3	0.4	0.0	0.4	0.3	0.6	0.0
Prostate	426	0	0	0	0	0	0	0.1	0	0.4	1.2	3.2	6.4	21.7	41.7	83.1	61.4	4.6	0.8	5.5	5.0	6.1	0.8
Testis	45	0.9	0	0	0.2	0.9	1.0	0.6	0.3	1.9	0	0	0	0	0.9	0	0	0.5	0.0	0.5	0.3	0.6	0.0
Other Male Genital	6	0	0	0	0	0	0.1	0	0	0.2	0	0.2	0	0	0.9	0	0.6	0.1	0.0	0.1	0.0	0.1	0.0
Kidney	124	0.8	0.5	0.1	0.1	0.4	0.2	0	0.7	1.3	2.3	4.1	6.4	6.7	6.1	3.7	1.7	1.3	0.2	1.5	1.2	1.8	0.2
Renal Pelvis	1	0	0	0	0	0	0	0	0	0	0	0	0	0.3	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0
Bladder	121	0.3	0	0	0	0	0.1	0.5	0.1	0.9	1.8	4.3	2.1	4.3	7.5	13.5	13.6	1.3	0.2	1.5	1.2	1.8	0.2
Other Urinary Organs	2	0	0	0	0	0	0	0	0	0	0	0.2	0	0.3	0	0	0	0.0	0.0	0.0	0.0	0.1	0.0
Eye	15	0.6	0	0	0.1	0	0	0	0.1	0.2	0	0	0.5	0.7	0	0.7	1.1	0.2	0.0	0.2	0.1	0.3	0.0
Brain, Nervous System	124	1.8	1.7	0.6	0.8	0.5	0.7	1.0	1.4	1.3	1.6	1.8	2.1	2.7	3.1	6.0	0.6	1.3	0.1	1.4	1.2	1.7	0.1
Thyroid	91	0	0	0	0.1	0.4	0.5	1.0	0.6	2.1	1.2	1.8	2.7	3.3	5.3	3.7	5.1	1.0	0.1	1.0	0.8	1.3	0.1
Adrenal Gland	14	0.8	0.1	0	0	0	0.1	0	0	0.4	0	0.3	0.3	0	0.7	0.6	0.1	0.0	0.2	0.1	0.1	0.3	0.0
Other Endocrine	11	0	0.2	0.2	0.3	0	0	0	0	0.2	0.2	0	0	0.4	0	0.6	0.1	0.0	0.1	0.0	0.2	0.2	0.0
Hodgkin Lymphoma	71	0	0.4	0.2	0.6	0.8	1.0	1.4	0.6	0.9	0.6	1.4	1.1	1.7	1.8	0.7	1.1	0.8	0.1	0.7	0.6	0.9	0.1
Non-Hodgkin Lymphoma	429	0.9	1.0	0.5	1.4	1.9	1.5	1.8	4.1	3.9	7.8	9.2	12.3	12.7	15.8	34.5	33.0	4.6	0.5	5.0	4.5	5.5	0.5
Immunoproliferative Diseases	18	0	0	0	0	0	0.1	0	0.1	0.2	0.6	0.9	0.8	0.7	0.4	0.7	0.6	0.2	0.0	0.2	0.1	0.3	0.0
Multiple Myeloma	76	0	0	0	0.1	0	0	0.1	0	0.8	2.1	1.8	3.5	4.0	6.6	6.0	2.3	0.8	0.1	0.9	0.7	1.2	0.1
Lymphoid Leukaemia	116	4.6	2.4	1.9	1.2	0.4	0.3	0.3	0.3	0.6	0.4	0.9	1.3	0.3	1.3	2.2	0	1.2	0.1	1.4	1.2	1.7	0.1
Myeloid Leukaemia	205	1.0	1.2	1.6	1.7	1.6	1.3	1.0	1.5	2.8	3.1	3.0	6.4	4.0	7.0	5.2	6.3	2.2	0.2	2.3	2.0	2.6	0.2
Leukaemia Unspecified	25	0	0	0	0.1	0.2	0.1	0	0.3	0.4	0	0.5	0.5	1.0	1.3	1.5	2.8	0.3	0.0	0.3	0.2	0.4	0.0
Myelodysplastic Syndromes	27	0	0	0	0	0.2	0.1	0	0	0	0	0.5	0.3	1.3	1.8	6.0	2.8	0.3	0.1	0.3	0.2	0.5	0.1
Myeloproliferative Disorders	21	0	0	0	0	0	0	0.1	0	0.2	0.4	0.2	1.1	1.0	1.8	3.7	0	0.2	0.0	0.3	0.2	0.4	0.0
Others & Unspecified	292	0	0	0.1	0.3	0.6	0.6	1.0	1.9	3.0	3.5	7.3	10.7	14.4	17.5	23.2	21.0	3.1	0.4	3.5	3.1	3.9	0.4
ALL SITES	7,300	13.5	8.5	9.9	12.0	14.3	14.6	23.0	40.2	71.4	115.1	173.9	255.0	343.8	409.6	547.6	487.5	78.0	10.3	87.4	85.3	89.4	9.8

Note: all 0.0 = value <0.1; presented as 0.0 due to rounding

Appendix 34. Number of new cancer cases by site and age group, Other Bumiputera females, 2017-2021

SITE	TOTAL	AGE U	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	(%)	ICD-10
Lip	15	0	0	0	0	0	0	0	0	0	1	2	1	2	1	2	3	3	0	C00
Tongue	64	0	0	0	0	0	0	1	4	5	5	10	7	13	8	1	3	7	1	C01-02
Mouth	83	0	1	0	0	0	0	3	1	2	2	4	8	11	15	12	7	17	1	C03-06
Salivary Glands	36	0	0	0	2	1	2	2	1	2	4	5	2	4	5	2	3	1	0	C07-08
Tonsil	8	0	0	0	0	0	0	0	1	0	0	0	1	1	0	1	1	3	0	C09
Other Oropharynx	6	0	0	0	0	0	0	0	0	0	0	0	1	2	0	1	1	1	0	C10
Nasopharynx	339	0	0	1	4	8	9	8	14	27	33	37	60	41	31	27	20	19	4	C11
Hypopharynx	17	0	0	0	0	0	1	0	0	0	1	2	5	0	3	2	3	0	0	C12-13
Pharynx Unspecified	4	0	0	0	0	0	0	0	0	0	0	0	2	0	1	1	0	0	0	C14
Oesophagus	50	0	0	0	0	0	0	0	0	1	2	4	5	3	10	7	8	10	1	C15
Stomach	260	0	0	0	0	1	2	6	7	7	12	12	21	34	36	38	38	46	3	C16
Small Intestine	33	0	0	0	0	0	0	1	0	3	4	3	3	4	3	4	2	6	0	C17
Colon	366	0	0	0	0	1	4	5	9	11	28	29	57	56	50	42	30	44	4	C18
Rectum	313	0	0	0	0	1	1	4	6	9	16	30	35	47	49	41	33	41	4	C19-20
Anus	30	0	0	0	0	0	1	0	2	2	4	0	0	4	4	6	2	5	0	C21
Liver	219	0	4	1	2	1	2	0	5	5	5	12	16	35	34	39	27	31	3	C22
Gallbladder etc	86	0	0	0	0	0	0	0	2	1	3	8	5	17	15	3	13	19	1	C23-24
Pancreas	109	0	0	0	1	0	1	1	0	4	0	8	8	25	12	17	16	16	1	C25
Nose, Sinuses etc	25	0	1	0	0	1	0	0	2	0	0	5	5	3	5	1	1	1	0	C30-31
Larynx	15	0	0	0	0	0	0	1	0	0	1	1	0	2	3	3	1	3	0	C32
Lung, Trachea & Bronchus	698	0	0	0	1	1	1	4	8	8	34	45	69	96	107	110	97	117	8	C33-34
Other Thoracic Organs	25	0	0	1	1	3	0	1	2	0	3	1	3	3	4	3	0	0	0	C37-38
Bone	45	0	0	7	5	9	2	2	3	3	2	1	4	1	1	2	0	3	1	C40-41
Melanoma of Skin	31	0	0	0	1	1	2	1	0	2	3	4	2	3	3	2	3	4	0	C43
Non-Melanoma Skin	247	0	0	0	0	0	1	2	4	4	6	11	13	24	34	40	35	73	3	C44
Mesothelioma	4	0	0	0	0	1	0	0	0	1	0	0	1	0	0	0	1	0	0	C45
Kaposi Sarcoma	4	0	1	0	0	0	0	0	0	0	0	2	0	0	1	0	0	0	0	C46
Connective, Soft Tissue	81	0	4	3	1	4	3	7	7	3	6	5	10	8	2	7	3	8	1	C47,C49
Breast	1,755	0	0	0	0	1	3	34	99	149	250	294	289	222	187	116	53	58	21	C50
Vulva	21	0	0	0	0	1	0	0	0	0	2	1	5	4	3	1	2	2	0	C51
Vagina	11	0	0	0	0	0	1	0	0	0	1	1	2	2	1	1	1	0	0	C52
Cervix Uteri	800	0	0	0	0	1	3	13	50	75	97	119	138	103	91	51	26	33	10	C53
Corpus Uteri	375	0	0	0	0	0	2	5	25	27	50	47	59	61	54	24	13	8	4	C54
Uterus Unspecified	72	0	0	0	0	0	0	2	3	6	9	10	7	18	10	1	4	2	1	C55
Ovary	379	0	3	1	4	18	13	19	18	27	35	46	56	47	39	23	16	14	5	C56
Other Female Genital	36	0	0	0	0	1	0	0	0	2	2	6	6	9	3	2	2	3	0	C57
Placenta	4	0	0	0	0	0	0	2	0	0	0	0	2	0	0	0	0	0	0	C58
Kidney	58	0	6	1	2	0	1	3	0	2	3	5	4	13	10	3	3	2	1	C64
Renal Pelvis	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	C65
Ureter	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	C66
Bladder	38	0	0	0	0	0	0	0	0	1	1	1	2	9	8	4	6	6	0	C67
Other Urinary Organs	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	C68
Eye	13	0	7	0	1	0	0	2	0	0	0	0	2	0	0	0	1	0	0	C69
Brain, Nervous System	110	0	11	10	11	4	7	5	9	10	4	9	9	4	4	7	1	5	1	C70-72
Thyroid	387	0	0	0	0	6	13	37	30	41	47	42	46	40	28	26	21	10	5	C73
Adrenal Gland	12	0	2	1	0	0	1	0	0	0	0	0	1	2	3	1	0	1	0	C74
Other Endocrine	5	0	1	0	0	0	1	0	0	0	1	1	0	1	0	0	0	0	0	C75
Hodgkin Lymphoma	47	0	0	0	3	5	9	7	8	3	4	2	0	1	3	0	2	0	1	C81
Non-Hodgkin Lymphoma	350	0	9	4	5	6	8	13	16	15	18	35	32	50	42	37	25	35	4	C82-85,C96
Immunoproliferative Diseases	3	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	C88
Multiple Myeloma	70	0	0	0	0	0	1	0	1	1	8	3	10	9	12	12	7	6	1	C90
Lymphoid Leukaemia	87	0	28	16	11	4	2	5	5	1	3	2	2	1	2	2	1	2	1	C91
Myeloid Leukaemia	172	0	11	4	10	6	13	11	12	11	12	15	20	17	13	6	4	7	2	C92-94
Leukaemia Unspecified	25	0	1	1	0	0	0	1	1	2	1	2	2	0	2	2	5	5	0	C95
Myelodysplastic Syndromes	13	0	0	0	0	1	0	0	0	1	0	1	1	2	0	2	4	1	0	MDS
Myeloproliferative Disorders	30	0	0	1	0	0	0	2	0	1	4	0	2	4	4	7	1	4	0	MPD
Others & Unspecified	254	0	4	0	2	2	5	3	6	8	13	21	27	40	37	36	21	29	3	O&U
ALL SITES	8,345	0	94	52	67	89	115	213	361	483	740	904	1,069	1,101	994	778	571	714	100	ALL

Appendix 35. Cancer incidence by site and age group, Other Bumiputera females, 2017-2021

SITE	TOTAL	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	CR	CR74	ASR	ASR(95% CL)	CumR	
Lip	15	0	0	0	0	0	0	0	0	0.2	0.4	0.2	0.5	0.4	1.0	2.2	1.7	0.2	0.0	0.2	0.1	0.3	0.0
Tongue	64	0	0	0	0	0	0.1	0.5	0.7	0.9	2.0	1.6	3.6	2.9	0.5	2.2	4.0	0.7	0.1	0.7	0.6	0.9	0.1
Mouth	83	0.1	0	0	0	0	0.3	0.1	0.3	0.4	0.8	1.9	3.0	5.5	5.9	5.0	9.6	0.9	0.1	1.0	0.8	1.3	0.1
Salivary Glands	36	0	0	0.2	0.1	0.2	0.2	0.1	0.3	0.7	1.0	0.5	1.1	1.8	1.0	2.2	0.6	0.4	0.0	0.4	0.3	0.6	0.0
Tonsil	8	0	0	0	0	0	0	0.1	0	0	0	0.2	0.3	0	0.5	0.7	1.7	0.1	0.0	0.1	0.0	0.2	0.0
Other Oropharynx	6	0	0	0	0	0	0	0	0	0	0	0.2	0.5	0	0.5	0.7	0.6	0.1	0.0	0.1	0.0	0.1	0.0
Nasopharynx	339	0	0.1	0.4	0.9	1.0	0.9	1.8	3.8	6.2	7.5	14.1	11.2	11.3	13.2	14.3	10.7	3.7	0.4	3.9	3.5	4.4	0.4
Hypopharynx	17	0	0	0	0	0.1	0	0	0	0.2	0.4	1.2	0	1.1	1.0	2.2	0	0.2	0.0	0.2	0.1	0.3	0.0
Pharynx Unspecified	4	0	0	0	0	0	0	0	0	0	0	0.5	0	0.4	0.5	0	0	0.0	0.0	0.1	0.0	0.1	0.0
Oesophagus	50	0	0	0	0	0	0	0	0.1	0.4	0.8	1.2	0.8	3.7	3.4	5.7	5.6	0.5	0.1	0.6	0.5	0.8	0.1
Stomach	260	0	0	0	0.1	0.2	0.7	0.9	1.0	2.2	2.4	4.9	9.3	13.2	18.6	27.2	26.0	2.8	0.4	3.2	2.8	3.6	0.4
Small Intestine	33	0	0	0	0	0	0.1	0	0.4	0.7	0.6	0.7	1.1	1.1	2.0	1.4	3.4	0.4	0.0	0.4	0.3	0.5	0.0
Colon	366	0	0	0	0.1	0.5	0.6	1.1	1.6	5.2	5.9	13.4	15.3	18.3	20.5	21.5	24.9	4.0	0.5	4.5	4.0	4.9	0.5
Rectum	313	0	0	0	0.1	0.1	0.5	0.8	1.3	3.0	6.1	8.2	12.9	17.9	20.0	23.7	23.2	3.4	0.5	3.9	3.5	4.3	0.5
Anus	30	0	0	0	0	0.1	0	0.3	0.3	0.7	0	0	1.1	1.5	2.9	1.4	2.8	0.3	0.0	0.4	0.2	0.5	0.0
Liver	219	0.6	0.1	0.2	0.1	0.2	0	0.6	0.7	0.9	2.4	3.8	9.6	12.4	19.1	19.4	17.5	2.4	0.4	2.8	2.4	3.2	0.4
Gallbladder etc	86	0	0	0	0	0	0	0.3	0.1	0.6	1.6	1.2	4.7	5.5	1.5	9.3	10.7	0.9	0.1	1.1	0.8	1.3	0.1
Pancreas	109	0	0	0.1	0	0.1	0.1	0	0.6	0	1.6	1.9	6.8	4.4	8.3	11.5	9.0	1.2	0.2	1.4	1.1	1.6	0.2
Nose, Sinuses etc	25	0.1	0	0	0.1	0	0	0.3	0	0	1.0	1.2	0.8	1.8	0.5	0.7	0.6	0.3	0.0	0.3	0.2	0.4	0.0
Larynx	15	0	0	0	0	0	0.1	0	0	0.2	0.2	0	0.5	1.1	1.5	0.7	1.7	0.2	0.0	0.2	0.1	0.3	0.0
Lung, Trachea & Bronchus	698	0	0	0.1	0.1	0.1	0.5	1.0	1.1	6.3	9.1	16.2	26.3	39.1	53.8	69.5	66.1	7.6	1.1	8.9	8.2	9.5	1.1
Other Thoracic Organs	25	0	0.1	0.1	0.3	0	0.1	0.3	0	0.6	0.2	0.7	0.8	1.5	1.5	0	0	0.3	0.0	0.3	0.2	0.4	0.0
Bone	45	0	0.9	0.5	1.0	0.2	0.2	0.4	0.4	0.4	0.2	0.9	0.3	0.4	1.0	0	1.7	0.5	0.0	0.5	0.3	0.6	0.0
Melanoma of Skin	31	0	0	0.1	0.1	0.2	0.1	0	0.3	0.6	0.8	0.5	0.8	1.1	1.0	2.2	2.3	0.3	0.0	0.4	0.2	0.5	0.0
Non-Melanoma Skin	247	0	0	0	0	0.1	0.2	0.5	0.6	1.1	2.2	3.1	6.6	12.4	19.6	25.1	41.2	2.7	0.4	3.1	2.7	3.5	0.4
Mesothelioma	4	0	0	0	0.1	0	0	0	0.1	0	0	0.2	0	0	0	0	0.6	0.0	0.0	0.0	0.0	0.1	0.0
Kaposi Sarcoma	4	0.1	0	0	0	0	0	0	0	0.4	0	0	0	0.4	0	0	0	0.0	0.0	0.1	0.0	0.1	0.0
Connective, Soft Tissue	81	0.6	0.4	0.1	0.5	0.3	0.8	0.9	0.4	1.1	1.0	2.4	2.2	0.7	3.4	2.2	4.5	0.9	0.1	0.9	0.7	1.1	0.1
Breast	1,755	0	0	0	0.1	0.3	3.9	12.4	21.0	46.6	59.5	67.9	60.7	68.4	56.7	38.0	32.8	19.2	2.2	20.4	19.4	21.4	2.2
Vulva	21	0	0	0	0.1	0	0	0	0	0.4	0.2	1.2	1.1	1.1	0.5	1.4	1.1	0.2	0.0	0.3	0.1	0.4	0.0
Vagina	11	0	0	0	0	0.1	0	0	0	0.2	0.2	0.5	0.5	0.4	0.5	0.7	0.6	0.1	0.0	0.1	0.1	0.2	0.0
Cervix Uteri	800	0	0	0	0.1	0.3	1.5	6.3	10.6	18.1	24.1	32.4	28.2	33.3	24.9	18.6	18.6	8.7	1.0	9.3	8.6	9.9	1.0
Corpus Uteri	375	0	0	0	0	0.2	0.6	3.1	3.8	9.3	9.5	13.9	16.7	19.7	11.7	9.3	4.5	4.1	0.5	4.4	3.9	4.8	0.5
Uterus Unspecified	72	0	0	0	0	0	0.2	0.4	0.8	1.7	2.0	1.6	4.9	3.7	0.5	2.9	1.1	0.8	0.1	0.8	0.6	1.0	0.1
Ovary	379	0.4	0.1	0.4	2.1	1.5	2.2	2.3	3.8	6.5	9.3	13.2	12.9	14.3	11.2	11.5	7.9	4.1	0.5	4.4	3.9	4.8	0.5
Other Female Genital	36	0	0	0	0.1	0	0	0	0.3	0.4	1.2	1.4	2.5	1.1	1.0	1.4	1.7	0.4	0.0	0.4	0.3	0.6	0.0
Placenta	4	0	0	0	0	0	0.2	0	0	0	0	0.5	0	0	0	0	0	0.0	0.0	0.0	0.0	0.1	0.0
Kidney	58	0.8	0.1	0.2	0	0.1	0.3	0	0.3	0.6	1.0	0.9	3.6	3.7	1.5	2.2	1.1	0.6	0.1	0.7	0.5	0.9	0.1
Renal Pelvis	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.7	0	0.0	0.0	0.0	0.0	0.0	0.0
Ureter	2	0	0	0	0	0	0	0	0	0	0	0	0.3	0	0	0.7	0	0.0	0.0	0.0	0.0	0.1	0.0
Bladder	38	0	0	0	0	0	0	0	0.1	0.2	0.2	0.5	2.5	2.9	2.0	4.3	3.4	0.4	0.1	0.5	0.3	0.6	0.1
Other Urinary Organs	2	0	0	0	0	0	0	0	0	0	0	0	0.3	0	0	0	0.6	0.0	0.0	0.0	0.0	0.1	0.0
Eye	13	1.0	0	0.1	0	0	0.2	0	0	0	0	0.5	0	0	0	0.7	0	0.1	0.0	0.2	0.1	0.3	0.0
Brain, Nervous System	110	1.5	1.3	1.2	0.5	0.8	0.6	1.1	1.4	0.7	1.8	2.1	1.1	1.5	3.4	0.7	2.8	1.2	0.1	1.3	1.0	1.5	0.1
Thyroid	387	0	0	0	0.7	1.5	4.2	3.8	5.8	8.8	8.5	10.8	10.9	10.2	12.7	15.1	5.6	4.2	0.5	4.3	3.9	4.7	0.5
Adrenal Gland	12	0.3	0.1	0	0	0.1	0	0	0	0	0	0.2	0.5	1.1	0.5	0	0.6	0.1	0.0	0.2	0.1	0.2	0.0
Other Endocrine	5	0.1	0	0	0	0.1	0	0	0	0.2	0.2	0	0.3	0	0	0	0	0.1	0.0	0.1	0.0	0.1	0.0
Hodgkin Lymphoma	47	0	0	0.3	0.6	1.0	0.8	1.0	0.4	0.7	0.4	0	0.3	1.1	0	1.4	0	0.5	0.0	0.5	0.3	0.6	0.0
Non-Hodgkin Lymphoma	350	1.2	0.5	0.5	0.7	0.9	1.5	2.0	2.1	3.4	7.1	7.5	13.7	15.4	18.1	17.9	19.8	3.8	0.5	4.2	3.8	4.7	0.5
Immunoproliferative Diseases	3	0	0	0	0	0	0	0	0	0	0	0.2	0.3	0.4	0	0	0	0.0	0.0	0.0	0.0	0.1	0.0
Multiple Myeloma	70	0	0	0	0	0.1	0	0.1	0.1	1.5	0.6	2.4	2.5	4.4	5.9	5.0	3.4	0.8	0.1	0.9	0.7	1.1	0.1
Lymphoid Leukaemia	87	3.9	2.1	1.2	0.5	0.2	0.6	0.6	0.1	0.6	0.4	0.5	0.3	0.7	1.0	0.7	1.1	1.0	0.1	1.1	0.9	1.4	0.1
Myeloid Leukaemia	172	1.5	0.5	1.1	0.7	1.5	1.3	1.5	1.6	2.2	3.0	4.7	4.7	4.8	2.9	2.9	4.0	1.9	0.2	2.0	1.7	2.2	0.2
Leukaemia Unspecified	25	0.1	0.1	0	0	0	0.1	0.1	0.3	0.2	0.4	0.5	0	0.7	1.0	3.6	2.8	0.3	0.0	0.3	0.2	0.4	0.0
Myelodysplastic Syndromes	13	0	0	0	0.1	0	0	0	0.1	0	0.2	0.2	0.5	0	1.0	2.9	0.6	0.1	0.0	0.2	0.1	0.3	0.0
Myeloproliferative Disorders	30	0	0.1	0	0	0	0.2	0	0.1	0.7	0	0.5	1.1	1.5	3.4	0.7	2.3	0.3	0.0	0.4	0.2	0.5	0.0
Others & Unspecified	254	0.6	0	0.2	0.2	0.6	0.3	0.8	1.1	2.4	4.3	6.3	10.9	13.5	17.6	15.1	16.4	2.8	0.4	3.1	2.8	3.5	0.4
ALL SITES	8,345	12.9	6.7	7.3	10.2	13.4	24.3	45.2	68.1	138.1	183.0	251.2	301.2	363.4	380.4	409.3	403.4	91.2	11.1	99.7	97.5	101.9	10.5

Appendix 36. List of ICD-10 and ICD-11 codes for each site

NO.	SITE	ICD-10	CORRESPONDING ICD-11
1	Lip	C00	2B60
2	Tongue	C01-02	2B61, 2B62
3	Mouth	C03-06	2B63-2B66
4	Salivary Glands	C07-08	2B67-2B68
5	Tonsil	C09	2B69
6	Other Oropharynx	C10	2B6A
7	Nasopharynx	C11	2B6B
8	Hypopharynx	C12-13	2B6C-2B6D
9	Pharynx Unspecified	C14	2B6E, 2B6Y, 2B6Z
10	Oesophagus	C15	2B70
11	Stomach	C16	2B58.2, 2B5B.0, 2B71, 2B72
12	Small Intestine	C17	2B5B.1, 2B80
13	Colorectal	C18-21	2B81, 2B90-2B92, 2C00
14	Liver	C22	2B56.3, 2C12.0
15	Gallbladder Etc	C23-24	2C13-2C18
16	Pancreas	C25	2C10
17	Other Digestive Organs	C26	2C1Z
18	Nose, Sinuses Etc	C30-31	2C20-2C22
19	Larynx	C32	2C23
20	Trachea, Bronchus & Lung	C33-34	2C24-2C25
21	Other Thoracic Organs	C37-38	2C26 -2C28 (Exclude 2C26.0)
22	Other Respiratory System	C39	2C29
23	Bone	C40-41	2B50-2B52 (Exclude 2B52.3), 2B5J
24	Melanoma of Skin	C43	2C30
25	Non-Melanoma Skin	C44	2C31-2C34, 2C3Y, 2C3Z
26	Mesothelioma	C45	2C26.0, 2C51.2, 2C53.1
27	Kaposi Sarcoma	C46	2B57
28	Connective, Soft Tissue	C47, C49	2B52.3, 2B53-2B56, 2B58-2B59 (Exclude 2B58.0, 2B58.1, 2B58.2, 2B59.1, 2B59.2), 2B5A, 2B5D-2B5F (Exclude 2B5D.0, 2B5D.1, 2B5F.0, 2B5F.1), 2C40-2C4Z
29	Retroperitoneum & Peritoneum	C48	2C50-2C5Z
30	Breast	C50	2C60-2C6Z (Exclude 2C65)
31	Vulva	C51	2C70
32	Vagina	C52	2C71
33	Cervix Uteri	C53	2C77
34	Corpus Uteri	C54	2C76
35	Uterus Unspecified	C55	2C78
36	Ovary	C56	2C73
37	Other Female Genital	C57	2C72, 2C74, 2C7Y, 2C7Z
38	Placenta	C58	2C75
39	Penis	C60	2C81
40	Prostate	C61	2C82
41	Testis	C62	2C80
42	Other Male Genital	C63	2C83-2C8Z
43	Kidney	C64	2C90
44	Renal Pelvis	C65	2C91
45	Ureter	C66	2C92
46	Bladder	C67	2C94
47	Other Urinary Organs	C68	2C93, 2C95-2C9Z
48	Eye	C69	2D00.Z-2D0Z
49	Brain, Nervous System	C70-72	2A00-2A02 (Exclude 2A02.3, 2A02.4)
50	Thyroid	C73	2D10
51	Adrenal Gland	C74	2D11
52	Other Endocrine	C75	2A00.20, 2D12
53	Lymphoma	C81-85, C96	2A21 (Exclude 2A21.00), 2A70, 2A80 (Exclude 2A80.5), 2A81 (Exclude 2A81.0), 2A82 (Exclude 2A82.00, 2A82.1-2A82.2), 2A85.0, 2A85.5, 2A85.6, 2A85.Y, 2A85.Z, 2A86, 2A8Z, 2A90.A-2A90.C, 2B01, 2B02, 2B0Y, 2B0Z, 2B2Y, 2B2Z, 2B30, 2B31 (Exclude 2B31.0), 2B33.5, 2B3Z
54	Immunoproliferative Diseases	C88	2A84, 2A85.1-2A85.4
55	Multiple Myeloma	C90	2A83
56	Leukaemia	C91-95	2A20.0, 2A21.00, 2A40-2A42, 2A50-2A5Z, 2A60.0-2A60.3 (Exclude 2A60.39), 2A60.41, 2A60.Y, 2A60.Z, 2A61, 2A82.00, 2A82.1, 2A82.2, 2A85.6, 2A90.0, 2A90.5, 2B33.0, 2B33.1, 2B33.3, 2B33.4, 2B33.Y
57	Myeloproliferative Disorders	MPD	2A20-2A22, 2A43, 2A44, 2A60.2Z, 2A90.2, 2A90.4, 2B31
58	Myelodysplastic Syndromes	MDS	2A30-2A3Z, 2A43
60	Others & Unspecified	O&U	2A60.5, 2A90.6 -2A90.9, 2B00, 2B03.0, 2D40, 2D41, 2D42, 2D4Y, 2D4Z

Note: This is with reference to the ICD-O-3.2 (International Classification of Diseases for Oncology, 3rd Edition, 2nd Revision) and ICD-11 (2022-02)

NOTES

NOTES

MALAYSIA NATIONAL CANCER REGISTRY REPORT *(MNCR) 2017-2021

e ISBN 978-967-16142-5-9



9 789671 614259

INSTITUT KANSER NEGARA

(online)

JABATAN REGISTRASI KANSER KEBANGSAAN
Institut Kanser Negara
No.4, Jalan P7, Presint 7,
62250 W.P. Putrajaya